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1. Introduction 
 3 
1.1 Inflammation and infection: an overview 
Inflammation is the first response of the immune system to infection or irritation. Through this process 
the white blood cells and chemicals released from them protect human organism against exogenous 
substances and pathogenic microorganisms such as bacteria and viruses.1 Nevertheless, if the injurious 
agent continues or the control of cellular recruitment breaks down, both acute and chronic inflammatory 
disorders will ensue.2 
Innate immunity is a very important mechanism in defending humans against infectious microbes but in 
some diseases the immune system inappropriately triggers an inflammatory response when there are no 
foreign substances to fight off.3 In these cases, the decompensations are called “autoimmune diseases” 
and the body responds as if normal tissues are infected or somehow abnormal: as result of this response, 
the normal protective immune system of the body causes damage to its own tissues. Thus, immune 
dysregulation exposes patients to life-threatening risks. As known, infection and inappropriate 
inflammatory processes play a central role in many diseases such as asthma, rheumatoid arthritis and 
multiple sclerosis. Moreover, as consequence of the increasing aging of the population, in more 
developed countries it was observed that older people exhibit a natural immune function dysregulation, 
which may be exacerbated in chronic stress conditions.4 In addition, the ongoing emergence of resistant 
bacterial and viral strains to multiple classes of chemotherapeutics increases morbidity, mortality, and 
costs associated with nosocomial infections.5  
Nowadays there is a large number of treatments for inflammatory diseases and many anti-inflammatory 
therapeutic agents have been developed. Unluckily, the most part of currently used anti-inflammatory 
drugs has some limitations due to their interference with pro-inflammatory mediators, whereas less is 
understood about the biochemical processes that resolve inflammation. Principally, selective activation 
of such a pathway might lead to an alternative treatment for inflammation.6 Moreover, identification of 
immunomodulatory agents enhancing innate immune responses represents a promising strategy for 
combating inflammation and infectious diseases and development of bioactive molecules that selectively 
stimulate the innate immune response is an important challenge both for biologists and chemists.7 
 
1.2 White blood cells or leukocytes 
White blood cells (WBCs), or leukocytes, are immune system cells delegated to defend the body against 
both infectious disease and foreign materials.8 There are several different types of white blood cells and 
they all derive from a multipotent cell in the bone marrow, known as a hematopoietic stem cell. 
Leukocytes are found throughout the body, including the blood and lymphatic system (figure 1.1).9 A 
major distinguishing feature of some leukocytes is the presence of granules, so that white blood cells are 
often characterized as granulocytes or agranulocytes. Granulocytes (neutrophils, basophils, eosinophils) 
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are polymorphonuclear leukocytes and they are characterised by the presence in their cytoplasm of 
differently staining granules visible under light microscopy. These granules are membrane-bound 
enzymes which primarily act in the digestion of endocytosed particles through the action of lysosomes. 
 
 
Figure 1.1. The different types of white blood cells and hematopoietic cells from which they derive. 
 
Agranulocytes (lymphocytes, monocytes, macrophages) are mononuclear leucocytes and they are 
characterized by the apparent absence of granules in their cytoplasm. Although the name implies a lack of 
granules, these cells contain lysosomes.10 Some leukocytes migrate into the tissues of the body to take up 
a permanent residence at that location rather than remaining in the blood. Often these cells have specific 
names depending on the tissue in which they settle in but, generically, they are well-known as “fixed 
macrophages” and dendritic cells. 
 
1.2.1 Neutrophils 
Neutrophils are the most abundant type of white blood cells in mammals and form an essential part of the 
innate immune system. They belong to polymorphonuclear leukocytes (PMNs) together with basophils 
and eosinophils (in fact, technically, PMN refers to all granulocytes). Normally found in the blood, 
neutrophils are usually the first responders to microbial infection, defending against bacteria, fungi and 
other inflammatory process.11 Being highly motile, they quickly congregate at the focus of inflammation. 
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Thus, neutrophils are the most common cells recruited in acute phase of inflammation, coming in and 
destroying foreign organisms or substances.12,13,14 Considering their ability to migrate toward the site of 
inflammation, through the blood vessels and the interstitial tissue, following “chemical signals” in the 
process of chemotaxis, neutrophils are recruited in the site of injury within few minutes from trauma and 
they should be considered as the hallmark of acute inflammation.15 Cell surface receptors allow 
neutrophils to detect chemical gradients of molecules such as interleukin-8 (IL-8), interferon gamma 
(IFN-gamma) and complement component 5a (C5a,) which these cells use to direct the path of their 
migration. They are very active in phagocytosing bacteria  and are able to release soluble anti-microbial 
proteins.16,17 As a consequence of their activity and death usually they determine pus formation. 
Moreover, neutrophils express and release cytokines,18 which, in turn, amplify inflammatory reactions 
through several other cell types. 
 
1.2.2 Basophils 
Basophils appear in many specific kinds of inflammatory reactions, particularly those that cause allergic 
symptoms. They can be found in unusually high numbers at sites of infection and play a crucial role in 
both parasitic infections and allergies.19 Basophils are usually chiefly responsible for allergic and 
antigenic response by releasing histamine, proteoglycans (e.g. heparin and chondroitin), proteolytic 
enzymes (e.g. elastase and lysophospholipase), causing inflammation and contributing in this manner to 
the severity of the allergic response. When activated, they also secrete lipid mediators like leukotrienes 
and several cytokines. Histamine and proteoglycans are pre-stored in the cell's granules while the other 
secreted substances are newly generated. Each of these substances contributes to inflammation.20 A 
specific receptor on basophilic cell surface is involved in the IgE binding and the interaction with this 
immunoglobulin involved in parasite defense and allergy confers to the basophils a selective response to 
environmental substances, such as pollen proteins or helminth antigens. Recent studies in mice suggest 
that basophils may also regulate the behavior of T cells and mediate the magnitude of the secondary 
immune response.21  
 
1.2.3 Eosinophils 
Among the immune system components, eosinophils are white blood cells responsible for combating 
multicellular parasites and certain infections.22 Usually they fight viral infections and helminth 
colonization, being slightly elevated in the presence of certain parasites. Eosinophils are also important 
mediators involved in the control of allergy and asthma and are closely associated with the severity of 
disease. In addition, the are frequently involved in many other biological processes, including allograft 
rejection and neoplasia.23 After maturation in bone marrow, eosinophils circulate in blood and migrate to 
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inflamed tissues in response to chemokines and certain leukotrienes (e.g. leukotriene B4).24 Following 
activation by an immune stimulus, eosinophils degranulate and release an array of cytotoxic granule 
cationic proteins that are capable to induce tissue damage and dysfunction.25,26 Their effector functions 
include also production of reactive oxygen species (such as superoxide, peroxide, and hypobromite), 
lipid mediators like the eicosanoids (leukotrienes and prostaglandins),27 growth factors,28,29 cytokines 
and TNF-α.23  
 
1.2.4 Lymphocytes 
Also lymphocytes are white blood cells of the vertebrate immune system and they are much more 
common in the lymphatic system. All lymphocytes originate during haematopoiesis process and, after 
maturation, enter in the circulation and peripheral lymphoid organs (e.g. the spleen and lymph nodes) 
where they survey for invading pathogens and/or tumor cells. The three major types of lymphocyte are 
natural killer (NK) cells, T cells and B cells.30 
NK cells are a part of the innate immune system and play a fundamental role in defending the host from 
both tumors and viral infected cells. They distinguish infected cells and tumors from normal and 
uninfected cells by recognizing changes of the level of a surface molecule called MHC (major 
histocompatibility complex) class I. NK cells are activated in response to a family of cytokines called 
interferons and they release cytotoxic granules which are able to destroy the altered cells.20  
T and B cells are the major cellular components of the adaptive immune response. T cells are involved in 
cell-mediated immunity whereas B cells are primarily responsible for humoral immunity (relating to 
antibodies). B cells mature into B lymphocytes at the level of the bone marrow, while T cells migrate to 
and mature in a distinct organ, called thymus.31 The function of T cells and B cells is to recognize 
specific “non-self” antigens, during a process known as “antigen presentation”. Once these cells have 
identified an invader, they generate specific responses that are tailored to maximally eliminate specific 
pathogens or pathogen infected cells. B cells respond to pathogens by producing large quantities of 
antibodies which neutralize foreign organism like bacteria and viruses. Always in response to pathogens, 
some T cells, called T helper cells (CD4+), produce cytokines that direct the immune response,32 while 
other T cells, called cytotoxic T cells (CD8+), produce toxic granules which induce the death of 
pathogen infected and tumor cells. Following activation, B cells and T cells leave a lasting legacy of the 
antigens they have encountered, in the form of “memory cells”. During all the host life, these memory 
cells will “remember” each specific pathogen encountered, and will be able to determine a strong 
response if the pathogen will be detected again.31 
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1.2.5 Monocytes 
Monocytes are white blood cells that develop in the bone marrow and then go into blood, where they 
circulate for few days to finally migrate into tissues. In response to inflammation signals, they can move 
quickly to the sites of infection and differentiate into resident macrophages and dendritic cells to elicit an 
immune response.33 Monocytes are responsible for phagocytosis of foreign substances in the body and 
this action is performed by using intermediary proteins such as antibodies or complement factors. In 
addition, they are able to directly bind the microbes via pattern-recognition receptors which recognize 
pathogens. Finally, monocytes are also capable to kill infected host cells through antibody recognition in 
a process called “antibody-mediated cellular cytotoxicity”.34,35 
 
1.2.6 Macrophages 
Macrophages are mononuclear leucocytes responsible to protect tissues from foreign substances. When a 
leukocyte enters injured tissues attracted by a range of various stimuli in the process of chemotaxis, it 
undergoes a series of changes to become a macrophage. The majority of macrophages migrate into the 
tissues of the body to take up a permanent residence at that location (“fixed macrophages”), rather than 
remain in the blood. Each type of macrophage has a specific name determined by its location. Some 
examples of this differentiation are the Kupffer cells (in the liver), the histiocytes (in the connective 
tissue), the microglia (in the neural tissue), the mesangial cells (in the kidney), sinusoidal lining cells (in 
the spleen), the osteoclasts (in the bone) and the dust cells (in the lung).20 As a consequence of their 
different fixed location, macrophages are versatile cells that play many roles. They act as phagocytes in 
both non-specific defense (innate immunity) and specific adaptive immunity. Their main roles consist to 
phagocytize necrotic tissues and pathogens, either as stationary or as mobile cells, and to stimulate 
lymphocytes and other immune cells to respond to the pathogen.  
  
1.2.7 Dendritic cells 
Dendritic cells (DCs) are immune cells that, as well as macrophages do, migrate into the tissues of the 
body to take up a permanent residence at that location. As mentioned above, these cells always arise 
from monocytes that depending on the specific signal, can became either dendritic cells or macrophages 
respectively. Dendritic cells can also be found as immature form in the blood,36 but they are usually 
found in lung, stomach, intestine and, in small amount, in tissues that are in contact with the external 
environment, such as the skin. Langerhans cells are indeed a specialized kind of dendritic cells. Their 
main function is to process antigen material and to present it on the surface to other cells of the immune 
system.37 They are the most potent of all the “antigen-presenting cells” and, once activated, they migrate 
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to the lymphoid tissues where they interact with T cells and B cells to initiate and shape the adaptive 
immune response.38 
 
1.3 Leukocytes: involvement in inflammation and infection 
The host defense response of humans is complex and multileveled, involving many cell types with 
distinct but overlapping roles. Leukocyte infiltration is an important feature in host response and defense 
to invading potentially pathogenic organisms and to fight a variety of inflammation processes. 
Phagocytic leukocytes are one of the earliest cell types responding to an inflammatory stimulus and they 
are key participants in innate immune response.39 Leukocytes accumulate at sites of inflammation and 
microbial infection as response to locally produced “chemical signals”.40 In fact their recruitment is 
strictly dependent on the presence of a gradient of chemotactic factors.41 In response to inflammatory 
challenges, phagocytes such as neutrophils, monocytes and macrophages migrate to the site of infection 
in a process of adhesion and transmigration through blood-vessel walls, where they engulf and destroy 
bacteria or other damage stimuli.42 They are usually activated by a wide variety of inflammatory stimuli, 
including cytokines and other endogenous chemical messengers, pathogen-associated molecular 
structures and oligopeptides derived from various pathogens or endogenously produced.43,44 After 
phagocytosis of microorganisms or other particulate substances, leukocytes secrete a variety of mediators 
that possess potent proinflammatory and antimicrobial activities. These mediators include antibiotic 
peptides and proteases which are sometimes stored in granules and are released during the process of 
degranulation.45 Leukocytes perform as well a variety of other complex microbicidal functions, including 
chemotaxis (migration to site of inflammation), margination (rolling and adhesion to vessel walls), 
diapedesis (transmigration across the endothelial barrier),46-47 phagocytosis of foreign particles, 
destruction of targeted organisms and reactive free radicals production.16  
In this scenario, more detailed signalling studies in leukocytes may help to identify new targets for 
potential therapeutic interventions. In addition, future combinatorial therapies with higher selectivity for 
certain leukocyte subsets promise improved approaches for treating acute and chronic inflammatory 
disorders. 
 
1.4 Formyl Peptide Receptors (FPRs) role in inflammation and infection 
Formyl peptide receptors (FPRs) are a small family of chemoattractant receptors and they play an 
essential role in host defense mechanisms against pathogen infection and trauma. In addition, they are 
involved at different levels in the regulation of inflammatory reactions and sensing cellular 
dysfunction.48 These receptors belong to the seven transmembrane domain G-protein-coupled receptor 
(GPCR) family which are expressed in the majority of white blood cells and are known to be important 
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in host defense and inflammation.49 All major neutrophil functions stimulated towards FPRs can be 
inhibited by treatment of the cells with pertussis toxin,42,50 indicating that the G proteins coupled to them 
belong to the Gi family of heterotrimeric proteins.51 Several studies conducted throughout the 1980s led 
to the identification of the formyl peptide receptors as highly promiscuous receptors that can be activated 
by a wide range of structurally unrelated non-peptide and peptide agonists, including synthetic, or both 
host-derived and pathogen-derived agents.42,48,50,52,53 Further investigations resulted in the identification 
of different chemotactic factors derived from bacteria as low-molecular weight peptides having a 
blocked amino terminus group, which were able to bond and activate FPRs. Because prokaryotes initiate 
protein synthesis with N-formyl methionine, short peptides starting with N-formyl methionine (CHOMet) 
were chemically synthesized and tested.54 It was found a potent chemotactic activity for neutrophils in 
many of the synthetic N-formyl peptides tested, especially peptides containing N-formyl-methionyl-
leucine and N-formyl-methionyl-phenylalanine.55 The above findings led Freer et al.56 to propose that the 
N-formyl group is essential for the bioactivity of these chemotactic peptides through interaction with 
FPRs. These studies resulted in identification of N-formyl-methionine-leucine-phenylalanine (fMet-Leu-
Phe, or fMLF) as the most potent agonist among 24 synthetic peptides tested in neutrophil chemotaxis 
assays.57  
Owing to its ability to bind and activate the G protein-coupled formyl peptide receptors (FPRs), the 
tripeptide fMLF became a prototype of formylated chemotactic peptides for neutrophils able to act 
through FPRs activation. At subnanomolar to nanomolar concentrations, this binding event translates 
into directional movement of neutrophils, while at higher concentrations (> 100 nM), the same peptide 
also stimulates bactericidal functions including lysosomal enzyme release,56 degranulation and 
production of superoxide.40,58,59 Because these peptides are derived from bacterial or mitochondrial 
proteins,1,55 it has been proposed that a primary FPR function is to promote trafficking of phagocytic 
myeloid cells to sites of infection and tissue damage, where they exert antibacterial effector functions 
and clear cell debris. In support of this hypothesis, mice lacking a known murine FPR variant were more 
susceptible to bacterial infections.60 Intriguingly, the bactericidal activities triggered by these 
chemotactic peptides contribute to tissue damage when neutrophils are activated in certain different 
pathological conditions. Therefore, an understanding of the pharmacological basis of FPR binding and 
signaling has the potential to enhance anti infective activity as well as to reduce unwanted neutrophil 
activation and the resulting tissue damage.61 
 
1.5 Formyl Peptide Receptors (FPRs) localization and classification 
Three FPR subtypes have been identified till now in humans (FPR1, FPR2/ALX , FPR3), whereas eight 
FPR-related receptors have been discovered in mice (figure 1.2).48 Activation of FPRs induces a variety 
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of responses, which depend on the agonist, cell type, receptor subtype and species involved. The 
receptors of the FPR gene family are primarily found in myeloid cells, but the distribution changes 
within myeloid cell subsets. Indeed, the three different FPRs display a quite different expression profile 
on phagocytic leukocytes (figure 1.2). For example, neutrophils express functional FPR1 and 
FPR2/ALX, while monocytes express all the three receptors at their surface. Differently, monocyte-
derived DCs express FPR1 and FPR3 when immature and only retain FPR3 after maturation.62,63 Many 
studies also indicate the presence of formyl peptide receptors in non-myeloid cells. In this contest, there 
is evidence that FPRs might play different key roles in the activation of the immune system cells and 
functions in different body districts.  
 
 
Figure 1.2. Sequence homology between the FPR family members and their tissue distribution. The predicted 
protein sequences of the three human (h) FPR genes, the eight mouse (m) Fpr genes, and the rabbit (r) FPR1 
gene were compared. Based on sequence homology, the hFPR1, mFpr1, and rFPR1 are in the same cluster. Note 
that some of these genes are not expressed in neutrophils and monocytes. The tissue expression profiles for 
mFpr-rs4, mFpr-rs5, and mFpr-rs8 have not been determined. Mo, monocytes; PMN, polymorphnuclear 
leukocytes; iDC, immature dendritic cells; astro, astrocytes; T, T lymphocytes. Adapted from Ye et al. (2009).49 
 
1.5.1 Formyl Peptide Receptor 1 (FPR1) 
Human FPR1 is a relatively abundant chemoattractant receptor on phagocytic cells and it was first 
defined biochemically in 1976,40 as a high affinity binding site on the surface of neutrophils for the 
prototypic peptide fMLF. Other names used in the literature to define FPR1 include FPR (“classic FPR”) 
and FMLPR (formil-metinine-leucine-phenilalanine receptor).49 Biochemical studies indicated that the 
receptor is a glycoprotein of 55-70 kDa that functionally couples to G proteins for transmembrane 
signalling.64 It was then cloned in 1990 by Boulay et al.65,66 from a differentiated HL-60 myeloid 
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leukemia-cell cDNA library. Cloning of the cDNA for FPR1 identified the receptor to be a single 
polypeptide of 350 amino acids with a typical hydropathy plot pattern for a seven transmembrane 
domain structure.65-68 In transfected cell lines, FPR1 binds fMLF with high affinity (Kd < 1 nM) and it is 
activated by picomolar to low nanomolar concentrations of fMLF in chemotaxis assays.40 Besides being 
expressed on phagocytes (e.g. neutrophils and monocytes) and a small number of non-phagocytic cells 
(e.g. hepatocytes, immature dendritic cells, astrocytes, microglial cells),69 FPR1 has been identified also 
in the tunica media of coronary arteries.40 Using an antibody recognizing the carboxyl terminal 11 amino 
acids of FPR1, Becker et al.70 found immunoreactivity for this subtype of receptor in multiple organs and 
tissues, including epithelial cells in organs with secretary functions, endocrine cells (including follicular 
cells of the thyroid and cortical cells of the adrenal gland), liver hepatocytes and Kupffer cells, smooth 
muscle cells and endothelial cells, brain, spinal cord and both motor and sensory neurons.49 
 
1.5.2 Formyl Peptide Receptor 2 (FPR2 or FPR2/ALX)  
In 1990s several laboratories reported the identification of a cDNA and a gene,71-74 coding for a putative 
seven transmambrane receptor that shares significant sequence homology to human FPR1. Different 
names were given to the gene product, including FPR2/ALX for its low-affinity binding of fMLF,73 
FPRL1 (formyl peptide receptor like1),71 FPRH1 (formyl peptide receptor-homolog 1),74 and “receptor 
related to formyl peptide receptor” based on its sequence homology to the human FPR1.72 Other names 
used in the literature include HM63,75 and FMLF-related receptor II.49 Pharmacological characterization 
has led to the identification of the eicosanoid lipoxin A4 (LXA4),76,77 of aspirin-triggered lipoxins,78,79 
and of a variety of peptides,80 as ligands for this receptor.40,48 Therefore, in addition to FPRL1, which 
frequently appears in the literature, the name ALX (or LXA4R, “Lipoxine A4 receptor”)  has been 
introduced to convey the ability of the receptor to interact with LXA4 and aspirin-triggered lipoxins.81 
FPR2/ALX is a 7TM receptor with 351 amino acids and shares 69% of amino acidic identity with human 
FPR1. Despite the relatively high level of sequence homology with FPR1, FPR2/ALX is a low-affinity 
receptor for fMLF, with a Kd of 430 nM .67,71,73 It has been reported that mitochondria-derived formyl 
peptides are more potent agonists for FPR2/ALX than fMLF,82 suggesting that its primary function may 
be to recognize host-driven mitochondrial peptides or possibly other bacterially derived formyl peptides. 
Human FPR2/ALX has a tissue distribution similar to that of FPR1, but FPR2/ALX is expressed also in 
other cell types, including phagocytic leukocytes, hepatocytes, epithelial cells, T lymphocytes, 
neuroblastoma cells, astrocytoma cells and microvascular endothelial cells.69 These patterns of tissue 
expression suggest that FPR1/FPR2/ALX may also participate in a number of functions other than host 
defense. In addition to formyl peptides and LXA4, FPR2/ALX  is also able to interact with non 
formylated peptides. Compared with FPR1, FPR2/ALX exhibits a high level of ligand promiscuity and it 
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is activated by numerous and chemically unrelated ligands, including synthetic peptides, pathogen 
derived peptides, host-derived peptides, lipids49 and small synthetic compounds.   
 
1.5.3 Formyl Peptide Receptor 3 (FPR3) 
A second gene with significant sequence homology to human FPR1 was identified using a similar 
cloning strategy used to discover FPR2/ALX. This gene encodes for FPR3,49 a putative 7TM receptor of 
352 amino acids initially named FPRL2,71 (formyl peptide receptor-like 2) and FPRH2 (formyl peptide 
receptor-homolog 2),74 taking into account the sequence homology to FPR1. FPR3 shares 56% and 83% 
sequence identity with human FPR1 and FPR2/ALX respectiely. FPR3 does not bind N-formyl 
peptides,83 such as fMLF, but it responds to some non formylated chemotactic peptides identified for 
FPR2/ALX.84,85 Migeotte et al.86 recently reported that a naturally occurring endogenous acylated 
peptide, derived from the N-terminal sequence of heme-binding protein, is a potent agonist for FPR3. 
Unlike FPR1 and FPR2/ALX, FPR3 had been not found in neutrophils.71 This receptor is characterized 
by its specific expression on monocytes and DCs.86 As already seen, monocytes express the three 
receptors at their surface, whereas monocyte-derived DCs express FPR1 and FPR3 when immature and 
only retain FPR3 after maturation.62,63 In particular, in the process of monocyte differentiation into 
immature dendritic cells (DCs), the cellular expression of FPR2/ALX progressively declines,63 whereas 
FPR2/ALX expression remains unchanged during monocyte differentiation into macrophages. There is 
also a progressive loss of FPR1 during differentiation of immature DC to mature DC, such that FPR3 
becomes the predominant human formyl peptide receptor in mature DC.62,86 The biological significance 
of differential expression of formyl peptide receptors in monocytes, macrophages and DCs has not yet 
been clearly defined, but it seems that the three receptors might play key role in the differential migration 
pattern of these antigen presenting cells.86 
 
1.6 FPRs activation and cell functions 
The stimulation of FPRs is regulated at the levels of receptor by G protein activation, transduction and 
amplification of signals through various effectors, including kinases and small GTPases (figure 1.3), and 
integration of effector signals leading to phagocyte functions such as chemotaxis, degranulation, and 
superoxide generation. Regulation of FPRs at the receptor level concern mainly three different processes: 
desensitization, phosphorilation and interaction with β-arrestins, which in turn involve the following 
uncoupling of G proteins and internalization of the receptors (figure 1.4). It is noteworthy that, although 
there are many similarities between FPR1 and FPR2/ALX  (and, perhaps, also FPR3),88 major differences 
exist between these receptors in signalling. 
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Figure 1.3. Signaling pathways of an activated FPR. On agonist binding, trimeric Gi-proteins are uncoupled and 
a series of signal transduction events ensue that result in cell activation and protein kinase C (PKC)-dependent 
desensitization of unrelated chemotactic receptors. CD38 induces the conversion of NAD+ to cyclic ADP-ribose 
(cADPR), which acts at ryanodine receptors to release calcium ions (Ca2+) from intracellular stores. This results 
in a sustained influx of extracellular Ca2+ required for fMLF-induced neutrophil migration. CKR, chemokine 
receptor; DAG, diacylglycerol; IP, inositol phosphate; MAPK, mitogen-activated protein kinase; PI3K, 
phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol diphosphate; PIP3, phosphatidylinositol trisphosphate; 
PKC, protein kinase C; PLA, phospholipase A; PLC, phospholipase C; PLD, phospholipase D; RAC, Rac 
guanine triphosphatase family; SRC, Src-like tyrosine kinases. Adapted from Le et al. (2002).40 
 
Evidence also suggests that the basic mechanism by which these receptors trigger a transient increase in 
intracellular Ca2+ may be different (figure 1.4).89 
 
Figure 1.4. Leukocyte migration cascade via the FPRs family. FPR1 is activated at low concentration of formyl 
peptide (yellow). With increasing concentration of formyl peptide (orange) can also instigate FPR2 signalling. 
FPR activation of leukocytes, results in integrin expression and activation. Adherent leukocytes are an 
interesting therapeutic target for FPR2: interaction with endogenous ligands can lead to either leukocyte 
detachment (AnxA1/LXA4) or tissue accumulation (SAA). High concentration (red) or repeated stimulation by 
formyl peptide can lead to receptor desensitisation. FPRs play distinct role in myeloid cell priming and 
macrophage phagocytosis, mast cell membrane stabilisation. Adapted from Dufton and Perretti (2010). 87 
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1.6.1 Chemotaxis 
FPR1, along with the receptor for C5a, was the first identified phagocyte chemoattractant receptor.90 
Chemotaxis is a multistep process, induced by various chemoattractants such as PAF,91 LTB4,92 C5a 
anaphylotoxin,93 and different chemokines such as the IL8.94 In comparison with “classic 
chemoattractants”, fMLF has predominant properties in cross-desensitization of other receptors,95 and it is 
a potent agonist for stimulating bactericidal functions such as superoxide generation. Once established 
that its responses are induced by activation of specific G-protein-coupled receptors (FPRs) which are 
expressed on target cells, several N-formyl peptides have been extensively studied due to their abilities to 
induce directional migration of neutrophils.96,97 Indeed, human neutrophils are able to detect a 
chemotactic gradient of subnanomolar concentrations of fMLF.56,57 Therefore, exposure of neutrophils to 
a chemotactic agent creates an intracellular gradient of signalling molecules that defines the leading edge 
as well as the direction of cell migration. In addition, several exogenously and endogenously produced 
leukocyte chemoattractants that initiate leukocyte migration and activation have been identified. 
Migrating neutrophils in tissues are then exposed to multiple chemoattractants so that different and 
sometimes conflicting signals can sort out. In this scenario, that “navigation” of neutrophils is considered 
as a multistep process, and a migrating cell not only detects multiple chemoattractants but also integrates 
these different signals.98-100 
A hierarchy in chemotactic signalling, determining the direction of migrating cells in opposing 
chemotactic gradients, have been identified and new insights into the molecular mechanisms that allow 
neutrophils to prioritize chemotactic signals have been provided.101 It resulted evident that “end-target 
chemoattractants” such as fMLF, dominate over the “intermediary chemoattractants” as IL-8 and LTB4. 
The ability of neutrophils to distinguish between these chemoattractants is crucial for their optimal 
migration toward bacteria with minimal interference by the “intermediary chemoattractants” which are 
also present in the inflammatory site.102 Considering all these evidences, it stands to reason to assume that 
net result of cell migration is determined by the type of orienting signals, the strength of the signals and 
the time sequence in which they appear. 
 
1.6.2 Superoxide generation  
Stimulation of neutrophils with fMLF, at concentrations higher than those required for chemotaxis, leads 
to generation of superoxide. In most published studies, fMLF concentrations of 50 to 100 nM are required 
for the induction of superoxide production by human neutrophils in suspension.103,104 Superoxide 
production in neutrophils results from membrane assembly and activation of NADPH oxidase, which is a 
multicomponent enzyme complex for electron transfer, leading to one-electron reduction of molecular 
oxygen.105 The different concentrations required for chemotaxis and superoxide generation, effectively 
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prevent oxidant-mediated tissue injury that may be caused by migrating neutrophils. It is not entirely clear 
why neutrophils require a 50- to 100-fold higher concentration of fMLF for superoxide production with 
respect to chemotaxis, but a high signalling strength is probably necessary for simultaneous activation of 
multiple pathways leading to NADPH oxidase activation in phagocytes. However, several studies 
reported in literature suggest that there are multiple mechanisms for the potentiation of the same 
enzyme.49 It is noteworthy that, when used at low concentrations (e.g., 5 nM), fMLF is unable to 
stimulate neutrophil superoxide production but it can synergize with other neutrophils activators for a 
more robust response and.106   
 
1.6.3 Degranulation  
In addition to the induction of superoxide generation, at higher concentrations (usually 10-50 times higher 
than the optimal concentration for chemotaxis) formyl peptides stimulate the release of granule 
constituents from neutrophils.57,107 The fMLF-induced mobilization of granules produces a variety of 
effects, including proteolytic cleavage of membrane-localized adhesion molecules such as L-selectin, cell 
surface expression of new adhesion molecules and release of proinflammatory proteins and enzymes that 
can cause tissue degradation and killing of bacteria. For instance, neutrophil myeloperoxidases, released 
from the azurophil granules, help to convert hydrogen peroxide to hypochlorous acid,108 a metabolite 
important both for killing invading microbes and for the resolution of inflammation. Moreover, most of 
the membrane associated with NADPH oxidase components are localized on mobilizable granules which, 
if activated, become more available for the assembly of NADPH oxidase it self. Last but not the least, 
there are intracellular pools of FPR1 as well as of FPR2/ALX that are up-regulated to the cell surface 
when cells are stimulated with inflammatory mediators that mobilize the granules.109,110 Degranulation in 
fMLF-stimulated neutrophils involves the second messenger diacylglycerol and PKCs which are 
activated by diacylglycerol and Ca2+.111 However, fMLF is still able to induce secretory granule release 
when extracellular and intracellular Ca2+ is chelated, suggesting the presence of Ca2+ independent 
pathways for degranulation.112 Further investigations will be necessary to determine the cross-talk 
between FPRs and other components taking place in process and their roles in regulating vesicular fusion 
during degranulation.  
 
1.6.4 Transcriptional regulation and anti-inflammatory functions  
Although neutrophils are terminally differentiated myeloid cells with special bactericidal functions, these 
cells retain the ability to synthesize selected proteins, including certain cytokines.113 fMLF has been 
found to stimulate neutrophil transcriptional regulation and cytokine production.114 fMLF-induced IL-8 
secretion is accompanied by the activation of NF-kB, a nuclear factor for transcription of a large number 
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of proinflammatory genes.115 In addition NF-kB activation is also mediated by FPR2/ALX, in response to 
SAA (serum amyloid A) stimulation, which leads to IL-8 secretion.116 These results are consistent with 
the ability of certain GPCRs to regulate transcriptional activation that contributes to the proinflammatory 
activities of the respective ligands.117 In contrast, FPR2/ALX ligands such as LXA4 (lipoxin A4) and 
ANXA1 (annexin A1) exhibit anti-inflammatory activities.76,79 ANXA1 has been shown to cause 
detachment of leukocytes and prevent transendothelial migration (diapedesis).118 In comparison, the anti-
inflammatory effect of LXA4 is shown to involve suppression of proinflammatory gene expression.119 It 
is not entirely clear if this action of LXA4 is mediated through FPR2/ALX-dependent negative signalling 
or blockade of FPR2/ALX binding and activation by an endogenous, proinflammatory agonist for this 
receptor,49 even if it is known that LXA4 can compete off the binding of FPR2/ALX agonists.120 
However, LXA4 stimulation does not lead to calcium mobilization in several types of transfected cells 
neither induce neutrophil degranulation and superoxide generation.121-123 In contrast, LXA4 has been 
shown to activate monocytes.124 The discrepancy suggests that signaling molecules essential for certain 
LXA4-induced functions might be missing in neutrophils and epithelial cells. It also reflects that LXA4 
lacks full agonistic activities at FPR2/ALX. 
 
1.6.5 Neutrophil apoptosis  
Neutrophils released to blood circulation have a half-life of 8 to 10 h. If not activated, these cells are 
destined for apoptosis.125 Stimulation of neutrophils with proinflammatory cytokines such as G-CSF 
(granulocyte macrophage-colony-stimulating factor) and IL-1β, but not with fMLF, C5a, or IL-8, 
prolongs the lifespan of neutrophils.126 Other reports have shown that stimulation of neutrophils with 
fMLF can induce apoptosis and this process requires superoxide generation.127 Neutrophil apoptosis and 
phagocytosis of apoptotic neutrophils are related to resolution of inflammation. Several ligands for the 
formyl peptide receptors are found to play different roles in neutrophil apoptosis. The underlying 
mechanism has not been fully identified, however these results suggest a potential role of FPRs, mainly of 
FPR2/ALX,49 in the regulation of neutrophil apoptosis, but other receptors may be involved as well and in 
the future it will be important to determine how a single class of receptors mediates different functions in 
cell survival and apoptosis when stimulated with different ligands.  
 
1.7 FPRs involvement in several diseases  
Till now, a part from the clear involvement of FPRs in inflammation, host defense against bacterial 
infection and as well as in the clearance of damaged cells, additional and more complex physiological 
functions have been proposed for FPRs. 
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Table 1.1. FPR1 and FPR2/ALX receptor associations with human disease. Adapted from Dufton and Perretti 
(2010).87 
 
Indeed these receptors have been found to interact with a menagerie of structurally different pro- and anti-
inflammatory ligands associated with different diseases (table 1.1 and 1.2), including amyloidosis and 
Alzheimer's disease,128 some kinds of cancers and related alopecia induced by most anticancer 
agents,129,130 prion disease,131 HIV,132-135 and stomach ulcer.136,137 In addition, it is has been demonstrated  
that exogenously administered  fMLF as well as other FPRs agonists can peripherally and centrally 
inhibit the nociceptive transmission associated with inflammatory processes through a mechanism that 
involves formyl peptide receptors.138 
 
 
Table 1.2. FPR2/ALX ligand association with human disease. Adapted from Dufton and Perretti (2010).87 
 
Moreover, these receptors have been proposed as prospective targets for therapeutic intervention against 
malignant gliomas.139 How these receptors recognize so different ligands and how they contribute to 
disease pathogenesis and host defense, are basic questions currently under investigation. 
 
1.8 FPRs ligands  
Ligand diversity is a prominent and unusual feature of the FPRs (table 1.3). With the exception of the 
eicosanoid LXA4, all known FPR family ligands are peptides. More recently, small synthetic molecules 
have emerged from a number of compound library screens as ligands for the formyl peptide 
receptors.40,48,80 Whereas many of the natural agonists and antagonists for FPRs are identified and 
purified from living organisms, a lot of peptides are synthesized based on the sequences of known 
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proteins of microbe and host origins (table 1.3). Whether these peptides are present in vivo and have 
physiological functions has yet to be determined for the most part of them. 
 
 
Table 1.3. Agonists for the human FPRs. The agonists are listed in the order of their potency within each group. The 
mitochondrial N-formylated peptides, listed in the first group, are also host-derived peptides and their potency is expressed in 
table 1.4, as well as the potency of other bacterial N-formylated peptides. Ligands that have been isolated from living 
organisms in the forms listed, and those generated by the actions of physiologically relevant enzymes, are indicated with an 
asterisk (*). aa., amino acid; pIC50, negative logarithm of the IC50; pEC50, negative logarithm of the EC50; pKd, negative 
logarithm of Kd. Adapted from Ye et al. (2009).49 
 
1.8.1 FPRs natural agonists 
A) N-Formyl Peptides. The E. coli-derived tripeptide fMLF (figure 1.5, table 1.4) is the most widely 
used chemotactic peptide for several reasons. It was one of the first characterized synthetic chemotactic 
peptides and has been extensively studied because it is the smallest formyl peptide that displays full 
agonistic activities. Its potency and efficacy in activating major bactericidal functions of neutrophils 
equals that of C5a. Whereas fMLF is by far the most frequently used chemotactic peptide in studies of 
neutrophil functions, this prototypic formyl peptide should not be taken as the sole standard in judging the 
presence of functional formyl peptide receptors.49  
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Figure 1.5. Chemical structures of fMLF, a FPR1 selective agonist. 
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Because bacterial protein synthesis starts with an N-formyl methionine, formyl peptides released from 
bacteria can be considered a type of microbe-associated molecular pattern, recognizable by specialized 
receptors in the innate immune cells of the host, such as the Toll-like receptors (TLRs). These non 
rearranging innate receptors have evolved to aid the host in detecting nonself such as bacterial 
products.140 Ample evidence shows that the formyl peptide receptors can detect not only the E. coli-
derived fMLF but also formyl peptides from other bacteria strains and from mitochondria of the host 
cells. Table 1.4 lists selected bacterial and mitochondrial Formyl peptides that have been characterized 
for their bioactivities. Given the variety of formyl peptides from both bacteria and mitochondria (table 
1.4), it is worthwhile to revisit some previous studies conducted with the use of fMLF and determine 
whether the receptors of interest are, at the present, more selective for formyl peptides of different 
sequences. For example, differently to FPR1, FPR2/ALX was first identified as a low affinity receptor for 
fMLF,82 but it is always able to detect and respond to several different formyl peptides. Moreover 
FPR2/ALX is able to discriminate between N-formyl peptides of different sizes, hydrophobicities, and 
charges.141 The biological relevance of this property of the receptor is not yet entirely understood but it is 
evident that several N-formyl peptides other than fMLF should demonstrate more selective for certain 
receptors (table 1.4). Indeed, although N-formyl peptides are a class of ligands representing a pattern 
recognized by the FPRs,55 there are important differences in potency and receptor selectivity among the 
individual peptides. 
 
 
Table 1.4. Binding affinity and potency of bacterial and mitochondrial formyl peptides. pEC50 is defined as the 
negative logarithm of the EC50 and pIC50 as the negative logarithm of the IC50. HL-60 cells transfected to 
express FPR1 or FPR2/ALX, and Chinese hamster ovary cells transfected to express FPR1 were used in some 
studies. Adapted from Ye et al. (2009).49 
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Furthermore, there are several examples in which addition of an N-formyl group increases agonistic 
activity of the peptides.142 Humanin is an endogenous peptide with neuroprotective activity that also 
binds to FPR2/ALX and FPR3.143,144 For example, when humanin is N-formylated became a more potent 
agonist for these receptors,145 in comparison to its non formilated form. In the latter example, although the 
primary sequences of FPR2/ALX and FPR3 differ considerably from those of FPR1, especially in the 
ligand binding domains,146 these two receptors seem to retain the ability to preferentially interact with 
formylated peptides. Despite their evident importance in FPRs binding, it is not yet known whether these 
peptides are produced in vivo and whether they modulate inflammation. 
 
B) Microbe-derived non-formyl peptides. Despite the absence of an N-formyl group, several different 
peptides have been found as FPRs full agonists (table 1.3).85,137  In this context, it is well known that 
HIV-1 envelope proteins, such us several fragments derived from gp41, contain peptide sequences 
capable of interacting with either or both FPR1 and FPR2/ALX.147-150 V3 peptide is another peptide 
derived from HIV-1 strain that showed to interact with FPRs.151 The existence of these peptides in vivo 
and their biological significance are not known at present. In addition to HIV-1 proteins, other viral 
proteins contain sequences that can work as ligands for FPRs when tested in the form of synthetic 
peptides. gG-2p20, is a peptide present in Herpes simplex virus type 2 (HSV-2), activates neutrophils and 
monocytes via FPR1.152 In addition, the same peptide activates phagocytes to release reactive oxygen 
species that inhibit NK cell cytotoxicity and accelerate apoptotic cell death. Recently, additional peptides 
from coronavirus have been identified as FPR1 ligands.153  
It will be interesting to understand whether and how these peptides are generated during viral infection 
and as well the functional consequences of phagocyte response to these peptides.  
 
C) Host-derived peptides. In addition to mitochondrial formyl peptides discussed above, a large number 
of endogenous peptides of various compositions (table 1.3), often without an N-formyl group, have been 
identified as agonists for the formyl peptide receptors, especially FPR2/ALX. Of particular interest are 
peptides associated with amyloidogenic diseases, peptides associated with inflammatory and antibacterial 
responses, and a peptide derived from heme-binding protein which acts as a potent endogenous FPR3 
agonist.49 
At least three amyloidogenic polypeptides, associated with chronic inflammation and amyloidosis, have 
been identified as FPR2/ALX agonists. Serum amyloid A (SAA) is an acute-phase protein whose serum 
concentration is increased by as much as 1000-fold in response to trauma, acute infection and other 
environmental stress causing acute-phase responses.154 Studies with recombinant human SAA identified it 
as the first mammalian hostderived chemotactic peptide ligand for FPR2/ALX.121 SAA, acting through 
1. Introduction 
 21 
FPR2/ALX, is chemotactic for monocytes, neutrophils, mast cells, and T lymphocytes. In addition this 
protein stimulates production of metalloproteases and cytokines and increases expression of cytokine 
receptors. In neutrophils, SAA activates FPR2/ALX and induces IL-8 secretion.116 In monocytes, SAA 
shows a peculiar pattern of cytokine induction via FPR2/ALX. Moreover, the cells respond to low 
concentrations of SAA by producing TNF-α while releasing IL-10 in response to high concentrations of 
SAA.155 The synovial tissues of patients with inflammatory arthritis express high levels of SAA and 
FPR2/ALX and the protein induces the expression of matrix metalloproteinase-1 and -3 in fibroblast-like 
synoviocytes.156,157 Furthermore, SAA promotes synovial hyperplasia and angiogenesis through 
activation of FPR2/ALX and,158 in addition to using the formyl peptide receptors, SAA activates 
neutrophil NADPH oxidase through a different receptor.159  
Another peptide, the 42-amino acid form of β-amyloid peptide (Aβ42), which is a cleavage product of the 
amyloid precursor protein in the brain and a pathologic protein in Alzheimer’s disease, was also found to 
activate FPR2/ALX.160,161 An additional amyloidogenic disease-associated FPR2/ALX agonist is 
represented by the prion protein fragment PrP(106–126), which is produced in human brains with prion 
disease.162 FPR2/ALX mediates the migration and activation of monocytic phagocytes, including 
macrophages and brain microglia, induced by β-amyloid (Aβ).160,163 Moreover, prolonged exposure of 
FPR2/ALX to this fragment peptide results in accumulation of the Aβ42 and culminates in progressive 
fibrillary aggregation of Aβ42 and macrophage death.164 Therefore, FPR2/ALX not only mediates the 
proinflammatory activity of the peptide agonists associated with amyloidogenic diseases, but it also 
participates to the regulation of fibrillary peptide formation and deposition, which contribute to tissue and 
organ destruction.128 The in vivo significance of this action for the pathogenesis of Alzheimer’s disease is 
not yet known.  
Humanin is a peptide encoded by a cDNA cloned from a relatively healthy region of an Alzheimer’s 
disease brain.165 Both secreted and synthetic humanin peptides protect neuronal cells from damage by 
Aβ42. Humanin uses human FPR2/ALX and FPR3 as functional receptors to induce chemotaxis of 
mononuclear phagocytes.166,167 In addition, humanin reduces aggregation and fibrillary formation by 
suppressing the interaction of Aβ42 with mononuclear phagocytes through FPR2/ALX. Moreover, human 
neuroblastoma cell lines express functional FPR2/ALX but not FPR1. In these cells, although humanin 
and Aβ42 both activate FPR2/ALX, only Aβ42 causes apoptotic death of the cells, a process blocked by 
humanin. These observations suggest that humanin may exert its neuroprotective effects by competitively 
inhibiting the access of Aβ42.167 
Urokinase-type plasminogen activator (uPA) is a serine protease known for its ability to regulate 
fibrinolysis binding to a specific high affinity surface receptor (uPAR). In addition to this action, the 
uPA-uPAR system is crucial for cell adhesion, migration and tissue repair. A cleaved soluble uPAR 
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fragment (D2D388–274) binds and activates FPR2/ALX in monocytes, inducing cell migration.77 The 
ability of cleaved soluble uPAR (c-suPAR) to activate other members of the FPR family has been 
reported. For instance, a peptide corresponding to residues 88 to 92 of uPAR, binds to and activates 
FPR1.168 Another fragment induces basophil migration by activating both FPR2/ALX and FPR3.136 
Recent studies showed that pretreatment of monocytes with the FPR2/ALX agonist D2D388–274 
strongly decreases chemokine-induced integrin-dependent rapidcell adhesion,169 indicating that FPRs 
regulate leukocyte chemotaxis at multiple levels and other than mediate cell migration, they may suppress 
cell responses to chemokines by desensitizing chemokine receptors.  
Furthermore, FPRs interact with several bactericidal peptides contained in human neutrophil granules. 
LL-37, an enzymatic cleavage fragment of the neutrophil granule protein cathelicidin, is an agonist for 
FPR2/ALX.170 LL-37 is expressed by leukocytes and epithelial cells and secreted into wounds and into 
the airway surface. In addition to its microbicidal activity, LL-37 induces directional migration of human 
monocytes, neutrophils, and T lymphocytes, a function mediated by FPR2/ALX. Recent studies showed 
that LL-37-induced angiogenesis is mediated by FPR2/ALX in vascular endothelial cells.171 LL-37 seems 
to be a multifunctional peptide with a central role in innate immunity against bacterial infection and in the 
induction of arteriogenesis.  
Another antibacterial granule protein, cathepsin G, which is a serine protease and participates in wound 
healing, is identified as a specific FPR1 agonist and it is considered responsible for chemotactic activity 
in phagocytes.172 
Annexin A1 (ANXA1) and its N-terminal peptides have interesting properties in activating formyl 
peptide receptors by playing a dual role in inflammatory host responses. ANXA1 (also termed lipocortin 
I) is a glucocorticoid-regulated, phospholipid-binding protein of 37 kDa that possesses both pro- and anti-
inflammatory activity, in part mediated by FPR1.173 Expressed in a variety of cell types, ANXA1 is 
particularly abundant in neutrophils. The protein is primarily cytosolic, but it may also be secreted 
through a non classic secretory process and found on the outer cell surface, causing leukocyte detachment 
and thereby inhibiting their transendothelial migration. At low concentrations, both ANXA1 holoprotein 
and its N-terminal peptides (Ac2–26 and Ac9–25) elicit Ca2+ transients through FPR1 without fully 
activating the MAPK pathway, causing neutrophil desensitization and inhibition of transendothelial 
migration induced by other chemoattractants such as the chemokine IL-8. In contrast, at high 
concentrations, the ANXA1 peptides fully activate neutrophils in vitro and they become potent 
proinflammatory stimulants. The antimigratory activity of exogenous and endogenous ANXA1 has been 
shown in both acute and chronic models of inflammation.118 Other studies have shown that the ANXA1 
N-terminal peptides use FPR2/ALX for its anti-inflammatory actions.76 These peptides are also ligands 
for FPR3.173 The utilization of the FPRs by ANXA1 and its amino terminal peptides for their various 
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function is a complex issue. To this end, one published report demonstrates that Ac9–25 stimulates 
neutrophil NADPH oxidase activation through FPR1, but its inhibitory effect is mediated through a 
receptor other than FPR1 or FPR2/ALX,174 suggesting the presence of additional receptors for ANXA1 
and its peptides. 
F2L is a highly potent and efficacious human FPR3 agonist peptide.86 It is an amino-terminally acetylated 
peptide resulting from the natural cleavage of human heme-binding protein, an intracellular tetrapyrrole-
binding protein. The peptide binds and activates FPR3 in the low nanomolar range, triggering typical G 
protein-mediated intracellular calcium release, inhibition of cAMP accumulation and phosphorylation of 
the ERK 1/2MAPKs. F2L also chemoattracts and activates monocyte-derived DCs. Thus, F2L seems to 
be a novel and unique natural chemotactic peptide for FPR3 in DCs and monocytes, in agreement with 
the selective expression of FPR3 in these cells.62 F2L may play a role in linking innate and adaptive 
immune responses by activating antigen-presenting DCs, which express little FPR1 and FPR2/ALX.  
 
D) Host-derived nonpeptide agonists. LXA4 (5S,6R,15S-trihydroxy-7,9,13-trans-11-eicosatetraenoic 
acid, figure 1.6) is a potent mediator biosynthesized from arachidonic acid. It is a small molecule with 
physical and chemical properties that differ from the most part of lipids: it has a unique structure and 
belongs to a class of conjugated tetraene containing eicosanoids that display stereoselective and highly 
potent anti-inflammatory effects in vivo, together with pro-resolving activities in many mammalian 
systems.175  
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Figure 1.6. Chemical structures of LXA4, a highly selective agonist for FPR2/ALX. 
 
This aspect is unusual since the most part of eicosanoids are pro-inflammatory. As an endogenous 
mediator, LXA4 displays multilevel control of relevant processes in acute inflammation through specific 
and selective actions on multiple cell types via specific receptors.176 In particular, LXA4 has been 
reported to directly interact with human FPR2/ALX and in addition it is the first identified endogenous 
ligand for this receptor (table 1.3). LXA4 has showed to be responsible for the specific LXA4 functions 
in neutrophils.177 In fact, it stimulates rapid (within seconds) phospholipase activation in these cells and 
this event directly correlates with the induction time course of specific LXA4 binding.178,179 In cell line 
HL-60, when differentiated into neutrophils, LXA4 gives high-affinity binding with FPR2/ALX as well 
as ligand selectivity, compared with other eicosanoids including LXB4, leukotriene B4, leucotriene D4, 
and PGE2. Each of the actions of LXA4 proved to be stereoselective, because double bond isomerization 
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and alcohol chirality (R or S), as well as dehydrogenation of alcohols and reduction of double bonds, are 
associated with changes in potency. Elimination of the carbon 15 position alcohol from LXA4, denoted 
15-deoxy-LXA4, is essentially inactive in vivo and does not stop either neutrophil transmigration or 
reduce adhesion.175 Moreover, several in vivo studies have shown that nanogram amounts of LXA4 stops 
neutrophil infiltration and blocks human neutrophil transmigration across mucosal epithelial cells and 
vascular endothelial cells.79,180-186 One of the mechanisms by which it inhibits neutrophil infiltration is the 
induction of NO production, which suppresses leukocyte-endothelial cell interaction.187 LXA4 inhibits as 
well TNFα-induced production of cytokines (IL-1β and IL-6),188 chemokines (IL-8),189 and consequently 
decreases LPS induced secretion of IL-1β, IL-6, and IL-8.190 Dendritic cell production of the 
immunomodulatory cytokine IL-12 is also regulated by LXA4.191,192 In addition to its inhibition of 
proinflammatory cytokine production, LXA4 plays a role in regulating inflammation-induced pain.193 
This function is probably mediated through alteration of spinal nociceptive processing via astrocyte 
activation. LXA4 also stimulates non phlogistic phagocytosis of apoptotic neutrophils, which accelerates 
the clearance of neutrophils and promotes resolution of inflammation.194 These examples show that, in 
general terms, LXA4 actively inhibits many endogenous processes which can amplify local acute 
inflammation, leading to potent anti-inflammatory as well as pro-resolving actions in vivo. The multilevel 
control by LXA4 on relevant processes of acute inflammation raises the intriguing question of how 
LXA4, binding to FPR2/ALX, might translate into the anti-inflammatory and pro-resolving activities and 
whether other receptors contribute to these activities.49  
 
 1.8.2 Agonists from peptide library 
Using combinatorial peptide library screens, a number of peptides have been identified as potent agonists 
for the formyl peptide receptors (table 1.3). WKYMVm, a hexapeptide representing a modified sequence 
isolated from a random peptide library, was found to be a highly efficacious stimulant for human B 
lymphocytes, monocytic cell lines and blood neutrophils.195 WKYMVm binds to FPR1, FPR2/ALX, and 
FPR3 for activation of human phagocytic cells.196,197 WKYMVm is by far the most potent peptide agonist 
for FPR2/ALX, with an EC50 well within the picomolar range in chemotaxis assays. WKYMVM, a 
derivative of WKYMVm with a L-methionine at the carboxyl terminus, is a highly selective agonist for 
FPR2/ALX and it is also a weaker activator of FPR3.84 A recent study investigated the relationship 
between FPR1 and FPR2/ALX, both found in neutrophils, in mediating the WKYMVm-stimulated 
cellular functions. It was found that WKMYVm activates neutrophils through FPR1 only when the signal 
through FPR2/ALX is blocked,198 suggesting its affinity for one type of receptor despite the presence of 
two different types of receptors in neutrophils. WKYMVm also inhibits LPS-induced maturation of 
human monocyte-derived dendritic cells via FPR1 and FPR3.197  
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The peptide MMK-1 was identified from a library screen and it was found to be a highly selective 
FPR2/ALX chemotactic agonist. 199-200 Furthemore, an additional peptide FPR1 agonist was identified 
from a library based on the activation mechanism of the thrombin receptor PAR-1.201 This peptide 
becomes 1000 times more potent when N-formylated, confirming the preferential recognition of N-
formylmethionine-containing peptides by FPR1.  
 
1.8.3 Agonists from nonpeptide library: synthetic small molecules 
Several laboratories have recently identified ligands for the FPRs through the screening of combinatorial 
libraries consisting of synthetic, non-peptide compounds. These synthetic small molecules belong to 
different chemical classes (figure 1.7) and are highly selective for either FPR1 or FPR2/ALX, providing 
useful tools for the characterization of formyl peptide receptors. A small molecule named Quin-C1 
(figure 1.7) with a quinazolinone scaffold was the first reported as a highly selective FPR2/ALX 
agonist.61 Quin-C1 (4-butoxy- N-[2-(4-methoxy-phenyl)-4-oxo-1,4-dihydro-2Hquinazolin-3-yl]-
benzamide) induces chemotaxis and secretion of β-glucuronidase in peripheral blood neutrophils with a 
potency approximately 1000 fold lower in comparison with WKYMVm, which is the most potent 
FPR2/ALX agonist identified till now. However, unlike most FPR2/ALX peptidic agonists, Quin-C1 did 
not induce substantial neutrophil superoxide generation, even at high concentrations (up to 100 µM). The 
structural basis for this particular agonistic activity is still unknown but it appeared attractive for its 
potential use as a therapeutic agent.  
A series of pyrazolone compounds were initially identified from a cell-based assay for high-throughput 
screening and subsequently modified.202,203 These ligands are also highly selective for FPR2/ALX and 
exhibit anti-inflammatory properties in mouse. Some pyrazolones belonging to this series were able to 
stimulate calcium flux in transfected cells expressing FPR2/ALX and the most interesting term, 
compound 43 (table 1.3 and figure 1.7), was formulated for oral administration and was found to 
significantly reduce inflammation in a mice model assay.  
 
O
O
NH
O
N O
OHN N
O
O
N
H
O
O
Quin-C1
N
N
O
H
N
O
H
N
Cl
Compd 43 AG-14
 
Figure 1.7. Chemical structures of selected small-molecule ligands for the formyl peptide receptors. Despite 
their abilities to bind to FPR1 and/or FPR2/ALX, these ligands have quite different structures. Quin-C1, and 
compound 43 are highly selective agonists for FPR2/ALX, whereas AG-14 is selective for FPR1.  
 
Using a strategy combining computer model-based virtual screening and high-throughput no-wash 
cytometry screening, from an initial pool of 480,000 compounds, 30 leads were identified as FPR1 partial 
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agonists or antagonists.139 The pharmacophore model for FPR1 developed in this study may be useful in 
future identification of agonists and antagonists for this class of receptors.  
Starting from a neutrophil superoxide production assay, combined with substructure screen, fragment 
focusing and structure-activity relationship analyses, t-butyl benzene and thiophene-2-amide-3-carboxylic 
ester derivatives were identified as potential agonists for neutrophil chemoattractant receptors.204 Among 
these compounds it emerged AG-14 (figure 1.7 and table 1.3) which was found to be able to activate 
neutrophils at nanomolar concentrations. Based on desensitization and antagonist inhibition data, the 
investigators concluded that AG-14 is a FPR1 agonist.  
Arylcarboxylic acid hydrazide derivatives were identified by the same investigators as agonists for 
FPR2/ALX that induce de novo production of TNF-α through activation of macrophages.205 
All these studies further demonstrate that agonists of FPR1/FPR2 include compounds with wide chemical 
diversity. The computational studies regarding both the pharmacophore models of FRRs and the 
structure-activity relationships analysis, 206-207 widely confirm the hypothesis that analysis of such diverse 
compounds can help to better understand the ligand/receptor interaction features.  
 
1.8.4 FPRs antagonists 
Early studies showed that replacing the formyl group of fMLF with tertiary butyloxycarbonyl group (t-
Boc) renders the peptide of antagonistic activity (table 1.5). t-Boc-Met-Leu-Phe (Boc1) and t-Boc-Phe-
D-Leu-Phe-DLeu-Phe (Boc2) are two frequently used antagonists for FPR1, with pIC50 values of 6.19 
and 6.59 respectively.56 In several recent studies, Boc2 was used at high concentrations (e.g., 100 µM) for 
inhibition of FPR2/ALX.208,209 A different study has shown that, when used at low micromolar 
concentrations, both Boc1 and Boc2 are selective FPR1 antagonists; at high micromolar concentrations, 
Boc2 partially inhibits FPR2/ALX in addition to FPR1.210 Therefore, the antagonistic effect of Boc2 at 
high concentrations is not specific for FPR2/ALX.  
Cyclosporin H (CsH) is a cyclic undecapeptide produced by fungi and it displays selective antagonistic 
activity at human FPR1.211 Studies have shown that CsH is 14-fold more potent than the tertiary 
butyloxycarbonyl analogs of formyl peptides such as Boc2 in FPR1 binding assays, and approximately 5-
fold more potent than Boc2 in the inhibition of fMLF-induced calcium flux and enzyme release.212 CsH is 
an inverse agonist (negative antagonist) that suppresses the constitutive activity of FPR1.213 The 
biological significance of constitutive activity for FPR is not established. Both Boc2 and CsH 
competitively displace FPR1-bound fMLF, indicating that its antagonistic activity is mediated through 
inhibition of fMLF binding. CsH did not displays any detectable inhibitory effect on FPR2/ALX-
mediated cellular functions.  
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Table 1.5. Antagonists for the human formyl peptide receptors. Antagonists for the FPRs are listed in the 
order of their approximate potency, except that antagonists of same types are listed together. t-Boc, N-tert-
butoxycarbonyl group; i-Boc, -butoxycarbonyl group; pIC50, negative logarithm of the IC50; pKi, negative 
logarithm of Ki; N.D., binding affinity or potency was not determined. Adapted from Ye et al. (2009).49 
 
Endogenous FPR1 antagonists have been as well identified. Spinorphin, an opioid, is an endogenous 
peptide antagonist for FPR1 with a pIC50 of 4.30.214,215 The bile acids deoxycholic acid (DCA) and 
chenodeoxycholic acid (CDCA) are two other identified FPR1 antagonists.216,217 Chemotaxis inhibitory 
protein of S. aureus (CHIPS) is a bacteria-derived protein of 14.1 kDa found in more than half of the 
clinical strains of S. aureus. CHIPS showed antagonistic activity for FPR1.218 The identification of a 
bacteria-derived FPR1 antagonist suggests a mechanism used by microorganisms to thwart host defenses. 
Indeed, the same researchers in a subsequent study reported the identification from S. aureus of a 105-
amino acid protein, termed FPRL1 inhibitory protein (FLIPr), that selectively inhibits the binding of and 
activation by FPR2/ALX agonists including MMK-1, WKYMVM, the prion fragement PrP106–126, and 
amyloid peptide Aβ1–42.123 At higher concentrations, FLIPr also inhibits fMLF binding to FPR1. FLIPr 
was found to bind directly FPR2/ALX and FPR1, but not FPR3. The biological function of this inhibition 
has not been identified.  
Quin-C7 (table 1.5 and figure 1.8) is a synthetic, nonpeptide FPR2/ALX antagonist, developed through 
chemical modification of the FPR2/ALX agonist Quin-C1.219  
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Figure 1.8. Chemical structures of Quin-C7 and Quin-C1, a synthetic pair of antagonist/agonist ligands for 
FPR2/ALX.  
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In binding assays, Quin-C7 inhibited iodinated WKYMVm binding to FPR2/ALX. This antagonist 
showed to be highly selective for FPR2/ALX. In summary, several FPR1 and FPR2/ALX antagonists 
have been identified and characterized. It is noteworthy that, in most cases, these antagonists differ 
considerably from the identified FPR1 and FPR2/ALX agonists. The observation that t-Boc peptides are 
antagonists while N-formyl peptides of the same or similar composition are agonists may be helpful to 
define the binding pocket of these peptides in FPR1. For the same reason, the synthetic nonpeptide 
antagonist Quin-C7 (figure 1.8), differing from the agonist Quin-C1 (figure 1.7) only in the para position 
of the phenyl ring,219 provides a potentially useful tool in study the binding properties of FPR2/ALX. 
 
1.9 FPRs: future  
It is clear that FPR family can convey a large variety of signals, thereby affecting an ever-increasing 
number of biological functions. The study of endogenous ligands for FPRs provides evidence of both 
activatory and inhibitory responses in experimental settings and validate endogenous anti-inflammation 
for successful drug discovery programs. However, the characterisation of the pharmacological properties 
of synthetic agonists for these receptors strongly suggests a prominent role in inflammation and in general 
in host defence context. The overarching hypothesis is that compounds that are able to mime specific 
pathways operative in the host to down-regulate inflammation could present beneficial reductions in side 
effects of potential therapeutics. 
In this scenario, the identification and development of small-molecules represent an ideal strategy to 
clarify FPR structures and functions, since such molecules are well defined and can be easily modified for 
structure-activity relationships (SAR) analysis. Moreover, this approach may provide a basis for 
construction of useful pharmacophore models of FPR ligands and contribute to the development of an 
innovative approach to modulate host defence in inflammatory pathologies. 
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The overall aim of this project is to exploit the versatility and usefulness of heterocyclic chemistry to 
generate a library of compounds able to act as FPRs agonists. Over the past thirty years, Prof. Dal Piaz 
and co-workers have shown that heterocyclic compounds such as isoxazoles, pyridazines, pyridazinones, 
pyrimidines, phtalazinones and pyrazoles, are good candidates to develop small molecules which achieve 
a high interaction with different biological systems.220-232 Taking advantage of these previous experiences 
acquired in these researches, a similar approach was undertaken to generate a number of FPRs agonists. 
To achieve this goal, it was initially necessary to identify in literature a lead compound working as FPRs 
agonist, and then to synthesize some different series of heterocyclic compounds.  
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Figure 2.1. The key reference molecules used as leads in ligand-based drug design approach for the synthesis of 
FPRs agonists.  
 
Thus, in the first instance, our project was based on the structural analysis of “Quin-C1” (figure 2.1),61,219 
the first synthetic compound reported in literature as FPR2 selective ligand; moreover, we took into 
account also some pyrazolone derivatives, which were among the most potent small molecules discovered 
as FPRs agonists (figure 2.1).202,203 
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Figure 2.2. Some examples of compounds designed and synthesized using different nitrogen heterocyclic 
scaffold and bearing the functional groups strictly required for the activity of the reference molecules.  
 
Thus, following a ligand-based drug design approach, we synthesized several series of nitrogen 
heterocyclic derivatives (figure 2.2) characterized by geometric, electronic, steric and lipophilic 
properties similar to that of the reference compounds. The aim of this approach was to allow the rapid 
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identification of the appropriate scaffold bearing the suitable substituents able to interact with the FPRs 
system. Thus the activity of the synthesized compounds was tested on HL-60 cells transfected with FPR1, 
FPR2 and FPR3 respectively. The biological tests were performed by Prof. Quinn and co-workers of 
Veterinary Molecular Biology Department, Montana State University. In this initial screening we luckily 
were able to identify compound 46a (scheme 12 in section 3 and table 4.1 in section 4), a potent mixed 
FPR1/FPR2 agonist.233 Thus, 46a became our lead compound, on which we planned to perform extensive 
structure-activity relationship (SAR) studies by modifying the nature and the length of the functionalized 
side chain and by changing as well the substituents and their position on the pyridazinone ring (figure 
2.3). Moreover, several groups were introduced to replace Br and OCH3 on both the aromatic systems of 
the lead compound. 
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Figure 2.3. Modification performed on the lead compound (46a, scheme 12, table 4.1). 
 
Once the reactions on the pyridazinone ring have been optimized, a small library of analogues was 
designed and synthesized in order to achieve a convenient chemical diversity on this scaffold (figure 2.3).  
The introduction of a chiral center on the phenylacetamide linker at N-2 position of the lead compound 
(figure 2.4), represent an additional project which led to the development of a new series of chiral and 
branched derivatives. 
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Figure 2.4. Homologue series of chiral derivatives. 
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During this research, the preliminary biological results prompted us to prepare and test as well the pure 
enantiomers in order to see if the enantioselectivity could produce an increase of the activity and/or 
selectivity. Since asymmetric synthesis did not allow us to obtain the pure enantiomers, chiral HPLC 
purification was performed to obtain both enantiomerically pure compounds. The analytical work was 
carried out in collaboration with Dr. Bartolucci and co-workers of Pharmaceutical Sciences Department, 
University of Florence. 
In the present thesis are reported the results of these chemical efforts as well as the biological activity of 
the novel synthesized molecules.  
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Initial investigations in the FPRs agonists field have been focused on the synthesis of small molecules 
based on different heterocyclic scaffolds, such as indole, indazole, quinoline, naphtyridone, 
phthalazinone, phthalhydrazide and pyridazinone (section 3.1). Using this approach a relevant number of 
functionalised aryl-substituted heterocycles were prepared in moderate to good yields. Among them a 
pyridazinone derivative (46a, scheme 12) was found to be an interesting FPR1/FPR2 mixed agonist 
(section 3.2).233 Therefore, the next progress of the project, concerned the optimization of the selected 
lead compound by modifying the position of the substituents on the pyridazinone ring and the nature and 
the length of the functionalized side chain (section 3.3). 
 
3.1 Investigating different heterocyclic scaffolds 
3.1.1 Synthesis of indole and indazole derivatives 
Indoles and indazoles 2a-d and 3a-h can be easily prepared in two steps using respectively the 
commercially available indole-3-carboxylic acid and indazole-3-carboxylic acid as starting material 
(scheme 1). These compounds were first treated with SOCl2, in presence of Et3N, to afford the 
intermediate acid chlorides. Addition of 4-butoxyaniline generated the corresponding amides 1a,b which 
in turn were transformed into the final compounds 2a-d, under coupling conditions with the appropriate 
phenylboronic acid in presence of Cu(OAc)2. Finally, the target compounds 3a-h were prepared by 
classical alkylation with the opportune benzyl halide. 
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Scheme 1. Reagents and conditions: A) SOCl2 (27 equiv), Et3N (catalytic), 1 h, 60 °C, then 4-n.butoxyaniline 
(2 equiv), anhydrous THF, 12 h, rt; B) 3- or 4-methoxy-phenylboronic acid (2 equiv), Cu(OAc)2 (1.5 equiv), 
Et3N (2 equiv), CH2Cl2, 5-12 h, rt; C) substituted benzyl halide (1.1 equiv), K2CO3 (2 equiv), anhydrous 
acetone, 2-10 h, reflux. 
 
In schemes 2 and 3 are depicted the synthetic pathways to prepare two “indomethacin-like” analogues. 
The amide intermediate 4 was obtained by coupling the 3-indoleacetic acid with 4-bromoaniline,234 both 
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commercially available, using DCC to activate the carboxylic group. The following alkylation with 3-
methoxybenyl chloride gave the final compound 5. 
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Scheme 2. Reagents and conditions: A) 4-bromoaniline (1 equiv), DCC (1 equiv), anhydrous CH2Cl2, 24 h, rt; 
B) 3-methoxybenzyl chloride (1.5 equiv), K2CO3 (2 equiv), anhydrous acetone, 4 h, reflux. 
 
The same coupling reaction with 4-bromoaniline was also carried out on indomethacin to give the final 
compound 6.  
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Scheme 3. Reagents and conditions: A) 4-Bromoaniline (1 equiv), DCC (1 equiv), anhydrous CH2Cl2 , 24 h, rt. 
 
3.1.2 Synthesis of quinoline derivatives 
Final compounds 8a-d with quinoline scaffold were prepared in two steps (scheme 4): the commercially 
available 3-aminoquinoline was firstly alkylated with the suitable substituted benzyl halide in standard 
conditions to give intermediates 7a-d which, in turn, by treatment with the 4-n.butoxyphenyl isocyanate 
afforded the desired urea derivatives 8a-d. 
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Scheme 4. Reagents and conditions: A) substituted benzyl halide (2 equiv), K2CO3 (2 equiv), anhydrous 
acetone, 3-7 h, 60 °C; B) 4-n.butoxyphenyl isocyanate (1.1 equiv), anhydrous CH2Cl2, 3-8 h, rt. 
 
3.1.3 Synthesis of naphtyridone derivatives 
The synthesis of naphtyridone scaffold 10 (scheme 5),235 was performed starting from commercially 
available 2-amino-6-methylpyridine and diethyl-2-(ethoxymethylene)malonate, followed by thermal ring 
closure of the diethyl-(6-methyl-2-pyridylaminomethylene)malonate 9.236 To prepare the final compounds 
14a,b and 16a,b, the intermediate 10 was coupled with the appropriate phenylboronic acid in presence of 
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Cu(OAc)2. An alkaline hydrolysis of the ester group afforded the carboxylic acids 12a,b which were 
converted in the acid chlorides using SOCl2. 4-Butoxyaniline was then added to intermediates 13a,b to 
give the final amides 14a,b.  
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Scheme 5. Reagents and conditions: A) 6 h, 100 °C; B) diphenyl ether, 0.5 h, 270 °C; C) 3- or 4-
methoxyphenylboronic acid (2 equiv), Cu(OAc)2 (1.5 equiv), Et3N (2 equiv), CH2Cl2, 15-20 h, rt; D) NaOH 6N, 
EtOH, 0.5-1 h, rt; E) SOCl2 (27 equiv), Et3N (catalytic), 2-3 h, rt; F) 4-n.butoxyaniline (2 equiv), anhydrous 
THF, 2 h, rt; G) SOCl2 (27 equiv), Et3N (catalytic), 2-3 h, 60 °C; H) see F; I) substituted benzyl halide (1.1 
equiv), K2CO3 (2 equiv), anhydrous acetone, 5-7 h, 60 °C; J) see D; K) 4-n.butoxyaniline (1 equiv), DCP (4 
equiv), Et3N (catalytic), anhydrous DMF, 15 h, rt. 
 
It is worth noting that treatment of the acids 12a,b with SOCl2, followed by heating at 60 °C afforded the 
corresponding trichloromethyl acid chlorides 15a,b. Indeed, it is well known in the literature that 
compounds such as 2-methylpyridines,237 2-methylquinolines,238 2-methyl-4(1H)-quinolones,239 react 
with different chlorinating agents to give the corresponding trichloromethyl derivatives.240 In our case, 
15a,b, were transformed into the final 16a,b (scheme 5) in moderate yields, monitoring the reactions by 
TLC, and the products were characterized by 1H NMR and MS spectroscopy. The synthesis of the final 
compounds 19a-c was performed in standard condition starting from the intermediate 10, through 
alkylation and alkaline hydrolysis, to give the carboxylic acids 18a-c. In the last step 18a-c were treated 
with the appropriate amine at room temperature in anhydrous DMF, using a catalytic amount of Et3N and 
diethyl cyanophosphonate (DCP) to activate the carboxylic group (scheme 5). 
In scheme 6 it is showed the synthetic pathway to prepare two nalidixic acid derivatives. The treatment of 
nalidixic acid with ethyl chloroformate, in THF and in presence of triethylamine, afforded the 
intermediate mixed anhydride, which was transformed into the final amide 20. On the contrary, 
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compound 21 was obtained using the same reaction sequence performed for the trichloromethyl 
analogues 16a,b (scheme 5). 
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Scheme 6. Reagents and conditions: A) ethyl chloroformate (1.1 equiv), Et3N (3.5 equiv), 4-bromoaniline (2 
equiv), anhydrous THF, 12 h, -5 °C → rt; B) SOCl2 (27 equiv), Et3N (catalytic), 2 h, 60 °C,  then 4-
n.butoxyaniline (2 equiv), anhydrous THF, 2 h, rt. 
 
3.1.4 Synthesis of phthalazinone derivative 
The synthetic route employed to obtain the phthalazinone derivative 23 is depicted in scheme 7. The 4-
bromoaniline was converted in good yield to the known phenylamide intermediate 22 following a 
procedure reported in literature.241 Alkylation in standard conditions of the phthalazin-1(2H)-one with 
compound 22 gave rise the final compound 23.   
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Scheme 7. Reagents and conditions: A) chloroacetyl chloride (1.2 equiv), K2CO3 (1.2 equiv), anhydrous 
CH2Cl2, 2 h, reflux; B) 1-(2H)-phthalazinone (0.9 equiv), K2CO3 (1.8 equiv), anhydrous CH3CN, 3 h, reflux. 
 
3.1.5 Synthesis of phthalhydrazide derivatives 
Scheme 8 outlines the synthetic procedure performed to get the final compounds 25a-c and 26.  
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Scheme 8. Reagents and conditions: A) substituted benzyl halide (1.1 equiv), K2CO3 (2 equiv), anhydrous 
DMF, 2-4 h, 80 °C; B) 4-n.butoxyphenyl isocyanate (2 equiv), anhydrous CH2Cl2, 14 h, 0 °C → rt; C) 22 (1.5 
equiv), K2CO3 (2 equiv), anhydrous CH3CN, 3 h, reflux. 
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The first step is the alkylation in standard conditions of the commercially available 2,3-diidrophthalazin-
1,4-dione with the suitable benzyl halide. For this reaction, anhydrous DMF gave the best results in terms 
of mono- and bi-alkylated ratio, although traces of product alkylated at both nitrogens were recovered in 
all reactions, as showed by chromatographic and 1H NMR analysis. The previously described 
intermediate 24c,242 and the new 24a,b were converted in the final urea derivatives 25a-c using 4-n-
butoxyphenyl isocyanate in anhydrous CH2Cl2. The final compound 26 was instead synthesized through 
the further alkylation of compound 24b, using the previously described intermediate 22 (scheme 7).  
 
3.1.6 Synthesis of N-2-benzyl pyridazinone derivatives  
In scheme 9 is depicted the synthesis of final compounds 29a,b and 30a,b starting from the cheap and 
commercially available 4,5-dichloro-3(2H)-pyridazinone. Following a procedure of N-benzylation at 2-
position of the pyridazinone ring reported in the literature,243 N-2-benzyl derivatives 27a,b were 
prepared in good yields by treatment with 3- or 4-methoxybenzyl bromide in anhydrous acetonitrile in the 
presence of potassium carbonate and tetrabutylammonium bromide.244 To synthesize final compounds 
30a,b starting from the 4,5-dichloro-3(2H)-pyridazinone, it was not possible to obtain selective 
monoarylation under Suzuky conditions. Interestingly, selective C-5 coupling with 4-
buthoxyphenyloronic acid was achieved using trans-dichlorobis(triethylphosphine)palladium (II) as 
catalist and 1M Na2CO3 as base in DMF at room temperature, as reported in the literature.245 An 
important strategy to achieve high mono- (versus di-) substitution is the use of a two fold excess of 
pyridazin-3(2H)-one versus boronic acid.  
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Scheme 9. Reagents and conditions: A) 3 or 4-methoxybenzyl chloride (1.5 equiv), K2CO3 (2 equiv), Bu4NBr 
(0.1 equiv), anhydrous CH3CN, 5-7 h, reflux; B) NaOCH3 (2 equiv), anhydrous CH3OH, 1 h, rt; C) 4-
n.butoxyphenylboronic acid (3 equiv), Pd(PPh3)4 (0.03 equiv), Na2CO3 2M in H2O (1 equiv), toluene, 5-8 h, 
reflux; D) 4-n.butoxyphenylboronic acid (0.5 equiv), PdCl2[(C2H5)3P]2 (0.1 equiv), Na2CO3 1M in H2O (1 
equiv), DMF, 6-12 h, rt. 
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The final compounds 29a,b were instead obtained in two steps starting from 27a,b (scheme 9) where the 
first nucleophilic reaction involved a selective displacement of the chlorine at C-5 of the pyridazinone 
ring,246 using sodium methoxide in anhydrous methanol; the second step was an oxidative addition to 
tetrakis(triphenylphosphine)palladium(0) catalist to give, in good yields, the final 4-arylated-5-
methoxypyridazinones using the 4-butoxyphenylboronic acid under classical Suzuki conditions.247 
 
3.1.7 Synthesis of N-2-phenyl pyridazinone derivatives233  
The synthetic pathway affording the final compounds 35-37 and 38a-c is depicted in scheme 10. The 
isoxazole 31, the isoxazolo[3,4-d]-pyridazinone 32 and the pyridazinones 33,34 were synthesized 
following the procedures previously described.248-251 Subsequently, the amide 35 was obtained from the 
primary amine 34 by treatment with the opportune aroylchloride in toluene at reflux, while coupling of 34 
with 4-butoxyphenylboronic acid in CH2Cl2 in presence of Cu(Ac)2 gave derivative 36.  
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Scheme 10. Reagents and conditions: A) NaOEt (1 equiv), anhydrous EtOH, 2 h, -5 °C → rt; B) NH2-NH-
C6H5 (2 equiv), PPA, anhydrous EtOH, 3.5 h, reflux; C) HCOONH4 (2.5 equiv), Pd/C 10% (catalytic), 
anhydrous EtOH, 1.5 h, reflux; D) HBr 48%, 1 h, 140 °C; E) 4-n.butoxybenzoyl chloride (0.9 equiv), Et3N (4.1 
equiv), anhydrous toluene, 4 h, reflux; F) 4-n.butoxyphenylboronic acid (2 equiv), Cu(OAc)2 (1.5 equiv), Et3N 
(2 equiv), CH2Cl2, 12 h, rt; G) NaOAc (2.4 equiv), CO(OCCl3)2 (3.5 equiv), anhydrous THF, 2 h, reflux, then 4-
n.butoxyaniline (2.4 equiv), 12 h, rt; H) substituted aryl isocyanate (1.1 equiv), anhydrous toluene, 4-7 h, reflux. 
 
Compound 34 in anhydrous toluene was refluxed with the appropriate aryl isocyanate to afford the urea 
derivatives 38a-c. The 4-butoxy analogue 37 was synthesized with an alternative procedure,2 starting 
from the same precursor 34 and using triphosgene in anhydrous THF, followed by treatment with the 
appropriate aniline.  
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3.2 6-Methyl-2,4-Disubstituted Pyridazin-3(2H)-ones: synthesis of the lead compound 46a233 
3.2.1 Synthesis of dihydropyridazinone scaffolds  
The dihydropyridazinones 42a-m (scheme 11) are the key building blocks for the synthesis of the 
pyridazinone class of compounds examined in the sections 3.2 and 3.3. As extensively reported in the 
literature, the γ-keto acids are the common starting material to easily achieve them.252-254 Some of the γ-
keto acids useful for the synthesis of the dihydropyridazinone scaffold are not commercially available. 
Thus, the first goal for this second part of the project was the development of an efficient synthetic route 
to obtain this starting material.  
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Scheme 11. Reagents and conditions: A) Fe(acac)3 (3 equiv), iPrMgCl (for compound 41b) 2M in diethyl ether 
(3 equiv), anhydrous THF, 12 h, rt; B) NaH 60% in mineral oil (1.3 equiv), ethyl bromoacetate (1 equiv), 
anhydrous THF, 15 h, rt; C) propionyl chloride (for compound 41a) or cyclohexylcarbonyl chloride (for 
compound 41c) (1 equiv), NaH 60% in mineral oil (1.05 equiv), anhydrous THF, 3 h, rt; D) p-toluenesulfonic 
acid • H2O (0.1 equiv), anhydrous toluene, 2.5 h, reflux, then EtOH, NaOH 1N, 4 h, rt; E) NH2NH2 • H2O (1 
equiv), EtOH, 1-3 h, 60 °C; F) 0.5 h, 160 °C. 
 
The synthesis of the γ-keto acid 41b was achieved following a procedure reported in the literature (A in 
scheme 11) starting from the cheap and commercially available succinic anhydride which was reacted 
with isopropyl magnesium chloride in anhydrous THF at 0 °C in presence of iron(III) acetylacetonate.255 
Since the obtained yields were lower compared to that reported in literature, to prepare quickly and 
efficiently the key starting materials another route was explored, in which the di-tert-butyl malonate was 
firstly alkylated with ethyl bromoacetate in the presence of NaH and the following acylation of 39 with 
the appropriate acid chlorides gave intermediates 40a,b. These intermediates were not isolated and were 
directly decarboxylated in presence of p-toluenesulfonic acid as catalist. Hydrolysis of the ethyl esters 
under basic conditions afforded the previously described γ-keto acids 41a,c in good yields.256-257 This 
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route resulted amenable for the synthesis of a large number of γ-keto acid analogues, using a wide range 
of cheap and commercially available acid chlorides.  
The following condensation of both commercially available and synthesized γ-keto acids with hydrazine 
hydrate afforded the previously described C-6 substituted dihydropyridazinones 42a-i,k,m,252,258-264 and 
the new 42j in good yields. A further synthetic step was required to obtain the compound 42l generated 
by melting and spontaneous decarboxylation of the carboxylic acid 42k at 160° C.265 
  
3.2.2 Synthesis of substituted N-arylacetamide pyridazinones233  
In scheme 12 is depicted the synthesis of compounds 46a-s. The dihydropyridazinone 42d was firstly 
converted into the 4-benzyl derivative 43 by Knoevenagel condensation using the appropriate aromatic 
aldehyde in the presence of KOH and then alkylated with ethyl bromoacetate to give 44. Alkaline 
hydrolysis of the ester afforded the carboxylic acid 45, which is the key intermediate for the synthesis of a 
range of substituted N-phenylacetamide pyridazinones. Indeed treatment with ethyl chloroformate in THF 
in presence of triethylamine, afforded the intermediate mixed anhydrous, which was transformed in good 
yields into the final amides by treatment with the appropriate aryl (46a-r) or cycloalkyl amine (46s).  
 
A
45
C
BHN N
O
42d
HN N
O
O
N N
O
O
O
OH
N N
O
O
O
O
N N
O
O
O
R
D
46a-s
4443
R
NH-C6H4-Br (p)
NH-C6H4-Br (m)
NH-C6H4-Br (o)
NH-C6H4-F (p)
NH-C6H4-Cl (p)
NH-C6H4-I (p)
NH-C6H5
NH-C6H4-CH3 (p)
NH-C6H4-C(CH3)3 (p)
NH-C6H4-OCH3 (p)
NH-C6H4-O-n.C4H9 (p)
NH-C6H3-(OCH3)2 (m, p)
NH-C6H3-3,4-methylenedioxy
NH-C6H4-CF3 (p)
NH-C6H4-OCF3 (p)
NH-C6H4-SCH3 (p)
NH-C6H4-CN (p)
NH-C6H4-NO2 (p)
1-methylpiperazine
46a
46b
46c
46d
46e
46f
46g
46h
46i
46j
46k
46l
46m
46n
46o
46p
46q
46r
46s
 
Scheme 12. Reagents and conditions: A) 3-methoxybenzaldehyde (1 equiv), KOH 5% (w/v) in anhydrous 
EtOH, 3 h, reflux; B) ethyl bromoacetate (3 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 6 h, reflux; C) NaOH 
6N, EtOH, 1 h, reflux; D) ethyl chloroformate (1.1 equiv), Et3N (3.5 equiv), substituted aryl(cycloalkyl)-amine 
(2 equiv), anhydrous THF, 12 h, -5 °C → rt. 
 
3.3 Optimization of the lead: 2,3,4,5,6-substituted pyridazinones  
3.3.1 Synthesis of C-6 modified N-arylacetamide pyridazinones 
The C-6 modified pyridazinones 50a-v (scheme 13) were prepared in four steps starting from the 
dihydropyridazinones 42a-c,e-j,l synthesized as shown in scheme 11 and using the same procedure 
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already described to get the final compounds 46a-s (scheme 12). Through Knoevenagel condensation 
with the commercially available 3- or 4-methoxybenzaldehyde, the previously described derivatives 
47h,j,l,266  and the new 47a-g,i,k,m-o were obtained in good yields. The following alkylation and alkaline 
hydrolysis were performed in standard conditions. The reaction of the carboxylic acids 49a-o with ethyl 
chloroformate, to give the anhydride intermediate, and then with the appropriate aryl amines, furnished 
the final compounds 50a-v. 
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Scheme 13. Reagents and conditions: A) 3 or 4-methoxybenzaldehyde (1 equiv), KOH 5% (w/v) in anhydrous 
EtOH, 1-3 h, reflux; B) ethyl bromoacetate (1.5 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 1-3 h, reflux; C) 
NaOH 6N, 1-2 h, 60-80 °C; D) ethyl chloroformate (1.1 equiv), Et3N (3.5 equiv), substituted aniline (2 equiv), 
anhydrous THF, 12 h, -5 °C → rt. 
 
3.3.2 Synthesis of C-4 modified N-arylacetamide pyridazinones 
The C-4 modified dihydropyridazinones 53a-d (scheme 14) were obtained in good yields carrying out the 
same reaction sequence (alkylation/hydrolysis/amide bond formation) shown in schemes 12 and 13 
starting from compounds 42d-m whose synthesis is reported in scheme 11.  
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Scheme 14. Reagents and conditions: A) ethyl bromoacetate (1.5 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 
2-3 h, reflux; B) NaOH 6N, 3-5 h, 80 °C; C) ethyl chloroformate (1.1 equiv), Et3N (3.5 equiv), substituted 
aniline (2 equiv), anhydrous THF, 12 h, -5 °C → rt. 
 
In scheme 15 is depicted the synthesis of compounds 57a-f, where the starting dihydropyridazinines 
42c,d,(±)-m (scheme 11) were, as first step, converted in the previously described pyridazinones 54a-c. 
The reaction was carried out using selenium dioxide or bromine in acetic acid as oxidizing 
agents.263,267,268 Then, the alkylation in standard condition with ethyl bromoacetate afforded the known 
55c,269 and the new 55a,b which were subjected to the usual hydrolysis and amide bond formation steps, 
performed as already described (schemes 12,13). 
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Scheme 15. Reagents and conditions: A) for compound 54c: Br2 (4 equiv), CH3COOH 100%, 4-5 h, reflux; for 
compunds 54a,b: SeO2 (3 equiv), anhydrous EtOH, 5-7 h, reflux; B) ethyl bromoacetate (1.5 equiv), K2CO3 (2 
equiv), anhydrous CH3CN, 2-3 h, reflux; C) NaOH 6N, 2 h, 80 °C; D) ethyl chloroformate (1.1 equiv), Et3N (3.5 
equiv), substituted aniline (2 equiv), anhydrous THF, 12 h, -5 °C → rt. 
 
The synthesis of final compounds 61a-p, where the 4-methoxybenzyl at the C-4 position of the 
pyridazinone ring was replaced with several heterocyclic or substituted benzyl moieties, is shown in 
scheme 16. The dihydropyridazinone 42d (scheme 11) was converted into the previously described 
derivatives 58b-e,i,270-273 and the new 58a,f-h,j-m by Knoevenagel condensation with the appropriate 
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aromatic aldehyde in the presence of KOH. Compounds 58a-m, in turn, were alkylated with ethyl 
bromoacetate to give the esters 59a-m, whose 59d,e,i were previously reported.271,272,274 Alkaline 
hydrolysis of compounds 59a-m gave the known 60i,270 and the new carboxylic acid derivatives 60a-h,j-
m. These compounds were treated with ethyl chloroformate in THF in presence of triethylamine, 
affording the mixed anhydrides, which in turn were transformed into the final amides 61a-p by treatment 
with the appropriate aryl amine.  
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Scheme 16. Reagents and conditions: A) substituted benzaldehyde (1 equiv), KOH 5% (w/v) in anhydrous 
EtOH, 3-5 h, reflux; B) ethyl bromoacetate (1.5 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 2-4 h, reflux; C) 
NaOH 6N, 1-2 h, 80 °C; D) ethyl chloroformate (1.1 equiv), Et3N (3.5 equiv), substituted aniline (2 equiv), 
anhydrous THF, 12 h, -5 °C → rt. 
 
In scheme 17 is shown the synthesis of final compounds 62a-c modified at the C-4 of the pyridazinone 
ring and bearing a 4-iodophenylacetamide chain at position 2. To get this compounds, the Koevenagel 
condensation with the appropriate aromatic aldehyde was performed on the intermediate 53a (scheme 
14). 
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Scheme 17. Reagents and conditions: A) substituted benzaldehyde (1 equiv), KOH 5% (w/v) in anhydrous 
EtOH, 1-5 h, reflux. 
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This alternative methodology was chosen over the previous synthetic pathway (scheme12) due to the 
exciting possibility to synthesize the suitable building block (53a, scheme 14) and then to condensate it 
with the convenient aromatic aldehyde. Despite the fact that Knoevenagel condensation appeared 
relatively simple and high-yielding on the C-4 of the pyridazinone ring (schemes 12 and 13), the N-
(phenylacetamido)pyridazinone 53a didn’t result suitable for the synthesis of a various range of 
compounds, probably due to the instability of the phenylacetamido moiety. Indeed, in this conditions, a 
mixture of products resulted and just three aromatic aldehydes were able to react in low to moderate 
yields. For these reasons the alternative route was not efficient for the preparation of analogues as we 
supposed. 
Moreover, a further procedure was required to get the final compounds 66a-c (scheme 18). Intermediates 
63 and 64 were obtained by Knovenagel condensation in the same conditions already described (scheme 
12), using the commercially available 3-pyridinecarboxaldehyde and 4-cyanobenzaldehyde respectively. 
Compound 65 was instead prepared from 64 by dehydration of the amide with phosphorus oxychloride. 
Due to their instability to strong base treatment, the intermediates 63-65 were directly converted in the 
final compounds 66a-c by alkylation in standard condition with compound 22 (scheme 7).  
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Scheme 18. Reagents and conditions: A) 3-pyridinecarboxaldehyde (1 equiv), KOH 5% (w/v) in anhydrous 
EtOH, 5 h, reflux; B) 4-cyanobenzaldehyde (2 equiv), KOH 5% (w/v) in anhydrous EtOH, 4 h, reflux; C) 
POCl3, 3 h, 60 °C; D) 22 (1.5 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 2-3 h, reflux; E) ethyl bromoacetate 
(1.5 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 2 h, reflux; F) NaOH 6N, 2 h, 60 °C; G) ethyl chloroformate 
(1.1 equiv), Et3N (3.5 equiv), 4-bromoaniline (2 equiv), anhydrous THF, 12 h, -5 °C → rt. 
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To get the pyridazinone 69 (scheme 18), the intermediate 64 was alkylated with ethyl bromoacetate to 
give 67 which, after alkaline hydrolysis of the ester moiety afforded the bicarboxylic acid 68. Treating 68 
firslty with ethyl chloroformate and then with 4-bromoaniline, in the usual conditions (scheme 12), it was 
possible to obtain in good yields compound 69, bearing two amide functions.  
In scheme 19 is depicted the synthesis of the 4-arylketone derivative 71 prepared from 44 (scheme 12) by 
oxidation of the benzylic methylene (70) with cerium ammonium nitrate (CAN) and subsequent 
alkylation in standard conditions with the previously described intermediate 22 (scheme 7). 
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Scheme 19. Reagents and conditions: A) CAN (3 equiv), CH3COOH 50%, 1.5 h, 60 °C; B) 22 (1.5 equiv), 
K2CO3 (2 equiv), anhydrous CH3CN, 6 h, reflux. 
 
The synthesis of compound 77 whit the 4-methoxyphenyl group directly bonded to the C-4 of the 
pyridazinone ring is shown in scheme 20. As reported in literature,275 the commercially available methyl 
4-methoxyphenylacetate can be easily converted in the previously described keto ester 72,276 by oxidation 
with tert-butyl hydroperoxide (TBHP) and a catalytic amount of  iron trichloride in pyridine at 85 °C. The 
intermediate 72 was then processed to Wittig reaction,277,278 using dimethyl acetylmethylphosphonate as 
phosphonium ylide source and sodium methoxyde in methanol at 0 °C, to afford the known γ-keto ester 
73.279 Condensation with hydrazine hydrate afforded the intermediate 74, which as usual, was subjected 
to alkylation with ethyl bromoacetate, alkaline hydrolysis and finally coupling with 4-bromoaniline, 
through the intermediate mixed anhydride to give the final amide 77 in good yield.  
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Scheme 20. Reagents and conditions: A) TBHP (3 equiv), FeCl3 • 6 H2O, pyridine, 8 h, 85 °C; B) NaOCH3 (2 
equiv), anhydrous CH3OH, 3.5 h, 0 °C → rt; C) NH2NH2 • H2O (2 equiv), anhydrous toluene, 2 h, reflux; D) 
ethyl bromoacetate (1.5 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 1.5 h, reflux; E) NaOH 6N, 0.5 h, 60 °C; 
F) ethyl chloroformate (1.1 equiv), Et3N (3.5 equiv), 4-Bromoaniline (2 equiv), anhydrous THF, 12 h, -5 °C → 
rt. 
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The synthetic pathway affording the final compounds 83, 87-89 and 92 is depicted in scheme 21. The 
isoxazoles 31 (scheme 10) and the isoxazolo[3,4-d]pyridazinones 78 were previously described.227, 280 
Reductive opening of the isoxazole ring carried out on the intermediate 78 with ammonium formate and a 
catalytic amount of carbon-supported palladium catalyst (Pd/C) in anhydrous ethanol at reflux, afforded 
the known 4-amino-5-acetyl pyridazinone derivative 79.223 Performing the usual alkylation/alkaline 
hydrolysis/amide bond formation reaction sequence (schemes 12 and 13) the final amide 83 was 
synthesized in good yields. The already described intermediate 84 was obtained by deacetylation of 79 
using 48% hydrobromic acid under pressure at high temperature (140 °C).231  
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Scheme 21. Reagents and conditions: A) NH2NH2 • H2O, 4 h, 180 °C; B) NH2-NH2 • H2O (2 equiv), EtOH, 10 
min, rt; C) HCOONH4 (2.5 equiv), Pd/C 10% (catalytic), anhydrous EtOH, 1.5 h, reflux; D) HBr 48%, 1 h, 140 
°C; E) ethyl bromoacetate (1.5 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 3 h, reflux; F) 4-
methoxyphenylboronic acid (2 equiv), Cu(OAc)2 (1.5 equiv), Et3N (2 equiv), CH2Cl2, 12 h, rt; G) NaOH 6N, 1.5 
h, 80 °C; H) ethyl chloroformate (1.1 equiv), Et3N (3.5 equiv), 4-bromoaniline (2 equiv), anhydrous THF, 12 h, 
-5 °C → rt; I) see E; L)  see G; M) see H; N) 4-methoxyphenylboronic acid (1 equiv), Cu(OAc)2 (1.5 equiv), 
Et3N (2 equiv), CH2Cl2, 12 h, rt; O) substituted benzoyl chloride (2.4 equiv), Et3N (catalytic), anhydrous 
CH2Cl2, 16 h, 0 °C → rt; P) see F; Q) see  G; R) see H. 
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To get 84 in high yields, a previously described procedure starting from 54b (scheme 15) and using  
hydrazine hydrate at 180 °C was as well tried.281 The high temperature of reaction afforded a mixture 
difficult to purify and the resulting yield was lower than that stated in the literature. Thus, the previous 
methodology based on deacetylation of 79 was elected to get the intermediate 84. This compound was 
processed to standard alkylation, hydrolysis and amidation reactions to generate the final 4-amino 
pyridazinone 87. Subsequently, the coupling of the amine group of 87 with 4-methoxyphenylboronic acid 
in presence of Cu(Ac)2 in CH2Cl2 gave the 4-arylamine 88, while the 4-arylamide analogues 89a,b were 
obtained from 87 by treatment with the opportune aroylchloride and triethylamine in CH2Cl2 at 0 °C. To 
synthesize the biarylamine 90 the intermediate 85 was coupled with a two-fold amount of 4-
methoxyphenylboronic acid in usual conditions and then, after hydrolysis of the ester group and following 
usual amidation, the final compound 92 was obtained in good yields.  
 
3.3.3 Synthesis of N-arylacetamide modified pyridazinone derivatives   
Scheme 22 depict the synthetic procedure for compounds 95-97. The precursor 43 was alkylated with the 
appropriate bromo ester to give compounds 93a,b, which, in turn, were converted in the corresponding 
acids 94a,b. The final step was the transformation of these compounds into the final amides 95a,b using 
the same procedure extensively described in the present section of the thesis.  
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Scheme 22. Reagents and conditions: A) ethyl 3-bromopropionate (for compound 93a) or (±)-ethyl-2-
bromopropionate (for compound 93b) (1.5 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 6 h, reflux; B) NaOH 
6N, 1 h, 80 °C; C) ethyl chloroformate (1.1 equiv), Et3N (3.5 equiv), 4-Bromoaniline (2 equiv), anhydrous THF, 
12 h, -5 °C → rt; D) alkyl halide (1.5 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 6 h, reflux; E) CH2O 40%, 
NH3 33%, dioxane, 1 h, 50 °C, then 4-bromophenyl isocyanate (for compound 97a) (1.1 equiv) or 4-
bromobenzoyl chloride (for compound 97b) (1.5 equiv), CH2Cl2, 6-12 h, rt (97a), 0 °C (97b). 
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On the other hand, compounds 96a,b were obtained by alkylation of 43 with the appropriate halide in 
standard conditions (scheme 22). Moreover the precursor 43 was converted into the final 97a,b through a 
multicomponent Mannich reaction (CH2O + NH3).282 The intermediate amine was not isolated and it was 
converted one-pot into the urea 97a by treatment with 4-bromophenyl isocyanate and into the amide 97b 
with 4-bromobenzoyl chloride. 
The final compounds 100, 101 and 103a,b were synthesized as shown in scheme 23. The intermediate 44 
was reduced with sodium borohydride in THF/MeOH to generate the primary alcohol 98. This compound 
was the starting material for the synthesis both of the ether 101, through a coupling reaction with the 4-
bromophenylboronic acid in presence of Cu(Ac)2, and of compound 100, through the mesylate 99,283 
which, in turn, was then converted into the final compound 100 by nucleophilic replacement with 4-
bromo aniline. Treatment of 99 with ammonia gave the intermediate 102, from which the urea 103a and 
the amide 103b were obtained using 4-bromophenyl isocyanate or 4-bromobenzoyl chloride respectively 
in CH2Cl2. 
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Scheme 23. Reagents and conditions: A) NaBH4 (5.6 equiv), anhydrous THF, anhydrous CH3OH, 1 h, 60 °C; 
B) methanesulfonyl chloride (1.5 equiv), pyridine (1.1 equiv), anhydrous CH2Cl2, 4 h, 0 °C → rt; C) 4-
bromoaniline (2 equiv), 2-propanol, 6 h, 60 °C; D) 4-bromophenylboronic acid (2 equiv), Cu(OAc)2 (1.5 equiv), 
Et3N (2 equiv), CH2Cl2, 12 h, rt; E) NH3 33%, 2-propanol, 3 h, 60 °C; F) 4-bromophenyl isocyanate (for 
compound 103a) (1.1 equiv) or 4-bromobenzoyl chloride (for compound 103b) (1.1 equiv), Et3N (2 equiv), 
anhydrous CH2Cl2, 6 h, 0 °C. 
 
To obtain the analogues 104a-c (scheme 24), the mixed anhydride generated as usual by treatment of the 
intermediate 45 (scheme 12) with ethyl chloroformate was transformed in good yields into the final 
compounds by treatment respectively with commercially available 4-bromobenzylamine (for 104a), 4-
bromophenol (for 104b) and N-methyl-4-bromobenzylamine (for 104c). 
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Scheme 24. Reagents and conditions: A) ethyl chloroformate (1.1 equiv), Et3N (3.5 equiv), 4-
bromobenzylamine or 4-bromo-N-methylaniline or 4-bromophenol (2 equiv), anhydrous THF, 12 h, -5 °C → rt. 
 
In scheme 25 is shown the synthesis of the thioamide analogue 105 directly generated from 46a (scheme 
12) using Lawesson’s reagent in toluene at 80 °C.284 
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Scheme 25. Reagents and conditions: A) Lawesson’s Reagent (2 equiv), anhydrous toluene, 3 h, 80 °C. 
 
There are two possible achievable mono-tioderivatives from this reaction: the first one, where the sulphur 
replace the oxygen of carbonyl group at C-3 of the pyridazinone ring, and the second, where the sulphur 
replaced the oxygen of CO in the exocyclic amide side chain (105). Thus, the relative position of 
tionation needed to be attributed, and the structure of 105 was confirmed by both 1H NMR and MS(ESI) 
analysis. 1H NMR experiments showed a clear difference in the chemical shift  between the methylene 
bonded to the carbonyl group in 46a and that bonded to the thiocarbonyl group in 105. In addition, LCMS 
experiments showed that it is evident a correlation between the fragments generated during the analysis 
and the structure 105. Indeed, leaving aside the fact that the exact mass was exactly the one expected for 
105, it resulted evident the presence of the pyridazinone fragment without the N-phenylacetamide or the 
N-phenylethanethioamide moiety. This result was a proof that the pyridazinone ring was unchanged and 
the sulphur is on the side chain as drawn (scheme 25). Thus, it is reasonable to presume that reaction via 
sulphur substitution by Lawesson’s reagent is favoured on the carbonyl group of the side chain. 
 
3.3.4 Synthesis of N-2/C-4 inverted pyridazinone analogues 
In scheme 26 is depicted the synthesis of compounds 108 and 109. Alkylation in standard condition of 
the 6-methylpyridazinone 54b (scheme 15) with 3-methoxybenzyl chloride in acetonitrile resulted in 
compound 106 which gave the corresponding 4-amino derivative 107 by heating with N2H4 · H2O in hard 
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conditions. The amide 108 and the urea 109 were obtained from 107 by treatment with the opportune 
aroyl chloride or the aryl isocyanate following the same conditions reported for 89a,b (scheme 21) and 
38a-c (scheme 10). 
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Scheme 26. Reagents and conditions: A) 3-methoxybenzyl chloride (1.5 equiv), K2CO3 (2 equiv), anhydrous 
CH3CN, 6 h, reflux; B) NH2NH2 • H2O, 12 h, 180 °C; C) 4-bromobenzoyl chloride (2.4 equiv), Et3N (catalytic), 
anhydrous CH2Cl2, 10 h, 0 °C; D) 4-bromophenyl isocyanate (2.2 equiv), anhydrous toluene, 7 h, reflux. 
 
3.3.5 Synthesis of C-3 susbstituted pyridazine analogue 
Scheme 27 outlines the synthetic procedure for compound 111. Using Lawesson’s reagent, as previously 
described, the precursor 58e (scheme 16) was transformed into intermediate 110 (scheme 25) which, in 
turn, was alkylated in standard condition using 22 (scheme 7) to afford the corresponding analogue 111, 
having the phenylacetamide moiety at the C-3 of the pyridazinone ring. 
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Scheme 27. Reagents and conditions: A) Lawesson’s Reagent (1 equiv), anhydrous toluene, 2 h, 80 °C; B) 22 
(1.5 equiv), K2CO3 (2 equiv), anhydrous CH3CN, 3 h, reflux. 
 
3.3.6 Synthesis of chiral pyridazinone analogues 
A further development of the project was the introduction of stereogenic center on the N-phenylacetamide 
linker of the lead compound 46a (scheme 12). The modification introduces stereochemical complexity 
into the products and, at the same time, it should be interesting to see the effect of the presence of a 
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stereogenic center on the biological activity, maintaining however the essential conformational shape of 
the molecules. The development of an homologous series of chiral compounds, possibly through 
enantioselective reaction, would be particularly desirable in the case of the synthesis of a group of 
biologically-useful small molecules due to the well known advantages of chirality when considering the 
interactions of small-molecules with biological systems. 
 
3.3.6.1    Enantioselective synthesis of the N-arylpropanamide analogue 
In the first instance, the asymmetric synthesis of enantiomers (+)-113 and (-)-113 had been tried (scheme 
28). Commercially available R-(+)- and S-(-)-bromopropionic acids were firstly treated with SOCl2 
affording the intermediate acid chlorides which in turn were transformed in the amides R-(+)-112 and S-
(-)-112 using 4-bromoaniline.285 As expected and as confirmed by chiral HPLC and polarographic 
analysis, the amide bond formation occurred by retention of the relative configuration of the starting 
carboxylic acids due to the missing participation of the chiral center in the reaction and to the not basic 
reaction conditions.286-287 The amides R-(+)-112 and S-(-)-112 were then used to alkylate in standard 
conditions the intermediate 43 (scheme 12) to give respectively the two pure enantiomers. Precedent 
literature described the alkylation on the N-2 of the pyridazinone ring as a classical SN2 reaction,288 so 
that this methodology could be theoretically applied to the synthesis of both enantiomers (+)-113 and (-)-
113, with complete inversion of the configuration of starting amides. Despite the fact that this reaction is 
simple and well known,289-292 it was found that it is not suitable for asymmetrical synthesis because the 
inversion of configuration was not complete and consequent racemization occurred. Inspection by chiral 
HPLC analysis of the chromatographically pure compounds showed the achievement of a mixture 70:30 
starting from S-(-)-112 and a mixture 60:40 from R-(+)-112. All attempts at doing this stereoselective 
alkylation reaction proved unsuccessful. 
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Scheme 28. Reagents and conditions: A) SOCl2 (6 equiv), anhydrous CH2Cl2, 4 h, reflux, then 4-bromoaniline 
(2 equiv), anhydrous THF, 4 h, rt; B) 43 (0.9 equiv), K2CO3 (1.8 equiv), anhydrous CH3CN, 2 h, reflux. 
 
3.3.6.2     Synthesis of the homologous series of N-aryl-(alkyl)-amide derivatives 
To get the chiral compounds (±)-117a-f as racemates and the dimethyl analogue 118, not optically 
active, the same synthetic pathway used for (+)-113/(-)-113 (scheme 28) has been performed as shown 
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in scheme 29. For the synthesis of the compound (±)-117f it was previously required the preparation of 
the starting bromo-derivative (±)-114, not commercially available and obtained as reported in literature 
by treatment with N-bromosuccinimide in CCl4 at reflux.293 After treatment with SOCl2 of the 
appropriate chiral carboxylic acids (scheme 29) the commercially available 4-bromophenyl amides (±)-
115a,c, the already described (±)-115e,f, 116,294-298 and the new (±)-115b,d were obtained in low yields 
as useful intermediates for the synthesis of the final compounds (±)-117a-f and 118.  
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Scheme 29. Reagents and conditions: A) NBS (1.05 equiv), CCl4, N2, 8 h, reflux; B) SOCl2 (6 equiv), 
anhydrous CH2Cl2, 4 h, reflux, then 4-bromoaniline (2 equiv), anhydrous THF, 4 h, rt; C) 43 (0.9 equiv), K2CO3 
(1.8 equiv), anhydrous CH3CN, 4-5 h, reflux. 
 
3.3.6.3     Chiral Chromatographic resolution of racemates (±)-95b and (±)-117a-f 
Due to the significant racemization during nucleophilic displacement of bromide with the pyridazinone 
intermediate 43 (scheme 28, section 3.3.6.2), an alternative strategy was required to get the pure 
enantiomers of (±)-95b and (±)-117a-f (schemes 29 and 30). Chiral HPLC is one of the most valid and 
efficient methods for obtaining both enantiomers of a chiral compound in high optical purity [> 97% 
enantiomeric excess (ee)]. This approach has now become an established procedure for in vitro 
comparative biological testing, where few milligrams of both enantiomers are required. In addition, the 
isolation of single enantiomers represents a strategy for rational drug design due to the role of 
stereochemistry in molecular interactions involving biological macromolecules. 
Compounds (±)-95b and (±)-117a-f (scheme 30) were then isolated as pure (ee = 97.4-99.9%) by semi-
preparative chiral HPLC (scheme 30) and two distinct polysaccharide based chiral stationary phases 
(CSPs) had to be employed to separate the different racemates. Indeed in the early stage of the 
chromatographic resolution a Chiralcel OD® column [cellulose tris(3,5-dimethylphenylcarbamate)] was 
used to separate racemates (±)-95b and (±)-117a (table 3.1), according to the literature for a series of 
pyridazinone like compounds.221 An isocratic elution mode was employed and detection by UV was 
carried out at 250 nm. 
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Scheme 30. Chromatographic resolution using Chiralcel OD®column for (±)-95b and (±)-117a (eluent: n-
hexane/2-propanol 95:5); Lux Amylose-2® column for (±)-117b-f (eluent: n-hexane/2-propanol 60:40). 
 
Unexpectedly, during the analytical work resulted a lack of selectivity of the Chiralcel OD® column by 
increasing the steric hindrance on the chiral center. Indeed, already the resolution of racemate (±)-117b, 
having a propyl group on the chiral center, resulted not possible due to poor resolution between two 
enantiomers (figure 3.1). 
 
Figure 3.1. Chiral semi-preparative HPLC resolution of racemates (±)-95b and (±)-117a. Conditions: Chiralcel 
OD column (10 µm, 4.6 mm I.D. x 250 mm), n-hexane/IPA 95:5 (v/v) as eluent, flow rate 1.2 mL/min, detection 
by UV at 250 nm, temperature 25 °C, . At the bottom it is shown the lack of selectivity resulted using Chiralcel 
OD column in the same conditions to separate racemate (±)-117b. 
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Enantiomer Stationary 
Phase 
Eluent 
(n-hexane/IPA) 
Flow rate 
(mL/min) 
Temperature 
(°C) 
Retention Time 
(tR, min) 
(+)-95b 19.2 
(-)-95b 
 
Chiralcel OD 
 
95:5 
 
1.2 
 
25 23.2 
(+)-117a 15.9 
(-)-117a 
 
Chiralcel OD 
 
95:5 
 
1.2 
 
25 17.9 
(+)-117b 5.1 
(-)-117b 
 
Amylose-2 
 
60:40 
 
1.5 
 
40 9.4 
(+)-117c 3.9 
(-)-117c 
 
Amylose-2 
 
60:40 
 
1.5 
 
40 10.1 
(+)-117d 5.4 
(-)-117d 
 
Amylose-2 
 
60:40 
 
1.5 
 
40 9.7 
(+)-117e 12.3 
(-)-117e 
 
Amylose-2 
 
60:40 
 
1.5 
 
40 7.6 
(+)-117f 8.6 
(-)-117f 
 
 Amylose-2 
 
60:40 
 
1.5 
 
40 6.7 
Table 3.1. Data of the chiral HPLC separations for the different racemates (±)-95b and (±)-117a-f related to 
semi-preparative conditions, column types (250 mm x 4.6 mm I.D.), mobile phases, flow rates, temperature and 
retention times (tR) detected by UV at 250 nm. 
 
In order to develop the semi-preparative resolution it was required to find another chiral stationary phase. 
As it shown in table 3.1 and in figure 3.2 a very good separation of the (+) and (-) enantiomers of 117b-f 
was achieved using Lux Amylose-2® column [amylose tris(5-chloro-2-methylphenyl-carbamate)] and the 
optically pure compounds were obtained as required. In all cases, an isocratic elution mode was employed 
and detection by UV was carried out at 250 nm.  
 
Figure 3.2. Chiral semi-preparative HPLC resolution of racemates (±)-117b-f. Conditions: Lux Amylose-2 
column (5 µm, 4.6 mm I.D. x 250 mm), n-hexane/IPA 60:40 (v/v) as eluent, flow rate 1.5 mL/min, detection by 
UV at 250 nm, temperature 40 °C. 
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After semipreparative HPLC the fractions collected were dried under nitrogen and analyzed on chiral 
analytical Lux Amylose-2® (3 µm, 4.6 mm I.D. x 50 mm) column to determine their enantiomeric excess 
(ee) (figure 3.3 and table 3.2).  
 
Figure 3.3. Chiral analytical HPLC analysis of the chromatographically resolved enantiomers (+)-95b/(-)-95b 
and (+)-117a-f/(-)-117a. Conditions: Lux Amylose-2 column (3 µm, 4.6 mm I.D. x 50 mm), n-hexane/IPA 
60:40 (v/v) as eluent, flow rate 1.0 mL/min, detection by UV at 250 nm, temperature 40 °C, injection volume of 
10 µL. For  analytical enantioseparations a standard solution was prepared by dissolving 0.1 mg of each 
enantiomer into 1 mL of ethanol. The ee values were calculated from relative peak areas (table 3.2). Arrows 
indicate the percentage of the enantiomeric impurities for (+)-95b, (-)-117a, (+)-117f whereas all the other 
enantiomers were obtained with a purity > 99.9%. 
 
Polarimetric analysis were as well performed by dissolving 20 mg of pure compounds into 2 mL of 
chloroform (c = 1) to establish the specific rotations ([α]20D) of enantiomers (table 3.2). The signal was 
measured at 589 nm using a polarimeter equipped with a Na lamp. 
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Enantiomer [α]
20
D 
(CHCl3, c = 1) 
Enantiomeric 
excess (ee, %) 
(+)-95b + 80° > 99.9 
(-)-95b - 78° 97.4 
(+)-117a + 129° > 99.9 
(-)-117a - 129° 98.0 
(+)-117b + 139° > 99.9 
(-)-117b - 137° > 99.9 
(+)-117c + 99° > 99.9 
(-)-117c - 97° > 99.9 
(+)-117d + 111° > 99.9 
(-)-117d - 110° > 99.9 
(+)-117e + 16° > 99.9 
(-)-117e - 17° > 99.9 
(+)-117f + 17° 99.3 
(-)-117f - 18° > 99.9 
Table 3.2. Data for the different racemates (±)-95b and (±)-117a-f of specific rotation factor ([α]20D), 
determined by polarimeter in CHCl3 (c = 1 mg/1 mL), and enantiomeric excess, determined by chiral analytical 
HPLC separations. 
 
Chiral HPLC and polarimetric analysis indicated that for racemates (±)-95b and (±)-117a-d the first 
eluted enantiomers using both Chiralcel OD or Lux Amylose-2 columns rotated polarized light in the 
positive direction, accordingly to the comparable nature of substituents on the stereogenic center (R = 
alkyl, R1 = H, schemes 29 and 30). Oppositely, the elution sequence was reversed in the case of 
racemates (±)-117e,f where the enantiomers (-)-117e,f eluted faster then the corresponding (+)-forms 
during the separating process. Enantiomer elution order is a very important topic in the determination of 
enantiomeric purity of chiral compounds as well as in the study of enantiorecognition mechanism.299 The 
polysaccharide-type CSPs are based on natural materials and are available only in one configuration. 
Although it is difficult to control the enantiomer elution order with these CSPs, examples of inversion 
enantiomer retention order have been reported by alteration of the mobile phase composition or 
enantioseparation temperature.300 In our case, these results appear to be consistent with the assumption 
that structural differences on the chiral center  between the analytes determined the reversal of the 
enantiomer elution order. Probably the bigger hindrance of the phenyl group in (±)-117e and the absence 
of H on the chiral center in (±)117f are the key determinants in this inversion of chromatographic elution. 
Thus, from seven separated compounds five [(±)-95b and (±)-117a-d] exhibited higher affinity of the (-)-
form for the stationary phase over the (+)-form and for the remaining two [(±)-117e,f] it was the opposite. 
It is as well interesting to note that enantiomer elution order was not influenced by changing the amount 
of alcohol (2-propanol) used in the mobile phase in both colums. 
 
3.3.6.4     Assignment of the absolute configurations 
To assign the absolute configuration to the pure enantiomers (+)-95b, (-)-95b, (+)-117a-f and (-)-117a-f, 
we made several attempts to get crystals suitable for single crystal X-ray analysis but, unluckily, none of 
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these analogues were amenable for configurational analysis by crystallization. Since this approach failed, 
for the configurational assignment we took into account the methodology based on the comparison of CD 
curve analysis of the unknown enantiomers and the CD profile of commercially available molecules or 
well known compounds whose absolute configuration was already been established. Examples of 
assignment of the absolute configuration using this approach have been extensively reported in the 
literature.301-308  
(+)-95b, (-)-95b (R = CH3)
N N
O
O
O
NH
R
Br
OH
O
NH
O
N -Acetyl-S-(-)-alanine
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Scheme 31. N-Acetyl-S-(-)-alanine and acetyl derivatives of R-(-)-2-phenylglycine [R-(-)-119] and S-(-)-α-
Methylvaline [S-(-)-120] used as reference compounds in CD experiments in comparison to enantiomeric pairs 
(+)-95b/(-)-95b, (+)-117e/(-)-117e, (+)-117f/(-)-117f due to their comparable substituents on the stereogenic 
center. The result obtained for  (+)-95b/(-)-95b can be extended as well for enantiomers (+)-117a-d/(-)-117a-d. 
Reagents and conditions: A) acetic anhydride (7.5 equiv), H2O, 0.5 h, 70 °C.  
 
Commercially available N-acetyl-S-(-)-alanine, R-(-)-2-phenylglycine and S-(-)-α-methylvaline were 
chosen as reference molecules considering that they are characterized by comparable substituents on the 
stereogenic centre. Indeed, as it shown in scheme 31, N-acetyl-S-(-)-alanine bearing a methyl group on 
the chiral center, an hydrogen, a carboxylic CO and an amidic NH can be used in CD analysis as 
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reference for (+)-95b/(-)-95b and the result can be extended as well for (+)-117a-d/(-)-117a-d 
enantiomeric pairs. R-(-)-2-phenylglycine and S-(-)-α-methylvaline were instead firstly converted into 
their acetyl derivatives R-(-)-119 [commercially available, N-acetyl-R-(-)-phenylglycine] and S-(-)-120 
[N-acetyl-S-(-)-α-methylvaline] to make the chiral center more similar to that of (+)-117e/(-) -117e and 
(+)-117f/(-)-117f respectively (scheme 31). The acetylation reaction was performed in H2O using acetic 
anhydride at 70 °C and it occurred by complete retention of the absolute configuration as reported in 
literature.309 Both enantiomers of (±)-95b were analyzed in comparison with N-acetyl-S-(-)-alanine 
([α]23D – 62° (c = 1, H2O) (scheme 31 and figure 3.4). The solutions of (+)-95b and (-)-95b in methanol 
(concentration about 0.25 mg/mL, optical pathway 0.1 cm) and of N-acetyl-S-(-)-alanine (concentration 
about 1 mg/mL, optical pathway 0.1 cm)  were analyzed in nitrogen atmosphere. CD spectra were 
scanned at 50nm/min with a spectral band width of 1 nm and data resolution of 0.2 nm. The spectra were 
averaged over five instrumental scans and the intensities are presented in terms of ellipticity values 
(mdeg) (figure 3.4). The CD spectrum of the (+)-95b enantiomer (figure 3.4) displays a broad positive 
Cotton effect around 300 nm. The (-)-95b enantiomer exhibited the corresponding mirror-image CD. In 
comparison, the positive Cotton effect of the N-acetyl-S-(-)-alanine is in the range of wavelength between 
215 and 250 nm. Therefore, (S)-absolute configuration of the reference compound may also be assigned 
to (+)-95b and (R)-absolute configuration to (-)-95b that oppositely showed a negative Cotton effect 
around 300 nm. The differences in the profile of the curves could depend on the different type of 
chromophore between (+)-95b/(-)-95b and the N-acetyl-S-(-)-alanine without any aromatic substituent.  
 
 
Figure 3.4. Experimental Circular dichroism (CD) spectra recorded in methanol at 25 °C of the pure 
enantiomeric pairs (+)-95b/(-)-95b, (+)-117e/(-)-117e, (+)-117f/(-)-117f and the reference compounds N-acetyl-
S-(-)alanine, R-(-)-119, S-(-)-120 (scheme 31). In each spectra black traces refers to the reference compounds, 
whereas solid and dashed red traces correspond respectively to the (S)- and (R)-enantiomers analyzed. 
 
Due to the similarity on the chiral center between compounds S-(+)-95b/R-(-)-95b  and enantiomeric 
pairs (+)-117a-d/(-)-117a-d (scheme 31), it seems then possible that enantiomers of the same sign of 
optical rotation may have the same absolute configuration. Some support for such a reasoning is in the 
fact that a correlation between the absolute configuration of these optically active analogues could be 
deduced as well from the same elution order showed during chiral HPLC analysis (section 3.3.6.3, figure 
3.2 and 3.3). Indeed analogues (+)-117a-d/(-)-117a-d exhibited same-sense chiral recognition mechanism 
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and, consequently, the same enantiomer elution order on both stationary phases used (Chiralcel OD and 
Lux Amylose-2) with preferential retention of the  (-)-enantiomer. These data support the presumption 
that all the enantiomers (+)-117a-d possess the same absolute (S)-configuration and, obviously, the 
absolute (R)-configuration is for levorotatory isomers (-)-117a-d.  
Similarity of CD spectra of reference molecule (R)-(-)-119 and (-)-117e (figure 3.4) is certainly in line 
with the rule that enantiomers with the same sign of Cotton effect may have the same absolute 
configuration. Enantiomers (-)-117e/(+)-117e display the Cotton effects between 230 and 270 nm and a 
maximum around 250 nm. Also in this case, it is noteworthy that differences in the profile of the curves 
could depend from different type of chromophore between (-)-117e/(+)-117e and the (R)-(-)-119. CD 
spectra of (-)-117e and (+)-117e, recorded in methanol, clearly are mirror images (figure 3.4), 
demonstrating again the enantiomeric relationship. The negative Cotton effect of (-)-117e is in agreement 
with negative Cotton effects of the previously described (R)-(-)-119,310-312 supporting the absolute R-(-)-
configuration assigned to this enantiomer (scheme 31).  
The configurational assignment for the last enantiomeric pair (-)-117f/(+)-117f was performed by 
comparing their circular dichroism spectra with that of S-(-)-120 (scheme 31), always characterized by 
similar substituents  on the stereogenic centers (two alkyl groups, a carboxylic CO and an amidic NH), 
whose configuration was already established. The spectra showed once more analogous profiles and 
comparable Cotton effects between S-(-)-120 and (+)-117f in the spectral region between 215 and 300 nm 
(figure 3.4). The bathochromic shift of the S-(-)-120 curve could depend on the differences between the 
different chromophores. Therefore the absolute configurations of S-(-)-120 may be proposed also for 
(+)117f and, consequently, the absolute R-configuration was assigned to (-)-117f (scheme 31).  
In conclusion, on the basis of combined chromatographic and chiroptical studies, the absolute 
configuration assignment was unambiguously completed, and configurations were assigned as follow to 
the seven enantiomeric pairs synthesized: S-(+)-95b/R-(-)-95b and S-(+)-117a-f/R-(-)-117a-f. Due to the 
comparable chiral centers in this group of homologue molecules, the results showed as well that (S)-
absolute configuration is for all dextrorotatory enantiomers of the series and (R)-absolute configuration is 
for the corresponding levorotatory isomers.  
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4.1 Results 
In the present study, we synthesized a library of 162 heterocyclic compounds which were screened in 
order to identify novel molecules able to activate human neutrophil through FPRs interaction. Thus the 
final compounds were evaluated for their ability to induce intracellular Ca2+ flux in HL-60 (Human 
promyelocytic leukemia) cells transfected with FPR1, FPR2, or FPR3. In fact it is well known that it is 
possible to estimate FPRs affinity by means of evaluation in Ca2+ flux changing.313-314 All compounds 
were also evaluated in WT (wild-type non-transfected HL-60 cells) and they where inactive. Moreover, 
both EC50 values and relative efficacy, compared to the peptide agonists fMLF and WKYMVm, were 
determined. Finally, the compounds that showed the best activity profile were selected to evaluate the 
activity as chemotactic agents and the capacity to mobilize Ca2+ in human neutrophils. 
 
4.1.1 Screening different nitrogen heterocyclic derivatives as FPRs agonists   
In the early phase of our project, we synthesized several compounds where functionalized side chains 
similar to that of the references compounds (Quin-C1 and pyrazolone derivatives in figure 2.1) are 
bonded to different heterocyclic scaffolds such as indazole, indole, quinoline, naphtyridone, 
phthalazinone and phthalhydrazide (schemes 1-8, section 3.1). Any activity was found for these 
compounds towards the three FPR subtypes. Some of them showed low activity as chemotactic agent 
(data not shown) probably due to the interaction with a different biological system or other receptors in 
the neutrophils. Likewise pyridazin-3(2H)-ones bearing a methoxybenzyl or a phenyl group at position 2 
and a functionalized side chain at positions 4 or 5 (schemes 9,10, section 3.1) were inactive as FPRs 
agonists. Performing further modifications on the same scaffold as the insertion of substituted benzyl at 
position 4 together with a functionalized chain at N-2 (scheme 12, section 3.1), we identified compound 
46a (table 4.1), as a potent mixed FPR1 and FPR2 agonist.233 Thus, this first active compound 46a was 
selected as lead and extensive structure-activity relationship (SAR) studies on this prototype were 
performed.  
 
During the development of the project, it became necessary to replace the initial cell line RBL-2H3 (Rat 
basophilic leukemia) cells, used to test agonistic activity of the compounds, with HL-60 cells, having 
higher expression of FPRs and as well higher response to reference molecule fMLF. In the meantime 
some modifications of the lead compound had been already performed, such as the introduction of a 
phenyl group in the position C-6 of the pyridazinone and a iodine on the phenyl of the acetamidic spacer. 
The biological tests carried out on the first cell line (RBL-2H3) showed for these compounds a very 
interesting activity and, thus, several analogues were designed and synthesized on the basis of this 
evidence. Unluckily, the same results were not confirmed by testing the same molecules in HL-60 cell.  
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 4.1.2 EC50 and efficacy of N-arylacetamide pyridazinones  
The nature and the position of the substituent on the phenyl group of the side chain proved to play a 
crucial role in ligand activity as it is shown in table 4.1. Moving Br of lead compound 46a from position 
para to meta (46b) and ortho (46c) resulted in a complete loss of FPR1/FPR2 activity. Among halo-
derivatives, the 4-chloro analogue 46e exhibited the same profile as 46a, while the corresponding 4-iodo 
derivative 46f was two times less potent for FPR2. For this compound, a weak effect at FPR3 was also 
observed. The 4-fluoro analogue 46d was less potent compared to 46a, but specificity for FPR1 was 
demonstrated.  
 
Table 4.1. Activity of the compounds 46a-s  (scheme 12) in HL-60 cells expressing human FPR1, FPR2, or FPR3. 
N
N
O
O
O
R
 
Ca2+ Mobilization EC50 (µM) and Efficacy (%)a  compd 
 
R FPR1 FPR2 FPR3 
46a NH-C6H4-Br (p) 3.4 ± 1.6 (75) 3.8 ± 1.5 (70) N.A. 
46b NH-C6H4-Br (m) N.A. N.A. N.A. 
46c NH-C6H4-Br (o) N.A. N.A. N.A. 
 
    
46d NH-C6H4-F (p) 7.6 ± 0.2 (40) N.A. N.A. 
46e NH-C6H4-Cl (p) 2.6 ± 0.3 (110) 4.0 ± 1.6 (35) N.A. 
46f NH-C6H4-I (p) 2.8 ± 0.2 (90) 6.8 ± 2.2 (40) 13.0 ± 3.1 (30) 
 
    
46g NH-C6H5 N.A. N.A. N.A. 
46h NH-C6H4-CH3 (p) 7.2 ± 2.2 (120) 10.9 ± 3.4 (50) N.A. 
46i NH-C6H4-tC4H9 (p) N.A. N.A. N.A. 
 
    
46j NH-C6H4-OCH3 (p) 7.7 ± 2.5 (65) 14.4 ± 2.0 (35) N.A. 
46k NH-C6H4-OC4H9 (p) N.A. N.A. N.A. 
46l NH-C6H3-(OCH3)2 (3, 4) 15.5 ± 2.9 (25) 16.8 ± 3.2 (25) N.A. 
46m NH-C6H3-3,4-methylenedioxy 2.3 ± 1.1 (50) N.A. N.A. 
 
    
46n NH-C6H4-CF3 (p) 5.7 ± 1.8 (50) 8.8 ± 2.3 (95) N.A. 
46o NH-C6H4-OCF3 (p) N.A. N.A. N.A. 
 
    
46p NH-C6H4-SCH3 (p) 26.4 14.7 N.A. 
46q NH-C6H4-CN (p) N.A. N.A. N.A. 
46r NH-C6H4-NO2 (p) 10.5 ± 2.9 (60) 12.3 ± 2.5 (55) N.A. 
46s 1-methylpiperazine N.A. N.A. N.A. 
 
    
fMLF  0.01 20.4 1.9 
WKYMVm  0.5 0.001 0.01 
aN.A., no activity was observed (no response was observed during first 2 min after addition of compounds under 
investigation) considering the limits of efficacy > 20 % and EC50 < 50 µM. The EC50 values are presented as the 
mean ± S.D. of three independent experiments, in which median effective concentration values (EC50) were 
determined by nonlinear regression analysis of the dose-response curves (5-6 points) generated using GraphPad 
Prism 5 with 95% confidential interval (p < 0.05). Efficacy (in bracket) is expressed as percent of the response 
induced by 5 nM fMLF (FPR1) or 5 nM WKYMVm (FPR2 and FPR3).  
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The elimination of Br (compound 46g) was associated with a complete loss of activity. Replacement of 
Br in 46a with substituents having similar steric properties, such as t-But (46i), OCF3 (46o), and CN 
(46q), led to loss of activity at both FPR1 and FPR2. The 4-trifluoromethyl and the 4-nitro analogues 
(46n and 46r, respectively) as well as compound 46h, bearing a methyl group at position 4, had relatively 
low activity. Introduction of alkoxy groups gave interesting results: the 4-methoxy derivative 46j and the 
3,4-dimethoxy derivative 46l had low activity at both receptors, whereas of the 3,4-methylendioxy 
derivative 46m showed specificity for FPR1. Differently compound 46p, with a methylthio group in the 
para position of the phenyl group showed a drastic decrease of activity. It is worth noting that compounds 
46k, where Br in the para position is substituted with a buthoxy, and 46s, where the amidic nitrogen is 
included in a piperazine nucleus, were found to be completely devoid of activity.  
 
4.1.3 EC50 and efficacy of C-6 modified N-arylacetamide pyridazinones 
SAR studies at position 6 of the pyridazinone ring were planned by modifying the methyl group of the 
lead compound 46a (table 4.1) as follow: elimination or replacement with superior homologues, 
cyclohexyl group, thiophene and (substituted)aryls (table 4.2).  
As it is possible to see from the biological results, the ethyl analogue (50b) displayed a very similar 
behaviour with respect to the lead compound (46a), whereas the isopropyl derivative (50a) resulted a 
mixed agonist for FPR1, FPR2 and FPR3. On the contrary, the introduction of a cyclohexyl at position C-
6 (50c) was associated with FPR1 selectivity. The elimination of the methyl group (50d) led to a quite 
potent but not selective compound, since it was able to activate all the three receptor subtypes. Among 
compounds having a phenyl group at C-6 only 50e, bearing Br in the phenylacetamide chain showed a 
relevant activity, mainly at FPR1 level. The 2-thienyl derivatives 50h-j were completely inactive, as well 
as all compounds bearing OCH3 (50k-m), Cl (50n-p), CH3 (50q-s), F (50t-v), in para position of the 
phenyl at C-6 of pyridazinone nucleous. It is worth nothing the inactivity of 4-F analogue 50t, in 
comparison with the above seen 50e unsubstituted analogue. This finding suggest that for these 
compounds electronic features play a more important role than steric properties.  
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Table 4.2. Activity of the compounds 50a-v (scheme 13) in HL-60 cells expressing human FPR1, FPR2, or FPR3. 
N
N
O
R
O
NH
R1Ar
 
Ca2+ Mobilization EC50 (µM) and 
Efficacy (%)a 
 
compd 
 
R 
 
R1 
 
Ar 
FPR1 FPR2 FPR3 
50a CH2CH3 OCH3 (m) NH-C6H4-I (p) 5.0 (95) 7.2 (75) N.A. 
50b CH(CH3)2 OCH3 (m) NH-C6H4-Br (p) 4.5 (135) 7.2 (90) 17.4 (30) 
50c C6H11 OCH3 (m) NH-C6H4-Br (p) 10.8 (80) N.A. N.A. 
50d H OCH3 (m) NH-C6H4-Br (p) 6.1 (125) 7.7 (60) 14.6 (25) 
 
      
50e C6H5 OCH3 (m) NH-C6H4-Br (p) 9.0 (110) 4.3 (25) N.A. 
50f C6H5 OCH3 (m) NH-C6H3-3,4-methylenedioxy N.A. N.A. N.A. 
50g C6H5 OCH3 (m) NH-C6H4-F (p) N.A. N.A. N.A. 
 
      
50h 2-thienyl OCH3 (p) NH-C6H4-Br (p) N.A. N.A. N.A. 
50i 2-thienyl OCH3 (m) NH-C6H3-3,4-methylenedioxy N.A. N.A. N.A. 
50j 2-thienyl OCH3 (m) NH-C6H4-F (p) N.A. N.A. N.A. 
 
      
50k C6H4-OCH3 OCH3 (p) NH-C6H4-Br (p) N.A. N.A. N.A. 
50l C6H4-OCH3 OCH3 (m) NH-C6H3-3,4-methylenedioxy N.A. N.A. N.A. 
50m C6H4-OCH3 OCH3 (m)  NH-C6H4-F (p) N.A. N.A. N.A. 
 
      
50n C6H4-Cl OCH3 (p) NH-C6H4-Br (p) N.A. N.A. N.A. 
50o C6H4-Cl OCH3 (m) NH-C6H3-3,4-methylenedioxy N.A. N.A. N.A. 
50p C6H4-Cl OCH3 (m) NH-C6H4-F (p) N.A. N.A. N.A. 
 
      
50q C6H4-CH3 OCH3 (p) NH-C6H4-Br (p) N.A. N.A. N.A. 
50r C6H4-CH3 OCH3 (m) NH-C6H3-3,4-methylenedioxy N.A. N.A. N.A. 
50s C6H4-CH3 OCH3 (m) NH-C6H4-F (p) N.A. N.A. N.A. 
 
      
50t C6H4-F OCH3 (p)  NH-C6H4-Br (p) N.A. N.A. N.A. 
50u C6H4-F OCH3 (m) NH-C6H3-3,4-methylenedioxy N.A. N.A. N.A. 
50v C6H4-F OCH3 (m) NH-C6H4-F (p) N.A. N.A. N.A. 
 
      
46a    3.4 (75) 3.8 (70) N.A. 
fMLF    0.01 20.4 1.9 
WKYMVm    0.5 0.001 0.01 
aN.A., no activity was observed (no response was observed during first 2 min after addition of compounds under 
investigation) considering the limits of efficacy > 20 % and EC50 < 50 µM. The EC50 values are presented as the 
mean of three independent experiments, in which median effective concentration values (EC50) were determined 
by nonlinear regression analysis of the dose-response curves (5-6 points) generated using GraphPad Prism 5 with 
95% confidential interval (p < 0.05). Efficacy (in bracket) is expressed as percent of the response induced by 5 
nM fMLF (FPR1) or 5 nM WKYMVm (FPR2 and FPR3).  
 
4.1.4 EC50 and efficacy of C-4 modified N-arylacetamide pyridazinones 
SAR studies at position 4 were performed on the lead compound 46a (table 4.1) as function of the 
following criteria:  
a) complete elimination of the substituents of the benzyl or replacement with a methyl group 
(table 4.3); 
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b) replacement of the methoxyphenyl in benzyl group with heterocycles or different aromatic 
groups (table 4.4); 
c) introduction of different substituents in meta position of the benzyl group (table 4.4); 
d) introduction of substituents in para position of the benzyl group (table 4.4); 
e) elimination of OCH3 on the benzyl group (table 4.4); 
f) elimination of the CH2-spacer of the benzyl group or introduction of different functionalized 
linkers (table 4.5). 
 
a) With the exception of low active agonists (±)-53b and 57c,d (table 4.3), the derivatives in which the 
methoxybenzyl is eliminated or replaced by a methyl group were completely devoid of activity and this 
behaviour is evident in both series of 4,5-dihydropyridazinones (53a-d) and pyridazinones (57a-f). 
 
Table 4.3. Activity of compounds 53a-d and 57a-f (schemes 14,15) in HL-60 cells expressing human FPR1, FPR2, or FPR3. 
N N
O R
R1
O H
N
N N
O R
R1
O H
NAr Ar
53a-d 57a-f
 
Ca2+ Mobilization EC50 (µM) and 
Efficacy (%)a 
 
compd 
 
R 
 
R1 
 
Ar 
FPR1 FPR2 FPR3 
53a CH3 H NH-C6H4-I (p) N.A. N.A. N.A. 
 
      
(±)-53b C6H5 CH3 NH-C6H4-Br (p) 23.5 (55) 7.0 (65) N.A. 
(±)-53c C6H5 CH3 NH-C6H4-F (p) N.A. N.A. N.A. 
(±)-53d C6H5 CH3 NH-C6H3-3,4-methylenedioxy N.A. N.A. N.A. 
 
      
57a C6H11 H NH-C6H4-F (p) N.A. N.A. N.A. 
57b C6H11 H NH-C6H3-3,4-methylenedioxy N.A. N.A. N.A. 
 
  
 
   
57c CH3 H NH-C6H4-I (p) 30.4 (45) 19.7 N.A. 
 
      
57d C6H5 CH3 NH-C6H4-Br (p) 21.5 (50) 10.1 (45) N.A. 
57e C6H5 CH3 NH-C6H4-F (p) N.A. N.A. N.A. 
57f C6H5 CH3 NH-C6H3-3,4-methylenedioxy N.A. N.A. N.A. 
 
      
46a    3.4 (75) 3.8 (70) N.A. 
fMLF    0.01 20.4 1.9 
WKYMVm    0.5 0.001 0.01 
aN.A., no activity was observed (no response was observed during first 2 min after addition of compounds under 
investigation) considering the limits of efficacy > 20 % and EC50 < 50 µM. The EC50 values are presented as the 
mean of three independent experiments, in which median effective concentration values (EC50) were determined 
by nonlinear regression analysis of the dose-response curves (5-6 points) generated using GraphPad Prism 5 with 
95% confidential interval (p < 0.05). Efficacy (in bracket) is expressed as percent of the response induced by 5 
nM fMLF (FPR1) or 5 nM WKYMVm (FPR2 and FPR3).  
 
b) Useful informations originated by replacement of methoxyphenyl group whit 5- and 6-membered 
heterocycles (table 4.4). Indeed, both thienyl derivatives (61b,c) showed an interesting level of potency 
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but a weak selectivity for FPR1, as well as furyl (61a) and piridyl (66c) analogues which had a similar 
profile of activity without relevant subtype-selectivity. On the contrary, the insertion of a naphtylmethyl 
(61d) and a 3,5 dimethoxybenzyl (61f, 62b) groups in the position 4 was associated with decrease or 
complete loss of the activity. 
 
Table 4.4. Activity of compounds 61a-p, 62a-c and 66a-c (schemes 16-18) in HL-60 cells expressing human FPR1, FPR2, or 
FPR3. 
N
N
O
RO
NHR1
 
Ca2+ Mobilization EC50 (µM) and Efficacy 
(%)a 
 
compd 
 
R
 
 
R1 
FPR1 FPR2 FPR3 
61a 3-furyl Br (p) 5.8 (100) 6.3 (75) N.A. 
61b 3-thienyl Br (p) 4.5 (100) 14.1 (65) N.A. 
61c 2-thienyl Br (p) 8.1 (140) 11.4 (60) 10.2 (25) 
61d 1-naphthyl Br (p) 13.8 (20) N.A. N.A. 
66c 3-pyridyl Br (p) 9.3 (85) 2.8 (90) N.A. 
 
     
61e C6H4-OCH3 (p) Br (p) N.A. 2.4 ± 0.9 (70) N.A. 
61f C6H3-(OCH3)2 (3,5) Br (p) N.A. N.A. N.A. 
62b C6H3-(OCH3)2 (3,5) I (p) 11.1 (90) 9.7 N.A. 
 
 
 
 
  
61g C6H4-F (m) Br (p) 6.6 (110) N.A. N.A. 
61h C6H4-Cl (m) Br (p) 10.5 (100) N.A. N.A. 
62c C6H4-Cl (m) I (p) 6.8 (65) 10.6 (30) N.A. 
61i C6H4-Br (m) Br (p) N.A. N.A. N.A. 
 
     
61j C6H4-SCH3 (p) Br (p) N.A. N.A. N.A. 
62a C6H4-SCH3 (p) I (p) 19.7 (60) 15.9 (90) 30.1 
61k C6H4-CF3 (p) Br (p) N.A. N.A. N.A. 
66a C6H4-CN (p) Br (p) N.A. N.A. N.A. 
66b C6H4-CONH2 (p) Br (p) 29.3 (40) 27.2 (80) N.A. 
 
     
61 l C6H5 Br (p) 5.5 (50) 11.6 (20) N.A. 
61m C6H5 F (p) N.A. N.A. N.A. 
61n C6H5 3,4-methylenedioxy 6.9 (55) N.A. N.A. 
 
     
61o C6H4-Cl (p) O-C4H9-n (p) N.A. N.A. N.A. 
61p C6H4-OCH3 (p) O-C4H9-n (p) N.A. N.A. N.A. 
 
     
46a   3.4 ± 1.6 (75) 3.8 ± 1.5 (70) N.A. 
fMLF   0.01 20.4 1.9 
WKYMVm   0.5 0.001 0.01 
aN.A., no activity was observed (no response was observed during first 2 min after addition of compounds under 
investigation) considering the limits of efficacy > 20 % and EC50 < 50 µM. The EC50 values are presented as the 
mean ± S.D. of three independent experiments, in which median effective concentration values (EC50) were 
determined by nonlinear regression analysis of the dose-response curves (5-6 points) generated using GraphPad 
Prism 5 with 95% confidential interval (p < 0.05). Efficacy (in bracket) is expressed as percent of the response 
induced by 5 nM fMLF (FPR1) or 5 nM WKYMVm (FPR2 and FPR3).  
 
c) Replacement of 3-methoxy group, on the benzyl at position 4 of the pyridazinone nucleous of the lead 
compound 46a, with different substituents showed as well attractive results (table 4.4). In fact, 
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introduction of F in meta position gave compound 61g which is a selective FPR1 agonist and a similar 
behaviour was evident for compound with Cl (61h). Differently, analogue 62c bearing a 4-iodophenyl in 
the acetamidic spacer was a mixed FPR1/FPR2 agonist. Introduction of a Br (61i) in the place of OCH3 
group of lead compound 46a was associated with loss of activity. All these data suggest that the presence 
of a substituents of limited hindrance in the meta position is an essential requirement for binding at FPR1 
and FPR2. 
 
d) Moving OCH3 from the meta to the para position (61e) surprisingly resulted in high activity (EC50 = 
2.4 µM) and selectivity for FPR2 (table 4.4). Oppositely, introduction of SCH3 (61j, 62a), CF3 (61k), CN 
(66a) and CONH2 (66b) in the para position was generally detrimental. However compound 62a, bearing 
a 4-iodophenyl moiety on the acetamidic linker, and the benzamide derivative 66b showed a weak mixed 
agonistic activity. These data confirmed that the methoxy group is the optimum for steric and electronic 
properties in the aromatic moiety at position 4 of the pyridazinone nucleous, as both biological results of 
old (46a, table 4.1) and new (61e, table 4.4) lead compounds showed. On the contrary, compounds 61o 
and 61p where a 4-Cl or a 4-OCH3 were introduced in the benzyl group and bearing a buthoxy group on 
the phenylacetamide spacer were completely devoid of activity. 
 
e) In comparison to lead compound 46a (table 4.1), when OCH3 group was eliminated from the benzyl 
fragment at position 4 of the pyridazinone scaffold (61 l) the activity lowered particularly as FPR2 
agonist (table 4.4), while the concomitant presence of an unsubstituted benzyl at C-4 and F (61m) or 
methylenedioxy (61n) in the aryl acetamide side chain was associated in the first case with a complete 
loss of activity and in the second with a weak agonistic FPR1 activity.  
 
f) Introduction of carbonyl group as spacer in the place of CH2 of the benzyl group at position 4 of the 
pyridazinone ring resulted in compound 71 which is a potent mixed agonist of both FPR1 and FPR2 
(table 4.5), while elimination of the methylenic linker originated a very selective ligand (77) at FPR1. 
When CH2 was replaced by NH (88) an interesting activity was found mainly at FPR2 and the same 
behaviour was shown by the 5-acetyl analogue (83), whereas the synthetic precursor 87 resulted less 
potent as FPR2 ligand. Substitution of CH2 with an amidic group was detrimental for activity, since 
compound 89a was totally inactive and the 3-methoxy analogue 89b showed low activity as FPR1/FPR2 
agonist. Lastly, when more hindered substituents were introduced in the position 4, the activity 
disappeared completely, being compound 69 and the biaryl derivative 92 completely devoid of activity.  
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Table 4.5. Activity of compounds 69, 71, 77, 83, 87-89a,b and 92 (schemes 18-21) in HL-60 cells expressing human FPR1, 
FPR2, or FPR3. 
N
N
O
RO
NH
Br
R1
 
Ca2+ Mobilization EC50 (µM) 
and Efficacy (%)a 
 
compd 
 
R 
 
R1 
FPR1 FPR2 FPR3 
69 CH2-C6H4-CONH(p)-C6H4-Br (p) H N.A. N.A. N.A. 
 
     
71 CO-C6H4-OCH3 (m) H 3.0 (140) 1.4 (100) N.A. 
77 C6H4-OCH3 (p) H 11.2 (55) N.A. N.A. 
 
     
83 NH-C6H4-OCH3 (p) COCH3 13.5 (75) 2.3 (80) N.A. 
 
     
87 NH2 H 8.1 (115) 29.4 (85) N.A. 
88 NH-C6H4-OCH3 (p) H 12.8 (100) 3.8 (85) N.A. 
89a NHCO-C6H4-Br (p) H N.A. N.A. N.A. 
89b NHCO-C6H4-OCH3 (m) H 9.3 (120) 6.4 (70) N.A. 
92 N-(C6H4-OCH3(p))2 H N.A. N.A. N.A. 
 
 
 
 
  
46a  
 
3.4 (75) 3.8 (70) N.A. 
fMLF   0.01 20.4 1.9 
WKYMVm   0.5 0.001 0.01 
aN.A., no activity was observed (no response was observed during first 2 min after addition of compounds under 
investigation) considering the limits of efficacy > 20 % and EC50 < 50 µM. The EC50 values are presented as the 
mean of three independent experiments, in which median effective concentration values (EC50) were determined 
by nonlinear regression analysis of the dose-response curves (5-6 points) generated using GraphPad Prism 5 with 
95% confidential interval (p < 0.05). Efficacy (in bracket) is expressed as percent of the response induced by 5 
nM fMLF (FPR1) or 5 nM WKYMVm (FPR2 and FPR3).  
 
4.1.5 EC50 and efficacy of N-arylacetamide modified pyridazinones, N-2/C-4 inverted 
pyridazinones and C-3 substituted pyridazine analogue 
Elongation of carbon chain from one to two methylene groups, at the level of aryl acetamide side chain of 
lead compound 46a, gave 95a which resulted less potent of the lead compound as FPR1/FPR2 ligand 
(table 4.6). More substantial modifications of the functionalized chain were obtained with compounds 
96a,b and were completely detrimental. Further inactive compounds were the urea derivative 97a, the 
inverse amide 97b, as well as their superior homologues 103a,b. Replacement of CH2CONH of the lead 
compound 46a with a secondary amine and an ether group gave compounds 100 and 101 respectively, 
which also resulted inactive. Other unproductive modifications of the functionalized chain were 
performed with the synthesis of compounds 104a,c, and replacement of CONH with COO (104b) gave 
the same effect. Differently when the amidic group of the lead compound 46a was changed into the 
corresponding thioamide (105) a low activity toward FPR2 is retained. Moreover, compounds 108 and 
109, in which the substituents at position 2 and 4 were interchanged, were inactive. Finally, moving the 4-
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bromo phenylacetamide moiety from the N-2 to the C-3 of the pyridazinone led to a decrease of activity, 
being the pyridazine derivative 111 a selective but weak FPR2 agonist.  
 
Table 4.6. Activity of compounds 95-97a,b, 100-102, 103a,b, 104a-c, 105, 108, 109 (structure A) and 111 (schemes 22-27) in 
HL-60 cells expressing human FPR1, FPR2, or FPR3. 
 
N
N
O
XY
R1
R HN
N
X
R1
S
Y
R
A 111
 
Ca2+ Mobilization EC50 (µM) and Efficacy 
(%)a 
 
Compd 
 
Y 
 
R 
 
X 
 
R1 
FPR1 FPR2 FPR3 
95a (CH2)2CONH Br (p) CH2 OCH3 (m) 9.7 ± 2.7 (30) 5.4 ± 1.2 (25) N.A. 
96a CH2 Br (p) CH2 OCH3 (m) N.A. N.A. N.A. 
96b CH2CO Br (p) CH2 OCH3 (m) N.A. N.A. N.A. 
 
    
  
 
97a CH2NHCONH Br (p) CH2 OCH3 (m) N.A. N.A. N.A. 
97b CH2NHCO Br (p) CH2 OCH3 (m) N.A. N.A. N.A. 
103a (CH2)2NHCONH Br (p) CH2 OCH3 (m) N.A. N.A. N.A. 
103b (CH2)2NHCO Br (p) CH2 OCH3 (m) N.A. N.A. N.A. 
 
      N.A. 
100 (CH2)2NH Br (p) CH2 OCH3 (m) N.A. N.A.  
101 (CH2)2° Br (p) CH2 OCH3 (m) N.A. N.A. N.A. 
 
      
 
104a CH2CONHCH2 Br (p) CH2 OCH3 (m) N.A. N.A. N.A. 
104b CH2COO Br (p) CH2 OCH3 (m) N.A. N.A. N.A. 
104c CH2CON(CH3) Br (p) CH2 OCH3 (m) N.A. N.A. N.A. 
105 CH2CSNH Br (p) CH2 OCH3 (m) N.A. 8.3 (< 25) N.A. 
 
    
 
  
108 CH2 OCH3 (m) NHCO Br (p) N.A. N.A. N.A. 
109 CH2 OCH3 (m) NHCONH  Br (p) N.A. N.A. N.A. 
 
    
 
  
111 CH2CONH Br (p) CH2 OCH3 (p) N.A. 14.7 (< 25) N.A. 
 
    
 
  
46a 
    
3.4 (75) 3.8 (70) N.A. 
fMLF     0.01 20.4 1.9 
WKYMVm     0.5 0.001 0.01 
aN.A., no activity was observed (no response was observed during first 2 min after addition of compounds under 
investigation) considering the limits of efficacy > 20 % and EC50 < 50 µM. The EC50 values are presented as the 
mean ± S.D. of three independent experiments, in which median effective concentration values (EC50) were 
determined by nonlinear regression analysis of the dose-response curves (5-6 points) generated using GraphPad 
Prism 5 with 95% confidential interval (p < 0.05). Efficacy (in bracket) is expressed as percent of the response 
induced by 5 nM fMLF (FPR1) or 5 nM WKYMVm (FPR2 and FPR3).  
 
4.1.6 EC50 and efficacy of chiral pyridazinone analogues 
The insertion of alkyl or aryl groups at the level of the methylene spacer in the acetamide side chain of 
the lead compound 46a (table 4.1, scheme 12) led to series of branched and chiral compounds which 
were tested both as racemates and as pure enantiomers. Starting from compound (±)-95b, data showed 
that the racemate did not activate FPR2 but retained activity for FPR1 similar to that of 46a (table 4.7). 
As soon as the biological tests on the pure enantiomers were ongoing, the higher activity of the R-(-)-
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forms of the alkyl derivatives was evident from the beginning. Indeed, the first tested enantiomers R-(-)-
95b and R-(-)-117a showed to be more active at both FPR1 and FPR2 compared to the corresponding S-
(+)-forms [S-(+)-95b and S-(+)-117a].  
 
Table 4.7. Activity of racemates and pure enantiomers (±)-95b, (±)-117a-f and non chiral homologue 118 (schemes 22, 29, 
30) in HL-60 cells expressing human FPR1, FPR2, or FPR3. 
N
N
O
∗
O
NH
O
R R1
Br
 
Ca2+ Mobilization EC50 (µM) and Efficacy 
(%)a 
 
compd 
 
R
 
 
R1 
FPR1 FPR2 FPR3 
(±)-95b H CH3 3.2 ± 1.5 (90) N.A. N.A. 
S-(+)-95b H CH3 17.9 (35) N.A. N.A. 
R-(-)-95b H CH3 8.4 (80) 14.4 (70) N.A. 
 
  
   
(±)-117a H C2H5 1.4 (160) 1.2 (100) N.A. 
S-(+)-117a H C2H5 15.7 (130) 23.1 (55) N.A. 
R-(-)-117a H C2H5 2.8 (135) 3.0 (70) N.A. 
 
     
(±)-117b H n-C3H7 2.8 (75) 2.3 (60) N.A. 
S-(+)-117b H n-C3H7 N.A. N.A. N.A. 
R-(-)-117b H n-C3H7 0.5 (90) 0.6 (90) N.A. 
 
     
(±)-117c H i-C3H7 2.0 (75) 13.5 (30) N.A. 
S-(+)-117c H i-C3H7 N.A. N.A. N.A. 
R-(-)-117c H i-C3H7 1.9 (95) 3.9 (70) N.A. 
 
  
 
  
(±)-117d H n-C4H9 1.1 (110) 0.20 (110) N.A. 
S-(+)-117d H n-C4H9 21.8 (40) 15.2 (45) N.A. 
R-(-)-117d H n-C4H9 0.7 (120) 0.10 (110) N.A. 
 
  
 
  
(±)-117e H C6H5 0.26 (80) 0.24 (45) N.A. 
S-(+)-117e H C6H5 0.16 (120) 0.18 (50) N.A. 
R-(-)-117e H C6H5 N.A. N.A. N.A. 
 
     
(±)-117f CH3 C2H5 1.5 (70) N.A. N.A. 
S-(+)-117f CH3 C2H5 2.1 (80) N.A. N.A. 
R-(-)-117f CH3  C2H5 4.8 (50) N.A. N.A. 
 
     
118 CH3 CH3 3.7 (50) N.A. N.A. 
 
  
 
  
46a 
  
3.4 ± 1.6 (75) 3.8 ± 1.5 (70) N.A. 
fMLF   0.01 20.4 1.9 
WKYMVm   0.5 0.001 0.01 
aN.A., no activity was observed (no response was observed during first 2 min after addition of compounds under 
investigation) considering the limits of efficacy > 20 % and EC50 < 50 µM. The EC50 values are presented as the 
mean ± S.D. of three independent experiments, in which median effective concentration values (EC50) were 
determined by nonlinear regression analysis of the dose-response curves (5-6 points) generated using GraphPad 
Prism 5 with 95% confidential interval (p < 0.05). Efficacy (in bracket) is expressed as percent of the response 
induced by 5 nM fMLF (FPR1) or 5 nM WKYMVm (FPR2 and FPR3).  
 
This behaviour was mainly confirmed by testing n-propyl and i-propyl derivatives (±)-117b and (±)-117c. 
In this case the (+)-forms were completely inactive, while enantiomers R-(-)-117b and R-(-)-117c 
4.Results and Conclusions 
 77 
showed an increase of activity being their EC50 in the sub-micromolar and low micromolar range 
respectively (table 4.7). Elongation of carbon chain on the chiral center gave n-butyl derivative (±)-117d 
which, even if it showed less stereoselectivity, in his (-)-form resulted the most potent FPR1/FPR2 mixed 
agonist of the series (EC50 = 100 nM for FPR2). Introduction of a phenyl group in the chiral center gave 
racemate (±)-117e having an activity in the sub-micromolar range. In this case, enantiomer S-(+)-117e is 
more potent of its racemate, while R-(-)-117e is completely devoid of activity. This is a surprising result 
in terms of stereoselectivity, also taking into account that the previously discussed alkyl derivatives have 
always in their R-(-)-forms the most potent compounds of each pair (see enantiomers (-)-95b and (-)-
117a-d, table 4.7). Introduction of an additional alkyl group on the chiral center raised a complete loss of 
stereoselectivity and a total shift of activity toward FPR1. Indeed compounds (+)-117f and   (-)-117f, 
bering on the chiral center a methyl and an ethyl group, are selective agonists of FPR1 and their racemate 
(±)-117f resulted more potent than the pure enantiomers on the same receptor. In this case the sterical 
hindrance on the chiral center seemed to be the main determinant for the activity and the selectivity, and 
this result was confirmed again by testing the non chiral analogue 118, which is as well a selective and 
relatively potent FPR1 agonist. 
 
4.1.7 Evaluation of chemotactic activity and Ca2+ mobilization 
Compounds that showed the best agonistic profiles were as well selected to evaluate their activity as 
chemotactic agents and their ability to produce Ca2+ mobilization in human neutrophils. 
 
Figure 4.1. Analysis of Ca2+ mobilization in phagocytes treated with compound 46a. HL-60-FPR1 and HL-60-
FPR2 cells (A) or human neutrophils (B) were loaded with FLIPR calcium 3 dye, and Ca2+ flux was analyzed, as 
described in section 6. Responses were normalized to the response induced by 5 nM fMLF for HL-60-FPR1 cells 
and neutrophils, or 5 nM WKYMVm for HL-60-FPR2 cells, which were assigned a value of 100%. (C) 
Representative kinetics of Ca2+ mobilization after treatment with compound 46a or fMLF. Human neutrophils 
were treated with the compound 46a (1.5 and 3 µM), 5 nM fMLF (positive control), or 1% DMSO (negative 
control), and Ca2+ flux was monitored for the indicated times. The data are from one experiment that is 
representative of three independent experiments. 
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Table 4.8. Ca2+ mobilization and chemotactic activity in human neutrophils treated with selected FPR1/FPRL1 agonists. 
EC50 (µM) 
Compd Ca2+ mobilization Chemotaxis 
46a 2.6 ± 0.3 2.1 ± 0.8 
46d 3.9 ± 0.6 8.2 ± 1.4 
46e 6.7 ± 1.1 1.6 ± 0.2 
46f 3.2 ± 1.2 1.8 ± 0.3 
46h 3.2 ± 0.3 0.6 ± 0.3 
46j 1.6 ± 0.8 0.9 ± 0.2 
46l 1.1 ± 0.6 1.1 ± 0.6 
46m 3.6 ± 1.0 1.2 ± 0.6 
46n 3.6 ± 0.8 4.5 ± 2.5 
46r 21.7 ± 4.2 1.9 ± 0.6 
61e 4.3 ± 1.1 13.1 ± 2.3 
95a 11.3 ± 2.8 11.8 ± 2.6 
(±)-95b 0.8 ± 0.2 0.6 ± 0.4 
The data are presented as the mean ± S.D. of three independent experiments with cells from different donors, in 
which median effective concentration values (EC50) were determined by nonlinear regression analysis of the 
dose-response curves (5-6 points) generated using GraphPad Prism 5 with 95% confidential interval (p < 0.05). 
 
Some of these FPRs agonists proved to be able to stimulate chemotaxis at sub-micromolar concentrations 
(table 4.8). Furthermore, the effect of selected agonists on Ca2+ flux in human neutrophils was also 
determined to verify if the results coming from HL-60 tests were confirmed in primary phagocytes (table 
4.8). We usually found that both selective and nonselective agonists identified in HL-60 cell assays also 
induced Ca2+ flux in human neutrophils, with EC50 values in the range 0.8-21.7 µM. Among compounds 
tested to evaluate the chemotactic activity, the most potent resulted 46h (EC50 = 0.6 µM) and 46j (EC50 = 
0.9 µM), which were both FPR1/FPR2 nonselective agonists. It is noteworthy that the FPR2-selective 
agonist (61e) showed lower potency (EC50 = 13.1 µM) as chemotactic agent.  
For lead compound 46a were also calculated dose-response curves as shown in figure 4.1. 
 
4.2 Conclusions 
In conclusion, the data acquired and processed till now showed that we have identified a novel chemotype 
endowed with interesting selective or mixed FPR1/FPR2 agonistic activity in human neutrophils. From 
biological tests it resulted evident that, by manipulating the chemical structure of a series of N-
arylacetamide pyridazinones (46a-s, scheme 12, table 4.1), it is possible to achieve potency and 
selectivity towards FPR1 and FPR2 subtype receptors.  
Going to analyse the data in our hands, we can observe that regarding the aromatic system at the end of 
the functionalized chain in position 2 (scheme 12, table 4.1), the presence of a lipophilic and/or 
electronegative substituent, such as F, Br, I or CH3, in position para is an essential requirement for 
potency and/or selectivity.  
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The position 6 (table 4.2) of the pyridazinone ring resulted poorly tolerant to modifications. A methyl 
group is the substituent that gives the best results regarding the activity as agonist, while its elimination or 
substitution with more hindered moiety produce a deep loss of activity. 
Likewise, the presence of an acetamide spacer at N-2 of the pyridazinone ring also plays a crucial role in 
specificity and potency (table 4.6). The role of both CO and NH in the side chain seems to indicate that a 
hydrogen bond donor (HBD) neighbouring an acceptor (HBA) system is also an essential requirement for 
binding at FPRs. Moreover, this HBD\HBA system must be placed at an appropriate distance from both 
the aromatic and the heterocyclic scaffold. The very low activity of the thioamide analogue 105 (table 
4.6) further support this hypothesis.  
Differently, the position 4 (tables 4.3-4.5) resulted more amenable to chemical manipulation, indeed 
heterocycles (e.g. thienyl, piridyl, furyl) or substituted benzyl groups and functionalised spacers (e.g. CO, 
NH) can be productively introduced at this level, retaining a good agonistic activity. 
Lastly, the chiral compounds reported in this work (table 4.7) represent a series of homologues 
differently hindered at stereocenter level and all of them show a different affinity for the three FPR 
isoforms. Enantioselectivity showed from the R-(-)-enantiomers, among the alkyl derivatives, may be 
related to the ability of these compounds to establish a better interaction with the receptors, compared to 
the respective S-(+)-forms. On the other hand, for enantiomers S-(+)-117e and R-(-)-117e the activity of 
the pure enantiomers resulted exactly the opposite, probably due to the high hindrance and lipophilicity of 
the phenyl group. Furthermore, in contrast with compounds having just one alkyl group on the chiral 
center, dialkylated enantiomers of (±)-117f did not show enantioselectivity and in addition, chirality 
doesn’t seem crucial for the activity. This result was evident testing non chiral dimethyl analogue 118; 
however both dimethyl and chiral ethyl-methyl derivatives showed selectivity for FPR1.  
 
Work is underway and further modification have been planned to develop new FPRs agonists hoping they 
may be useful to gain further structure-activity relationships in this class of compounds in order to 
optimize the potency and selectivity and to increase the knowledge of the pharmacological basis of FPRs 
binding and signalling. 
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5.1 Materials and Methods 
Reagents and starting materials were obtained from commercial sources. Extracts were dried over 
Na2SO4, and the solvents were removed under reduced pressure. All reactions were monitored by thin 
layer chromatography (TLC) using commercial plates precoated with Merck silica gel 60 F-254. 
Visualization was performed by UV fluorescence (λmax = 254 nm) or by staining with iodine or potassium 
permanganate. Chromatographic separations were performed on a silica gel column by gravity 
chromatography (Kieselgel 40, 0.063-0.200 mm; Merck), flash chromatography (Kieselgel 40, 0.040-
0.063 mm; Merck), silica gel preparative TLC (Kieselgel 60 F254, 20 x 20 cm, 2 mm), or CombiFlash® Rf 
System (using RediSep® Rf Silica Columns, Teledyne Isco, Lincoln, Nebraska, USA). Yields refer to 
chromatographically and spectroscopically pure compounds, unless otherwise stated. When reactions 
were performed in anhydrous conditions, the mixtures were maintained under nitrogen atmosphere. 
Compounds were named following IUPAC rules as applied by Beilstein-Institut AutoNom 2000 
(4.01.305) or CA Index Name.  
The identity and purity of intermediates and final compounds was ascertained through NMR and TLC 
chromatography. All melting points were determined on a microscope hot stage Büchi apparatus and are 
uncorrected. 
1H NMR spectra were recorded with Avance 400 instruments (Bruker Biospin Version 002 with SGU). 
Chemical shifts (δ) are reported in ppm to the nearest 0.01 ppm, using the solvent as internal standard. 
Coupling constants (J values) are given in Hz and were calculated using ‘TopSpin 1.3’ software rounded 
to the nearest 0.1 Hz. Data are reported as follows: chemical shift, multiplicity [exch, exchange; br, broad; 
s, singlet; d, doublet; t, triplet; q, quartet; quin, quintet; sext, sextet; sept, septet; m, multiplet; or as a 
combination of these (e.g. dd, dt etc.)], integration, assignment and coupling constant(s). Diastereotopic 
protons are assigned as CH-H. Mass spectra (m/z) were recorded on a ESI-TOF mass spectrometer 
(Bruker Micro TOF) and reported mass values are within the error limits of ± 5 ppm mass units. IR 
spectra were measured as Nujol mulls for solids and neat for liquids with a PerkinElmer Spectrum (RX I 
FT-IR, Spectrum 1000) spectrometer. Absorption maxima (λmax) are reported in wavenumbers (cm-1).  
Semi-preparative HPLC enantioseparations were performed using stainless-steel Chiralcel OD® (250 mm 
x 4.6 mm I.D., 10 µm particle size, Chiral Technologies Europe, Illkirch, France) and Lux Amylose-2® 
(250 mm x 4.6 mm I.D., 5 µm particle size, Phenomenex,  Bologna, Italy) columns. The HPLC apparatus 
consisted of a Perkin-Elmer (Norwalk, CT) series 200 composed by quaternary pump, autosampler, 
Peltier column oven and UV-VIS detector coupled with a Biologic BioFrac fraction collector (from Bio-
Rad, Milan, Italy). UV detector wavelength was fixed at 250 nm. HPLC-grade solvents were supplied by 
Sigma-Aldrich (Milan, Italy). The mobile phases were a mixtures of n-hexane/IPA and they were 
degassed by sonication just before use. The signal was acquired and processed by Totalchrom 6.3.1.0504 
5. Experimental Chemistry 
 
 84 
software. The values of retention time (tR) are given in minutes. After semipreparative separation, the 
collected fractions were analyzed on the same HPLC instrument by chiral Lux Amylose-2® (50 mm x 4.6 
mm I.D., 3 µm particle size, Phenomenex, Bologna, Italy) column to determine their enantiomeric excess 
(ee). The ee values were calculated from relative peak areas of enatiomeric pairs. The mobile phase was 
n-hexane/IPA 60:40. In analytical enantioseparations, a standard solution was prepared by diluting 0.1 mg 
of compounds into 1 mL of ethanol. The injection volume was 10 µL, the flow rate 1.0 mL/min, the 
temperature of column was 40 °C and UV detector wavelength was fixed at 250 nm.  
Specific rotations of enantiomers were measured at 589 nm with a Perkin-Elmer polarimeter model 241 
equipped with a Na lamp. The volume of the cell was 2 mL, and the optical path was 10 cm. A standard 
solution was prepared by dissolving 20 mg of compounds into 2 mL of CHCl3 (c = 1). The system was set 
at a temperature of 20 °C using a Neslab RTE 740 cryostat. 
The circular dichroism (CD) spectra of enantiomers, dissolved in methanol (concentrations are about 0.25 
mg/mL for analytes and 1 mg/mL for reference molecules) in a quartz cell (0.1 cm-path length) at 25 °C 
were measured using a Jasco model J-810 spectropolarimeter (Jasco, Ishikawa-cho, Hachioji City, Tokyo, 
Japan). The spectra were averaged over five instrumental scans from 350 to 215 nm at 50nm/min 
scanning speed, acquired and processed with Spectra Analysis software and the intensities are presented 
in terms of ellipticity values (mdeg). 
 
5.2 Experimental 
General Procedure for 1a,b. To a cooled (0 °C) and stirred suspension of commercially available 
indazole-3-carboxylic or indole-3-carboxylic acid (1.55 mmol) in SOCl2 (3 mL), Et3N (0.2 mL) was 
added. After 1 h at 60 °C, the mixture was cooled and the excess of SOCl2 was removed in vacuo. The 
residue was then dissolved in anhydrous THF (1.5 mL) and cooled at 0 °C. A solution of 4-
n.butoxyaniline (3.10 mmol) in anhydrous THF (1 mL) was added dropwise and the reaction was carried 
out at room temperature for 12 h. The mixture was concentrated in vacuo, diluted with ice-cold water (10 
mL) and kept under stirring at 0 °C for 0.5 h; then the precipitate was filtered off and purified by 
crystallization from ethanol to afford intermediate compounds 1a,b.  
5.2.1 N-(4-Butoxyphenyl)-1H-indazole-3-carboxamide (1a) 
N
H
N
O H
N
O
 
Yield = 97 %; mp = 157-159 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 6.7 Hz), 1.52 
(sext, 2H, CH2CH3, J = 7.4 Hz), 1.80 (quin, 2H, CH2CH2CH2, J = 6.9 Hz), 4.00 (t, 2H, OCH2, J = 6.6 
Hz), 6.94 (d, 2H, Ar, J = 8.3 Hz), 7.36 (t, 1H, Ar, J = 8.0 Hz), 7.50 (t, 1H, Ar, J = 8.4 Hz), 7.57 (d, 1H, 
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Ar, J = 8.4 Hz), 7.67 (d, 2H, Ar, J = 8.3 Hz), 8.49 (d, 1H, Ar, J = 8.2 Hz), 8.85 (exch br s, 1H, NH), 10.42 
(exch br s, 1H, NH). 
5.2.2 N-(4-Butoxyphenyl)-1H-indole-3-carboxamide (1b) 
N
H
O H
N
O
 
Yield = 94 %; mp = 181-182 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.3 Hz), 1.52 
(sext, 2H, CH2CH3, J = 7.5 Hz), 1.79 (quin, 2H, CH2CH2CH2, J = 6.7 Hz), 3.97 (t, 2H, OCH2, J = 6.4 
Hz), 6.93 (d, 2H, Ar, J = 8.4 Hz), 7.31 (t, 2H, Ar, J = 3.2 Hz), 7.48 (d, 1H, Ar, J = 5.9 Hz), 7.56 (d, 2H, 
Ar, J = 8.5 Hz), 7.86 (s, 1H, Ar), 8.06 (d, 1H, Ar, J = 3.7 Hz), 8.78 (exch br s, 1H, NH), 9.21 (exch br s, 
1H, NH). 
 
General Procedure for 2a-d. To the suspension of 1a or 1b (0.32 mmol), copper acetate (0.48 
mmol) and 3- or 4-methoxyphenylboronic acid (0.64 mmol) in CH2Cl2 (2 mL), Et3N (0.96 mmol) was 
added and the mixture was stirred at room temperature for 5-12 h. The suspension was extracted with 
15% aqueous ammonia (10 mL), and the organic layer was washed with 10 mL of water and dried over 
Na2SO4. After removal of the solvent under reduced pressure, the residue was purified by flash column 
chromatography using as eluents CH2Cl2 for 2a,b and CH2Cl2/MeOH 99:1 for 2c,d.  
5.2.3 N-(4-Butoxyphenyl)-1-(3-methoxyphenyl)-1H-indazole-3-carboxamide (2a) 
N
N
O
H
N
O
O
 
Yield = 46 %; colorless-yellowish oil. 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.4 Hz), 1.53 (sext, 
2H, CH2CH3, J = 7.4 Hz), 1.80 (quin, 2H, CH2CH2CH2, J = 8.1 Hz), 3.94 (s, 3H, OCH3), 4.00 (t, 2H, 
OCH2, J = 6.5 Hz), 6.95 (d, 2H, Ar, J = 7.9 Hz), 7.03 (dd, 1H, Ar, J = 6.1 Hz, J = 2.2 Hz), 7.36 (s, 1H, 
Ar), 7.38 (dd, 1H, Ar, J = 1.0 Hz, J = 1.0 Hz), 7.42 (d, 1H, Ar, J = 7.9 Hz) 7.52 (t, 2H, Ar, J = 8.2 Hz), 
7.68 (d, 2H, Ar, J = 8.9 Hz), 7.77 (d, 1H, Ar, J = 8.6 Hz), 8.56 (d, 1H, Ar, J = 8.1 Hz), 8.86 (exch br s, 
1H, NH). 
5.2.4 N-(4-Butoxyphenyl)-1-(4-methoxyphenyl)-1H-indazole-3-carboxamide (2b) 
N
N
O
H
N
O
O
 
Yield = 60 %; colorless-yellowish oil. 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.5 Hz), 1.53 (sext, 
2H, CH2CH3, J = 7.4 Hz), 1.80 (quin, 2H, CH2CH2CH2, J = 8.0 Hz), 3.94 (s, 3H, OCH3), 4.00 (t, 2H, 
5. Experimental Chemistry 
 
 86 
OCH2, J = 6.6 Hz), 6.94 (d, 2H, Ar, J = 8.8 Hz), 7.13 (d, 2H, Ar, J = 9.0 Hz), 7.39 (t, 1H, Ar, J = 7.0 Hz), 
7.49 (t, 1H, Ar, J = 8.4 Hz), 7.63-7.70 (m, 5H, Ar), 8.55 (d, 1H, Ar, J = 8.1 Hz), 8.85 (exch br s, 1H, NH). 
5.2.5 N-(4-Butoxyphenyl)-1-(3-methoxyphenyl)-1H-indole-3-carboxamide (2c) 
N
O
H
N
O
O
 
Yield = 23 %; colorless-yellowish oil. 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.4 Hz), 1.53 (sext, 
2H, CH2CH3, J = 7.4 Hz), 1.80 (quin, 2H, CH2CH2CH2, J = 7.8 Hz), 3.90 (s, 3H, OCH3), 4.00 (t, 2H, 
OCH2, J = 6.6 Hz), 6.94 (d, 2H, Ar, J = 6.5 Hz), 7.01 (d, 1H, Ar, J = 8.2 Hz), 7.06 (s, 1H, Ar), 7.12 (d, 
1H, Ar, J = 7.4 Hz), 7.36 (quin, 2H, Ar, J = 7.3 Hz), 7.48 (t, 1H, Ar, J = 8.0 Hz), 7.56-1.62 (m, 3H, Ar), 
7.94 (br s, 1H, Ar), 8.15 (d, 2H, Ar, J = 7.2 Hz), 9.72 (exch br s, 1H, NH). 
5.2.6 N-(4-Butoxyphenyl)-1-(4-methoxyphenyl)-1H-indole-3-carboxamide (2d) 
N
O
H
N
O
O
 
Yield = 15 %; colorless-yellowish oil. 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.4 Hz), 1.48 (sext, 
2H, CH2CH3, J = 7.4 Hz), 1.80 (quin, 2H, CH2CH2CH2, J = 7.8 Hz), 3.92 (s, 3H, OCH3), 4.00 (t, 2H, 
OCH2, J = 6.5 Hz), 6.94 (d, 2H, Ar, J = 8.9 Hz), 7.08 (d, 2H, Ar, J = 8.8 Hz), 7.33 (quin, 2H, Ar, J = 8.1 
Hz), 7.42 (d, 2H, Ar, J = 8.7 Hz), 7.47 (d, 1H, Ar, J = 8.3 Hz), 7.57(d, 2H, Ar, J = 8.9 Hz ), 7.88 (br s, 
1H, Ar), 8.14 (d, 1H, Ar, J = 7.2 Hz). 
 
General Procedure for 3a-h. Compounds 3a-h were obtained starting from 1a for 3a-d and from 
1b for 3e-h respectively. A mixture of 1a or 1b (0.32 mmol), K2CO3 (0.65 mmol), and the appropriate 
substituted benzyl halide (0.36 mmol) in anhydrous acetone (2 mL) was refluxed under stirring for 2-10 
h. The mixture was then concentrated in vacuo, diluted with cold water, and extracted with CH2Cl2 (3 x 
15 mL). The organic layer was dried with Na2SO4, evaporated in vacuo, and compounds 3a-h were 
purified by column chromatography using alternatively CH2Cl2 (for 3a-d,g) or CH2Cl2/MeOH 99:1 (for 
3e,f,h) as eluent.  
5.2.7 N-(4-Butoxyphenyl)-1-(3-methoxybenzyl)-1H-indazole-3-carboxamide (3a) 
N
N
O
H
N
O
O
 
Yield = 65 %; colorless-yellowish oil. 1H NMR (CDCl3) δ 1.00 (t, 3H, CH2CH3, J = 7.4 Hz), 1.52 (sext, 
2H, CH2CH3, J = 5.4 Hz), 1.79 (quin, 2H, CH2CH2CH2, J = 6.4 Hz), 3.63 (s, 3H, OCH3), 4.00 (t, 2H, 
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OCH2, J = 6.5 Hz), 5.74 (s, 2H, CH2N), 6.29 (s, 1H, Ar), 6.80 (d, 1H, Ar, J = 8.8 Hz), 6.94 (d, 2H, Ar, J = 
9.0 Hz), 7.29 (s, 1H, Ar), 7.36 (d, 2H, Ar, J = 8.8 Hz), 7.44 (t, 2H, Ar, J = 8.2 Hz), 7.66 (d, 2H, Ar, J = 
9.0 Hz), 8.49 (d, 1H, Ar, J = 8.2 Hz), 8.77 (exch br s, 1H, NH). 
5.2.8 N-(4-Butoxyphenyl)-1-(4-methoxybenzyl)-1H-indazole-3-carboxamide (3b) 
N
N
O
H
N
O
O
 
Yield = 73 %; mp = 115-16 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.4 Hz), 1.53 (sext, 
2H, CH2CH3, J = 7.4 Hz), 1.78 (quin, 2H, CH2CH2CH2, J = 8.0 Hz), 3.79 (s, 3H, OCH3), 3.99 (t, 2H, 
OCH2, J = 6.5 Hz), 5.60 (s, 2H, CH2N), 6.87 (d, 2H, Ar, J = 8.5 Hz), 6.94 (d, 2H, Ar, J = 8.9 Hz), 7.19 (d, 
2H, Ar, J = 8.6 Hz), 7.30-7.34 (m, 1H, Ar), 7.40 (s, 2H, Ar), 7.67 (d, 2H, Ar, J = 8.9 Hz), 8.47 (d, 1H, Ar, 
J = 8.2 Hz), 8.80 (exch br s, 1H, NH). 
5.2.9 N-(4-Butoxyphenyl)-1-(3-chlorobenzyl)-1H-indazole-3-carboxamide (3c) 
N
N
O
H
N
O
Cl
 
Yield = 86 %; mp = 119-20 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.4 Hz), 1.52 (sext, 
2H, CH2CH3, J = 7.6 Hz), 1.81 (quin, 2H, CH2CH2CH2, J = 6.6 Hz), 4.00 (t, 2H, OCH2, J = 6.5 Hz), 5.63 
(s, 2H, CH2N), 6.94 (d, 2H, Ar, J = 9.0 Hz), 7.08 (d, 2H, Ar, J = 6.7 Hz), 7.24 (s, 1H, Ar), 7.30-7.27 (m, 
1H, Ar), 7.33-7.39 (m, 2H, Ar), 7.43-7.47 (m, 1H, Ar), 7.67 (d, 2H, Ar, J = 9.0 Hz), 8.49 (d, 1H, Ar, J = 
8.1 Hz), 8.76 (exch br s, 1H, NH). 
5.2.10   1-(1,3-Benzodioxol-5-ylmethyl)-N-(4-butoxyphenyl)-1H-indazole-3-carboxamide (3d) 
N
N
O
H
N
O
O
O
 
Yield = 78 %; mp = 134-35 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.3 Hz), 1.53 (sext, 
2H, CH2CH3, J = 7.4 Hz), 1.76-1.83 (m, 2H, CH2CH2CH2), 4.00 (t, 2H, OCH2, J = 6.5 Hz), 5.56 (s, 2H, 
CH2N), 5.95 (s, 2H, OCH2O), 6.72 (s, 1H, Ar), 6.78 (s, 2H, Ar), 6.94 (d, 2H, Ar, J = 8.9 Hz), 7.30-7.34 
(m, 1H, Ar), 7.42 (s, 2H, Ar), 7.67 (d, 2H, Ar, J = 8.9 Hz), 8.47 (d, 1H, Ar, J = 8.1 Hz), 8.78 (exch br s, 
1H, NH). 
5.2.11    N-(4-Butoxyphenyl)-1-(3-methoxybenzyl)-1H-indole-3-carboxamide (3e) 
N
O
H
N
O
O
 
Yield = 58 %; mp = 166-67 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.3 Hz), 1.52 (sext, 
2H, CH2CH3, J = 7.6 Hz), 1.80 (quin, 2H, CH2CH2CH2, J = 7.0 Hz), 3.77 (s, 3H, OCH3), 3.99 (t, 2H, 
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OCH2, J = 6.5 Hz), 5.31 (s, 2H, CH2N), 6.71 (s, 1H, Ar), 6.75 (d, 1H, Ar, J = 7.5 Hz), 6.85 (d, 1H, Ar, J = 
8.3 Hz), 6.92 (d, 2H, Ar, J = 8.8 Hz) 7.25 (d, 1H, Ar, J = 7.8 Hz), 7.29-7.33 (m, 2H, Ar), 7.38 (d, 1H, Ar, 
J = 8.0 Hz), 7.53 (d, 2H, Ar, J = 8.3 Hz), 7.73 (br s, 1H, Ar), 8.10 (d, 1H, Ar, J = 7.1 Hz). 
5.2.12    N-(4-Butoxyphenyl)-1-(4-methoxybenzyl)-1H-indole-3-carboxamide (3f) 
N
O
H
N
O
O
 
Yield = 29 %; mp = 160-62 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.4 Hz), 1.52 (sext, 
2H, CH2CH3, J = 7.6 Hz), 1.79 (quin, 2H, CH2CH2CH2, J = 7.1 Hz), 3.81 (s, 3H, OCH3), 3.98 (t, 2H, 
OCH2, J = 6.6 Hz), 5.28 (s, 2H, CH2N), 6.89 (q, 4H, Ar, J = 8.4 Hz), 7.13 (d, 2H, Ar, J = 8.7 Hz), 7.29-
7.34 (m, 2H, Ar), 7.40 (d, 1H, Ar, J = 8.8 Hz), 7.53 (d, 2H, Ar, J = 8.9 Hz), 7.73 (br s, 1H, Ar), 8.10 (d, 
1H, Ar, J = 12.1 Hz). 
5.2.13    N-(4-Butoxyphenyl)-1-(3-chlorobenzyl)-1H-indole-3-carboxamide (3g) 
N
O
H
N
O
Cl
 
Yield = 51 %; mp = 136-37 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.3 Hz), 1.52 (sext, 
2H, CH2CH3, J = 7.6 Hz), 1.80 (quin, 2H, CH2CH2CH2, J = 7.0 Hz), 3.99 (t, 2H, OCH2, J = 6.5 Hz), 5.32 
(s, 2H, CH2N), 6.92 (d, 2H, Ar, J = 8.9 Hz), 7.02 (d, 1H, Ar, J = 7.1 Hz), 7.17 (s, 1H, Ar), 7.25-7.34 (m, 
5H, Ar), 7.53 (d, 2H, Ar, J = 8.3 Hz), 7.75 (br s, 1H, Ar), 8.10 (d, 1H, Ar, J = 8.4 Hz). 
5.2.14       1-(1,3-Benzodioxol-5-ylmethyl)-N-(4-butoxyphenyl)-1H-indole-3-carboxamide (3h) 
N
O
H
N
O
O
O
 
Yield = 42 %; mp = 165-67 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.4 Hz), 1.52 (sext, 
2H, CH2CH3, J = 7.4 Hz), 1.80 (quin, 2H, CH2CH2CH2, J = 6.8 Hz), 3.99 (t, 2H, OCH2, J = 6.6 Hz), 5.23 
(s, 2H, CH2N), 5.96 (s, 2H, OCH2O), 6.64 (s, 1H, Ar, J = 8.4 Hz), 6.71 (d, 1H, Ar, J = 7.9 Hz), 6.78 (d, 
1H, Ar, J = 7.9 Hz), 6.92 (d, 2H, Ar, J = 8.9 Hz), 7.31-7.33 (m, 2H, Ar), 7.40 (m, 1H, Ar), 7.53 (d, 2H, 
Ar, J = 8.2 Hz), 7.71 (br s, 1H, Ar), 8.09 (d, 1H, Ar, J = 7.7 Hz). 
 
5.2.15    N-(4-Bromophenyl)-2-(1-(3-methoxybenzyl)-1H-indol-3-yl)acetamide (5) 
N O
H
N
Br
O
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A mixture of 4 (0.46 mmol), K2CO3 (0.92 mmol) and 3-methoxybenzyl chloride (0.69 mmol) in 
anhydrous acetone (3 mL) was refluxed under stirring for 4 h and then concentrated in vacuo. After 
dilution with cold water, it was extracted with CH2Cl2 (3 x 15 mL) and the solvent was evaporated in 
vacuo to afford the crude 5, which was purified by column chromatography using toluene/ethyl acetate 
7:3 as eluent. Yield = 29 %; mp = 153-55 °C (EtOH). 1H NMR (CDCl3) δ 3,77 (s, 3H, OCH3); 3,90 (s, 
2H, COCH2); 5,33 (s, 2H, CH2N); 6,68 (s, 1H, CH); 6,76 (d, 1H, Ar, J = 7.1 Hz); 7,84 (dd, 1H, Ar, J = 
8.5 Hz, J = 1.9 Hz ); 7,17-7,30 (m, 5H, Ar); 7,36-7,41 (m, 4H, Ar); 7,63 (d, 1H, Ar, J = 8.2 Hz). 
 
5.2.16  N-(4-Bromophenyl)-2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-
yl]acetamide (6) 
N
O
N
HO
O Cl
Br
 
To a solution of indomethacin (0.28 mmol) in anhydrous CH2Cl2 (5 ml) were added DCC (0.28 mmol) 
and 4-Bromoaniline (0.28 mmol). The reaction mixture was stirred at room temperature for 24 h. The 
solid residue was filtered off in vacuo and the solution was washed with HCl 2 N (2 x 10 mL) and with 
H2O (10 mL). The organic phase was dried over NaSO4 and concentrated under reduce pressure. The 
resulting residue was purified by flash column chromatography using CH2Cl2/MeOH 99:1 as eluent to 
furnish 6 as a white solid. Yield = 35 %; mp = 200-01 °C (EtOH). 1H NMR (CDCl3) δ 2,48 (s, 3H, CH3); 
3,83 (s, 5H, OCH3 + COCH2); 6,74 (dd, 1H, Ar, J = 6.6 Hz, J = 2.5 Hz); 6,88 (d, 1H, Ar, J = 9.1 Hz); 
6,94 (d, 1H, Ar, J = 2.3 Hz); 7,25 (exch, br, s, 1H, NH); 7,31 (d, 2H, Ar, J = 8.8 Hz); 7,41 (d, 2H, Ar, J = 
8.7 Hz); 7,52 (d, 2H, Ar, J = 8.4 Hz); 7,71 (d, 2H, Ar, J = 8.4 Hz). 
 
General Procedure for 7a-d. A mixture of 3-aminoquinoline (0.69 mmol), K2CO3 (1.38 mmol) 
and the appropriate substituted benzyl halide (0.69 mmol) in anhydrous acetone (3 mL) was refluxed 
under stirring for 1-3 h. Extra benzyl halide (0.69 mmol) was added and the reaction was kept refluxing 
for additional 2-4 h. The mixture was then concentrated in vacuo, diluted with cold water and extracted 
with CH2Cl2 (3 x 15 mL). The organic layer was dried over Na2SO4 and evaporated in vacuo to afford the 
crude compounds 7a-d which were purified by column chromatography using cyclohexane/ethyl acetate 
1:2 (for 7a,b,d) or 2:1 (for 7c) respectively as eluent.  
5.2.17    N-(3-Methoxybenzyl)quinolin-3-amine (7a) 
N
H
N O
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Yield = 49 %; clear oil. 1H NMR (CDCl3) δ 3.82 (s, 3H, OCH3), 4.44 (s, 2H, CH2N), 4.67 (exch br s, 1H, 
NH), 6.86 (dd, 1H, Ar, J = 8.2 Hz, J = 2.5 Hz), 6.98 (s, 1H, Ar), 7.02 (d, 1H, Ar, J = 7.6 Hz), 7.07 (d, 1H, 
Ar, J = 2.7 Hz), 7.31 (t, 1H, Ar, J = 7.9 Hz), 7.43-7.45 (m, 2H, Ar), 7.59-7.61 (m, 2H, Ar), 7.98-8.01 (m, 
1H, Ar), 8.59 (d, 1H, Ar, J = 2.8 Hz). 
5.2.18    N-(4-Methoxybenzyl)quinolin-3-amine (7b) 
N
H
N
O
 
Yield = 60 %; mp = 80-82 °C (EtOH). 1H NMR (CDCl3) δ 3.83 (s, 3H, OCH3), 4.37 (s, 2H, CH2N), 4.43 
(exch br s, 1H, NH), 6.92 (d, 2H, Ar, J = 8.7 Hz), 7.05 (d, 1H, Ar, J = 2.7 Hz), 7.34 (d, 2H, Ar, J = 8.6 
Hz), 7.42-7.44 (m, 2H, Ar), 7.59-7.63 (m, 1H, Ar), 7.95-7.98 (m, 1H, Ar), 8.50 (d, 1H, Ar, J = 2.8 Hz). 
5.2.19    N-(1,3-Benzodioxol-5-ylmethyl)quinolin-3-amine (7c) 
N
H
N O
O
 
Yield = 26 %; brown oil. 1H NMR (CDCl3) δ 4.40 (s, 2H, CH2N), 5.21 (exch br s, 1H, NH), 5.97 (s, 3H, 
OCH2O), 6.81 (d, 1H, Ar, J = 7.8 Hz), 6.91 (d, 1H, Ar, J = 11.2 Hz), 7.13 (s, 1H, Ar), 7.46-7.49 (m, 2H, 
Ar), 7.62-7.65 (m, 1H, Ar), 8.06-8.09 (m, 1H, Ar), 8.78 (s, 1H, Ar). 
5.2.20    N-(3-Chlorobenzyl)quinolin-3-amine (7d) 
N
H
N Cl
 
Yield = 22 %; clear oil. 1H NMR (CDCl3) δ 4.51 (d, 2H, CH2N, J = 4.5 Hz), 5.73 (exch br s, 1H, NH), 
7.13 (d, 1H, Ar, J = 2.6 Hz), 7.29-7.34 (m, 3H, Ar), 7.44 (s, 1H, Ar), 7.49-7.52 (m, 2H, Ar), 7.63-7.65 (m, 
1H, Ar), 8.13 (t, 1H, Ar, J = 6.3 Hz), 8.94 (s, 1H, Ar). 
 
General Procedure for 8a-d. The appropriate amine of type 7 (7a-d) (0.34 mmol) was dissolved 
in 2 mL of anhydrous CH2Cl2 and 4-n.butoxyphenyl isocyanate (0.37 mmol) was added under stirring. 
The reaction was carried out at room temperature for 3-8 h, then the solid residue was filtered off and the 
solution was evaporated in vacuo to afford compounds 8a-d, which were purified by flash column 
chromatography using cyclohexane/ethyl acetate 1:1 (for 7a,b) or 2:1 (for 7c,d) respectively as eluent.  
5.2.21    3-(4-Butoxyphenyl)-1-(3-methoxybenzyl)-1-(quinolin-3-yl)urea (8a) 
N
N
OH
N
O
O
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Yield = 58 %; clear oil. 1H NMR (CDCl3) δ 0.98 (t, 3H, CH2CH3, J = 7.4 Hz), 1.48 (sext, 2H, CH2CH3, J 
= 7.6 Hz), 1.75 (quin, 2H, CH2CH2CH2, J = 7.0 Hz), 3.77 (s, 3H, OCH3), 3.93 (t, 2H, OCH2, J = 6.5 Hz), 
5.04 (s, 2H, CH2N), 6.10 (exch br s, 1H, NH), 6.81-6.84 (m, 3H, Ar), 6.88 (d, 2H, Ar, J = 7.4 Hz), 7.19-
7.25 (m, 3H, Ar), 7.63 (t, 1H, Ar, J = 8.2 Hz), 7.78-7.82 (m, 2H, Ar), 8.01 (s, 1H, Ar), 8.18 (d, 1H, Ar, J 
= 8.7 Hz), 8.79 (d, 1H, Ar, J = 2.4 Hz). 
5.2.22    3-(4-Butoxyphenyl)-1-(4-methoxybenzyl)-1-(quinolin-3-yl)urea (8b) 
N
N
H
N
O
O
O
 
Yield = 47 %; clear oil. 1H NMR (CDCl3) δ 0.97 (t, 3H, CH2CH3, J = 7.4 Hz), 1.48 (sext, 2H, CH2CH3, J 
= 7.6 Hz), 1.74 (quin, 2H, CH2CH2CH2, J = 7.0 Hz), 3.79 (s, 3H, OCH3), 3.92 (t, 2H, OCH2, J = 6.5 Hz), 
4.97 (s, 2H, CH2N), 6.18 (exch br s, 1H, NH), 6.81 (dd, 4H, Ar, J = 2.0 Hz, J = 6.6 Hz), 7.21 (dd, 4H, Ar, 
J = 6.4 Hz, J = 2.1 Hz), 7.62 (t, 1H, Ar, J = 7.0 Hz), 7.78 (t, 2H, Ar, J = 7.2 Hz), 7.97 (s, 1H, Ar), 8.14 (d, 
1H, Ar, J = 8.0 Hz), 8.71 (d, 1H, Ar, J = 2.3 Hz). 
5.2.23    1-(1,3-Benzodioxol-5-ylmethyl)-3-(4-butoxyphenyl)-1-(quinolin-3-yl)urea (8c) 
N
N
O
H
N
O
O
O
 
Yield = 36 %; brown oil. 1H NMR (CDCl3) δ 0.97 (t, 3H, CH2CH3, J = 7.4 Hz), 1.48 (sext, 2H, CH2CH3, 
J = 7.6 Hz), 1.75 (quin, 2H, CH2CH2CH2, J = 7.0 Hz), 3.92 (t, 2H, OCH2, J = 6.6 Hz), 4.96 (s, 2H, 
CH2N), 5.96 (s, 3H, OCH3), 6.20 (exch br s, 1H, NH), 6.65-6-71 (m, 2H, Ar), 6.81 (d, 2H, Ar, J = 9.0 
Hz), 6.91 (s, 1H, Ar), 7.21 (d, 2H, Ar, J = 9.0 Hz), 7.66 (t, 1H, Ar, J = 7.2 Hz), 7.82 (q, 2H, Ar, J = 6.7 
Hz), 8.06 (s, 1H, Ar), 8.21 (d, 1H, Ar, J = 8.5 Hz), 8.75 (d, 1H, Ar, J = 2.4 Hz). 
5.2.24    3-(4-Butoxyphenyl)-1-(3-chlorobenzyl)-1-(quinolin-3-yl)urea (8d) 
N
N
ClH
N
O
O
 
Yield = 44 %; colorless oil. 1H NMR (CDCl3) δ 0.98 (t, 3H, CH2CH3, J = 7.4 Hz), 1.48 (sext, 2H, 
CH2CH3, J = 7.6 Hz), 1.75 (quin, 2H, CH2CH2CH2, J = 7.1 Hz), 3.93 (t, 2H, OCH2, J = 6.6 Hz), 5.03 (s, 
2H, CH2N), 6.33 (exch br s, 1H, NH), 6.82 (d, 2H, Ar, J = 9.0 Hz), 7.17-7.26 (m, 5H, Ar), 7.35 (s, 1H, 
Ar), 7.67 (t, 1H, Ar, J = 7.8 Hz), 7.79-7.85 (m, 2H, Ar), 8.06 (s, 1H, Ar), 8.19 (d, 1H, Ar, J = 8.4 Hz), 
8.77 (d, 1H, Ar, J = 2.4 Hz). 
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General Procedure for 11a,b. To a suspension of 10 (0.86 mmol), copper acetate (1.29 mmol) 
and the appropriate butoxyphenylboronic acid (1.72 mmol) in CH2Cl2 (2 mL), Et3N (1.72 mmol) was 
added. The mixture was stirred at room temperature for 15-20 h. The suspension was extracted with 33% 
aqueous ammonia/saturated aqueous EDTA 1:1 solution (3 x 10 mL) and the organic layer was washed 
with 10 mL of water and dried over Na2SO4. After removal of the solvent, the residue was purified by 
flash column chromatography using as eluent cyclohexane/ethyl acetate 1:3. 
5.2.25  Ethyl-1-(4-methoxyphenyl)-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-
carboxylate (11a) 
N N
O
O
O
O
 
Yield = 34 %; mp = 146-47 °C (EtOH). 1H NMR (CDCl3) δ 1.42 (t, 3H, CH2CH3, J = 7.1 Hz), 2.52 (s, 
3H, CH3C=N), 3.92 (s, 3H, OCH3), 4.41 (q, 2H, OCH2, J = 7.1 Hz), 7.06 (d, 2H, Ar, J = 9.0 Hz), 7.25 (d, 
1H, Ar, J = 8.1 Hz), 7.35 (d, 2H, Ar, J = 8.9 Hz), 8.67 (s, 1H, Ar), 8.69 (d, 1H, Ar, J = 8.1 Hz). 
5.2.26  Ethyl-1-(3-methoxyphenyl)-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-
carboxylate (11b) 
N N
O
O
O
O
 
Yield = 14 %; mp = 165-66 °C (EtOH). 1H NMR (CDCl3) δ 1.43 (t, 3H, CH2CH3, J = 7.1 Hz), 2.54 (s, 
3H, CH3C=N), 3.89 (s, 3H, OCH3), 4.42 (q, 2H, OCH2, J = 7.1 Hz), 6.99 (t, 1H, Ar, J = 2.2 Hz), 7.03 (d, 
1H, Ar, J = 7.8 Hz), 7.08 (d, 1H, Ar, J = 7.7 Hz), 7.27 (d, 1H, Ar, J = 8.5 Hz), 7.48 (t, 1H, Ar, J = 8.1 
Hz), 8.69 (s, 1H, Ar), 8.70 (d, 1H, Ar, J = 8.1 Hz). 
 
General Procedure for 12a,b. A suspension of the appropriate derivative 11a or 11b respectively 
(0.29 mmol), and 6 N NaOH (3 mL) in ethanol (3 mL) was stirred at rt for 0.5-1 h. The mixture was then 
concentrated in vacuo, diluted with cold water and acidified with 6 N HCl. The final product was filtered 
off by suction and recrystallized from ethanol. 
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5.2.27  1-(4-Methoxyphenyl)-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-
carboxylic acid (12a) 
N N
O
OH
O
O
 
Yield = ~ 100 %; mp = 268-70 °C (EtOH). 1H NMR (CDCl3) δ 2.61 (s, 3H, CH3C=N), 3.94 (s, 3H, 
OCH3), 7.08 (d, 2H, Ar, J = 9.0 Hz), 7.35 (d, 2H, Ar, J = 9.0 Hz), 7.41 (d, 1H, Ar, J = 8.2 Hz), 8.73 (d, 
1H, Ar, J = 8.2 Hz), 8.97 (s, 1H, Ar), 14.60 (exch br s, 1H, COOH). 
5.2.28  1-(3-Methoxyphenyl)-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-
carboxylic acid (12b) 
N N
O
OH
O
O
 
Yield = 80 %; mp = 217-19 °C (EtOH). 1H NMR (CDCl3) δ 2.61 (s, 3H, CH3C=N), 3.90 (s, 3H, OCH3), 
6.97 (t, 1H, Ar, J = 2.2 Hz), 7.01 (d, 1H, Ar, J = 7.8 Hz), 7.12 (d, 1H, Ar, J = 6.0 Hz), 7.42 (d, 1H, Ar, J = 
8.2 Hz), 7.50 (t, 1H, Ar, J = 8.1 Hz), 8.74 (d, 1H, Ar, J = 8.2 Hz), 8.98 (s, 1H, Ar), 14.58 (exch br s, 1H, 
COOH). 
 
General Procedure for 14a,b. To cooled (0 °C) and stirred suspension of 12a or 12b (0.19 
mmol) in SOCl2 (1.5 mL), Et3N (0.2 mL) was added. After 2-3 h at room temperature the excess of 
SOCl2 was removed in vacuo. Due to their instability, the intermediates 13a,b obtained were not isolated 
and characterized. Thus, the residue was dissolved in anhydrous THF (2 mL) and cooled to 0 °C. A 
solution of 4-n.butoxyaniline (0.38 mmol) in anhydrous THF (1 mL) was added dropwise to the mixture 
and the reaction was carried out at room temperature for 2 h. The mixture was concentrated under 
reduced pressure and, after dilution with ice-cold water (10 mL), the precipitate was then filtered and 
purified by flash column chromatography using cyclohexane/ethyl acetate 2:1 (for 14a) or 
cyclohexane/ethyl acetate 1:1 (for 14b) as eluent. 
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5.2.29  N-(4-Butoxyphenyl)-1-(4-methoxyphenyl)-7-methyl-4-oxo-1,4-dihydro-1,8-
naphthyridine-3-carboxamide (14a) 
N N
O
N
H
O
O
O
 
Yield = 35 %; mp = 154-55 °C (EtOH). 1H NMR (CDCl3) δ 1.00 (t, 3H, CH2CH3, J = 7.4 Hz), 1.52 (sext, 
2H, CH2CH3, J = 7.6 Hz), 1.79 (quin, 2H, CH2CH2CH2, J = 7.9 Hz), 2.58 (s, 3H, CH3C=N), 3.94 (s, 3H, 
OCH3), 3.99 (t, 2H, OCH2, J = 6.5 Hz), 6.92 (d, 2H, Ar, J = 9.0 Hz), 7.07 (d, 2H, Ar, J = 8.9 Hz), 7.35 (d, 
1H, Ar, J = 8.2 Hz), 7.38 (d, 2H, Ar, J = 8.9 Hz), 7.70 (d, 2H, Ar, J = 9.0 Hz), 8.74 (d, 1H, Ar, J = 8.2 
Hz), 9.08 (s, 1H, Ar), 11.97 (exch br s, 1H, NH). 
5.2.30  N-(4-Butoxyphenyl)-1-(3-methoxyphenyl)-7-methyl-4-oxo-1,4-dihydro-1,8-
naphthyridine-3-carboxamide (14b) 
N N
O
N
H
O
O
O
 
Yield = 44 %; mp = 203-05 °C (EtOH). 1H NMR (CDCl3) δ 1.00 (t, 3H, CH2CH3, J = 7.4 Hz), 1.52 (sext, 
2H, CH2CH3, J = 7.6 Hz), 1.79 (quin, 2H, CH2CH2CH2, J = 7.1 Hz), 2.59 (s, 3H, CH3C=N), 3.89 (s, 3H, 
OCH3), 3.99 (t, 2H, OCH2, J = 6.5 Hz), 6.92 (d, 2H, Ar, J = 9.0 Hz), 7.01 (s, 1H, Ar), 7.05 (d, 1H, Ar, J = 
7.8 Hz), 7.10 (d, 1H, Ar, J = 7.7 Hz), 7.35 (d, 1H, Ar, J = 8.2 Hz), 7.48 (t, 1H, Ar, J = 8.1 Hz), 7.70 (d, 
2H, Ar, J = 9.0 Hz), 8.74 (d, 1H, Ar, J = 8.2 Hz), 9.09 (s, 1H, Ar), 11.95 (exch br s, 1H, NH). 
 
General Procedure for 16a,b. To cooled (0 °C) and stirred suspensions of 12a or 12b (0.29 
mmol) in SOCl2 (1.5 mL), Et3N (0.2 mL) was added. After 2-3 h at 60 °C, the mixture was allowed to 
cool down and the excess of SOCl2 was removed in vacuo. Due to their instability, the intermediates 
15a,b obtained were not isolated and characterized. Thus, the residue was dissolved in anhydrous THF (1 
mL) and cooled to 0 °C. A solution of 4-n.Butoxyaniline (0.58 mmol) in anhydrous THF (1 mL) was 
added dropwise to the mixture and the reaction was carried out at room temperature for 2 h. The mixture 
was then concentrated in vacuo and diluted with ice-cold water (10 mL). The precipitate was filtered off 
and purified by flash column chromatography using CH2Cl2 (for 15a) or CH2Cl2/MeOH 99:1 (for 15b) as 
eluent. 
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5.2.31  N-(4-Butoxyphenyl)-1-(4-methoxyphenyl)-4-oxo-7-trichloromethyl-1,4-
dihydro-1,8-naphthyridine-3-carboxamide (16a) 
N N
O
N
H
O O
O
Cl Cl
Cl
 
Yield = 49 %; mp = 289-91 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.4 Hz), 1.52 (sext, 
2H, CH2CH3, J = 7.6 Hz), 1.81 (quin, 2H, CH2CH2CH2, J = 6.6 Hz), 3.94 (s, 3H, OCH3), 4.00 (t, 2H, 
OCH2, J = 6.5 Hz), 6.93 (d, 2H, Ar, J = 9.0 Hz), 7.07 (d, 2H, Ar, J = 8.9 Hz), 7.44 (d, 2H, Ar, J = 8.9 
Hz), 7.70 (d, 2H, Ar, J = 9.00 Hz), 8.15 (d, 1H, Ar, J = 8.4 Hz), 9.02 (d, 1H, Ar, J = 8.4 Hz), 9.20 (s, 1H, 
Ar), 11.75 (exch br s, 1H, NH). MS (ESI), calcd. For C27H24Cl3N3O4, 560,86. Found: m/z 560.36 [M]+, 
562.36 [M + H]+. 
5.2.32  N-(4-Butoxyphenyl)-1-(3-methoxyphenyl)-4-oxo-7-trichloromethyl-1,4-
dihydro-1,8-naphthyridine-3-carboxamide (16b) 
N N
O
N
H
O
O
O
Cl Cl
Cl
 
Yield = 54 %; mp = 148-50 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.4 Hz), 1.52 (sext, 
2H, CH2CH3, J = 7.6 Hz), 1.80 (quin, 2H, CH2CH2CH2, J = 6.8 Hz), 3.88 (s, 3H, OCH3), 3.99 (t, 2H, 
OCH2, J = 6.5 Hz), 6.93 (d, 2H, Ar, J = 8.9 Hz), 7.08 (s, 1H, Ar), 7.10 (d, 2H, Ar, J = 8.1 Hz), 7.49 (t, 
1H, Ar, J = 8.1 Hz), 7.70 (d, 2H, Ar, J = 8.9 Hz), 8.15 (d, 1H, Ar, J = 8.4 Hz), 9.02 (d, 1H, Ar, J = 8.4 
Hz), 9.23 (s, 1H, Ar), 11.73 (exch br s, 1H, NH). MS (ESI), calcd. For C27H24Cl3N3O4, 560,86. Found: 
m/z 560.36 [M]+, 562.36 [M + H]+, 584.18 [M + Na]+. 
 
General Procedure for 17a-c. A mixture of 10 (0.65 mmol), K2CO3 (1.30 mmol), and the 
appropriate substituted benzyl halide (0.71 mmol) in anhydrous acetone (3 mL) was refluxed under 
stirring for 5-7 h. The mixture was then concentrated in vacuo, diluted with cold water and extracted with 
CH2Cl2 (3 x 15 mL). The organic layer was dried over Na2SO4,  evaporated in vacuo and compounds 
17a-c were purified by column chromatography using alternatively cyclohexane/ethyl acetate 1:6 (for 
17a,b) or cyclohexane/ethyl acetate 1:9 (for 17c) as eluent.  
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5.2.33  Ethyl-1-(4-methoxybenzyl)-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-
carboxylate (17a) 
N N
O
O
O
O
 
Yield = 35 %; mp = 107-09 °C (EtOH). 1H NMR (CDCl3) δ 1.41 (t, 3H, CH2CH3, J = 7.1 Hz), 2.69 (s, 
3H, CH3C=N), 3.80 (s, 3H, OCH3), 4.40 (q, 2H, OCH2, J = 7.1 Hz), 5.59 (s, 2H, NCH2), 6.88 (d, 2H, Ar, 
J = 8.6 Hz), 7.26 (d, 1H, Ar, J = 8.1 Hz), 7.32 (d, 2H, Ar, J = 8.1 Hz), 8.66 (d, 1H, Ar, J = 8.1 Hz), 8.71 
(s, 1H, Ar). 
5.2.34  Ethyl-1-(3-methoxybenzyl)-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-
carboxylate (17b) 
N N
O
O
O
O
 
Yield = 18 %; colorless oil. 1H NMR (CDCl3) δ 1.43 (t, 3H, CH2CH3, J = 7.0 Hz), 2.69 (s, 3H, CH3C=N), 
3.80 (s, 3H, OCH3), 4.43 (q, 2H, OCH2, J = 7.1 Hz), 5.69 (s, 2H, NCH2), 6.87 (d, 1H, Ar, J = 8.5 Hz), 
6.92 (s, 1H, Ar), 6.93 (d, 1H, Ar, J = 8.2 Hz), 7.26-7.31 (m, 2H, Ar), 8.68 (d, 1H, Ar, J = 8.0 Hz), 8.71 (s, 
1H, Ar). 
5.2.35  Ethyl-1-(1,3-benzodioxol-5-ylmethyl)-7-methyl-4-oxo-1,4-dihydro-1,8-
naphthyridine-3-carboxylate (17c) 
N N
O
O
O
O
O
 
Yield = 70 %; mp = 152-54 °C (EtOH). 1H NMR (CDCl3) δ 1.42 (t, 3H, CH2CH3, J = 7.1 Hz), 2.69 (s, 
3H, CH3C=N), 4.40 (q, 2H, OCH2, J = 7.1 Hz), 5.54 (s, 2H, NCH2), 5.96 (s, 2H, OCH2O), 6.78 (d, 1H, 
Ar, J = 7.7 Hz), 6.87 (d, 2H, Ar, J = 8.2 Hz), 7.28 (d, 1H, Ar, J = 3.0 Hz), 8.66 (d, 2H, Ar, J = 7.3 Hz). 
 
General Procedure for 18a-c. A suspension of the appropriate derivative 17a-c (0.65 mmol), and 
6 N NaOH (6 mL) in ethanol (5 mL) was stirred at rt 2 h. The mixture was then concentrated in vacuo, 
diluted with cold water and acidified with 6 N HCl. The pure final compound of type 18 was filtered off 
by suction and recrystallized from ethanol. 
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5.2.36  1-(4-Methoxybenzyl)-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-
carboxylic acid (18a) 
N N
O
OH
O
O
 
Yield = 67 %; mp = 215-17 °C (EtOH). 1H NMR (CDCl3) δ 2.79 (s, 3H, CH3C=N), 3.81 (s, 3H, OCH3), 
5.69 (s, 2H, NCH2), 6.89 (d, 2H, Ar, J = 8.5 Hz), 7.36 (d, 2H, Ar, J = 8.5 Hz), 7.42 (d, 1H, Ar, J = 8.2 
Hz), 8.70 (d, 1H, Ar, J = 8.2 Hz), 8.97 (s, 1H, Ar), 14.63 (exch br s, 1H, OH). 
5.2.37  1-(3-Methoxybenzyl)-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-
carboxylic acid (18b) 
N N
O
OH
O
O
 
Yield = 77 %; mp = 244-46 °C (EtOH). 1H NMR (CDCl3) δ 2.77 (s, 3H, CH3C=N), 3.80 (s, 3H, OCH3), 
5.73 (s, 2H, NCH2), 6.87-6.91 (m, 2H, Ar), 6.93 (d, 1H, Ar, J = 7.7 Hz), 7.29 (t, 2H, Ar, J = 8.1 Hz), 7.42 
(d, 1H, Ar, J = 8.2 Hz), 8.71 (d, 1H, Ar, J = 8.2 Hz), 8.97 (s, 1H, Ar), 14.60 (exch br s, 1H, OH). 
5.2.38  1-(1,3-Benzodioxol-5-ylmethyl)-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-
3-carboxylic acid (18c) 
N N
O
OH
O
O
O
 
Yield = 68 %; mp = 237-39 °C (EtOH). 1H NMR (CDCl3) δ 2.79 (s, 3H, CH3C=N), 5.66 (s, 2H, NCH3), 
5.98 (s, 2H, OCH2O), 6.80 (d, 1H, Ar, J = 7.9 Hz), 6.88 (s, 1H, Ar), 6.90 (d, 1H, Ar, J = 7.9 Hz), 7.43 (d, 
1H, Ar, J = 8.2 Hz), 8.70 (d, 1H, Ar, J = 8.2 Hz), 8.95 (s, 1H, Ar). 
 
General Procedure for 19a-c. To a cooled (0 °C) and stirred solution of compound of type 18 
(18a-c) (0.17 mmol) in anhydrous DMF (1 mL), Et3N (5 drops), diethyl cyanophosphonate (0.68 mmol) 
and 4-n.Butoxyaniline (0.17 mmol) were added. After 0.5 h at 0 °C, the reaction was keept at room 
temperature for 15 h. The mixture was then diluted with ice-cold water (10 mL) and kept under stirring 
for 0.5 h at 0 °C. The precipitate was filtered off and purified by flash column chromatography using 
cyclohexane/ethyl acetate 2:1 as eluent.  
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5.2.39  N-(4-Butoxyphenyl)-1-(4-methoxybenzyl)-7-methyl-4-oxo-1,4-dihydro-1,8-
naphthyridine-3-carboxamide (19a) 
N N
O
N
H
O O
O
 
Yield = 75 %; mp = 190-91 °C (EtOH). 1H NMR (CDCl3) δ 1.00 (t, 3H, CH2CH3, J = 7.4 Hz), 1.51 (sext, 
2H, CH2CH3, J = 7.6 Hz), 1.79 (quin, 2H, CH2CH2CH2, J = 7.0 Hz), 2.75 (s, 3H, CH3C=N), 3.80 (s, 3H, 
OCH3), 3.98 (t, 2H, OCH2, J = 6.5 Hz), 5.68 (s, 2H, NCH2), 6.89 (qd, 4H, Ar, J = 3.5 Hz, J = 9.0 Hz), 
7.34-7.37 (m, 3H, Ar), 7.68 (d, 2H, Ar, J = 7.9 Hz), 8.69 (d, 1H, Ar, J = 8.1 Hz), 9.08 (s, 1H, Ar), 11.97 
(exch br s, 1H, NH). 
5.2.40  N-(4-Butoxyphenyl)-1-(3-methoxybenzyl)-7-methyl-4-oxo-1,4-dihydro-1,8-
naphthyridine-3-carboxamide (19b) 
N N
O
N
H
O O
O
 
Yield = 71 %; mp = 145-47 °C (EtOH). 1H NMR (CDCl3) δ 1.00 (t, 3H, CH2CH3, J = 7.4 Hz), 1.51 (sext, 
2H, CH2CH3, J = 7.6 Hz), 1.79 (quin, 2H, CH2CH2CH2, J = 6.9 Hz), 2.74 (s, 3H, CH3C=N), 3.80 (s, 3H, 
OCH3), 3.98 (t, 2H, OCH2, J = 6.5 Hz), 5.72 (s, 2H, NCH2), 6.86 (d, 1H, Ar, J = 8.5 Hz), 6.91 (d, 2H, Ar, 
J = 8.9 Hz), 6.95-7.02 (m, 2H, Ar), 7.27 (t, 1H, Ar, J = 7.9 Hz), 7.37 (d, 1H, Ar, J = 7.0 Hz), 7.69 (d, 2H, 
Ar, J = 8.2 Hz), 8.71 (d, 1H, Ar, J = 8.2 Hz), 9.08 (s, 1H, Ar), 11.97 (exch br s, 1H, NH). 
5.2.41  1-(1,3-Benzodioxol-5-ylmethyl)-N-(4-butoxyphenyl)-7-methyl-4-oxo-1,4-
dihydro-1,8-naphthyridine-3-carboxamide (19c) 
N N
O
N
H
O
O
O
O
 
Yield = 62 %; mp = 181-83 °C (EtOH). 1H NMR (CDCl3) δ 1.00 (t, 3H, CH2CH3, J = 7.3 Hz), 1.51 (sext, 
2H, CH2CH3, J = 7.8 Hz), 1.79 (quin, 2H, CH2CH2CH2, J = 6.8 Hz), 2.77 (s, 3H, CH3C=N), 3.98 (t, 2H, 
OCH2, J = 6.4 Hz), 5.65 (s, 2H, NCH2), 5.96 (s, 2H, OCH2O), 6.79 (d, 1H, Ar, J = 7.8 Hz), 6.91 (d, 4H, 
Ar, J = 8.5 Hz), 7.38 (d, 1H, Ar, J = 6.7 Hz), 7.69 (d, 2H, Ar, J = 5.6 Hz), 8.71 (d, 1H, Ar, J = 8.0 Hz), 
9.06 (s, 1H, Ar), 11.97 (exch br s, 1H, NH). 
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5.2.42  N-(4-Bromophenyl)-1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-
carboxamide (20) 
N N
O
N
H
O
Br
 
To a cooled (-5 °C) and stirred solution of nalidixic acid (0.43 mmol) in anhydrous tetrahydrofuran (3 
mL), Et3N (1.50 mmol) was added. After 30 min, the mixture was allowed to warm up to 0 °C, and ethyl 
chloroformate (0.47 mmol) was added. After 1 h 4-bromo aniline was added and the reaction was carried 
out at room temperature for 12 h. The mixture was then concentrated in vacuo, diluted with cold water 
(20 mL) and extracted with CH2Cl2 (3 x 15 mL). The solvent was evaporated to afford final compound 
20, which was purified by two consecutive flash chromatography using firstly cyclohexane/ethyl acetate 
2:1 and then CH2Cl2 as eluents. Yield = 18 %; mp = 290-92 °C (EtOH). 1H NMR (CDCl3) δ 1.56 (t, 3H, 
CH2CH3, J = 7.2 Hz), 2.74 (s, 3H, CH3C=N), 4.62 (q, 2H, NCH2, J = 7.2 Hz), 7.97 (d, 1H, Ar, J = 8.2 
Hz), 7.48 (d, 2H, Ar, J = 8.7 Hz ), 7.70 (d, 2H, Ar, J = 8.8 Hz), 8.70 (d, 1H, Ar, J = 8.1 Hz), 9.00 (s, 1H, 
Ar), 12.24 (exch br s, 1H, NH). 
 
5.2.43  N-(4-Butoxyphenyl)-1-ethyl-4-oxo-7-trichloromethyl-1,4-dihydro-1,8-
naphthyridine-3-carboxamide (21) 
N N
O
N
H
O
Cl Cl
Cl
O
 
To a cooled (0 °C) and stirred suspension of nalidixic acid (0.43 mmol) in SOCl2 (1.5 mL), Et3N (0.2 mL) 
was added. After 2 h at 60 °C, the mixture was allowed to cool down and the excess of SOCl2 was 
removed in vacuo. The residue was dissolved in anhydrous THF (3 mL) and cooled again to 0 °C. A 
solution of 4-n.butoxyaniline (0.86 mmol) in anhydrous THF (2 mL) was then added dropwise to the 
mixture. Finally, the reaction was carried out at room temperature for 2 h. The mixture was concentrated 
under reduced pressure and diluted with ice-cold water (10 mL). The precipitate was then filtered off and 
purified by flash column chromatography using CH2Cl2/MeOH/CH3COOH 99:1:0.1 as eluent. 
Yield = 15 %; mp = 162-63 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH2CH3, J = 7.4 Hz), 1.52 
(sext, 2H, CH2CH2CH3, J = 7.6 Hz), 1.62 (t, 3H, NCH2CH3, J = 7.2 Hz), 1.80 (quin, 2H, CH2CH2CH2, J 
= 7.1 Hz), 4.00 (t, 2H, OCH2, J = 6.6 Hz), 4.64 (q, 2H, NCH2, J = 7.2 Hz), 6.93 (d, 2H, Ar, J = 9.0 Hz), 
7.69 (d, 2H, Ar, J = 9.0 Hz), 8.15 (d, 1H, Ar, J = 8.4 Hz), 8.99 (d, 1H, Ar, J = 8.4 Hz ), 9.12 (s, 1H, Ar), 
11.76 (exch br s, 1H, NH). 
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5.2.44  N-(4-Bromophenyl)-2-(1-oxophthalazin-2(1H)-yl)acetamide (23) 
N
N
O H
N
O
Br
 
A solution of  22 (1.54 mmol) in anhydrous acetonitrile (1 ml) was added dropwise to a stirred solution of 
commercially available 1-(2H)-phthalazinone (1.03 mmol) in anhydrous acetonitrile (3 mL). K2CO3 (2.06 
mmol) was added and the reaction was carried out for 3 h at reflux. Removal of the solvent gave a residue 
which was poured into ice-cold water and after 1 h stirring in ice-bath the final product was filtered off by 
suction and recrystallized from ethanol. Yield = 45 %; mp = 245-46 °C (EtOH). 1H NMR (CDCl3) δ 4.97 
(s, 2H, NCH2CO), 7.53 (qd, 4H, Ar, J = 13.9 Hz, J = 8.3 Hz), 7.91 (m, 1H, Ar), 7.99 (d, 2H, Ar, J = 5.8 
Hz), 8.26 (d, 1H, Ar, J = 8.0 Hz), 8.48 (s, 1H, Ar), 10.46 (exch br s, 1H, NH). 
 
General Procedure for 24a-c. Commercially available 2,3-diidrophthalazin-1,4-dione (4.93 
mmol), K2CO3 (9.80 mmol) and the suitable benzyl halide (5.43 mmol) were stirred in anhydrous DMF 
(5 mL) for 2-4 h at 80 °C. The mixture was then diluted with ice-cold water and extracted with CH2Cl2 (3 
x 15 mL). The organic layer was dried over Na2SO4 and evaporated in vacuo. Compounds 24a-c were 
then purified by flash column chromatography using cyclohexane/ethyl acetate 1:1 as eluent.  
5.2.45  2-(4-Methoxybenzyl)-2,3-dihydrophthalazine-1,4-dione (24a) 
NH
N
O
O
O
 
Yield = 23 %; mp = 150-52 °C (EtOH). 1H NMR (CDCl3) δ 3.86 (s, 3H, OCH3), 5.31 (s, 2H, NCH2), 6.96 
(d, 2H, Ar, J = 8.6 Hz), 7.44 (d, 2H, Ar, J = 8.5 Hz), 7.83 (quin, 2H, Ar, J = 3.7 Hz), 8.07 (dd, 1H, Ar, J = 
3.1 Hz, J = 3.5 Hz), 8.41 (dd, 1H, Ar, J = 2.4 Hz, J = 2.8 Hz), 9.98 (exch br s, 1H, NH). 
5.2.46  2-(3-Methoxybenzyl)-2,3-dihydrophthalazine-1,4-dione (24b) 
NH
N
O
O O
 
Yield = 18 %; mp = 184-86 °C (EtOH). 1H NMR (CDCl3) δ 3.87 (s, 3H, OCH3), 5.36 (s, 2H, NCH2), 6.93 
(dd, 1H, Ar, J = 5.8 Hz, J = 2.4 Hz), 7.06 (s, 1H, Ar), 7.09 (d, 1H, Ar, J = 7.6 Hz), 7.36 (t, 1H, Ar, J = 7.9 
Hz), 7.82-7.89 (m, 2H, Ar), 8.09 (dd, 1H, Ar, J = 6.9 Hz, J = 1.9 Hz), 8.44 (dd, 1H, Ar, J = 4.0 Hz, J = 
2.1 Hz), 9.94 (exch br s, 1H, NH). 
 
General Procedure for 25a-c. The appropriate derivative of type 24 (24a-c) (1.10 mmol) was 
dissolved in 3 mL of anhydrous CH2Cl2 and 4-butoxyphenyl isocyanate (2.20 mmol) was added under 
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stirring at 0 °C. The reaction was carried out at 0 °C for 2 h and subsequently at room temperature for 12 
h. The solid residue was filtered off and the solution was evaporated in vacuo to afford compounds 25a-c, 
which were purified by flash column  chromatography using CH2Cl2 as eluent.  
5.2.47  N-(4-Butoxyphenyl)-3-(4-methoxybenzyl)-1,4-dioxo-3,4-dihydro-phthalazine-
2(1H)-carboxamide (25a) 
N
N
O
O
H
N
O
O
O
 
Yield = 53 %; mp = 117-19 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.4 Hz), 1.52 (sext, 
2H, CH2CH3, J = 7.5 Hz), 1.80 (quin, 2H, CH2CH2CH2, J = 6.8 Hz), 3.84 (s, 3H, OCH3), 3.99 (t, 2H, 
OCH2, J = 6.5 Hz), 5.51 (s, 2H, NCH2), 6.95 (t, 4H, Ar, J = 8.7 Hz), 7.56 (d, 2H, Ar, J = 8.5 Hz), 7.62 (d, 
2H, Ar, J = 8.9 Hz), 7.86 (quin, 2H, Ar, J = 7.8 Hz), 8.06 (d, 1H, Ar, J = 7.8 Hz), 8.47 (d, 1H, Ar, J = 7.6 
Hz), 11.86 (exch br s, 1H, NH). 
5.2.48  N-(4-Butoxyphenyl)-3-(3-methoxybenzyl)-1,4-dioxo-3,4-dihydro-phthalazine-
2(1H)-carboxamide (25b) 
N
N
O
O
H
N
O
O
O
 
Yield = 75 %; mp = 104-06 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.4 Hz), 1.52 (sext, 
2H, CH2CH3, J = 7.6 Hz), 1.80 (quin, 2H, CH2CH2CH2, J = 7.0 Hz), 3.87 (s, 3H, OCH3), 3.99 (t, 2H, 
OCH2, J = 6.5 Hz), 5.56 (s, 2H, NCH2), 6.93 (dd, 3H, Ar, J = 4.6 Hz, J = 3.2 Hz), 7.18 (d, 1H, Ar, J = 7.0 
Hz), 7.19 (s, 1H, Ar), 7.35 (t, 1H, Ar, J = 7.7 Hz), 7.61 (d, 2H, Ar, J = 9.0 Hz), 7.84-7.92 (m, 2H, Ar), 
8.10 (d, 1H, Ar, J = 7.1 Hz), 8.49 (d, 1H, Ar, J = 7.2 Hz), 11.84 (exch br s, 1H, NH). 
5.2.49  3-Benzyl-N-(4-butoxyphenyl)-1,4-dioxo-3,4-dihydrophthalazine-2(1H)-
carboxamide (25c) 
N
N
O
O
H
N
O
O
 
Yield = 86 %; mp = 117-19 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.4 Hz), 1.52 (sext, 
2H, CH2CH3, J = 7.6 Hz), 1.80 (quin, 2H, CH2CH2CH2, J = 6.9 Hz), 3.99 (t, 2H, OCH2, J = 6.5 Hz), 5.59 
(s, 2H, NCH2), 6.94 (d, 2H, Ar, J = 8.9 Hz), 7.37-7.46 (m, 3H, Ar), 7.62 (dd, 4H, Ar, J = 1.3 Hz, J = 5.3 
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Hz), 7.84-7.92 (m, 2H, Ar), 8.09 (d, 1H, Ar, J = 7.8 Hz), 8.49 (d, 1H, Ar, J = 7.5 Hz), 11.85 (exch br s, 
1H, NH). 
 
5.2.50  N-(4-Bromophenyl)-2-(3-(3-methoxybenzyl)-1,4-dioxo-3,4-dihydro-phthalazin-
2(1H)-yl)acetamide (26) 
N
N
O
O
N
H
O
Br
O
 
A suspension of the intermediate 24b (0.18 mmol), K2CO3 (0.36 mmol) and amide 22 (0.27 mmol) in 
anhydrous acetonitrile (1 mL) was stirred at reflux for 3 h. The solvent was then evaporated in vacuo and 
the mixture was puored into ice-cold water. After 1 h stirring in ice-bath, the precipitate was filtered off 
and purified through two consecutive crystallization from ethanol. Yield = 45 %; mp = 178-80 °C 
(EtOH). 1H NMR (CDCl3) δ 3.85 (s, 3H, OCH3), 4.95 (s, 2H, NCH2-C6H3), 5.39 (s, 2H, NCH2CO), 6.91 
(d, 1H, Ar, J = 8.5 Hz), 7.06 (s, 1H, Ar), 7.09 (d, 1H, Ar, J = 6.7 Hz), 7.34 (t, 1H, Ar, J = 7.6 Hz), 7.43 (s, 
4H, Ar), 7.78 (t, 2H, Ar, J = 4.8 Hz), 8.09-8.12 (m, 1H, Ar), 8.45-8.48 (m, 1H, Ar), 8.80 (exch br s, 1H, 
NH). 
 
General Procedure for 27a,b. K2CO3 (6.06 mmol) and tetrabutylammonium bromide (0.30 
mmol) were added to a srirred solution of 4,5-dichloro-3(2H)-pyridazinone (3.03 mmol) in anhydrous 
acetonitrile (3 mL). The appropriate benzyl chloride (3- or 4-methoxybenzyl chloride) (4.54 mmol) was 
added and the reaction was carried out at reflux for 5-7 h. The mixture was then allowed to cool down and 
the solvent was evaporated in vacuo. Ice-cold water was added to the residue and after 1 h stirring in ice-
bath, compounds 27a,b were filtered off and recrystallized from ethanol. 
5.2.51    4,5-Dichloro-2-(4-methoxybenzyl)pyridazin-3(2H)-one (27a) 
NN
Cl Cl
O
O
 
Yield = 81 %; mp = 116-17 °C (EtOH). 1H NMR (CDCl3) δ 3.81 (s, 3H, OCH3), 5.28 (s, 2H, NCH2), 6.88 
(d, 2H, Ar, J = 8.6 Hz), 7.42 (d, 2H, Ar, J = 8.5 Hz), 7.79 (s, 1H, Ar). 
5.2.52    4,5-Dichloro-2-(3-methoxybenzyl)pyridazin-3(2H)-one (27b) 
NN
Cl Cl
O
O
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Yield = 60 %; mp = 80-82 °C (EtOH). 1H NMR (CDCl3) δ 3.82 (s, 3H, OCH3), 5.31 (s, 2H, NCH2), 6.87 
(dd, 1H, Ar, J = 5.6 Hz, J = 2.6 Hz), 6.99-7.05 (m, 2H, Ar), 7.27 (t, 1H, Ar, J = 3.6 Hz), 7.80 (s, 1H, Ar). 
 
General Procedure for 28a,b. Compound 27a or 27b (0.88 mmol) was added to a stirred solution 
of Na° (1.76 mmol) in 3 mL of anhydrous methanol. The reaction mixture was stirred for 1 h at room 
temperature. After removal of the solvent in vacuo, ice-cold water was added to the residue and the 
precipitate was filtered off by suction and purified by crystallization from ethanol. 
5.2.53    4-Chloro-5-methoxy-2-(4-methoxybenzyl)pyridazin-3(2H)-one (28a) 
NN
Cl O
O
O
 
Yield = 53 %; mp = 135-37 °C (EtOH). 1H NMR (CDCl3) δ 3.80 (s, 3H, C6H4-OCH3), 4.06 (s, 3H, OCH3 
pyridaz.), 5.31 (s, 2H, NCH2), 6.87 (d, 2H, Ar, J = 8.6 Hz), 7.42 (d, 2H, Ar, J = 8.6 Hz), 7.80 (s, 1H, Ar). 
5.2.54    4-Chloro-5-methoxy-2-(3-methoxybenzyl)pyridazin-3(2H)-one (28b) 
NN
Cl O
O
O
 
Yield = 60 %; mp = 80-82 °C (EtOH). 1H NMR (CDCl3) δ 3.81 (s, 3H, C6H4-OCH3), 4.07 (s, 3H, OCH3 
pyridaz.), 5.34 (s, 2H, NCH2), 6.85 (dd, 1H, Ar, J = 6.2 Hz, J = 1.89 Hz), 6.99 (s, 1H, Ar), 7.03 (d, 1H, 
Ar, J = 7.3 Hz), 7.26 (t, 1H, Ar, J = 7.9 Hz), 7.83 (s, 1H, Ar). 
 
General Procedure for 29a,b. To the suspension of 28a or 28b (0.71 mmol), Pd(PPh3)4 
[tetrakis(triphenylphosphine)palladium(0), 0.02 mmol] and 4-butoxyphenylboronic acid (1.07 mmol) in 
toluene (2 mL), Na2CO3 (1.42  mmol, 2 M in H2O) was added and the mixture was stirred at reflux for 2 
h. Extra 4-butoxyphenylboronic acid (1.07 mmol) was added and the reaction was refluxed for additional 
3-6 h. The solvent was evaporated under vacuo, then the suspension was diluted with ice-cold water and 
extracted with CH2Cl2. The organic layer was dried over Na2SO4 and the residue was purified by flash 
column chromatography using cyclohexane/ethyl acetate 3:1 as eluent.  
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5.2.55    4-(4-Butoxyphenyl)-5-methoxy-2-(4-methoxybenzyl)pyridazin-3(2H)-one (29a) 
NN
O
O
O
O
 
Yield = 82 %; colorless oil. 1H NMR (CDCl3) δ 0.99 (t, 2H, CH2CH3, J = 7.4 Hz), 1.51 (sext, 2H, 
CH2CH3, J = 7.6 Hz), 1.79 (quin, 2H, CH2CH2CH2, J = 6.9 Hz), 3.80 (s, 3H, C6H4-OCH3), 3.89 (s, 3H, 
OCH3 pyridaz.), 4.01 (t, 2H, OCH2, J = 6.5 Hz), 5.31 (s, 2H, NCH2), 6.87 (d, 2H, Ar, J = 8.6 Hz), 6.94 (d, 
2H, Ar, J = 8.8 Hz), 7.48 (q, 4H, Ar, J = 8.0 Hz), 7.89 (s, 1H, Ar). 
5.2.56    4-(4-Butoxyphenyl)-5-methoxy-2-(3-methoxybenzyl)pyridazin-3(2H)-one (29b) 
NN
O
O
O
O
 
Yield = 28 %; colorless oil. 1H NMR (CDCl3) δ 0.99 (t, 2H, CH2CH3, J = 7.4 Hz), 1.51 (sext, 2H, 
CH2CH3, J = 7.4 Hz), 1.79 (quin, 2H, CH2CH2CH2, J = 6.9 Hz), 3.81 (s, 3H, C6H4-OCH3), 3.90 (s, 3H, 
OCH3 pyridaz.), 4.00 (t, 2H, OCH2, J = 6.5 Hz), 5.35 (s, 2H, NCH2), 6.84 (dd, 1H, Ar, J = 6.0 Hz, J = 2.3 
Hz), 6.94 (d, 2H, Ar, J = 8.7 Hz), 7.02 (s, 1H, Ar), 7.06 (d, 1H, Ar, J = 7.6 Hz), 7.26 (t, 1H, Ar, J = 8.0 
Hz), 7.51 (d, 2H, Ar, J = 8.7 Hz), 7.91 (s, 1H, Ar). 
 
General Procedure for 30a,b. To a suspension of 27a or 27b (0.53 mmol), PdCl2[(C2H5)3P]2 
[trans-dichlorobis(triethylphosphine)palladium(II), 0.05 mmol] and 4-butoxyphenylboronic acid (0.26 
mmol) in DMF (2 mL), Na2CO3 (0.53  mmol, 1 M in H2O) was added and the mixture was stirred at room 
temperature for 6-12 h. The suspension was diluted with ice-cold water and extracted with CH2Cl2. The 
organic layer was dried over Na2SO4 and the residue was purified by flash column chromatography using 
CH2Cl2 (for 30a) and CH2Cl2/MeOH/NH4OH 99:1:0.1 (for 30b) as eluents. 
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5.2.57    5-(4-Butoxyphenyl)-4-chloro-2-(4-methoxybenzyl)pyridazin-3(2H)-one (30a) 
NN
Cl
O
O
O
 
Yield = 22 %; mp = 84-85 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 2H, CH2CH3, J = 7.4 Hz), 1.53 (sext, 
2H, CH2CH3, J = 7.6 Hz), 1.82 (quin, 2H, CH2CH2CH2, J = 6.8 Hz), 3.81 (s, 3H, OCH3), 4.03 (t, 2H, 
OCH2, J = 6.5 Hz), 5.34 (s, 2H, NCH2), 6.90 (d, 2H, Ar, J = 8.4 Hz), 7.01 (d, 2H, Ar, J = 8.6 Hz), 7.48 
(dd, 4H, Ar, J = 5.9 Hz, J = 8.6 Hz), 7.78 (s, 1H, Ar). 
5.2.58    5-(4-Butoxyphenyl)-4-chloro-2-(3-methoxybenzyl)pyridazin-3(2H)-one (30b) 
NN
Cl
O
O
O
 
Yield = 14 %; mp = 73-75 °C (EtOH). 1H NMR (CDCl3) δ 1.01 (t, 2H, CH2CH3, J = 7.4 Hz), 1.53 (sext, 
2H, CH2CH3, J = 7.5 Hz), 1.82 (quin, 2H, CH2CH2CH2, J = 7.0 Hz), 3.83 (s, 3H, OCH3), 4.04 (t, 2H, 
OCH2, J = 6.5 Hz), 5.38 (s, 2H, NCH2), 6.88 (dd, 1H, Ar, J = 5.7 Hz, J = 2.6 Hz), 7.02 (d, 2H, Ar, J = 8.8 
Hz), 7.07 (s, 1H,Ar), 7.10 (d, 1H, Ar, J = 7.6 Hz), 7.29 (t, 1H, Ar, J = 8.0 Hz), 7.47 (d, 2H, Ar, J = 8.7 
Hz), 7.79 (s, 1H, Ar). 
 
5.2.59    4-Butoxy-N-(6-methyl-3-oxo-2-phenyl-2,3-dihydropyridazin-4-yl)benzamide (35) 
NN
O
HN
O
O
 
4-Butoxybenzoic acid (0.36 mmol) was converted into the corresponding chloride as follows: SOCl2 
(20.7 mmol) was added and the stirred suspension was cooled to 0 °C and treated with Et3N (0.99 mmol). 
After 4 h of reflux, the mixture was evaporated in vacuo and the residue was washed with cyclohexane (3 
x 5 mL). The residue was dissolved in anhydrous toluene (5 mL), then added of compound 34 (0.40 
mmol) dissolved in anhydrous toluene (1 mL) and Et3N (1.48 mmol). After 4 h of reflux the solvent was 
removed in vacuo, cold water was added and the aqueous layer was extracted with CH2Cl2 (3 x 20 mL). 
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Evaporation of the organic solvent in vacuo gave a residue that was purified by column chromatography 
(eluent: cyclohexane/ethyl acetate 3:1). Yield = 37 %; mp = 95-97 °C (EtOH). IR (cm-1) 3269 (NH), 1682 
(CO), 1644 (CO). 1H NMR (CDCl3) δ 1.01 (t, 3H,CH2CH3, J = 7.4 Hz), 1.53 (sext, 2H, CH2CH3, J = 7.5 
Hz), 1.82 (quin, 2H, CH2CH2CH2, J = 7.0 Hz), 2.45 (s, 3H, 6-CH3), 4.06 (t, 2H, CH2O, J = 6.5 Hz), 6.99 
(d, 2H, Ar, J = 8.8 Hz), 7.43 (t, 1H, Ar, J = 7.4 Hz), 7.52 (t, 2H, Ar, J = 7.8 Hz), 7.65 (d, 2H, Ar, J = 7.7 
Hz), 7.91 (d, 2H, Ar, J = 8.8 Hz), 8.24 (s, 1H, Ar), 9.46 (exch br s, 1H, NH). MS (ESI) calcd. For 
C22H23N3O3, 377,44. Found: m/z 378.18 [M + H]+.  
 
5.2.60    4-(4-Butoxyphenylamino)-6-methyl-2-phenylpyridazin-3(2H)-one (36) 
NN
O
HN
O
 
To a suspension of 34 (0.55 mmol), copper acetate (0.82 mmol) and 4-butoxyphenylboronic acid (1.08 
mmol) in CH2Cl2 (2 mL), Et3N (1.08 mmol) was added and the mixture was stirred at room temperature 
for 12 h. The suspension was extracted with 15% aqueous ammonia (10 mL), and the organic layer was 
washed with 10 mL of water and dried over Na2SO4. After removal of the solvent, the residue was 
purified by column chromatography using as eluent cyclohexane/ethyl acetate 3:1. The analytical sample 
was obtained through a further purification performed on silica gel preparative TLC (eluent: 
cyclohexane/ethyl acetate 3:1). Yield = 16 %; mp = 137-139 °C (EtOH). IR (cm-1) 3275 (NH), 1633 
(CO). 1H NMR (CDCl3) δ 1.02 (t, 3H, CH2CH3, J = 7.4 Hz), 1.54 (sext, 2H, CH2CH3, J = 7.0 Hz), 1.81 
(quin, 2H, CH2CH2CH2), 2.31 (s, 3H, 6-CH3), 4.01 (t, 2H, CH2O, J = 6.5 Hz), 6.40 (s, 1H, Ar), 6.97 (d, 
2H, Ar, J = 8.9 Hz), 7.20 (d, 2H, Ar, J = 8.8 Hz), 7.41 (t, 1H, Ar, J = 7.4 Hz), 7.51 (t, 3H, Ar, J = 7.7 Hz), 
7.64 (d, 2H, Ar, J = 8.0 Hz). MS (ESI) calcd. For C21H23N3O2, 349.43. Found: m/z 350.19 [M + H]+. 
 
5.2.61   1-(4-Butoxyphenyl)-3-(6-methyl-3-oxo-2-phenyl-2,3-dihydro pyridazin-4-yl)urea (37) 
NN
O
HN
O
NH
O
 
To a cooled and stirred suspension of 34 (0.50 mmol) and anhydrous sodium acetate (1.20 mmol) in 
anhydrous THF (5 mL), triphosgene (1.75 mmol) was added. The mixture was stirred for additional 10 
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min at 0 °C and refluxed for 2 h. The solvent was removed in vacuo, and the residue was dissolved in 
anhydrous THF (2 mL). 4-Butoxyaniline (1.20 mmol) was added and the mixture was stirred at room 
temperature for 12 h. After dilution with ice-cold water, the suspension was extracted with CH2Cl2 (3 x 
20 mL). Removal of the solvent in vacuo afforded a crude residue which was purified by column 
chromatography using absolute EtOH/CH2Cl2/petroleum ether/toluene/33% ammonia 3.3:19.7:6.5:70:0.5 
as eluent. Yield = 31 %; mp =189-191 °C (EtOH). IR (cm-1) 3270 (NH), 3255 (NH), 1705 (CO), 1625 
(CO). 1H NMR (CDCl3) δ 1.01 (t, 3H, CH2CH3, J = 7.4 Hz), 1.52 (sext, 2H, CH2CH3, J = 7.4 Hz), 1.79 
(quin, 2H, CH2CH2CH2, J = 7.0 Hz), 2.40 (s, 3H, 6-CH3), 3.95 (t, 2H, OCH2, J = 6.6 Hz), 6.70 (s, 4H, 
Ar), 7.17 (t, 1H, Ar, J = 7.5 Hz), 7.32 (t, 2H, Ar, J = 7.8 Hz), 7.61 (d, 2H, Ar, J = 7.9 Hz), 8.11 (exch br s, 
1H, NH), 8.14 (s, 1H, Ar), 9.33 (exch br s, 1H, NH). MS (ESI) calcd. For C22H24N4O3, 392.45. Found: 
m/z 393.19 [M + H]+. 
 
General Procedure for 38a-c. To a stirred solution of compound 34 (0.35 mmol) in anhydrous 
toluene (2 mL), the proper aryl isocyanate (0.40 mmol) was added. The mixture was refluxed for 4-7 h. 
After cooling, the precipitate was collected by suction and purified by crystallization from toluene (38b 
and 38c). In the case of 38a, after cooling, cold water was added and the mixture was extracted with 
CH2Cl2 (3 x 20 mL). Removal of the solvent gave a residue that was purified by column chromatography 
using CH2Cl2/CH3OH 9.9:0.1 as eluent.  
5.2.62      1-(4-Iodophenyl)-3-(6-methyl-3-oxo-2-phenyl-2,3-dihydropyridazin-4-yl)urea (38a) 
NN
O
HN
O
NH
I
 
Yield = 45 %; mp = 264-265 °C (EtOH/toluene). IR (cm-1) 3270 (NH), 3256 (NH), 1708 (CO), 1627 
(CO). 1H NMR (CDCl3) δ 2.44 (s, 3H,CH3), 6.50 (d, 2H, Ar, J = 8.7 Hz), 7.21 (t, 1H, Ar, J = 7.5 Hz), 
7.36-7.41 (m, 4H, Ar), 7.68 (d, 2H, Ar, J = 7.7 Hz), 8.15 (s, 1H, Ar), 8.41 (exch br s, 1H, NH), 9.38 (exch 
br s, 1H, NH). MS (ESI) calcd. For C18H15IN4O2, 446.24. Found: m/z 447.03 [M + H]+. 
5.2.63   1-(4-Bromophenyl)-3-(6-methyl-3-oxo-2-phenyl-2,3-dihydropyridazin-4-yl)urea (38b) 
NN
O
HN
O
NH
Br
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Yield = 50 %; mp = 263-265 °C (toluene). IR (cm-1) 3271 (NH), 3250 (NH), 1704 (CO), 1625 (CO). 1H 
NMR (CDCl3) δ 2.43 (s, 3H,CH3), 6.60 (d, 2H, Ar, J = 8.6 Hz), 7.19-7.22 (m, 3H, Ar), 7.38 (t, 2H, Ar, J 
= 7.8 Hz), 7.69 (d, 2H, Ar, J = 7.9 Hz), 8.16 (s, 1H, Ar), 8.44 (exch, br, s, 1H, NH), 9.40 (exch br s, 1H, 
NH). MS (ESI) calcd. For C18H15BrN4O2, 399.24. Found: m/z 399.05  [M]+. 
5.2.64   1-(4-Chlorophenyl)-3-(6-methyl-3-oxo-2-phenyl-2,3-dihydropyridazin-4-yl)urea (38c) 
NN
O
HN
O
NH
Cl
 
Yield = 85 %; mp = 274-276 °C (toluene). IR (cm-1) 3269 (NH), 3255 (NH), 1705 (CO), 1626 (CO). 1H 
NMR (CDCl3) δ 2.44 (s, 3H, CH3), 6.65 (d, 2H, Ar, J = 8.8 Hz), 7.07 (d, 2H, Ar, J = 8.8 Hz), 7.21 (t, 1H, 
Ar, J = 7.5 Hz), 7.38 (t, 2H, Ar, J = 7.9 Hz), 7.69 (d, 2H, Ar, J = 7.6 Hz), 8.16 (s, 1H, Ar), 8.43 (exch br 
s, 1H, NH), 9.40 (exch br s, 1H, NH). MS (ESI) calcd. For C18H15ClN4O2, 354.79. Found: m/z 355.10 [M 
+ H]+. 
 
General Procedure for 42a-m. To a stirred solution of the suitable commercially available or 
synthesized γ-keto acid (1.00 mmol) in EtOH (2 mL), hydrazine hydrate (1.00 mmol) was added 
dropwise. The mixture was heated at 60 °C for 1-3 h. After cooling, the precipitate was collected by 
suction and purified by recrystallization alternatively from toluene or ethanol. 
5.2.65    6-(4-Fluorophenyl)-4,5-dihydropyridazin-3(2H)-one (42j) 
HN N
O F
 
Yield = 95 %; mp = 192-93 °C (EtOH). 1H NMR (CDCl3) δ 2.64 (dd, 2H, COCH2CH2, J = 1.2 Hz, J = 
7.9 Hz), 3.00 (dd, 2H, COCH2CH2, J = 1.2 Hz, J = 7.3 Hz), 7.13 (qd, 2H, Ar, J = 1.8 Hz, J = 4.7 Hz), 
7.72-7.76 (qd, 2H, Ar, J = 0.4 Hz, J = 3.1 Hz), 8.51 (exch br s, 1H, NH). 
 
5.2.66    4-(3-Methoxybenzyl)-6-methylpyridazin-3(2H)-one (43) 
HN N
O
O
 
To 7 mL of KOH in absolute EtOH (5%, w/v), 42d (1.79 mmol) and 3-methoxybenzaldehyde (1.79 
mmol) were added. The reaction was carried out under stirring for 3 h. After cooling, the mixture was 
concentrated in vacuo, diluted with cold water (10-15 mL) and acidified with 2 N HCl. The suspension 
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was extracted with CH2Cl2 (3 x 15 mL). The organic phase was dried (Na2SO4) and evaporated in vacuo 
to afford compound 43, which was purified by flash column chromatography using cyclohexane/ethyl 
acetate 1:1 as eluent. Yield = 61 %; mp =133-134 °C (EtOH). 1H NMR (CDCl3) δ 2.26 (s, 3H, 6-CH3), 
3.82 (s, 3H, OCH3), 3.90 (s, 2H, CH2-Ar), 6.73 (s, 1H, Ar), 6.82-6.86 (m, 3H, Ar), 7.276-7.28 (m, 1H, 
Ar).  
 
5.2.67    [5-(3-Methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-yl]-acetic acid ethyl ester (44) 
N N
O
O
O
O
 
A mixture of 43 (1.13 mmol), K2CO3 (2.26 mmol), and ethyl bromoacetate (3.40 mmol) in CH3CN (3 
mL) was refluxed under stirring for 6 h. The mixture was then concentrated in vacuo, diluted with cold 
water, and extracted with CH2Cl2 (3 x 15 mL). The solvent was evaporated in vacuo and compound 44 
was purified by column chromatography using cyclohexane/ethyl acetate 1:1 as eluent. Yield = 98 %; oil. 
1H NMR (CDCl3) δ 1.29 (t, 3H, CH2CH3, J = 7.1 Hz), 2.22 (s, 3H, 3-CH3), 3.80 (s, 3H, OCH3), 3.86 (s, 
2H, CH2-Ar), 4.22-4.25 (m, 2H, OCH2CH3), 4.85 (s, 2H, NCH2CO), 6.67 (s, 1H, Ar), 6.78-6.82 (m, 3H, 
Ar), 7.26 (t, 1H, Ar, J =7.8 Hz).  
 
5.2.68    [5-(3-Methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-yl]-acetic Acid (45) 
N N
O
O
O
OH
 
A suspension of 44 (0.5 mmol), 6 N NaOH (6 mL) and ethanol (2 mL) was stirred at rt to 80 °C for 1 h. 
The mixture was then concentrated in vacuo, diluted with cold water and acidified with 6 N HCl. The 
final product 45 was filtered off with suction and recrystallized from ethanol. Yield = 97 %; mp =194-195 
°C (EtOH). 1H NMR (DMSO-d6) δ 2.21 (s, 3H, 3-CH3), 3.72 (s, 3H, OCH3), 3.76 (s, 2H, CH2-Ar), 4.69 
(s, 2H, NCH2CO), 6.79-6.85 (m, 3H, Ar), 7.07 (s, 1H, Ar), 7.22 (t, 1H, Ar, J = 7.8 Hz). 
 
General Procedure for 46a-s. To a cooled (-5 °C) and stirred solution of compound 45 (0.35 
mmol) in anhydrous tetrahydrofuran (3-5 mL), Et3N (1.22 mmol) was added. After 30 min, the mixture 
was allowed to warm up to 0 °C and ethyl chloroformate (0.38 mmol) was added. After 1 h, the 
appropriate substituted aryl(cycloalkyl)amine (0.7 mmol), was added and the reaction was carried out at 
room temperature for 12 h. The mixture was then concentrated in vacuo, diluted with cold water (20-30 
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mL) and extracted with CH2Cl2 (3 x 15 mL). The solvent was evaporated to afford final compounds 46a-
s, which were purified by column chromatography using cyclohexane/ethyl acetate 1:1 as eluent for 
compounds 46a,d,e,g-m,p,q, toluene/NH4OH/EtOH/CH2Cl2/petroleum ether 7:0.05:0.30:2: 0.65 for 
compounds 46b,c, cyclohexane/ethyl acetate 1:2 for compounds 46f,n,o,r, CH2Cl2/ CH3OH 9.5:0.5 for 
compound 46s.  
5.2.69  N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-
yl]-acetamide (46a)  
N N
O
O
O H
N Br
 
Yield = 86 %; mp = 171-172 °C (EtOH). IR (cm-1) 3300 (NH), 1708 (CO), 1644 (CO). 1H NMR (CDCl3) 
δ 2.20 (s, 3H, 3-CH3), 3.70 (s, 3H, OCH3), 3.73 (s, 2H, CH2-Ar), 4.80 (s, 2H,NCH2CO), 6.77-6.82 (m, 
3H, Ar), 7.13 (s, 1H, Ar), 7.20 (t, 1H, Ar, J = 8.0 Hz), 7.47 (s, 4H, Ar). MS (ESI) calcd. For 
C21H20BrN3O3, 442.31. Found: m/z 442.08 [M ]+. 
5.2.70  N-(3-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-
yl]-acetamide (46b)  
N N
O
O
O H
N
Br
 
Yield = 85 %; mp = 73-75 °C (EtOH). IR (cm-1) 3295 (NH), 1708 (CO), 1642 (CO). 1H NMR (CDCl3) δ 
2.30 (s, 3H, 3-CH3), 3.80 (s, 3H, OCH3), 3.92 (s, 2H, CH2-Ar), 4.95 (s, 2H, NCH2CO), 6.80-6.86 (m, 4H, 
Ar), 7.14 (t, 1H, Ar, J = 8.0 Hz), 7.22 (m, 1H, Ar, J = 8.2 Hz), 7.27- 7.31 (m, 1H, Ar), 7.39 (d, 1H, Ar, J 
= 8.0 Hz), 7.77 (s, 1H, Ar), 9.05 (exch br s, 1H, NH). MS (ESI) calcd. For C21H20BrN3O3, 442.31. Found: 
m/z 441.11. [M - H]+. 
5.2.71  N-(2-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-
yl]-acetamide (46c)  
N N
O
O
O H
N
Br
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Yield = 80 %; oil. IR (cm-1) 3300 (NH), 1708 (CO), 1644 (CO). 1H NMR (CDCl3) δ 2.30 (s, 3H, 3-CH3), 
3.82 (s, 3H, OCH3), 3.92 (s, 2H, CH2-Ar), 5.00 (s, 2H, NCH2CO), 6.76 (s, 1H, Ar), 6.80-6.86 (m, 3H, 
Ar), 7.00 (t, 1H, Ar, J = 7.7 Hz), 7.27-7.34 (m, 2H, Ar), 7.52 (d, 1H, Ar, J = 8.0 Hz), 8.36 (d, 1H, Ar, J = 
8.2 Hz), 8.54 (exch br s, 1H, NH). MS (ESI) calcd. For C21H20BrN3O3, 442.31. Found: m/z 443.08. [M + 
H]+. 
5.2.72  N-(4-Fluorophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-
yl]-acetamide (46d)  
N N
O
O
O H
N F
 
Yield = 97 %; mp = 145-147 °C (EtOH). IR (cm-1) 3300 (NH), 1707 (CO), 1643 (CO). 1H NMR (CDCl3) 
δ 2.30 (s, 3H, 3-CH3), 3.80 (s, 3H, OCH3), 3.90 (s, 2H, CH2-Ar), 4.95 (s, 2H, NCH2CO), 6.80-6.84 (m, 
4H, Ar), 6.90 (t, 2H, Ar, J = 8.7 Hz), 7.25-7.29 (m, 1H, Ar), 7.39-7.42 (m, 2H, Ar), 9.21 (exch br s, 1H, 
NH). MS (ESI) calcd. For C21H20FN3O3, 381.40. Found: m/z 382.16  [M + H]+. 
5.2.73  N-(4-Chlorophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-
yl]-acetamide (46e)  
N N
O
O
O H
N Cl
 
Yield = 86 %; mp = 170-171 °C (EtOH). IR (cm-1) 3296 (NH), 1705 (CO), 1644 (CO). 1H  NMR (CDCl3) 
δ 2.30 (s, 3H, 3-CH3), 3.80 (s, 3H, OCH3), 3.90 (s, 2H, CH2-Ar), 4.95 (s, 2H, NCH2CO), 6.79 (s, 1H, Ar), 
6.80-6.85 (m, 3H, Ar), 7.16 (d, 2H, Ar, J = 8.8 Hz), 7.25-7.29 (m, 1H, Ar), 7.38 (d, 2H, Ar, J = 8.8 Hz), 
9.28 (exch br s, 1H, NH). MS (ESI) calcd. For C21H20ClN3O3, 397.85. Found: m/z 398.13 [M + H]+. 
5.2.74 N-(4-Iodophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-yl]-
acetamide (46f)  
N N
O
O
O H
N I
 
Yield = 99 %; mp = 179-180 °C (EtOH). IR (cm-1) 3300 (NH), 1707 (CO), 1645 (CO). 1H  NMR (CDCl3) 
δ 2.30 (s, 3H, 3-CH3), 3.79 (s, 3H, OCH3), 3.88 (s, 2H, CH2-Ar), 4.95 (s, 2H, NCH2CO), 6.78-6.84 (m, 
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4H, Ar), 7.17 (d, 2H, Ar, J = 8.7 Hz), 7.24-7.28 (m, 1H, Ar), 7.45 (d, 2H, Ar, J = 8.7 Hz), 9.41 (exch br s, 
1H, NH). MS (ESI) calcd. For C21H20IN3O3, 489.31. Found: m/z 490.06 [M + H]+. 
5.2.75  2-[5-(3-Methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-yl]-N-phenyl- 
acetamide (46g)  
N N
O
O
O H
N
 
Yield = 97 %; oil. IR (cm-1) 3295 (NH), 1708 (CO), 1644 (CO). 1H NMR (CDCl3) δ 2.28 (s, 3H, 3-CH3), 
3.81 (s, 3H, OCH3), 3.91 (s, 2H, CH2-Ar), 4.96 (s, 2H, NCH2CO), 6.78-6.86 (m, 4H, Ar), 7.08 (t, 1H, Ar, 
J = 7.4 Hz), 7.26-7.30 (m, 3H, Ar), 7.50 (d, 2H, Ar, J = 8.0Hz), 8.93 (exch br s, 1H, NH). MS (ESI) 
calcd. For C21H21N3O3, 363.41. Found: m/z 364.16 [M + H]+. 
5.2.76  2-[5-(3-Methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-yl]-N-4-tolyl-
acetamide (46h)  
N N
O
O
O H
N
 
Yield = 78 %; mp =142-144 °C (EtOH). IR (cm-1) 3300 (NH), 1708 (CO), 1644 (CO). 1H NMR (CDCl3) 
δ 2.28 (s, 3H, 3-CH3), 2.30 (s, 3H, CH3-Ar), 3.81 (s, 3H, OCH3), 3.90 (s, 2H, CH2-Ar), 4.94 (s, 2H, 
NCH2CO), 6.76 (s, 1H, Ar), 6.80-6.86 (m, 3H, Ar), 7.08 (d, 2H, Ar, J = 8.3 Hz), 7.26-7.30 (m, 1H, Ar), 
7.38 (d, 2H, Ar, J = 8.4 Hz), 8.82 (exch br s, 1H, NH). MS (ESI) calcd. For C22H23N3O3, 377.44. Found: 
m/z 378.18 [M + H]+. 
5.2.77  N-(4-tert-Butylphenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-
1-yl]-acetamide (46i)  
N N
O
O
O H
N
 
Yield = 95 %; mp = 54-56 °C (EtOH). IR (cm-1) 3296 (NH), 1705 (CO), 1644 (CO). 1H NMR (CDCl3) δ 
1.30 (s, 9H, C-(CH3)3), 2.27 (s, 3H, 3-CH3), 3.81 (s, 3H, OCH3), 3.90 (s, 2H, CH2-Ar), 4.96 (s, 2H, 
NCH2CO), 6.76 (s, 1H, Ar), 6.80 (s, 1H, Ar), 6.81-6.86 (m, 2H, Ar), 7.26-7.30 (m, 3H, Ar), 7.43 (d, 2H, 
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Ar, J = 8.6 Hz), 8.88 (exch br s, 1H, NH). MS (ESI) calcd. For C25H29N3O3, 419.52. Found: m/z 420.22 
[M + H]+. 
5.2.78  2-[5-(3-Methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-yl]-N-(4-
methoxyphenyl)-acetamide (46j)  
N N
O
O
O H
N O
 
Yield = 75 %; mp = 65-67 °C (EtOH). IR (cm-1) 3300 (NH), 1705 (CO), 1644 (CO). 1H NMR (CDCl3) δ 
2.28 (s, 3H, 3-CH3), 3.80 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.91 (s, 2H, CH2-Ar), 4.94 (s, 2H, 
NCH2CO), 6.77 (s, 1H, Ar), 6.80 (s, 1H, Ar), 6.81-6.86 (m, 4H, Ar), 7.27-7.30 (m, 1H, Ar), 7.42 (d, 2H, 
Ar, J = 8.9 Hz), 8.71 (exch br s, 1H, NH). MS (ESI) calcd. For C22H23N3O4, 393.44. Found: m/z 394.18 
[M + H]+. 
5.2.79  N-(4-Butoxyphenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-
yl]-acetamide (46k)  
N N
O
O
O H
N O
 
Yield = 73 %; oil. IR (cm-1) 3300 (NH), 1708 (CO), 1645 (CO). 1H NMR (CDCl3) δ 0.99 (t, 3H, 
O(CH2)3CH3, J = 7.5 Hz), 1.50 (sext, 2H, OCH2CH2CH2, J = 7.5 Hz), 1.76 (quin, 2H, OCH2CH2CH2, J = 
7.0 Hz), 2.28 (s, 3H, 3-CH3), 3.81 (s, 3H, OCH3), 3.90 (s, 2H, CH2-Ar), 3.93 (t, 2H, OCH2CH2CH2, J = 
6.5 Hz), 4.94 (s, 2H, NCH2CO), 6.76 (s, 1H, Ar), 6.80-6.86 (m, 5H, Ar), 7.26-7.30 (m, 1H, Ar), 7.40 (d, 
2H,   Ar, J = 8.9 Hz), 8.76 (exch br s, 1H, NH). MS (ESI) calcd. For C25H29N3O4, 435.52. Found: m/z 
436.23 [M + H]+. 
5.2.80  N-(3,4-Dimethoxyphenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-
pyridazin-1-yl]-acetamide (46 l)  
N N
O
O
O H
N O
O
 
Yield = 74 %; mp = 57-59 °C (EtOH). IR (cm-1) 3298 (NH), 1708 (CO), 1640 (CO). 1H NMR (CDCl3) δ 
2.29 (s, 3H, 3-CH3), 3.80 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.90 (s, 2H, CH2-Ar), 
5. Experimental Chemistry 
 
 114
4.95 (s, 2H, NCH2CO), 6.72 (d, 1H, Ar, J = 8.6 Hz), 6.78 (s, 2H, Ar), 6.82-6.88 (m, 3H, Ar), 7.25-7.29 
(m, 1H, Ar), 7.32 (d, 1H, Ar, J = 2.2 Hz), 8.93 (exch br s, 1H, NH). MS (ESI) calcd. For C23H25N3O5, 
423.46. Found: m/z 424.19 [M + H]+. 
5.2.81  N-Benzo-1,3-dioxol-5-yl-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-
1-yl]-acetamide (46m)  
N N
O
O
O H
N
O
O
 
Yield = 98 %; oil. IR (cm-1) 3300 (NH), 1707 (CO), 1643 (CO). 1H NMR (CDCl3) δ 2.28 (s, 3H, 3-CH3), 
3.81 (s, 3H, OCH3), 3.89 (s, 2H, CH2-Ar), 4.93 (s, 2H, NCH2CO), 5.92 (s, 2H, O-CH2-O), 6.65 (d, 1H, 
Ar, J = 8.3 Hz), 6.77-6.85 (m, 5H, Ar), 7.21 (d, 1H, Ar, J = 2.0 Hz), 7.25-7.29 (m, 1H, Ar), 9.04 (exch br 
s, 1H, NH). MS (ESI) calcd. For C22H21N3O5, 407.42. Found: m/z 408.16 [M + H]+. 
5.2.82  2-[5-(3-Methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-yl]-N-(4-trifluoro 
methylphenyl)-acetamide (46n)  
N N
O
O
O H
N
F
F
F
 
Yield = 80 %; mp = 175-176 °C (EtOH). IR (cm-1) 3297 (NH), 1708 (CO), 1646 (CO). 1H NMR (CDCl3) 
δ 2.33 (s, 3H, 3-CH3), 3.79 (s, 3H, OCH3), 3.91 (s, 2H, CH2-Ar), 5.00 (s, 2H, NCH2CO), 6.81-6.85 (m, 
3H, Ar), 6.89 (s, 1H, Ar), 7.25-7.29 (m, 1H, Ar), 7.38 (d, 2H, Ar, J = 8.7 Hz), 7.47 (d, 2H, Ar, J = 8.7 
Hz), 9.62 (exch br s, 1H, NH). MS (ESI) calcd. For C22H20F3N3O3, 431.41. Found: m/z 432.16 [M + H]+. 
5.2.83  2-[5-(3-Methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-yl]-N-(4-trifluoro 
methoxyphenyl)-acetamide  (46o)  
N N
O
O
O H
N O
F
F
F
 
Yield = 87 %; mp = 168-169 °C (EtOH). IR (cm-1) 3300 (NH), 1708 (CO), 1644 (CO). 1H NMR (CDCl3) 
δ 2.31 (s, 3H, 3-CH3), 3.78 (s, 3H, OCH3), 3.89 (s, 2H, CH2-Ar), 5.00 (s, 2H, NCH2CO), 6.79-6.83 (m, 
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3H, Ar), 6.87 (s, 1H, Ar), 7.00 (d, 2H, Ar, J = 8.6 Hz), 7.24- 7.28 (m, 1H, Ar), 7.41 (d, 2H, Ar, J = 9.0 
Hz), 9.54 (exch br s, 1H, NH). MS (ESI) calcd. For C22H20F3N3O4, 447.41. Found: m/z 448.15 [M + H]+. 
5.2.84  2-[5-(3-Methoxybenzyl)-3-methyl-6-oxopyridazin-1(6H)-yl]-N-[4-(methylthio) 
phenyl]acetamide (46p)  
N N
O
O
O H
N S
 
Yield = ~ 100 %; mp = 166-167 °C (EtOH). IR (cm-1) 3285 (NH), 1720 (CO), 1634 (CO). 1H NMR 
(CDCl3) δ 2.28 (s, 3H, 3-CH3), 2.45 (s, 3H, SCH3), 3.80 (s, 3H, OCH3), 3.89 (s, 2H, CH2-Ar), 4.958 (s, 
2H, NCH2CO), 6.79-6.85 (m, 4H, Ar), 7.12-7.15 (m, 1H, Ar), 7.27 (t, 1H, Ar, J = 7.8 Hz), 7.39 (dd, 2H, 
Ar, J = 5.0 Hz), 9.13 (exch br s, 1H, NH).  
5.2.85  N-(4-Cyanophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-
yl]-acetamide (46q) 
N N
O
O
O H
N
N
 
Yield = 55 %; mp = 156-158 °C (EtOH). IR (cm-1) 3285 (NH), 2221 (CN), 1716 (CO), 1644 (CO). 1H 
NMR (CDCl3) δ 2.32 (s, 3H, 3-CH3), 3.80 (s, 3H, OCH3), 3.91 (s, 2H, CH2-Ar), 4.98 (s, 2H, NCH2CO), 
6.80-6.88 (m, 4H, Ar), 7.26-7.30 (m, 1H, Ar), 7.50-7.57 (m, 4H, Ar), 9.60 (exch br s, 1H, NH). MS (ESI) 
calcd. For C22H20N4O3, 388.42. Found: m/z 389.16 [M + H]+. 
5.2.86  2-[5-(3-Methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-yl]-N-(4-nitrophenyl)-
acetamide (46r)  
N N
O
O
O H
N NO2
 
Yield = 49 %; mp = 165-166 °C (EtOH). IR (cm-1) 3298 (NH), 1708 (CO), 1644 (CO). 1H NMR (CDCl3) 
δ 2.34 (s, 3H, 3-CH3), 3.79 (s, 3H, OCH3), 3.92 (s, 2H, CH2-Ar), 5.01 (s, 2H, NCH2CO), 6.80-6.84 (m, 
3H, Ar), 6.94 (s, 1H, Ar), 7.25-7.28 (m, 1H, Ar), 7.49 (d, 2H, Ar, J = 9.2 Hz), 7.99 (d, 2H, Ar, J = 9.2 
Hz), 9.92 (exch br s, 1H, NH). MS (ESI) calcd. For C21H20N4O5, 408.41. Found: m/z 409.15 [M + H]+. 
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5.2.87  4-(3-Methoxybenzyl)-6-methyl-2-[2-(4-methylpiperazin-1-yl)-2-oxo-ethyl]-
pyridazin-3(2H)-one (46s)  
N N
O
O
O
N N
 
Yield = 62 %; oil. IR (cm-1) 1673 (CO), 1644 (CO). 1H NMR (CDCl3) δ 2.25 (s, 3H, 3-CH3), 2.55 (s, 3H, 
CH3N), 2.74-2.81 (m, 4H, Ar), 3.77-3.82 (m, 7H (4H, Ar; 3H, OCH3)), 3.87 (s, 2H, CH2-Ar), 4.96 (s, 2H, 
NCH2CO), 6.69 (s, 1H, Ar), 6.80 (s, 1H, Ar), 6.82-6.85 (m, 2H, Ar), 7.26-7.30 (m, 1H, Ar). MS (ESI) 
calcd. For C20H26N4O3, 370.45. Found: m/z 371.21 [M + H]+. 
 
General procedure for 47a-o. To 8 mL of KOH in absolute EtOH (5%, w/v), the appropriate 
compound of type 42 (42a-c,e-j,l) (1.39 mmol) and 3- or 4-methoxybenzaldehyde (1.39 mmol) were 
added. The mixture was refluxed under stirring for 1-3 h. After cooling, the mixture was concentrated in 
vacuo, diluted with cold water (10-15 mL) and acidified with 2 N HCl. For compounds 47a-e the 
suspension was extracted with CH2Cl2 (3 x 15 mL). Removal of the solvent afforded the final 
compounds, which were purified by column chromatography using respectively cyclohexane/ethyl acetate 
1:1 (for 47a,e), 2:1 (for 47b,c) and 1:3 (for 47d) as eluent. On the contrary, compounds 47f-o, after 1 h 
stirring in ice-bath, were filtered off by suction from the acidic solutions and recrystallized from ethanol. 
5.2.88    6-Ethyl-4-(3-methoxybenzyl)pyridazin-3(2H)-one (47a) 
HN N
O
O
 
Yield = 20 %; colorless oil. 1H NMR (CDCl3) δ 1.18 (t, 3H, CH2CH3, J = 7.5 Hz), 2.55 (q, 2H, CH2CH3, 
J = 7.6 Hz), 3.83 (s, 3H, OCH3), 3.90 (s, 2H, C6H4-CH2), 6.75 (s, 1H, Ar), 6.82-6.86 (m, 3H, Ar), 7.29 (t, 
1H, Ar, J = 7.8 Hz), 11.12 (exch br s, 1H, NH).  
5.2.89    6-Isopropyl-4-(3-methoxybenzyl)pyridazin-3(2H)-one (47b) 
HN N
O
O
 
Yield = 44 %; colorless oil. 1H NMR (CDCl3) δ 1.19 (d, 6H, CH(CH3)2, J = 8.3 Hz), 2.83 (sept, 1H, 
CH(CH3)2, J = 8.3 Hz), 3.83 (s, 3H, OCH3), 3.91 (s, 2H, C6H4-CH2), 6.83-6.87 (m, 4H, Ar), 7.29 (t, 1H, 
Ar, J = 8.0 Hz).  
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5.2.90    6-Cyclohexyl-4-(3-methoxybenzyl)pyridazin-3(2H)-one (47c) 
HN N
O
O
 
Yield = 96 %; colorless oil. 1H NMR (CDCl3) δ 1.28-1.37 (m, 4H, 2 x CH2 cyclohexyl), 1.62-1.83 (m, 
6H, 3 x CH2 cyclohexyl), 2.35-2.45 (m, 1H, CH cyclohexyl), 3.81 (s, 3H, OCH3), 3.88 (s, 2H, C6H4-
CH2), 6.34-6.88 (m, 2H, Ar), 6.97 (d, 2H, Ar, J = 7.3 Hz), 7.30 (t, 1H, Ar, J = 8.0 Hz).  
5.2.91    4-(3-Methoxybenzyl)pyridazin-3(2H)-one (47d) 
HN N
O
O
 
Yield = 27 %; colorless oil. 1H NMR (CDCl3) δ 3.83 (s, 3H, OCH3), 3.92 (s, 2H, C6H4-CH2), 6.81-6.89 
(m, 4H, Ar), 7.29 (t, 2H, Ar, J = 8.1 Hz), 7.77 (d, 1H, Ar, J = 4.0 Hz).  
5.2.92    4-(3-Methoxybenzyl)-6-phenylpyridazin-3(2H)-one (47e)  
HN N
O
O
 
Yield = 45 %; mp = 103-05 °C (EtOH). 1H NMR (CDCl3) δ 3.84 (s, 3H, OCH3), 4.00 (s, 2H, C6H4-CH2), 
6.85-6.92 (m, 3H, Ar), 6.96 (d, 2H, Ar, J = 8.5 Hz), 7.28-7.38 (m, 2H, Ar), 7.43-7.45 (m, 2H, Ar), 7.69-
7.71 (m, 1H, Ar). 
5.2.93    4-(4-Methoxybenzyl)-6-(thiophen-2-yl)pyridazin-3(2H)-one (47f) 
HN N
O
O
S
 
Yield = 97 %; mp = 125-26 °C (EtOH). 1H NMR (CDCl3) δ 3.84 (s, 3H, OCH3), 3.94 (s, 2H, C6H4-CH2), 
6.91-6.98 (m, 3H, Ar), 7.03-7.08 (m, 1H, Ar), 7.22-7.25 (m, 2H, Ar), 7.31-7.33 (m, 1H, Ar), 7.36 (d, 2H, 
Ar, J = 6.5 Hz). 
5.2.94    4-(3-Methoxybenzyl)-6-(thiophen-2-yl)pyridazin-3(2H)-one (47g)  
HN N
O
O
S
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Yield = 97 %; mp = 132-34 °C (EtOH). 1H NMR (CDCl3) δ 3.84 (s, 3H, OCH3), 3.97 (s, 2H, C6H4-CH2), 
6.86-6.90 (m, 3H, Ar), 7.05 (dd, 1H, Ar, J = 1.1 Hz, J = 3.8 Hz), 7.24-7.33 (m, 3H, Ar), 7.37 (d, 2H, Ar, J 
= 5.1 Hz). 
5.2.95    4-(3-Methoxybenzyl)-6-(4-methoxyphenyl)pyridazin-3(2H)-one (47i)  
HN N
O
O
O
 
Yield = 99 %; mp = 150-152 °C (EtOH). 1H NMR (CDCl3) δ 3.83 (s, 3H, C6H4-OCH3), 3.86 (s, 3H, CH2-
C6H4-OCH3), 3.98 (s, 2H, C6H4-CH2), 6.86 (d, 1H, Ar, J = 7.0 Hz), 6.95 (d, 2H, Ar, J = 7.6 Hz), 7.30-
7.32 (m, 2H, Ar), 7.62 (d, 2H, Ar, J = 8.8 Hz). 
5.2.96    6-(4-Chlorophenyl)-4-(3-methoxybenzyl)pyridazin-3(2H)-one (47k)  
HN N
O
O
Cl
 
Yield ~ 100 %; mp = 164-166 °C (EtOH). 1H NMR (CDCl3) δ 3.83 (s, 3H, OCH3), 3.98 (s, 2H, C6H4-
CH2), 6.86-6.90 (m, 3H, Ar), 7.29-7.33 (m, 2H, Ar), 7.40 (d, 2H, Ar, J = 8.6 Hz), 7.62 (d, 2H, Ar, J = 8.8 
Hz). 
5.2.97    4-(3-Methoxybenzyl)-6-p-tolylpyridazin-3(2H)-one (47m)  
HN N
O
O
 
Yield = 98 %; mp = 138-140 °C (EtOH). 1H NMR (CDCl3) δ 2.40 (s, 3H, C6H4-CH3), 3.83 (s, 3H, 
OCH3), 3.98 (s, 2H, C6H4-CH2), 6.86 (d, 2H, Ar, J = 6.7 Hz), 6.91 (s, 1H, Ar), 7.24 (d, 2H, Ar, J = 8.0 
Hz), 7.30-7.33 (m, 1H, Ar), 7.35 (s, 1H, Ar), 7.58 (d, 2H, Ar, J = 8.3 Hz). 
5.2.98    6-(4-Fluorophenyl)-4-(4-methoxybenzyl)pyridazin-3(2H)-one (47n)  
HN N
O
O
F
 
Yield = 70 %; mp = 106-108 °C (EtOH). 1H NMR (CDCl3) δ 3.84 (s, 3H, OCH3), 3.94 (s, 2H, C6H4-
CH2), 6.92 (d, 2H, Ar, J = 5.0 Hz), 7.12 (d, 2H, Ar, J = 8.4 Hz), 7.22 (d, 2H, Ar, J = 8.4 Hz), 7.65-7.69 
(m, 2H, Ar). 
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5.2.99    6-(4-Fluorophenyl)-4-(3-methoxybenzyl)pyridazin-3(2H)-one (47o)  
HN N
O
O
F
 
Yield = 70 %; mp = 106-108 °C (EtOH). 1H NMR (CDCl3) δ 3.83 (s, 3H, OCH3), 3.98 (s, 2H, C6H4-
CH2), 6.86-6.91 (m, 3H, Ar), 7.12 (t, 2H, Ar, J = 8.5 Hz), 7.29-7.33 (m, 2H, Ar), 7.66-7.69 (m, 2H, Ar). 
 
General procedure for 48a-o. A mixture of the appropriate intermediate 47 (47a-o) (1.34 mmol), 
K2CO3 (2.68 mmol), and ethyl bromoacetate (2.01 mmol) in CH3CN (8 mL) was refluxed under stirring 
for 1-3 h. The mixture was then concentrated in vacuo, diluted with cold water and extracted with CH2Cl2 
(3 x 15 mL). The solvent was evaporated in vacuo and compounds 48a-o were purified by column 
chromatography using cyclohexane/ethyl acetate 2:1 as eluent.  
5.2.100 Ethyl-2-[3-ethyl-5-(3-methoxybenzyl)-6-oxopyridazin-1(6H)-yl]acetate (48a)  
N N
O
O
O
O
 
Yield = 98 %; oil. 1H NMR (CDCl3) δ 1.15 (t, 3H, CH2CH3, J = 4.1 Hz), 1.30 (t, 3H, OCH2CH3, J = 6.9 
Hz), 2.53 (q, 2H, CH2CH3, J = 7.6 Hz), 3.82 (s, 3H, OCH3), 3.88 (s, 2H, CH2-Ar), 4.26 (q, 2H, 
OCH2CH3, J = 7.1 Hz), 4.87 (s, 2H, NCH2CO), 6.72 (s, 1H, Ar), 6.80-6.85 (m, 3H, Ar), 7.28 (t, 1H, Ar, J 
= 6.2 Hz).  
5.2.101         Ethyl-2-[3-isopropyl-5-(3-methoxybenzyl)-6-oxopyridazin-1(6H)-yl]acetate (48b)  
N N
O
O
O
O
 
Yield = 93 %; oil. 1H NMR (CDCl3) δ 1.15 (d, 6H, CH(CH3)2, J = 6.9 Hz), 1.28-1.32 (m, 3H, OCH2CH3), 
2.73-2.83 (m, 1H, CH(CH3)2), 3.81 (s, 3H, OCH3), 3.89 (s, 2H, CH2-Ar), 4.23-4.28 (m, 2H, OCH2CH3), 
4.86 (s, 2H, NCH2CO), 6.77 (s, 1H, Ar), 6.80-6.84 (m, 3H, Ar), 7.27 (t, 1H, Ar, J = 7.8 Hz).  
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5.2.102       Ethyl-2-[3-cyclohexyl-5-(3-methoxybenzyl)-6-oxopyridazin-1(6H)-yl]acetate (48c)  
N N
O
O
O
O
 
Yield = 58 %; oil. 1H NMR (CDCl3) δ 1.28-1.34 (m, 9H, 3 x CH2 cyclohexyl + OCH2CH3), 1.70-1.82 (m, 
4H, 2 x CH2 cyclohexyl), 2.42-2.51 (m, 1H, CH cyclohexyl), 3.83 (s, 3H, OCH3), 3.89 (s, 2H, CH2-Ar), 
4.23-4.29 (m, 2H, OCH2CH3), 4.87 (s, 2H, NCH2CO), 6.76 (s, 1H, Ar), 6.80-6.95 (m, 3H, Ar), 7.27 (dt, 
1H, Ar, J = 11.7 Hz, J = 2.0 Hz).  
5.2.103 Ethyl-2-[5-(3-methoxybenzyl)-6-oxopyridazin-1(6H)-yl]acetate (48d) 
N N
O
O
O
O
 
Yield = 47 %; oil. 1H NMR (CDCl3) δ 1.31 (t, 3H, CH2CH3, J = 7.1 Hz), 3.82 (s, 3H, OCH3), 3.91 (s, 2H, 
CH2-Ar), 4.27 (q, 2H, OCH2CH3, J = 7.2 Hz), 4.92 (s, 2H, NCH2CO), 6.79-6.80 (m, 2H, Ar), 6.83 (d, 2H, 
Ar, J = 7.8 Hz), 7.28 (t, 1H, Ar, J = 8.0 Hz), 7.67 (d, 1H, Ar, J = 4.1 Hz).  
5.2.104 Ethyl-2-[5-(3-methoxybenzyl)-6-oxo-3-phenylpyridazin-1(6H)-yl]acetate (48e) 
N N
O
O
O
O
 
Yield = 47 %; oil. 1H NMR (CDCl3) δ 1.29-1.33 (td, 3H, CH2CH3, J = 6.8 Hz, J = 1.9 Hz), 3.80 (s, 3H, 
OCH3), 3.95 (s, 2H, CH2-Ar), 4.27 (q, 2H, OCH2CH3, J = 7.1 Hz), 4.99 (s, 2H, NCH2CO), 6.81-6.89 (m, 
3H, Ar), 6.92-94 (m, 2H, Ar), 7.24-7.31 (m, 2H, Ar), 7.40-7.42 (m, 2H, Ar), 7.66-7.68 (m, 1H, Ar).  
5.2.105 Ethyl-2-[5-(4-methoxybenzyl)-6-oxo-3-(thiophen-2-yl)pyridazin-1(6H)-
yl]acetate (48f) 
N N
O
O
S
O
O
 
5. Experimental Chemistry 
 121 
Yield = 91 %; mp = 127-29 °C (EtOH). 1H NMR (CDCl3) δ 1.32 (t, 3H, CH2CH3, J = 6.9 Hz), 3.84 (s, 
3H, OCH3), 3.93 (s, 2H, CH2-Ar), 4.28 (q, 2H, OCH2CH3, J = 7.1 Hz), 4.94 (s, 2H, NCH2CO), 6.92 (d, 
2H, Ar, J = 8.0 Hz), 7.03 (t, 1H, Ar, J = 4.0 Hz), 7.20-7.28 (m, 4H, Ar), 7.35 (d, 1H, Ar, J = 4.4 Hz).  
5.2.106 Ethyl-2-[5-(3-methoxybenzyl)-6-oxo-3-(thiophen-2-yl)pyridazin-1(6H)-
yl]acetate (48g) 
N N
O
S
O
O
O
 
Yield ~ 100 %; mp = 149-51 °C (EtOH). 1H NMR (CDCl3) δ 1.32 (t, 3H, CH2CH3, J = 7.0 Hz), 3.84 (s, 
3H, OCH3), 3.96 (s, 2H, CH2-Ar), 4.28 (q, 2H, OCH2CH3, J = 7.1 Hz), 4.94 (s, 2H, NCH2CO), 6.87 (t, 
3H, Ar, J = 8.4 Hz), 7.03-7.05 (m, 1H, Ar), 7.23-7.40 (m, 4H, Ar).  
5.2.107 Ethyl-2-[5-(4-methoxybenzyl)-3-(4-methoxyphenyl)-6-oxopyridazin-1(6H)-
yl]acetate (48h) 
N N
O
O
O
O
O
 
Yield ~ 100 %; oil. 1H NMR (CDCl3) δ 1.31 (t, 3H, CH2CH3, J = 3.9 Hz), 3.82 (s, 3H, CH2-C6H4-OCH3), 
3.84 (s, 3H, C6H4-OCH3), 3.88 (s, 2H, CH2-Ar), 4.26 (q, 2H, OCH2CH3, J = 7.1 Hz), 4.97 (s, 2H, 
NCH2CO), 6.88-6.99 (m, 5H, Ar), 7.21 (q, 2H, Ar, J = 6.7 Hz), 7.60 (d, 2H, Ar, J = 8.8 Hz).  
5.2.108 Ethyl-2-[5-(3-methoxybenzyl)-3-(4-methoxyphenyl)-6-oxopyridazin-1(6H)-
yl]acetate (48i) 
N N
O
O
O
O
O
 
Yield ~ 100 %; oil. 1H NMR (CDCl3) δ 1.32 (t, 3H, CH2CH3, J = 7.2 Hz), 3.82 (s, 3H, CH2-C6H4-OCH3), 
3.84 (s, 3H, C6H4-OCH3), 3.97 (s, 2H, CH2-Ar), 4.28 (q, 2H, OCH2CH3, J = 7.1 Hz), 4.98 (s, 2H, 
NCH2CO), 6.84-6.95 (m, 6H, Ar), 7.27-7.31 (m, 1H, Ar), 7.61 (dd, 2H, Ar, J = 4.8 Hz, J = 2.0 Hz).  
 
 
5. Experimental Chemistry 
 
 122
5.2.109 Ethyl-2-[3-(4-chlorophenyl)-5-(4-methoxybenzyl)-6-oxopyridazin-1(6H)-
yl]acetate (48j) 
N N
O
O
O
Cl
O
 
Yield ~ 100 %; oil. 1H NMR (CDCl3) δ 1.31 (t, 3H, CH2CH3, J = 7.1 Hz), 3.82 (s, 3H, CH2-C6H4-OCH3), 
3.87 (s, 2H, CH2-Ar), 4.24 (q, 2H, OCH2CH3, J = 6.2 Hz), 4.98 (s, 2H, NCH2CO), 6.90 (d, 2H, Ar, J = 
8.5 Hz), 7.21 (t, 2H, Ar, J = 7.4 Hz), 7.35-7.39 (m, 3H, Ar), 7.60 (d, 2H, Ar, J = 8.6 Hz).  
5.2.110 Ethyl-2-[3-(4-chlorophenyl)-5-(3-methoxybenzyl)-6-oxopyridazin-1(6H)-
yl]acetate (48k) 
N N
O
O
O
O
Cl
 
Yield ~ 100 %; oil. 1H NMR (CDCl3) δ 1.32 (t, 3H, CH2CH3, J = 7.2 Hz), 3.82 (s, 3H,  OCH3), 3.97 (s, 
2H, CH2-Ar), 4.27 (q, 2H, OCH2CH3, J = 4.0 Hz), 4.99 (s, 2H, NCH2CO), 6.84-6.86 (m, 3H, Ar), 7.26-
7.32 (m, 2H, Ar), 7.38 (d, 2H, Ar, J = 8.6 Hz), 7.61 (d, 2H, Ar, J = 8.6 Hz).  
5.2.111  Ethyl-2-[5-(4-methoxybenzyl)-6-oxo-3-(p-tolyl)pyridazin-1(6H)-yl]acetate (48l) 
N N
O
O
O
O
 
Yield = 98 %; oil. 1H NMR (CDCl3) δ 1.31 (t, 3H, CH2CH3, J = 7.1 Hz), 2.38 (s, 3H, C6H4-CH3), 3.83 (s, 
3H, OCH3), 3.93 (s, 2H, CH2-Ar), 4.27 (q, 2H, OCH2CH3, J = 7.1 Hz), 4.83 (s, 2H, NCH2CO), 6.88-6.97 
(m, 5H, Ar), 7.27 (d, 2H, Ar, J = 8.5 Hz), 8.07 (d, 2H, Ar, J = 9.0 Hz).  
5.2.112          Ethyl-2-[5-(3-methoxybenzyl)-6-oxo-3-(p-tolyl)pyridazin-1(6H)-yl]acetate (48m) 
N N
O
O
O
O
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Yield = 97 %; oil. 1H NMR (CDCl3) δ 1.31 (t, 3H, CH2CH3, J = 7.1 Hz), 2.39 (s, 3H, C6H4-CH3), 3.82 (s, 
3H, CH2-C6H4-OCH3), 3.97 (s, 2H, CH2-Ar), 4.27 (q, 2H, OCH2CH3, J = 7.2 Hz), 4.99 (s, 2H, NCH2CO), 
6.84-6.89 (m, 3H, Ar), 6.95-6.97 (m, 1H, Ar), 7.22 (d, 2H, Ar, J = 7.9 Hz), 7.27-7.31 (m, 1H, Ar), 8.07 
(d, 2H, Ar, J = 6.6 Hz).  
5.2.113 Ethyl-2-[3-(4-fluorophenyl)-5-(4-methoxybenzyl)-6-oxopyridazin-1(6H)-
yl]acetate (48n) 
N N
O
O
O
F
O
 
Yield = 92 %; oil. 1H NMR (CDCl3) δ 1.32 (t, 3H, CH2CH3, J = 7.1 Hz), 3.84 (s, 3H, OCH3), 3.94 (s, 2H, 
CH2-Ar), 4.27 (q, 2H, OCH2CH3, J = 7.1 Hz), 4.99 (s, 2H, NCH2CO), 6.92 (d, 3H, Ar, J = 8.6 Hz), 7.10 
(t, 2H, Ar, J = 8.5 Hz), 7.21 (d, 2H, Ar, J = 9.9 Hz), 7.63-7.67 (m, 3H, Ar).  
5.2.114  Ethyl-2-[3-(4-fluorophenyl)-5-(3-methoxybenzyl)-6-oxopyridazin-1(6H)-
yl]acetate (48o) 
N N
O
O
O
O
F
 
Yield = 88 %; oil. 1H NMR (CDCl3) δ 1.32 (td, 3H, CH2CH3, J = 5.9 Hz, J = 1.3 Hz), 3.82 (s, 3H, OCH3), 
3.98 (s, 2H, CH2-Ar), 4.27 (q, 2H, OCH2CH3, J = 7.1 Hz), 4.99 (s, 2H, NCH2CO), 6.84-6.89 (m, 3H, Ar), 
7.10 (t, 2H, Ar, J = 8.6 Hz), 7.25-7.30 (m, 2H, Ar), 7.63-7.67 (m, 3H, Ar).  
 
General procedure for 49a-o. A suspension of the appropriate compound type 48 (48a-o) (1.33 
mmol) in 6 N NaOH (10 mL) was stirred at rt to 80 °C for 1-2 h. The mixture was diluted with cold water 
and acidified with 6 N HCl. After 1 h stirring in ice-bath, the products 49a-o were filtered off by suction 
and recrystallized from ethanol.  
5.2.115 2-[3-Ethyl-5-(3-methoxybenzyl)-6-oxopyridazin-1(6H)-yl]acetic acid (49a) 
N N
O
O
OH
O
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Yield ~ 100 %; mp = 117-19 °C (EtOH). 1H NMR (CDCl3) δ 1.17 (t, 3H, CH2CH3, J = 7.5 Hz), 2.55 (q, 
2H, CH2CH3, J = 7.5 Hz), 3.82 (s, 3H, OCH3), 3.91 (s, 2H, CH2-Ar), 4.94 (s, 2H, NCH2CO), 6.75 (s, 1H, 
Ar), 6.79 (s, 1H, Ar), 6.82-6.85 (m, 2H, Ar), 7.28 (t, 1H, Ar, J = 7.2 Hz).  
5.2.116 2-[3-Isopropyl-5-(3-methoxybenzyl)-6-oxopyridazin-1(6H)-yl]acetic acid (49b) 
N N
O
O
OH
O
 
Yield = 69 %; oil. 1H NMR (CDCl3) δ 1.16 (d, 6H, CH(CH3)2, J = 6.9 Hz), 2.75-2.85 (m, 1H, CH(CH3)2), 
3.81 (s, 3H, OCH3), 3.91 (s, 2H, CH2-Ar), 4.93 (s, 2H, NCH2CO), 6.70 (exch br s, 1H, OH), 6.82 (t, 4H, 
Ar, J = 8.0 Hz), 7.27 (t, 1H, Ar, J = 4.2 Hz).  
5.2.117 2-[3-Cyclohexyl-5-(3-methoxybenzyl)-6-oxopyridazin-1(6H)-yl]acetic acid (49c) 
N N
O
O
OH
O
 
Yield = 70 %; oil. 1H NMR (CDCl3) δ 1.21-1.40 (m, 6H, 3 x CH2 cyclohexyl), 1.70-1.82 (m, 4H, 2 x CH2 
cyclohexyl), 2.41-2.50 (m, 1H, CH cyclohexyl), 3.83 (s, 3H, OCH3), 3.88 (s, 2H, CH2-Ar), 4.65 (s, 2H, 
NCH2CO), 6.79 (s, 1H, Ar), 6.81-6.98 (m, 3H, Ar), 7.30 (t, 1H, Ar, J = 7.1 Hz).  
5.2.118 2-[5-(3-Methoxybenzyl)-6-oxopyridazin-1(6H)-yl]acetic acid (49d) 
N N
O
O
OH
O
 
Yield ~ 100 %; oil. 1H NMR (CDCl3) δ 3.81 (s, 3H, OCH3), 3.91 (s, 2H, CH2-Ar), 4.98 (s, 2H, 
NCH2CO), 6.49 (exch br s, 1H, OH), 6.78 (s, 1H, Ar), 6.81-6.85 (m, 3H, Ar), 7.28 (t, 1H, Ar, J = 4.6 Hz), 
7.72 (d, 1H, Ar, J = 4.1 Hz).  
5.2.119 2-[5-(3-Methoxybenzyl)-6-oxo-3-phenylpyridazin-1(6H)-yl]acetic acid (49e) 
N N
O
O
OH
O
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Yield = 60 %; mp = 173-75 °C (EtOH). 1H NMR (CDCl3) δ 3.79 (s, 3H, OCH3), 3.93 (s, 2H, CH2-Ar), 
5.03 (s, 2H, NCH2CO), 5.57 (exch br s, 1H, OH), 6.82-6.84 (m, 3H, Ar), 6.93 (t, 2H, Ar, J = 4.16 Hz), 
7.24-7.31 (m, 2H, Ar), 7.41 (t, 2H, Ar, J = 3.84 Hz), 7.66-7.68 (m, 1H, Ar).  
5.2.120 2-[5-(4-Methoxybenzyl)-6-oxo-3-(thiophen-2-yl)pyridazin-1(6H)-yl]acetic acid 
(49f) 
N N
O
O
S
OH
O
 
Yield = 89 %; mp = 159-61 °C (EtOH). 1H NMR (CDCl3) δ 3.84 (s, 3H, OCH3), 3.94 (s, 2H, CH2-Ar), 
5.01 (s, 2H, NCH2CO), 6.92 (dd, 2H, Ar, J = 9.2 Hz, J = 1.4 Hz), 7.04 (dd, 1H, Ar, J = 1.4 Hz, J = 6.0 
Hz), 7.20-7.23 (m, 3H, Ar), 7.25 (dd, 1H, J = 6.4 Hz, J = 1.0 Hz), 7.37 (dd, 1H, Ar, J = 6.4 Hz, J = 1.1 
Hz).  
5.2.121 2-[5-(3-Methoxybenzyl)-6-oxo-3-(thiophen-2-yl)pyridazin-1(6H)-yl]acetic acid 
(49g) 
N N
O
S
O
OH
O
 
Yield ~ 100 %; mp = 185-87 °C (EtOH). 1H NMR (CDCl3) δ 3.82 (s, 3H, OCH3), 3.97 (s, 2H, CH2-Ar), 
5.01 (s, 2H, NCH2CO), 6.84-6.88 (m, 3H, Ar), 7.03 (t, 1H, Ar, J = 4.8 Hz), 7.23 (t, 2H, Ar, J = 3.2 Hz), 
7.28 (t, 1H, Ar, J = 4.4 Hz), 7.36 (d, 1H, Ar, J = 5.0 Hz).  
5.2.122 2-[5-(4-Methoxybenzyl)-3-(4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl]acetic 
acid (49h) 
N N
O
OH
O
O
O
 
Yield = 99 %; mp = 115-17 °C (EtOH). 1H NMR (CDCl3) δ 3.64 (s, 3H, CH2-C6H4-OCH3), 3.66 (s, 3H, 
C6H4-OCH3), 3.79 (s, 2H, CH2-Ar), 4.88 (s, 2H, NCH2CO), 6.65-6.75 (m, 4H, Ar), 6.90-7.01 (m, 1H, 
Ar), 7.05-7.15 (m, 1H, Ar), 7.28-7.37 (m, 3H, Ar).  
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5.2.123 2-[5-(3-Methoxybenzyl)-3-(4-methoxyphenyl)-6-oxopyridazin-1(6H)-yl]acetic acid 
(49i) 
N N
O
O
OH
O
O
 
Yield = 98 %; 110-12 °C (EtOH). 1H NMR (CDCl3) δ 3.82 (s, 3H, CH2-C6H4-OCH3), 3.84 (s, 3H, C6H4-
OCH3), 3.88 (s, 2H, CH2-Ar), 5.03 (s, 2H, NCH2CO), 6.89-6.94 (m, 4H, Ar), 7.19 (d, 2H, Ar, J = 8.6 Hz), 
7.24 (s, 1H, Ar), 7.60 (d, 2H, Ar, J = 8.8 Hz).  
5.2.124 2-[3-(4-Chlorophenyl)-5-(4-methoxybenzyl)-6-oxopyridazin-1(6H)-yl]acetic 
acid (49j) 
N N
O
OH
O
Cl
O
 
Yield ~ 100 %; mp = 147-49 °C (EtOH). 1H NMR (CDCl3) δ 3.83 (s, 3H, CH2-C6H4-OCH3), 3.92 (s, 2H, 
CH2-Ar), 5.05 (s, 2H, NCH2CO), 6.92 (d, 2H, Ar, J = 8.5 Hz), 7.20 (d, 2H, Ar, J = 8.5 Hz), 7.25 (s, 1H, 
Ar), 7.39 (d, 2H, Ar, J = 8.5 Hz), 7.61 (d, 2H, Ar, J = 8.6 Hz).  
5.2.125 2-[3-(4-Chlorophenyl)-5-(3-methoxybenzyl)-6-oxopyridazin-1(6H)-yl]acetic 
acid (49k) 
N N
O
O
OH
O
Cl
 
Yield ~ 100 %; mp = 142-44 °C (EtOH). 1H NMR (CDCl3) δ 3.81 (s, 3H,  OCH3), 3.97 (s, 2H, CH2-Ar), 
5.04 (s, 2H, NCH2CO), 6.83-6.87 (m, 3H, Ar), 7.28 (d, 2H, Ar, J = 7.8 Hz), 7.38 (d, 2H, Ar, J = 8.7 Hz), 
7.60 (d, 2H, Ar, J = 8.7 Hz).  
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5.2.126 2-[5-(4-Methoxybenzyl)-6-oxo-3-(p-tolyl)pyridazin-1(6H)-yl]acetic acid (49l) 
N N
O
OH
O
O
 
Yield = 98 %; mp = 158-60 °C (EtOH). 1H NMR (CDCl3) δ 2.39 (s, 3H, C6H4-CH3), 3.83 (s, 3H, OCH3), 
3.95 (s, 2H, CH2-Ar), 5.05 (s, 2H, NCH2CO), 6.89-6.97 (m, 4H, Ar), 7.21 (dd, 2H, Ar, J = 1.9 Hz, J = 6.3 
Hz), 7.29 (s, 1H, Ar), 7.56 (d, 2H, Ar, J = 8.1 Hz).  
5.2.127 2-[5-(3-Methoxybenzyl)-6-oxo-3-(p-tolyl)pyridazin-1(6H)-yl]acetic acid (49m) 
N N
O
O
OH
O
 
Yield = 97 %; mp = 150-52 °C (EtOH). 1H NMR (CDCl3) δ 2.26 (s, 3H, C6H4-CH3), 3.66 (s, 3H, CH2-
C6H4-OCH3), 3.82 (s, 2H, CH2-Ar), 4.85 (s, 2H, NCH2CO), 6.70 (d, 2H, Ar, J = 5.3 Hz), 6.95 (s, 1H, Ar), 
7.03-7.12 (m, 3H, Ar), 7.28 (t, 1H, Ar, J = 7.9 Hz), 7.40 (d, 2H, Ar, J = 7.8 Hz).  
5.2.128 2-[3-(4-Fluorophenyl)-5-(4-methoxybenzyl)-6-oxopyridazin-1(6H)-yl]acetic 
acid (49n) 
N N
O
OH
O
F
O
 
Yield = 57 %; mp = 82-84 °C (EtOH). 1H NMR (CDCl3) δ 3.83 (s, 3H, OCH3), 3.93 (s, 2H, CH2-Ar), 
5.03 (s, 2H, NCH2CO), 6.91 (d, 2H, Ar, J = 7.8 Hz), 7.10 (t, 2H, Ar, J = 8.4 Hz), 7.14-7.23 (m, 3H, Ar), 
7.65 (t, 2H, Ar, J = 5.2 Hz).  
5.2.129 2-[3-(4-Fluorophenyl)-5-(3-methoxybenzyl)-6-oxopyridazin-1(6H)-yl]acetic 
acid (49o) 
N N
O
O
OH
O
F
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Yield = 75 %; mp = 103-05 °C (EtOH). 1H NMR (CDCl3) δ 3.81 (s, 3H, OCH3), 3.97 (s, 2H, CH2-Ar), 
5.03 (s, 2H, CH2CO), 6.83-6.87 (m, 3H, Ar), 7.10 (t, 2H, Ar, J = 6.6 Hz), 7.27-7.31 (m, 2H, Ar), 7.63-
7.67 (m, 3H, Ar). 
 
General procedure for 50a-v. To a cooled (-5 °C) and stirred solution of compound type 49 
(49a-o) (0.60 mmol) in anhydrous tetrahydrofuran (6 mL), Et3N (2.10 mmol) was added. After 30 min, 
the mixture was allowed to warm up to 0 °C and ethyl chloroformate (0.66 mmol) was added. After 1 h, 
the commercially available substituted arylamine (1.20 mmol) was added. The reaction was carried out at 
room temperature for 12 h, then the mixture was concentrated in vacuo, diluted with cold water (20-30 
mL) and extracted with CH2Cl2 (3 x 15 mL). The solvent was evaporated to afford final compounds 46a-
s, which were purified by column chromatography using cyclohexane/ethyl acetate 2:1 for compounds 
50a,g, cyclohexane/ethyl acetate 3:1 for compounds 50b,e, CH2Cl2/ CH3OH/NH4OH 96:4:0.4 for 
compound 50c, cyclohexane/ethyl acetate 1:1 for compounds 50d,f,i,j and n-hexane/ethyl acetate 3:2 for 
compound 50h,k-v as eluents.  
5.2.130 N-(4-Bromophenyl)-2-[3-ethyl-5-(3-methoxybenzyl)-6-oxopyridazin-1(6H)-
yl]acetamide (50a) 
N N
O
O
H
N
O
Br
 
Yield = 61 %; mp = 150-52 °C (EtOH). 1H NMR (CDCl3) δ 1.20 (t, 3H, CH2CH3, J = 7.6 Hz), 2.59 (q, 
2H, CH2CH3, J = 7.6 Hz), 3.81 (s, 3H, OCH3), 3.91 (s, 2H, CH2-Ar), 4.95 (s, 2H, NCH2CO), 6.80-6.86 
(m, 4H, Ar), 7.24-7.30 (m, 3H, Ar), 7.55 (d, 2H, Ar, J = 8.7 Hz), 9.18 (exch br s, 1H, NH). 
5.2.131 N-(4-Bromophenyl)-2-[3-isopropyl-5-(3-methoxybenzyl)-6-oxopyridazin-
1(6H)-yl]acetamide (50b) 
N N
O
O
H
N
O
Br
 
Yield = 67 %; mp = 60-62 °C (EtOH). 1H NMR (CDCl3) δ 1.20 (d, 6H, CH(CH3)2, J = 6.9 Hz), 2.82-2.90 
(m, 1H, CH(CH3)2), 3.81 (s, 3H, OCH3), 3.92 (s, 2H, CH2-Ar), 4.95 (s, 2H, NCH2CO), 6.82-6.85 (m, 3H, 
Ar), 6.92 (s, 1H Ar), 7.28 (t, 1H, Ar, J = 7.8 Hz), 7.37 (s, 4H, Ar), 9.23 (exch br s, 1H, NH). 
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5.2.132 N-(4-Bromophenyl)-2-[3-cyclohexyl-5-(3-methoxybenzyl)-6-oxopyridazin-
1(6H)-yl]acetamide (50c) 
N N
O
O
H
N
O
Br
 
Yield = 36 %; colorless oil. 1H NMR (CDCl3) δ 1.30-1.35 (m, 6H, 3 x CH2 cyclohexyl), 1.70-1.82 (m, 
4H, 2 x CH2 cyclohexyl), 2.45-2.55 (m, 1H, CH cyclohexyl),  3.82 (s, 3H, OCH3), 3.92 (s, 2H, CH2-Ar), 
4.95 (s, 2H, NCH2CO), 6.81-6.88 (m, 4H, Ar), 7.28 (t, 1H, Ar, J = 9.4 Hz), 7.41 (s, 4H, Ar), 9.15 (exch br 
s, 1H, NH). 
5.2.133 N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-6-oxopyridazin-1(6H)-
yl]acetamide (50d) 
N N
O
O
H
N
O
Br
 
Yield = 70 %; mp = 138-40 °C (EtOH). 1H NMR (DMSO-d6) δ 3.73 (s, 3H, OCH3), 3.79 (s, 2H, CH2-
Ar), 4.90 (s, 2H, NCH2CO), 6.83 (t, 3H, Ar, J = 9.5 Hz), 7.14 (d, 1H, Ar, J = 3.8 Hz), 7.23 (t, 1H, Ar, J = 
7.7 Hz), 7.53 (q, 4H, Ar, J = 8.2 Hz), 7.85 (d, 1H, Ar, J = 3.9 Hz), 10.47 (exch br s, 1H, NH). 
5.2.134 N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-6-oxo-3-phenyl-pyridazin-1(6H)-
yl]acetamide (50e) 
N N
O
O
H
N
O
Br
 
Yield = 56 %; mp = 85-87 °C (EtOH). 1H NMR (DMSO-d6) δ 3.73 (s, 3H, OCH3), 3.89 (s, 2H, CH2-Ar), 
4.99 (s, 2H, NCH2CO), 6.80 (d, 1H, Ar, J = 8.0 Hz), 7.93 (d, 2H, Ar, J = 9.1 Hz), 7.23 (t, 1H, Ar, J = 7.9 
Hz), 7.45-7.51 (m, 5H, Ar), 7.56 (d, 2H, Ar, J = 8.9 Hz), 7.83 (d, 2H, Ar, J = 7.1 Hz), 7.86 (s, 1H, Ar), 
10.51 (exch br s, 1H, NH). 
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5.2.135 N-(1,3-Benzodioxol-5-yl)-2-[5-(3-methoxybenzyl)-6-oxo-3-phenylpyridazin-
1(6H)-yl]acetamide (50f) 
N N
O
O
H
N
O
O
O
 
Yield = 41 %; mp = 201-03 °C (EtOH). 1H NMR (DMSO-d6) δ 3.73 (s, 3H, OCH3), 3.88 (s, 2H, CH2-
Ar), 4.95 (s, 2H, NCH2CO), 5.99 (s, 2H, OCH2O), 6.80 (d, 1H, Ar, J = 6.0 Hz), 6.87 (d, 1H, Ar, J = 8.3 
Hz), 6.92-6.97 (m, 3H, Ar), 7.23 (t, 1H, Ar, J = 7.8 Hz), 7.28 (s, 1H, Ar), 7.44-7.52 (m, 3H, Ar), 7.83 (d, 
2H, Ar, J = 6.8 Hz), 7.95 (s, 1H, Ar), 10.27 (exch br s, 1H, NH). 
5.2.136 N-(4-Fluorophenyl)-2-[5-(3-methoxybenzyl)-6-oxo-3-phenyl-pyridazin-1(6H)-
yl]acetamide (50g) 
N N
O
O
H
N
O
F
 
Yield = 78 %; mp = colorless oil. 1H NMR (CDCl3) δ 3.81 (s, 3H, OCH3), 4.01 (s, 2H, CH2-Ar), 5.10 (s, 
2H, NCH2CO), 6.85-6.90 (m, 3H, Ar), 6.96-7.04 (m, 2H, Ar), 7.29-7.34 (m, 1H, Ar), 7.43-7.49 (m, 6H, 
Ar), 7.71-7.74 (m, 2H, Ar), 8.95 (exch br s, 1H, NH). 
5.2.137 N-(4-Bromophenyl)-2-[5-(4-methoxybenzyl)-6-oxo-3-(thiophen-2-yl)pyridazin-
1(6H)-yl]acetamide (50h) 
N N
O
O
S
H
N
O
Br
 
Yield = 77 %; mp = 193-94 °C (EtOH). 1H NMR (CDCl3) δ 3.83 (s, 3H, OCH3), 3.95 (s, 2H, CH2-Ar), 
5.02 (s, 2H, NCH2CO), 6.91 (dd, 2H, Ar, J = 4.6 Hz, J = 2.0 Hz), 7.06 (dd, 1H, Ar, J = 1.4 Hz, J = 3.9 
Hz), 7.21 (d, 2H, Ar, J = 6.7 Hz), 7.30 (dd, 1H, Ar, J = 2.6 Hz, J = 1.0 Hz), 7.32-7.38 (m, 5H, Ar), 7.83 
(dd, 1H, Ar, J = 4.0 Hz, J = 1.1 Hz), 9.00 (exch br s, 1H, NH). 
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5.2.138 N-(1,3-Benzodioxol-5-yl)-2-[5-(3-methoxybenzyl)-6-oxo-3-(thiophen-2-
yl)pyridazin-1(6H)-yl]acetamide (50i) 
N N
O
S
O
H
N
O
O
O
 
Yield = 41 %; mp = 192-94 °C (EtOH). 1H NMR (CDCl3) δ 3.82 (s, 3H, OCH3), 3.98 (s, 2H, CH2-Ar), 
5.02 (s, 2H, NCH2CO), 5.94 (s, 2H, OCH2O), 6.71 (d, 1H, Ar, J = 8.3 Hz), 6.81-6.89 (m, 4H, Ar), 7.05 
(dd, 1H, Ar, J = 1.3 Hz, J = 3.7 Hz), 7.23 (d, 1H, Ar, J = 1.9 Hz), 7.28-7.32 (m, 3H, Ar), 7.38 (dd, 1H, 
Ar, J = 4.2 Hz, J = 0.9 Hz), 8.71 (exch br s, 1H, NH). 
5.2.139 N-(4-Fluorophenyl)-2-[5-(3-methoxybenzyl)-6-oxo-3-(thiophen-2-yl)pyridazin-
1(6H)-yl]acetamide (50j) 
N N
O
S
O
H
N
O
F
 
Yield = 37 %; mp = 187-89 °C (EtOH). 1H NMR (CDCl3) δ 3.81 (s, 3H, OCH3), 3.99 (s, 2H, CH2-Ar), 
5.03 (s, 2H, NCH2CO), 6.85-6.89 (m, 3H, Ar), 6.96 (t, 2H, Ar, J = 8.6 Hz), 7.05 (dd, 1H, Ar, J = 1.4 Hz, 
J = 3.7 Hz), 7.27-7.30 (m, 2H, Ar), 7.32 (s, 1H, Ar), 7.39 (dd, 1H, Ar, J = 4.0 Hz, J = 1.1 Hz), 7.43 (m, 
2H, Ar), 8.89 (exch br s, 1H, NH). 
5.2.140 N-(4-Bromophenyl)-2-[5-(4-methoxybenzyl)-3-(4-methoxyphenyl)-6-
oxopyridazin-1(6H)-yl]acetamide (50k) 
N N
O
H
N
O
Br
O
O
 
Yield = 32 %; mp = 203-04 °C (EtOH). 1H NMR (CDCl3) δ 3.83 (s, 3H, CH2C6H4-OCH3), 3.86 (s, 3H, 
C6H4-OCH3), 3.97 (s, 2H, CH2-Ar), 5.07 (s, 2H, NCH2CO), 6.90-6.96 (m, 4H, Ar), 7.22 (d, 2H, Ar, J = 
8.6 Hz), 7.36-7.38 (m, 5H, Ar), 7.67 (d, 1H, Ar, J = 8.8 Hz), 9.14 (exch br s, 1H, NH). 
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5.2.141 N-(1,3-Benzodioxol-5-yl)-2-[5-(3-methoxybenzyl)-3-(4-methoxy-phenyl)-6-
oxopyridazin-1(6H)-yl]acetamide (50l) 
N N
O
O
H
N
O
O
O
O
 
Yield = 89 %; mp = 184-85 °C (EtOH). 1H NMR (CDCl3) δ 3.81 (s, 3H, CH2C6H4-OCH3), 3.85 (s, 3H, 
C6H4-OCH3), 3.99 (s, 2H, CH2-Ar), 5.05 (s, 2H, NCH2CO), 5.93 (s, 2H, OCH2O), 6.68 (d, 1H, Ar, J = 8.3 
Hz), 6.79 (dd, 1H, Ar, J = 6.2 Hz, J = 2.1 Hz), 6.84-6.90 (m, 3H, Ar), 6.94 (dd, 2H, Ar, J = 4.9 Hz, J = 
2.0 Hz), 7.22 (d, 1H, Ar, J = 2.0 Hz), 7.27-7.31 (m, 1H, Ar),  7.38 (s, 1H, Ar), 7.66 (d, 2H, Ar, J = 1.9 
Hz), 8.95 (exch br s, 1H, NH). 
5.2.142 N-(4-Fluorophenyl)-2-[5-(3-methoxybenzyl)-3-(4-methoxyphenyl)-6-
oxopyridazin-1(6H)-yl]acetamide (50m)  
N N
O
O
H
N
O
O
F
 
Yield = 84 %; mp = 164-65 °C (EtOH). 1H NMR (CDCl3) δ 3.80 (s, 3H, CH2C6H4-OCH3), 3.86 (s, 3H, 
C6H4-OCH3), 3.99 (s, 2H, CH2-Ar), 5.07 (s, 2H, NCH2CO), 6.83-6.96 (m, 7H, Ar), 7.29 (t, 1H, Ar, J = 
1.8 Hz), 7.40-7.45 (m, 3H, Ar), 7.67 (d, 2H, Ar, J = 7.5 Hz), 9.17 (exch br s, 1H, NH). 
5.2.143 N-(4-Bromophenyl)-2-[3-(4-chlorophenyl)-5-(4-methoxybenzyl)-6-
oxopyridazin-1(6H)-yl]acetamide (50n) 
N N
O
H
N
O
Br
Cl
O
 
Yield = 27 %; mp = 219-21 °C (EtOH). 1H NMR (CDCl3) δ 3.82 (s, 3H, OCH3), 3.97 (s, 2H, CH2-Ar), 
5.08 (s, 2H, NCH2CO), 6.91 (d, 2H, Ar, J = 8.7 Hz), 7.21 (d, 2H, Ar, J = 8.7 Hz), 7.32-7.37 (m, 5H, Ar), 
7.41 (d, 2H, Ar, J = 8.8 Hz), 7.66 (d, 2H, Ar, J = 8.7 Hz), 9.12 (exch br s, 1H, NH). 
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5.2.144 N-(1,3-Benzodioxol-5-yl)-2-[3-(4-chlorophenyl)-5-(3-methoxy-benzyl)-6-
oxopyridazin-1(6H)-yl]acetamide (50o) 
N N
O
O
H
N
O
O
O
Cl
 
Yield = 99 %; mp = 202-203 °C (EtOH). 1H NMR (CDCl3) δ 3.82 (s, 3H, OCH3), 4.01 (s, 2H, CH2-Ar), 
5.05 (s, 2H, NCH2CO), 5.95 (s, 2H, OCH2O), 6.73 (d, 1H, Ar, J = 8.4 Hz), 6.80-6.90 (m, 4H, Ar), 7.23 
(d, 1H, Ar, J = 1.8 Hz), 7.30 (t, 1H, Ar, J = 8.2 Hz), 7.36 (s, 1H, Ar), 7.41 (d, 2H, Ar, J = 8.5 Hz), 7.66 
(d, 2H, Ar, J = 8.5 Hz), 8.70 (exch br s, 1H, NH). 
5.2.145 N-(4-Fluorophenyl)-2-[3-(4-chlorophenyl)-5-(3-methoxybenzyl)-6-
oxopyridazin-1(6H)-yl]acetamide (50p)  
N N
O
O
H
N
O
F
Cl
 
Yield = 63 %; mp = 143-45 °C (EtOH). 1H NMR (CDCl3) δ 3.80 (s, 3H, OCH3), 4.00 (s, 2H, CH2-Ar), 
5.08 (s, 2H, NCH2CO), 6.84-6.95 (m, 5H, Ar), 7.27-7.31 (m, 1H, Ar), 7.39-7.44 (m, 5H, Ar), 7.66 (d, 2H, 
Ar, J = 8.5 Hz), 9.06 (exch br s, 1H, NH). 
5.2.146 N-(4-Bromophenyl)-2-[5-(4-methoxybenzyl)-6-oxo-3-(p-tolyl) pyridazin-1(6H)-
yl]acetamide (50q) 
N N
O
H
N
O
Br
O
 
Yield = 58 %; mp = 273-274 °C (EtOH). 1H NMR (CDCl3) δ 2.40 (s, 3H, C6H4-CH3), 3.81 (s, 3H, 
OCH3), 3.95 (s, 2H, CH2-Ar), 5.09 (s, 2H, NCH2CO), 6.89 (d, 2H, Ar, J = 8.1 Hz), 7.20-7.33 (m, 8H, Ar), 
7.41 (s, 1H, Ar), 7.62 (d, 2H, Ar, J = 7.7 Hz), 9.38 (exch br s, 1H, NH). 
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5.2.147 N-(1,3-Benzodioxol-5-yl)-2-[5-(3-methoxybenzyl)-6-oxo-3-(p-tolyl) pyridazin-
1(6H)-yl]acetamide (50r) 
N N
O
O
H
N
O
O
O
 
Yield = 66 %; mp = 198-99 °C (EtOH). 1H NMR (CDCl3) δ 2.40 (s, 3H, C6H4-CH3), 3.81 (s, 3H, OCH3), 
4.00 (s, 2H, CH2-Ar), 5.06 (s, 2H, NCH2CO), 5.94 (s, 2H, OCH2O), 6.70 (d, 1H, Ar, J = 8.4 Hz), 6.79-
6.90 (m, 4H, Ar), 7.24 (d, 3H, Ar, J = 8.0 Hz), 7.29 (t, 1H, Ar, J = 7.8 Hz), 7.40 (s, 1H, Ar), 7.61 (d, 2H, 
Ar, J = 8.1 Hz), 8.84 (exch br s, 1H, NH). 
5.2.148 N-(4-Fluorophenyl)-2-[5-(3-methoxybenzyl)-6-oxo-3-(p-tolyl) pyridazin-1(6H)-
yl]acetamide (50s) 
N N
O
O
H
N
O
F
 
Yield = 54 %; mp = 173-74 °C (EtOH). 1H NMR (CDCl3) δ 2.40 (s, 3H, C6H4-CH3), 3.80 (s, 3H, OCH3), 
3.99 (s, 2H, CH2-Ar), 5.08 (s, 2H, NCH2CO), 6.83-6.95 (m, 5H, Ar), 7.23-7.26 (m, 2H, Ar), 7.28 (t, 1H, 
Ar, J = 5.3 Hz), 7.42-7.45 (m, 3H, Ar), 7.61 (d, 2H, Ar, J = 8.2 Hz), 9.11 (exch br s, 1H, NH). 
5.2.149 N-(4-Bromophenyl)-2-[3-(4-fluorophenyl)-5-(4-methoxybenzyl)-6-
oxopyridazin-1(6H)-yl]acetamide (50t) 
N N
O
H
N
O
Br
F
O
 
Yield = 75 %; mp = 188-90 °C (EtOH). 1H NMR (CDCl3) δ 3.82 (s, 3H, OCH3), 3.97 (s, 2H, CH2-Ar), 
5.07 (s, 2H, NCH2CO), 6.91 (dd, 2H, Ar, J = 4.6 Hz, J = 2.0 Hz ), 7.12 (t, 2H, Ar, J = 6.7 Hz), 7.21 (d, 
2H, Ar, J = 8.6 Hz), 7.30-7-40 (m, 5H, Ar), 7.69-7.73 (m, 2H, Ar), 9.15 (exch br s, 1H, NH). 
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5.2.150 N-(1,3-Benzodioxol-5-yl)-2-[3-(4-fluorophenyl)-5-(3-methoxy-benzyl)-6-
oxopyridazin-1(6H)-yl]acetamide (50u) 
N N
O
O
H
N
O
O
O
F
 
Yield = 75 %; mp = 188-90 °C (EtOH). 1H NMR (CDCl3) δ 3.82 (s, 3H, OCH3), 4.00 (s, 2H, CH2-Ar), 
5.05 (s, 2H, NCH2CO), 5.95 (s, 2H, OCH2O), 6.72 (d, 1H, Ar, J = 8.3 Hz), 6.80-6.90 (m, 4H, Ar), 7.12 (t, 
2H, Ar, J = 8.8 Hz), 7.23 (s, 1H, Ar), 7.30 (t, 1H, Ar, J = 8.8 Hz), 7.36 (s, 1H, Ar), 7.71 (dd, 2H, Ar, J = 
2.4 Hz, J = 5.3 Hz), 8.74 (exch br s, 1H, NH). 
5.2.151 N-(4-Fluorophenyl)-2-[3-(4-fluorophenyl)-5-(3-methoxybenzyl)-6-
oxopyridazin-1(6H)-yl]acetamide (50v) 
N N
O
O
H
N
O
F
F
 
Yield = 58 %; mp = 152-53 °C (EtOH). 1H NMR (CDCl3) δ 3.81 (s, 3H, OCH3), 4.00 (s, 2H, CH2-Ar), 
5.08 (s, 2H, NCH2CO), 6.85-6.89 (m, 3H, Ar), 6.92-6.96 (m, 2H, Ar), 7.10-7.15 (m, 2H, Ar), 7.28-7.32 
(m, 1H, Ar), 7.39 (s, 1H, Ar), 7.42-7.46 (m, 2H, Ar), 7.69-7.73 (m, 2H, Ar), 9.02 (exch br s, 1H, NH). 
 
General procedure for 51a,(±)-51b. A mixture of 42d or (±)-42m (7.41 mmol), K2CO3 (14.82 
mmol) and ethyl bromoacetate (11.12 mmol) in CH3CN (5 mL) was refluxed under stirring for 2-3 h. The 
mixture was then concentrated in vacuo, diluted with cold water, and extracted with CH2Cl2 (3 x 15 mL). 
The organic layer was evaporated in vacuo, and the final compounds 51a,(±)-b were purified by column 
chromatography using cyclohexane/ethyl acetate 1:1 as eluent.  
5.2.152         Ethyl-2-[3-Methyl-6-oxo-5,6-dihydropyridazin-1(4H)-yl]acetate (51a) 
N N
O
O
O
 
Yield = 98 %; oil. 1H NMR (CDCl3) δ 1.22 (t, 3H, CH2CH3, J = 7.1 Hz), 2.01 (s, 3H, 3-CH3), 2.48 (qd, 
2H, CH2CH2 pyridaz., J = 7.9 Hz, J = 5.0 Hz), 4.15 (q, 2H, CH2CH3, J = 7.1 Hz), 4.40 (s, 2H, NCH2CO). 
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5.2.153 (±)-Ethyl-2-[5-methyl-6-oxo-3-phenyl-5,6-dihydropyridazin-1(4H)-yl]acetate 
[(±)-51b] 
N
∗
N
O
O
O
 
Yield ~ 100 %; oil. 1H NMR (CDCl3) δ 1.28 (m, 6H, CH2CHCH3 + CH2CH3), 2.67-2.79 (m, 2H, 
CH2CHCH3), 3.07-3.14 (m, 1H, CH2CHCH3), 4.24 (q, 2H, CH2CH3, J = 6.9 Hz), 4.59 (d, 2H, NCH2CO, 
J = 8.0 Hz), 7.40-7.43 (m, 3H, Ar), 7.72-7.75 (m, 2H, Ar). 
 
General procedure for 52a,(±)-52b. A suspension of 51a or (±)-52b (7.29 mmol) in 6 N NaOH 
(10 mL) was stirred at rt to 80 °C for 3-5 h. The mixture was then diluted with cold water and acidified 
with 6 N HCl. Products 52a and (±)-52b were filtered off by suction and recrystallized from cyclohexane 
(52a) or ethanol [(±)-52b].  
5.2.154 2-[3-Methyl-6-oxo-5,6-dihydropyridazin-1(4H)-yl]acetic acid (52a) 
N N
O
O
OH
 
Yield = 86 %; mp = 171-73 °C (EtOH). 1H NMR (CDCl3) δ 1.96 (s, 3H, 3-CH3), 2.35-2.39 (m, 2H, CH2 
pyridaz.), 2.40-2.49 (m, 2H, CH2 pyridaz.), 4.23 (s, 2H, NCH2CO). 
5.2.155 (±)-2-[5-Methyl-6-oxo-3-phenyl-5,6-dihydropyridazin-1(4H)-yl]acetic acid [(±)-
52b] 
N
∗
N
O
O
OH
 
Yield ~ 100 %; mp = 87-89 °C (EtOH). 1H NMR (CDCl3) δ 1.31 (d, 3H, CH2CHCH3, J = 6.7 Hz), 2.68-
2.78 (m, 2H, CH2CHCH3), 3.04-3.16 (m, 1H, CH2CHCH3), 4.64 (s, 2H, NCH2CO), 6.98 (exch br s, 1H, 
OH), 7.41-7.43 (m, 3H, Ar), 7.73-7.75 (m, 2H, Ar). 
 
General procedure for 53a,(±)-53b-d. To a cooled (-5 °C) and stirred solution of the appropriate 
derivative 52 [52a,(±)-52b] (2.06 mmol) in anhydrous tetrahydrofuran (6 mL), Et3N (7.21 mmol) was 
added. After 30 min, the mixture was allowed to warm up to 0 °C and ethyl chloroformate (2.27 mmol) 
was added. After 1 h, the appropriately substituted arylamine (4.12 mmol) was added. The reaction was 
carried out at room temperature for 12 h. The mixture was then concentrated in vacuo, diluted with cold 
water (20-30 mL) and extracted with CH2Cl2 (3 x 15 mL). The solvent was evaporated to afford final 
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compounds 53a,(±)-53b-d, which were purified by column chromatography using cyclohexane/ethyl 
acetate 1:3 (for compound 53a), cyclohexane/ethyl acetate 2:1 (for compound (±)-53b) and n-
hexane/ethyl acetate 3:2 (for compounds (±)-53c,d) as eluents.  
5.2.156 N-(4-Iodophenyl)-2-[3-methyl-6-oxo-5,6-dihydropyridazin-1(4H)-yl]acetamide 
(53a) 
N N
O
O H
N I
 
Yield = 98 %; mp = 174-76 °C (EtOH). 1H NMR (CDCl3) δ 2.11 (s, 3H, 3-CH3), 2.55-2.60 (m, 4H, 
CH2CH2 pyridaz.), 4.52 (s, 2H, NCH2CO), 7.31 (d, 2H, Ar, J = 8.8 Hz), 7.62 (d, 2H, Ar, J = 8.8 Hz), 8.11 
(exch br s, 1H, NH). 
5.2.157 (±)-N-(4-Bromophenyl)-2-[5-methyl-6-oxo-3-phenyl-5,6-dihydropyridazin-
1(4H)-yl]acetamide [(±)-53b] 
N
∗
N
O
O H
N Br
 
Yield = 23 %; mp = 148-149 °C (EtOH). 1H NMR (CDCl3) δ 1.37 (d, 3H, CH2CHCH3, J = 6.3 Hz), 2.74-
2.81 (m, 2H, CH2CHCH3), 3.14-3.22 (quin, 1H, CH2CHCH3, J = 11.6 Hz), 4.68 (s, 2H, NCH2CO), 7.28 
(d, 2H, Ar, J = 10.1 Hz), 7.44 (t, 4H, Ar, J = 7.0 Hz), 7.60 (d, 1H, Ar, J = 3.9 Hz), 7.77-7.79 (m, 2H, Ar), 
8.15 (exch, br, s, 1H, NH). 
5.2.158 (±)-N-(4-Fluorophenyl)-2-[5-methyl-6-oxo-3-phenyl-5,6-dihydropyridazin-
1(4H)-yl]acetamide [(±)-53c] 
N
∗
N
O
O H
N F
 
Yield = 61 %; mp = 164-165 °C (EtOH). 1H NMR (CDCl3) δ 1,35 (d, 3H, CH2CHCH3, J = 6.4 Hz), 2,69-
2.80 (m, 2H, CH2CHCH3), 3,11-3,20 (m, 1H, CH2CHCH3), 4,68 (s, 2H, NCH2CO), 6.98 (t, 2H, Ar, J = 
8.8 Hz), 7,42-7.49 (m, 5H, Ar), 7,76-7.78 (m, 2H, Ar), 8.25 (exch, br, s, 1H, NH). 
5.2.159 (±)-N-(1,3-Benzodioxol-5-yl)-2-[5-methyl-6-oxo-3-phenyl-5,6-dihydro 
pyridazin-1(4H)-yl]acetamide [(±)-53d] 
N
∗
N
O
O H
N O
O
 
5. Experimental Chemistry 
 
 138
Yield = 88 %; mp = 170-171 °C (EtOH). 1H NMR (CDCl3) δ 1.35 (d, 3H, CH2CHCH3, J = 6.4 Hz), 2.69-
2.80 (m, 2H, CH2CHCH3), 3.16 (q, 1H, CH2CHCH3, J = 10.1 Hz), 4.66 (s, 2H, NCH2CO), 5.94 (s, 2H, 
OCH2O), 6.72 (d, 1H, Ar, J = 8.3 Hz), 6.80 (dd, 1H, Ar, J = 6.2 Hz, J = 2.1 Hz), 7.24 (s, 1H, Ar), 7.44 (t, 
3H, Ar, J = 2.8 Hz), 7.77-7.79 (m, 2H, Ar), 8.01 (exch, br, s, 1H, NH). 
 
General procedure for 55a-c. A mixture of compound type 42 [42c,d and (±)-42m] (2.27 mmol), 
K2CO3 (4.54 mmol), and ethyl bromoacetate (3.41 mmol) in CH3CN (3 mL) was refluxed under stirring 
for 2-3 h. The mixture was then concentrated in vacuo, diluted with cold water and extracted with CH2Cl2 
(3 x 15 mL). The organic layer was evaporated in vacuo, and compounds 55a-c were used for the 
following reactions without further purification.  
5.2.160 Ethyl-2-[3-cyclohexyl-6-oxopyridazin-1(6H)-yl]acetate (55a) 
N N
O
O
O
 
Yield ~ 100 %; oil. 1H NMR (CDCl3) δ 1.28-1.46 (m, 8H, (2 x CH2 + CH-H) cyclohexyl + CH2CH3), 
1.71-1.86 (m, 5H, 2 x CH2 + CH-H cyclohexyl), 2.51-2.60 (m, 1H, CH, cyclohexyl), 4.23 (dt, 2H, 
CH2CH3, J = 4.3 Hz, J = 1.4 Hz), 4.83 (s, 2H, NCH2CO), 6.90 (d, 1H, Ar, J = 9.0 Hz), 7.17 (d, 1H, Ar, J 
= 9.6 Hz). 
5.2.161 Ethyl-2-[3-methyl-6-oxopyridazin-1(6H)-yl]acetate (55b) 
N N
O
O
O
 
Yield ~ 100 %; oil. 1H NMR (CDCl3) δ 1.30 (t, 3H, CH2CH3, J = 7.1 Hz), 2.37 (s, 3H, 3-CH3), 4.26 (q, 
2H, CH2CH3, J = 7.1 Hz), 4.87 (s, 2H, NCH2CO), 7.02 (d, 1H, Ar, J = 9.4 Hz), 7.20 (d, 1H, Ar, J = 9.4 
Hz). 
 
General procedure for 56a-c. A suspension of derivative 55 (55a-c) (0.91 mmol) in 6 N NaOH 
(4 mL) was stirred at rt to 80 °C for 2 h. The mixture was then diluted with cold water and acidified with 
6 N HCl. Products 56a,c were filtered off by suction and recrystallized from ethanol.  
5.2.162 2-[3-Cyclohexyl-6-oxopyridazin-1(6H)-yl]acetic acid (56a) 
N N
O
O
OH
 
Yield = 82 %; mp = 195-97 °C (EtOH). 1H NMR (CDCl3) δ 1.25-1.34 (m, 1H, CH-H cyclohexyl), 1.37-
1.46 (m, 4H, 2 x CH2 cyclohexyl), 1.76 (m, 1H, CH-H cyclohexyl), 1.79-1.93 (m, 4H, 2 x CH2 
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cyclohexyl), 2.50-2.60 (m, 1H, CH cyclohexyl), 4.94 (s, 2H, NCH2CO), 6.99 (d, 1H, Ar, J = 9.5 Hz), 7.24 
(d, 1H, Ar, J = 9.6 Hz). 
5.2.163 2-[3-Methyl-6-oxopyridazin-1(6H)-yl]acetic acid (56b) 
N N
O
O
OH
 
Yield = 72 %; mp = 247-49 °C (EtOH). 1H NMR (CDCl3) δ 2.37 (s, 3H, 3-CH3), 4.94 (s, 2H, NCH2CO), 
6.97 (d, 1H, Ar, J = 9.5 Hz), 7.19 (d, 1H, Ar, J = 9.6 Hz). 
5.2.164 2-[5-Methyl-6-oxo-3-phenylpyridazin-1(6H)-yl]acetic acid (56c) 
N N
O
O
OH
 
Yield = 90 %; mp = 92-94 °C (EtOH). 1H NMR (CDCl3) δ 2.34 (s, 3H, CH3), 3.48 (exch br s, 1H, OH), 
5.05 (s, 2H, CH2COO), 7.45-7.50 (m, 3H, Ar), 7.63 (s, 1H, Ar), 7.78 (d, 2H, Ar, J = 4.5 Hz). 
 
General procedure for 57a-f. To a cooled (-5 °C) and stirred solution of the appropriate 
compound 56 (56a-c) (0.59 mmol) in anhydrous tetrahydrofuran (3 mL), Et3N (2.06 mmol) was added. 
After 30 min, the mixture was allowed to warm up to 0 °C and ethyl chloroformate (0.65 mmol) was 
added. After 1 h, the appropriately substituted arylamine (1.18 mmol) was added. The reaction was 
carried out at room temperature for 12 h. The mixture was then concentrated in vacuo, diluted with cold 
water (10-15 mL), and extracted with CH2Cl2 (3 x 15 mL). The solvent was evaporated to afford final 
compounds 57a-f, which were purified by column chromatography using cyclohexane/ethyl acetate 1:1 
(for compound 57a,d-f), cyclohexane/ethyl acetate 1:2 (for compound 57b) and CH2Cl2/CH3OH 9.9:0.1 
(for compound 57c) as eluents.  
5.2.165 N-(4-Fluorophenyl)-2-[3-cyclohexyl-6-oxopyridazin-1(6H)-yl]acetamide (57a) 
N N
O
O H
N F
 
Yield = 98 %; mp = 149-51 °C (EtOH). 1H NMR (CDCl3) δ 1.21-1.30 (m, 1H, CH-H cyclohexyl), 1.39-
1.48 (m, 4H, 2 x CH2 cyclohexyl), 1.77 (d, 1H, CH-H cyclohexyl, J = 12.6 Hz), 1.85-1.93 (m, 4H, 2 x 
CH2 cyclohexyl), 2.56-2.63 (m, 1H, CH cyclohexyl), 4.96 (s, 2H, NCH2CO), 6.94-7.02 (m, 3H, Ar), 7.27 
(d, 1H, Ar, J = 9.7 Hz), 7.46-7.49 (m, 2H, Ar), 9.10 (exch br s, 1H, NH). 
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5.2.166      N-(1,3-Benzodioxol-5-yl)-2-[3-cyclohexyl-6-oxopyridazin-1(6H)-yl]acetamide (57b) 
N N
O
O H
N O
O
 
Yield ~ 100 %; mp = 185-87 °C (EtOH). 1H NMR (CDCl3) δ 1.20-1.28 (m, 1H, CH-H cyclohexyl), 1.30-
1.48 (m, 4H, 2 x CH2 cyclohexyl), 1.76 (d, 1H, CH-H cyclohexyl, J = 12.8 Hz), 1.85-1.93 (m, 4H, 2 x 
CH2 cyclohexyl), 2.59-2.61 (m, 1H, CH cyclohexyl), 4.93 (s, 2H, NCH2CO), 5.94 (s, 2H, OCH2O), 6.72 
(d, 1H, Ar, J = 8.4 Hz), 6.81 (dd, 1H, Ar, J = 6.3 Hz, J = 2.1 Hz), 7.00 (d, 1H, Ar, J = 9.5 Hz), 7.25-7.28 
(m, 2H, Ar), 8.86 (exch br s, 1H, NH). 
5.2.167     N-(4-Iodophenyl)-2-[3-methyl-6-oxopyridazin-1(6H)-yl]acetamide (57c) 
N N
O
O H
N I
 
Yield ~ 100 %; mp = 160-61 °C (EtOH). 1H NMR (CDCl3) δ 2.39 (s, 3H, 3-CH3), 4.96 (s, 2H, NCH2CO), 
6.97 (d, 1H, Ar, J = 9.5 Hz), 7.20-7.26 (m, 3H, Ar), 7.50 (dt, 2H, Ar, J = 5.2 Hz, J = 1.8 Hz), 9.27 (exch 
br s, 1H, NH). 
5.2.168    N-(4-Bromophenyl)-2-[5-methyl-6-oxo-3-phenylpyridazin-1(6H)-yl]acetamide (57d) 
N N
O
O H
N Br
 
Yield = 38 %; mp = 149-51 °C (EtOH). 1H NMR (CDCl3) δ 2.37 (s, 3H, CH3), 5.08 (s, 2H, CH2CO), 
7.40-7.49 (m, 7H, Ar), 7.68 (s, 1H, Ar), 7.82 (dd, 2H, Ar, J = 5.8 Hz, J = 1.4 Hz), 9.02 (exch br s, 1H, 
NH). 
5.2.169    N-(4-Fluorophenyl)-2-[5-methyl-6-oxo-3-phenylpyridazin-1(6H)-yl]acetamide (57e) 
N N
O
O H
N F
 
Yield = 45 %; mp = 117-19 °C (EtOH). 1H NMR (CDCl3) δ 2.34 (s, 3H, CH3), 5.11 (s, 2H, CH2CO), 
6.89-6.93 (td, 2H, Ar, J = 3.7 Hz, J = 2.1 Hz), 7.44-7.49 (m, 5H, Ar), 7.65 (s, 1H, Ar), 7.79-7.82 (dd, 2H, 
Ar, J = 3.1 Hz, J = 1.9 Hz), 9.21 (exch br s, 1H, NH). 
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5.2.170 N-(1,3-Benzodioxol-5-yl)-2-[5-methyl-6-oxo-3-phenylpyridazin-1(6H)-
yl]acetamide (57f) 
N N
O
O H
N O
O
 
Yield = 25 %; mp = 215-17 °C (EtOH). 1H NMR (DMSO-d6) δ 2.19 (s, 3H, CH3), 4.95 (s, 2H, OCH2O), 
5.99 (s, 2H, CH2CO), 6.87 (d, 1H, Ar, J = 8.3 Hz), 6.96 (d, 1H, Ar, J = 8.5 Hz), 7.29 (s, 1H, Ar), 7.49 (q, 
3H, Ar, J = 7.5 Hz), 7.89 (d, 2H, Ar, J = 7.1 Hz), 8.04 (s, 1H, Ar), 10.26 (exch br s, 1H, NH). 
 
General Procedure for 58a-m. To 12 mL of KOH in absolute EtOH (5%, w/v), 42d (4.46 mmol) 
and the appropriate substituted aromatic aldehyde (4.46 mmol) were added. The mixture was refluxed 
under stirring for 3-5 h. After cooling, it was concentrated in vacuo, diluted with ice-cold water (20-25 
mL) and acidified with 2 N HCl. The suspension was extracted with CH2Cl2 (3 x 25 mL). Removal of the 
solvent afforded compounds 58a-m, which were purified by crystallization in ethanol. For compound 58f 
was necessary to perform an additional purification step by flash column chromatography using 
cyclohexane/ethyl acetate 2:1 as eluent.  
5.2.171 4-(Furan-3-ylmethyl)-6-methylpyridazin-3(2H)-one (58a) 
HN N
O
O
 
Yield = 24 %; mp = 137-39 °C (EtOH). 1H NMR (CDCl3) δ 2.29 (s, 3H, CH3), 3.74 (s, 2H, CH2), 6.33 (s, 
1H, Ar), 6.86 (s, 1H, Ar), 7.39 (s, 1H, Ar), 7.46 (s, 1H, Ar). 
5.2.172 4-(3,5-Dimethoxybenzyl)-6-methylpyridazin-3(2H)-one (58f) 
HN N
O
O
O
 
Yield = 56 %; mp = 167-69 °C (EtOH). 1H NMR (CDCl3) δ 2.27 (s, 3H, CH3), 3.81 (s, 6H, 2 x OCH3), 
3.85 (s, 2H, CH2), 6.41 (s, 3H, Ar), 6.77 (s, 1H, Ar). 
5.2.173 4-(3-Fluorobenzyl)-6-methylpyridazin-3(2H)-one (58g) 
HN N
O
F
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Yield = 95 %; mp = 114-16 °C (EtOH). 1H NMR (CDCl3) δ 2.28 (s, 3H, CH3), 3.91 (s, 2H, CH2), 6.75 (s, 
1H, Ar), 6.98-7.07 (m, 3H, Ar), 7.30-7.36 (m, 1H, Ar), 11.31 (exch br s, 1H, NH). 
5.2.174 4-(3-Chlorobenzyl)-6-methylpyridazin-3(2H)-one (58h) 
HN N
O
Cl
 
Yield = 81 %; mp = 124-26 °C (EtOH). 1H NMR (CDCl3) δ 2.28 (s, 3H, CH3), 3.89 (s, 2H, CH2), 6.75 (s, 
1H, Ar), 7.16-7.18 (m, 1H, Ar), 7.26-7.31 (m, 3H, Ar), 11.09 (exch br s, 1H, NH). 
5.2.175 4-(3-Bromobenzyl)-6-methylpyridazin-3(2H)-one (58j) 
HN N
O
Br
 
Yield = 28 %; mp = 147-49 °C (EtOH). 1H NMR (CDCl3) δ 2.28 (s, 3H, CH3), 3.88 (s, 2H, CH2), 6.75 (s, 
1H, Ar), 7.24 (d, 2H, Ar, J = 5.2 Hz), 7.45 (d, 2H, Ar, J = 9.1 Hz), 10.82 (exch br s, 1H, NH). 
5.2.176 6-Methyl-4-[4-(methylthio)benzyl]pyridazin-3(2H)-one (58k) 
HN N
O
S
 
Yield = 46 %; mp = 151-53 °C (EtOH). 1H NMR (CDCl3) δ 2.,26 (s, 3H, CH3), 2.51 (s, 3H, SCH3), 3.87 
(s, 2H, CH2), 6.71 (s, 1H, Ar), 7.18 (d, 2H, Ar, J = 8.2 Hz), 7.27 (dd, 3H, Ar, J = 9.3 Hz, J = 1.8 Hz). 
5.2.177 6-Methyl-4-[4-(trifluoromethyl)benzyl]pyridazin-3(2H)-one (58l) 
HN N
O
F
F
F
 
Yield = 94 %; mp = 153-55 °C (EtOH). 1H NMR (CDCl3) δ 2.29 (s, 3H, CH3), 3.97 (s, 2H, CH2), 6.77 (s, 
1H, Ar), 7.40 (d, 2H, Ar, J = 8.0 Hz), 7.62 (d, 2H, Ar, J = 8.1 Hz), 11.19 (exch br s, 1H, NH). 
5.2.178 4-Benzyl-6-methylpyridazin-3(2H)-one (58m) 
HN N
O
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Yield ~ 100 %; mp = 113-15 °C (EtOH). 1H NMR (CDCl3) δ 2.26 (s, 3H, CH3), 3.92 (s, 2H, CH2), 6.73 
(s, 1H, Ar), 7.26-7.33 (m, 3H, Ar), 7.28 (t, 2H, Ar, J = 6.9 Hz). 
 
General Procedure for 59a-m. A mixture of the suitable intermediate type 58 (58a-m) (4.50 
mmol), K2CO3 (9.00 mmol) and ethyl bromoacetate (6.75 mmol) in CH3CN (10 mL) was refluxed under 
stirring for 2-4 h. The mixture was then concentrated in vacuo, diluted with cold water and extracted with 
CH2Cl2 (3 x 15 mL). The solvent was evaporated in vacuo and compounds 59a-m were purified by 
crystallization from ethanol (compounds 59a,g,h,j,k) or by flash column chromatography using 
cyclohexane/ethyl acetate 2:1 (for 59b-e) and cyclohexane/ethyl acetate 1:1 (for 59f,i,l,m) as eluents.  
5.2.179 Ethyl-2-[5-(furan-3-ylmethyl)-3-methyl-6-oxopyridazin-1(6H)-yl]acetate (59a) 
N N
O
O
O
O
 
Yield = 69 %; mp = 61-67 °C (EtOH). 1H NMR (CDCl3) δ 1.31 (t, 3H, CH2CH3, J = 7.1 Hz), 2.27 (s, 3H, 
3-CH3), 3.73 (s, 2H, CHCCH2), 4.27 (q, 2H, OCH2CH3, J = 7.1 Hz), 4.87 (s, 2H, NCH2CO), 6.32 (s, 1H, 
Ar), 6.82 (s, 1H, Ar), 7.37 (s, 1H, Ar), 7.45 (s, 1H, Ar). 
5.2.180       Ethyl-2-[3-methyl-6-oxo-5-(thiophen-3-ylmethyl)pyridazin-1(6H)-yl]acetate (59b) 
N N
O
S
O
O
 
Yield = 91 %; oil. 1H NMR (CDCl3) δ 1.31 (t, 3H, CH2CH3, J = 7.1 Hz), 2.25 (s, 3H, 3-CH3), 3.93 (s, 2H, 
CHCCH2), 4.25 (q, 2H, CH2CH3, J = 5.8 Hz), 4.86 (s, 1H, NCH2CO), 6.72 (s, 1H, Ar), 6.97 (dd, 1H, Ar, 
J = 3.64 Hz, J = 1.2 Hz), 7.11 (s, 1H, Ar), 7.33 (dd, 1H, Ar, J = 2.0 Hz, J = 4.6 Hz). 
5.2.181        Ethyl-2-[3-methyl-6-oxo-5-(thiophen-2-ylmethyl)pyridazin-1(6H)-yl]acetate (59c) 
N N
O
S
O
O
 
Yield ~ 100 %; oil. 1H NMR (CDCl3) δ 1.30 (t, 3H, CH2CH3, J = 7.1 Hz), 2.26 (s, 3H, 3-CH3), 4.11 (s, 
2H, CHCCH2), 4.25 (q, 2H, CH2CH3, J = 7.1 Hz), 4.86 (s, 2H, NCH2CO), 6.82 (s, 1H, Ar), 6.92 (d, 1H, 
Ar, J = 3.3 Hz), 7.00 (t, 1H, Ar, J = 3.9 Hz), 7.22 (d, 1H, Ar, J = 5.1 Hz). 
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5.2.182        Ethyl-2-[5-(3,5-dimethoxybenzyl)-3-methyl-6-oxopyridazin-1(6H)-yl]acetate (59f) 
N N
O
O
O
O
O
 
Yield = 95 %; brown oil. 1H NMR (CDCl3) δ 1.31 (t, 3H, CH2CH3), 2.24 (s, 3H, 3-CH3), 3.79 (s, 6H, 2 x 
OCH3), 3.84 (s, 2H, CHCCH2), 4.24 (q, 2H, OCH2CH3, J = 7.1 Hz), 4.86 (s, 2H, NCH2CO), 6.39 (s, 3H, 
Ar), 6.70 (s, 1H, Ar). 
5.2.183 Ethyl-2-[5-(3-fluorobenzyl)-3-methyl-6-oxopyridazin-1(6H)-yl]acetate (59g) 
N N
O
F
O
O
 
Yield = 89 %; mp = 74-76 °C (EtOH). 1H NMR (CDCl3) δ 1.31 (t, 3H, CH2CH3, J = 7.2 Hz), 2.26 (s, 3H, 
3-CH3), 3.91 (s, 2H, CHCCH2), 4.26 (q, 2H, OCH2CH3, J = 7.2 Hz), 4.87 (s, 2H, NCH2CO), 6.71 (s, 1H, 
Ar), 6.95-7.05 (m, 3H, Ar), 7.30 (q, 1H, Ar, J = 6.5 Hz). 
5.2.184 Ethyl-2-[5-(3-chlorobenzyl)-3-methyl-6-oxopyridazin-1(6H)-yl]acetate (59h) 
N N
O
Cl
O
O
 
Yield ~ 100 %; mp = 89-91 °C (EtOH). 1H NMR (CDCl3) δ 1.31 (t, 3H, CH2CH3, J = 7.2 Hz), 2.27 (s, 
3H, 3-CH3), 3.88 (s, 2H, CHCCH2), 4.27 (q, 2H, OCH2CH3, J = 7.2 Hz), 4.86 (s, 2H, NCH2CO), 6.71 (s, 
1H, Ar), 7.15 (dd, 1H, Ar, J = 4.5 Hz, J = 1.8 Hz), 7.24-7.30 (m, 3H, Ar). 
5.2.185 Ethyl-2-[5-(3-bromobenzyl)-3-methyl-6-oxopyridazin-1(6H)-yl]acetate (59j) 
N N
O
Br
O
O
 
Yield = 82 %; mp = 98-100 °C (EtOH). 1H NMR (CDCl3) δ 1.31 (t, 3H, CH2CH3, J = 7.0 Hz), 2.27 (s, 
3H, 3-CH3), 3.88 (s, 2H, CHCCH2), 4.27 (q, 2H, OCH2CH3, J = 7.0 Hz), 4.86 (s, 2H, NCH2CO), 6.71 (s, 
1H, Ar), 7.21-7.25 (m, 2H, Ar), 7.42 (d, 2H, Ar, J = 11.9 Hz). 
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5.2.186      Ethyl-2-{3-methyl-5-[4-(methylthio)benzyl]-6-oxopyridazin-1(6H)-yl}acetate (59k) 
N N
O
S
O
O
 
Yield ~ 100 %; mp = 129-31 °C (EtOH). 1H NMR (CDCl3) δ 1.31 (t, 3H, CH2CH3, J = 6.8 Hz), 2.24 (s, 
3H, 3-CH3), 2.51 (s, 3H, SCH3), 3.87 (s, 2H, CHCCH2), 4.27 (q, 2H, OCH2CH3, J = 6.8 Hz), 4.86 (s, 2H, 
NCH2CO), 6.68 (s, 1H, Ar), 7.17 (d, 2H, Ar, J = 7.3 Hz), 7.25-7.29 (m, 2H, Ar). 
5.2.187 Ethyl-2-{3-methyl-6-oxo-5-[4-(trifluoromethyl)benzyl]pyridazin-1(6H)-
yl}acetate (59l) 
N N
O
F
F
F
O
O
 
Yield ~ 100 %; brown oil. 1H NMR (CDCl3) δ 1.30 (t, 3H, CH2CH3, J = 7.0 Hz), 2.27 (s, 3H, 3-CH3), 
3.96 (s, 2H, CHCCH2), 4.26 (q, 2H, OCH2CH3, J = 7.1 Hz), 4.86 (s, 2H, NCH2CO), 6.73 (s, 1H, Ar), 7.38 
(d, 2H, Ar, J = 8.0 Hz), 7.60 (d, 2H, Ar, J = 8.0 Hz). 
5.2.188 Ethyl-2-[5-benzyl-3-methyl-6-oxopyridazin-1(6H)-yl]acetate (59m) 
N N
O
O
O
 
Yield = 98 %; oil. 1H NMR (CDCl3) δ 1.31 (t, 3H, CH2CH3, J = 7.1 Hz), 2.22 (s, 3H, 3-CH3), 3.90 (s, 2H, 
CHCCH2), 4.24 (q, 2H, CH2CH3, J = 7.1 Hz), 4.85 (s, 2H, NCH2CO), 6.66 (s, 1H, Ar), 7.23-7.28 (m, 3H, 
Ar), 7.33-7.37 (m, 2H, Ar). 
 
General Procedure for 60a-m. A suspension of the suitable intermediate type 59 (59a-m) (4.4 
mmol) in 6 N NaOH (10 mL) was stirred at rt to 80 °C for 1-2 h. The mixture was firstly diluted with ice-
cold water and then acidified with 6 N HCl. Products 60a-m were filtered off by suction and 
recrystallized from ethanol.  
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5.2.189 2-[5-(Furan-3-ylmethyl)-3-methyl-6-oxopyridazin-1(6H)-yl]acetic acid (60a) 
N N
O
O
OH
O
 
Yield = 69 %; mp = 62-64 °C (EtOH). 1H NMR (CDCl3) δ 2.29 (s, 3H, 3-CH3), 3.46 (exch br s, 1H, OH), 
3.75 (s, 2H, CHCCH2), 4.93 (s, 2H, NCH2CO), 6.31 (s, 1H, Ar), 6.86 (s, 1H, Ar), 7.37 (s, 1H, Ar), 7.45 
(s, 1H, Ar). 
5.2.190 2-[3-Methyl-6-oxo-5-(thiophen-3-ylmethyl)pyridazin-1(6H)-yl]acetic acid (60b) 
N N
O
S
OH
O
 
Yield ~ 100 %; mp = 123-25 °C (EtOH). 1H NMR (CDCl3) δ 2.27 (s, 3H, 3-CH3), 3.95 (s, 2H, CHCCH2), 
4.93 (s, 2H, NCH2CO), 5.21 (exch br s, 1H, OH), 6.76 (s, 1H, Ar), 6.97 (d, 1H, Ar, J = 4.8 Hz), 7.12 (s, 
1H, Ar), 7.35 (t, 1H, Ar, J = 4.4 Hz). 
5.2.191 2-[3-Methyl-6-oxo-5-(thiophen-2-ylmethyl)pyridazin-1(6H)-yl]acetic acid (60c) 
N N
O
S
OH
O
 
Yield = 88 %; mp = 123-25 °C (EtOH). 1H NMR (CDCl3) δ 2.28 (s, 3H, 3-CH3), 4.13 (s, 2H, CHCCH2), 
4.93 (s, 2H, NCH2CO), 6.85 (s, 1H, Ar), 6.94 (d, 1H, Ar, J = 3.4 Hz), 7.01 (dd, 1H, Ar, J = 1.6 Hz, J = 
3.4 Hz), 7.24 (dd, 1H, Ar, J = 4.0 Hz, J = 1.0 Hz),  8.41 (exch br s, 1H, OH). 
5.2.192        2-[3-Methyl-5-(naphthalen-1-ylmethyl)-6-oxopyridazin-1(6H)-yl]acetic acid (60d) 
N N
O
OH
O
 
Yield = 98 %; mp = 198-200 °C (EtOH). 1H NMR (CDCl3) δ 2.11 (s, 3H, 3-CH3), 4.39 (s, 2H, CHCCH2), 
5.01 (s, 2H, NCH2CO), 5.83 (exch br s, 1H, OH), 6.42 (s, 1H, Ar), 7.41 (d, 1H, Ar, J = 6.8 Hz), 7.47-7.54 
(m, 3H, Ar), 7.79 (d, 1H, Ar, J = 7.4 Hz), 7.86 (d, 1H, Ar, J = 8.2 Hz), 7.91 (d, 1H, Ar, J = 7.3 Hz). 
5. Experimental Chemistry 
 147 
5.2.193 2-[5-(4-Methoxybenzyl)-3-methyl-6-oxopyridazin-1(6H)-yl]acetic acid (60e) 
N N
O
O
O
OH
 
Yield = 96 %; mp = 144-45 °C (EtOH). 1H NMR (CDCl3) δ 2.26 (s, 3H, 3-CH3), 3.84 (s, 3H, OCH3), 
3.87 (s, 2H, CHCCH2), 4.93 (s, 2H, NCH2CO), 6.69 (s, 1H, Ar), 6.91 (d, 2H, Ar, J = 8.5 Hz), 7.16 (d, 2H, 
Ar, J = 8.5 Hz). 
5.2.194 2-[5-(3,5-Dimethoxybenzyl)-3-methyl-6-oxopyridazin-1(6H)-yl]acetic acid (60f) 
N N
O
O
O
OH
O
 
Yield = 76 %; mp = 112-14 °C (EtOH). 1H NMR (CDCl3) δ 2.26 (s, 3H, 3-CH3), 3.37 (exch br s, 1H, 
OH), 3.80 (s, 6H, 2 x OCH3), 3.85 (s, 2H, CHCCH2), 4.93 (s, 2H, NCH2CO), 6.40 (s, 3H, Ar), 6.75 (s, 
1H, Ar). 
5.2.195 2-[5-(3-Fluorobenzyl)-3-methyl-6-oxopyridazin-1(6H)-yl]acetic acid (60g) 
N N
O
F
OH
O
 
Yield = 82 %; mp = 124-26 °C (EtOH). 1H NMR (CDCl3) δ 2.27 (s, 3H, 3-CH3), 3.92 (s, 2H, CHCCH2), 
4.92 (s, 2H, NCH2CO), 6.35 (exch br s, 1H, OH), 6.72 (s, 1H, Ar), 6.95-7.04 (m, 3H, Ar), 7.30-7.36 (q, 
1H, Ar, J = 6.1 Hz). 
5.2.196 2-[5-(3-Chlorobenzyl)-3-methyl-6-oxopyridazin-1(6H)-yl]acetic acid (60h) 
N N
O
Cl
OH
O
 
Yield = 75 %; mp = 162-64 °C (EtOH). 1H NMR (CDCl3) δ 2.28 (s, 3H, 3-CH3), 3.90 (s, 2H, CHCCH2), 
4.93 (s, 2H, NCH2CO), 6.72 (s, 1H, Ar), 7.14 (d, 1H, Ar, J = 5.6 Hz), 7.23-7.45 (m, 1H, Ar). 
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5.2.197   2-[5-(3-Bromobenzyl)-3-methyl-6-oxopyridazin-1(6H)-yl]acetic acid (60j) 
N N
O
Br
O
OH
 
Yield = 89 %; mp = 173-75 °C (EtOH). 1H NMR (CDCl3) δ 2.29 (s, 3H, 3-CH3), 3.90 (s, 2H, CHCCH2), 
4.92 (s, 2H, NCH2CO), 6.74 (s, 1H, Ar), 7.19-7.26 (m, 2H, Ar), 7.43 (t, 2H, Ar, J = 7.4 Hz). 
5.2.198          2-{3-Methyl-5-[4-(methylthio)benzyl]-6-oxopyridazin-1(6H)-yl}acetic acid (60k) 
N N
O
S
O
OH
 
Yield ~ 100 %; mp = 87-89 °C (EtOH). 1H NMR (CDCl3) δ 2.25 (s, 3H, 3-CH3), 2.51 (s, 3H, SCH3), 3.87 
(s, 2H, CHCCH2), 4.91 (s, 2H, NCH2CO), 6.69 (s, 1H, Ar), 7.16 (d, 2H, Ar, J = 7.6 Hz), 7.25 (d, 2H, Ar, 
J = 7.6 Hz). 
5.2.199    2-{3-Methyl-6-oxo-5-[4-(trifluoromethyl)benzyl]pyridazin-1(6H)-yl}acetic acid (60l) 
N N
O
F
F
F
OH
O
 
Yield = 82 %; mp = 127-29 °C (EtOH). 1H NMR (CDCl3) δ 2.28 (s, 3H, 3-CH3), 3.98 (s, 2H, CHCCH2), 
4.93 (s, 2H, NCH2CO), 6.74 (s, 1H, Ar), 7.37 (d, 2H, Ar, J = 8.0 Hz), 7.61 (d, 2H, Ar, J = 8.0 Hz). 
5.2.200 2-[5-Benzyl-3-methyl-6-oxopyridazin-1(6H)-yl]acetic acid (60m) 
N N
O
OH
O
 
Yield = 92 %; mp = 120-22 °C (EtOH). 1H NMR (CDCl3) δ 2.25 (s, 3H, 3-CH3), 3.93 (s, 2H, CHCCH2), 
4.94 (s, 2H, NCH2CO), 5.50 (exch br s, 1H, OH), 6.70 (s, 1H, Ar), 7.24-7.32 (m, 3H, Ar), 7.35-7.39 (m, 
2H, Ar). 
5. Experimental Chemistry 
 149 
General Procedure for 61a-p. To a cooled (-5 °C) and stirred solution of the appropriate 
compound 60 (60a-m) (0.90 mmol), in anhydrous tetrahydrofuran (6 mL), Et3N (3.15 mmol) was added. 
After 30 min, the mixture was allowed to warm up to 0 °C and ethyl chloroformate (0.99 mmol) was 
added. After 1 h, the appropriately substituted arylamine (1.80 mmol) was added. The reaction was 
carried out at room temperature for 12 h. The mixture was then concentrated in vacuo, diluted with cold 
water (10-15 mL), and extracted with CH2Cl2 (3 x 15 mL). The solvent was evaporated to afford final 
compounds 61a-p, which were purified by column chromatography using cyclohexane/ethyl acetate 1:1 
for compounds 61a,b,f,j,n,o, CH2Cl2/CH3OH 9.8:0.2 for compound 48c, cyclohexane/ethyl acetate 2:1 
for compounds 61d,g-i,l,m, toluene/NH4OH/EtOH/CH2Cl2/petroleum ether 7:0.05:0.30:2:0.65 for 
compound 61e and cyclohexane/ethyl acetate 1:2 for compounds 61k,p.  
5.2.201 N-(4-Bromophenyl)-2-[5-(furan-3-ylmethyl)-3-methyl-6-oxo-pyridazin-1(6H)-
yl]acetamide (61a) 
N N
O
O
H
N
O
Br
 
Yield = 50 %; mp = 67-69 °C (EtOH). 1H NMR (CDCl3) δ 2.32 (s, 3H, 3-CH3), 3.76 (s, 2H, CHCCH2), 
4.96 (s, 2H, NCH2CO), 6.31 (s, 1H, Ar), 6.91 (s, 1H, Ar), 7.38-7.40 (m, 5H, Ar), 7.46 (s, 1H, Ar), 9.05 
(exch br s, 1H, NH). 
5.2.202 N-(4-Bromophenyl)-2-[3-methyl-6-oxo-5-(thiophen-3-ylmethyl)- pyridazin-
1(6H)-yl]acetamide (61b) 
N N
O
S
H
N
O
Br
 
Yield = 24 %; mp = 93-95 °C (EtOH). 1H NMR (CDCl3) δ 2.31 (s, 3H, 3-CH3), 3.96 (s, 2H, CHCCH2), 
4.95 (s, 2H, NCH2CO), 6.84 (s, 1H, Ar), 6.97 (d, 1H, Ar, J = 1.9 Hz), 7.12 (s, 1H, Ar), 7.35 (q, 1H, Ar, J 
= 4.8 Hz), 7.39 (s, 4H, Ar), 9.04 (exch br s, 1H, NH). 
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5.2.203 N-(4-Bromophenyl)-2-[3-methyl-6-oxo-5-(thiophen-2-ylmethyl)-pyridazin-
1(6H)-yl]acetamide (61c) 
N N
O
S
H
N
O
Br
 
Yield = 80 %; colorless oil. 1H NMR (CDCl3) δ 2.32 (s, 3H, 3-CH3), 4.14 (s, 2H, CHCCH2), 4.97 (s, 2H, 
NCH2CO), 6.93-6.95 (m, 2H, Ar), 6.99-7.01 (m, 1H, Ar), 7.24 (dd, 1H, Ar, J = 4.0 Hz, J = 1.0 Hz), 7.33 
(q, 4H, Ar, J = 4.2 Hz), 9.25 (exch br s, 1H, NH). 
5.2.204 N-(4-Bromophenyl)-2-[3-methyl-5-(naphthalen-1-ylmethyl)-6-oxo-pyridazin-
1(6H)-yl]acetamide (61d) 
N N
O
H
N
O
Br
 
Yield = 77 %; mp = 208-09 °C (EtOH). 1H NMR (CDCl3) δ 2.16 (s, 3H, 3-CH3), 4.39 (s, 2H, CHCCH2), 
5.04 (s, 2H, NCH2CO), 6.54 (s, 1H, Ar), 7.33 (d, 2H, Ar, J = 8.8 Hz), 7.39 (d, 3H, Ar, J = 9.2 Hz), 7.45-
7.54 (m, 3H, Ar), 7.80 (d, 1H, Ar, J = 8.2 Hz), 7.86 (d, 1H, Ar, J = 8.2 Hz), 7.92 (d, 1H, Ar, J = 7.8 Hz), 
9.38 (exch br s, 1H, NH). 
5.2.205 N-(4-Bromophenyl)-2-[5-(4-methoxybenzyl)-3-methyl-6-oxo-pyridazin-1(6H)-
yl]acetamide (61e) 
N N
O
O
O H
N Br
 
Yield = 73 %; mp = 139-141 °C (EtOH). IR (cm-1) 3300 (NH), 1709 (CO), 1644 (CO). 1H NMR (CDCl3) 
δ 2.29 (s, 3H, 3-CH3), 3.83 (s, 3H, OCH3), 3.88 (s, 2H, CH2-Ar), 4.94 (s, 2H, NCH2CO), 6.78 (s, 1H, Ar), 
6.90 (d, 2H, Ar, J = 8.6 Hz), 7.17 (d, 2H, Ar, J = 8.6 Hz), 7.40 (s, 4H, Ar), 9.01 (exch br s, 1H, NH). MS 
(ESI) calcd. For C21H20BrN3O3, 442,31. Found: m/z 442.08 [M]+. 
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5.2.206 N-(4-Bromophenyl)-2-[5-(3,5-dimethoxybenzyl)-3-methyl-6-oxo-pyridazin-
1(6H)-yl]acetamide (61f) 
N N
O
O
O
H
N
O
Br
 
Yield = 62 %; mp = 87-89 °C (EtOH). 1H NMR (CDCl3) δ 2.29 (s, 3H, 3-CH3), 3.77 (s, 6H, 2 x OCH3), 
3.83 (s, 2H, CHCCH2), 4.94 (s, 2H, NCH2CO), 6.37 (s, 3H, Ar), 6.85 (s, 1H, Ar), 7.27 (q, 4H, Ar, J = 
11.4 Hz), 9.49 (exch br s, 1H, NH). 
5.2.207 N-(4-Bromophenyl)-2-[5-(3-fluorobenzyl)-3-methyl-6-oxopyridazin-1(6H)-
yl]acetamide (61g) 
N N
O
F
H
N
O
Br
 
Yield = 47 %; mp = 88-89 °C (EtOH). 1H NMR (CDCl3) δ 2.32 (s, 3H, 3-CH3), 3.93 (s, 2H, CHCCH2), 
4.95 (s, 2H, NCH2CO), 6.85 (s, 1H, Ar), 6.97-7.05 (m, 3H, Ar), 7.28-7.34 (m, 5H, Ar), 9.14 (exch br s, 
1H, NH).  
5.2.208 N-(4-Bromophenyl)-2-[5-(3-chlorobenzyl)-3-methyl-6-oxopyridazin-1(6H)-
yl]acetamide (61h) 
N N
O
Cl
H
N
O
Br
 
Yield = 26 %; mp = 185-187 °C (EtOH). 1H NMR (CDCl3) δ 2.33 (s, 3H, 3-CH3), 3.89 (s, 2H, CHCCH2), 
4.94 (s, 2H, NCH2CO), 6.86 (s, 1H, Ar), 7.14 (s, 1H, Ar), 7.28 (dd, 7H, Ar, J = 1.3 Hz, J = 5.4 Hz), 9.26 
(exch br s, 1H, NH).  
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5.2.209 N-(4-Bromophenyl)-2-[5-(3-bromobenzyl)-3-methyl-6-oxopyridazin-1(6H)-
yl]acetamide (61i) 
N N
O
Br
O H
N Br
 
Yield = 47 %; mp = 99-101 °C (EtOH). 1H NMR (CDCl3) δ 2.33 (s, 3H, 3-CH3), 3.90 (s, 2H, CHCCH2), 
4.94 (s, 2H, NCH2CO), 6.85 (s, 1H, Ar), 7.19-7.23 (m, 2H, Ar), 7.35-7.40 (m, 4H, Ar), 7.43 (t, 2H, Ar, J 
= 3.6 Hz), 9.00 (exch br s, 1H, NH).  
5.2.210 N-(4-Bromophenyl)-2-{3-methyl-5-[4-(methylthio)benzyl]-6-oxo-pyridazin-
1(6H)-yl}acetamide (61j) 
N N
O
S
O H
N Br
 
Yield = 10 %; mp = 97-99 °C (EtOH). 1H NMR (CDCl3) δ 2.30 (s, 3H, 3-CH3), 2.50 (s, 3H, SCH3), 3.89 
(s, 2H, CHCCH2), 4.94 (s, 2H, NCH2CO), 6.80 (s, 1H, Ar), 7.17 (d, 2H, Ar, J = 8.2 Hz), 7.24 (d, 2H, Ar J 
= 8.2 Hz), 7.39 (dd, 4H, Ar, J = 2.6 Hz, J = 5.7 Hz), 9.01 (exch br s, 1H, NH).  
5.2.211 N-(4-Bromophenyl)-2-{3-methyl-6-oxo-5-[4-(trifluoromethyl) benzyl]pyridazin 
-1(6H)-yl}acetamide (61k) 
N N
O
F
F
F
H
N
O
Br
 
Yield = 44 %; mp = 81-83 °C (EtOH). 1H NMR (CDCl3) δ 2.32 (s, 3H, 3-CH3), 3.99 (s, 2H, CHCCH2), 
4.94 (s, 2H, NCH2CO), 6.84 (s, 1H, Ar), 7.32-7.40 (m, 6H, Ar), 7.61 (d, 2H, Ar, J = 8.1 Hz), 8.99 (exch 
br s, 1H, NH).  
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5.2.212   2-[5-Benzyl-3-methyl-6-oxopyridazin-1(6H)-yl]-N-(4-bromophenyl) acetamide (61 l) 
N N
O
H
N
O
Br
 
Yield = 47 %; colorless oil. 1H NMR (CDCl3) δ 2.30 (s, 3H, 3-CH3), 3.93 (s, 2H, CHCCH2), 4.94 (s, 2H, 
NCH2CO), 6.82 (s, 1H, Ar), 7.24-7.28 (m, 2H, Ar), 7.30-7.38 (m, 7H, Ar), 9.18 (exch br s, 1H, NH).  
5.2.213   N-(4-Fluorophenyl)-2-[5-benzyl-3-methyl-6-oxopyridazin-1(6H)-yl]acetamide (61m) 
N N
O
H
N
O
F
 
Yield = 53 %; mp = 175-76 °C (EtOH). 1H NMR (CDCl3) δ 2.29 (s, 3H, 3-CH3), 3.94 (s, 2H, CHCCH2), 
4.95 (s, 2H, NCH2CO), 6.80 (s, 1H, Ar), 6.97 (t, 2H, Ar, J = 8.7 Hz), 7.25-7.28 (m, 2H, Ar), 7.30-7.38 
(m, 3H, Ar), 7.41-7.44 (m, 2H, Ar), 9.05 (exch br s, 1H, NH).  
5.2.214 N-(1,3-Benzodioxol-5-yl)-2-[5-benzyl-3-methyl-6-oxopyridazin-1(6H)-
yl]acetamide (61n) 
N N
O
H
N
O
O
O
 
Yield = 26 %; mp = 63-65 °C (EtOH). 1H NMR (CDCl3) δ 2.22 (s, 3H, 3-CH3), 3.80 (s, 2H, CHCCH2), 
4.79 (s, 2H, NCH2CO), 5.99 (s, 2H, OCH2O), 6.86 (d, 1H, Ar, J = 8.4 Hz), 6.93-6.95 (m, 1H, Ar), 7.08 (s, 
1H, Ar), 7.22-7.34 (m, 7H, Ar), 10.19 (exch br s, 1H, NH).  
5.2.215 N-(4-Butoxyphenyl)-2-[5-(4-chlorobenzyl)-3-methyl-6-oxopyridazin-1(6H)-
yl]acetamide (61o) 
N N
O
Cl
O H
N O
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Yield = 70 %. mp =146-147 °C (EtOH). IR (cm-1) 3298 (NH), 1708 (CO), 1642 (CO). 1H NMR (CDCl3) 
δ 0.99 (t, 3H, O(CH2)3CH3, J = 7.4 Hz), 1.49 (sext, 2H, OCH2CH2CH2CH3, J = 7.5 Hz), 1.76 (quint, 2H, 
OCH2CH2CH2CH3, J = 7.0 Hz), 2.29 (s, 3H, 3-CH3), 3.88 (s, 2H, CHCCH2), 3.93 (t, 2H, OCH2, J = 6.5 
Hz), 4.94 (s, 2H, NCH2CO), 6.76 (s, 1H, Ar), 6.81 (d, 2H, Ar, J = 9.0 Hz), 7.18 (d, 2H, Ar, J = 8.4 Hz), 
7.32 (d, 2H, Ar, J = 8.4 Hz), 7.38 (d, 2H, Ar, J = 9.0 Hz), 8.69 (exch br s, 1H, NH). MS (ESI) calcd. For 
C24H26ClN3O3, 439,93. Found: m/z 440.17 [M + H]+. 
5.2.216 N-(4-Butoxyphenyl)-2-[5-(4-methoxybenzyl)-3-methyl-6-oxo-pyridazin-1(6H)-
yl]acetamide (61p) 
N N
O
O
O H
N O
 
Yield = 60 %; mp = 160-161 °C (EtOH). IR (cm-1) 3300 (NH), 1707 (CO), 1644 (CO). 1H NMR (CDCl3) 
δ 0.98 (t, 3H, O(CH2)3CH3, J = 7.4 Hz), 1.45-1.54 (m, 2H, OCH2CH2CH2CH3), 1.77(quint, 2H, 
OCH2CH2CH2CH3, J = 7.1 Hz), 2.28 (s, 3H, 3-CH3), 3.83 (s, 3H, OCH3), 3.88 (s, 2H, CHCCH2), 3.94 (t, 
2H, OCH2, J = 6.5 Hz), 4.93 (s, 2H, NCH2CO), 6.74 (s, 1H, Ar), 6.82 (d, 2H, Ar, J = 9.0 Hz), 6.90 (d, 
2H, Ar, J = 8.6 Hz), 7.17 (d, 2H, Ar, J = 8.5 Hz), 7.39 (d, 2H, Ar, J = 9.0 Hz), 8.67 (exch br s, 1H, NH).  
MS (ESI) calcd. For C25H29N3O4, 435,52. Found: m/z 436.23 [M + H]+. 
 
General Procedure for 62a-c. To 5 mL of KOH in absolute EtOH (5%, w/v), 53a (0.13 mmol) 
and the appropriate substituted aromatic aldehyde (0.13 mmol) were added. The mixture was refluxed 
under stirring for 1-5 h. After cooling, the suspension was concentrated in vacuo, diluted with ice-cold 
water (5-10 mL), acidified with 2 N HCl and extracted with CH2Cl2 (3 x 25 mL). Removal of the solvent 
afforded compounds 62a-c, which were purified by flash column chromatography using 
cyclohexane/ethyl acetate 2:1 (for 62a) and cyclohexane/ethyl acetate 1:1 (for 62b,c) as eluents.  
5.2.217  N-(4-Iodophenyl)-2-{3-methyl-5-[4-(methylthio)benzyl]-6-oxo-pyridazin-
1(6H)-yl}acetamide (62a) 
N N
O
S
O H
N I
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Yield = 46 %; mp = 68-70 °C (EtOH). 1H NMR (CDCl3) δ 2.30 (s, 3H, 3-CH3), 2.51 (s, 3H, SCH3), 3.89 
(s, 2H, CHCCH2), 4.93 (s, 2H, NCH2CO), 6.80 (s, 1H, Ar), 7.18 (d, 2H, Ar, J = 8.4 Hz), 7.24-7.28 (m, 
4H, Ar), 7.61 (d, 2H, Ar, J = 8.8 Hz), 8.92 (exch br s, 1H, NH).  
5.2.218 N-(4-Iodophenyl)-2-[5-(3,5-dimethoxybenzyl)-3-methyl-6-oxo pyridazin-1(6H)-
yl]- acetamide (62b) 
N N
O
O
O
H
N
O
I
 
Yield = 30 %; mp = 63-65 °C (EtOH). 1H NMR (CDCl3) δ 2.30 (s, 3H, 3-CH3), 3.79 (s, 6H, 2 x OCH3), 
3.87 (s, 2H, CHCCH2), 4.94 (s, 2H, NCH2CO), 6.40 (s, 3H, Ar), 6.82 (s, 1H, Ar), 7.28 (d, 2H, Ar, J = 5.7 
Hz), 7.58 (d, 2H, Ar, J = 8.6 Hz), 9.01 (exch br s, 1H, NH).  
5.2.219 N-(4-Iodophenyl)-2-[5-(3-chlorobenzyl)-3-methyl-6-oxopyridazin-1(6H)-
yl]acetamide (62c) 
N N
O
Cl
H
N
O
I
 
Yield = 25 %; mp = 58-60 °C (EtOH). 1H NMR (CDCl3) δ 2.33 (s, 3H, 3-CH3), 3.90 (s, 2H, CHCCH2), 
4.94 (s, 2H, NCH2CO), 6.86 (s, 1H, Ar), 7.13-7.16 (m, 1H, Ar), 7.20 (d, 2H, Ar, J = 7.0 Hz), 7.28 (d, 3H, 
Ar, J = 4.2 Hz), 7.52 (d, 2H, Ar, J = 8.7 Hz), 9.14 (exch br s, 1H, NH).  
 
5.2.220 6-Methyl-4-(pyridin-3-ylmethyl)pyridazin-3(2H)-one (63) 
HN N
O
N
 
To 6 mL of KOH in absolute EtOH (5%, w/v), 42d (1.78 mmol) and commercially available pyridine-3-
carbaldehyde (1.78 mmol) were added. The mixture was refluxed under stirring for 5 h. After cooling, the 
suspension was concentrated in vacuo, diluted with ice-cold water (10 mL), acidified with 2 N HCl and 
extracted with CH2Cl2 (3 x 25 mL). Removal of the solvent afforded compound 63, which was purified 
by flash column chromatography using NH4OH/EtOH/CH2Cl2/petroleum ether 4:25:150:50 as eluents. 
Yield = 53 %; mp = 181-183 °C (EtOH). 1H NMR (CDCl3) δ 2.28 (s, 3H, 6-CH3), 3.93 (s, 2H, CHCCH2), 
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6.80 (s, 1H, Ar), 7.33 (dd, 1H, Ar, J = 2.7 Hz, J = 5.0 Hz), 7.70 (dd, 1H, Ar, J = 6.1 Hz, J = 1.8 Hz), 8.57 
(s, 2H, Ar), 11.53 (exch br s, 1H, NH).   
 
5.2.221         4-[(6-Methyl-3-oxo-2,3-dihydropyridazin-4-yl)methyl]benzamide (64) 
 
HN N
O
O
NH2
 
To 6 mL of KOH in absolute EtOH (5%, w/v), 42d (1.78 mmol) and commercially available 4-
cyanobenzaldehyde (3.56 mmol) were added. The mixture was refluxed under stirring for 4 h. After 
cooling, the suspension was concentrated in vacuo, diluted with ice-cold water (10 mL) and acidified with 
2 N HCl. After 1 h stirring in ice-bath, the precipitate was filtered off and purified by crystallization in 
ethanol. Yield = 70 %; mp = 164-166 °C (EtOH). IR (cm-1) 3300 (NH), 3200 (NH2), 1649 (CO), 1608 
(CO). 1H NMR (CDCl3) δ 2.18 (s, 3H, 6-CH3), 3.80 (s, 2H, CHCCH2), 7.06 (s, 1H, Ar), 7.33 (d, 2H, Ar, J 
= 8.2 Hz), 7.80 (d, 2H, Ar, J = 8.1 Hz), 12.72 (exch br s, 1H, NH2).   
 
5.2.222       4-[(6-Methyl-3-oxo-2,3-dihydropyridazin-4-yl)methyl]benzonitrile (65) 
HN N
O
CN
 
A suspension of 64 (0.82 mmol) in 5 mL of POCl3 was stirred at 60 °C for 3 h. After cooling, the mixture 
was concentrated in vacuo, diluted with ice-cold water (10 mL) and extracted with CH2Cl2 (3 x 15 mL). 
The organic layer was dried (Na2SO4) and concentrated in vacuo, to afford a yellow solid which was 
purified by flash column chromatography using CH2Cl2/CH3OH 7:3 as eluent. Yield = 60 %; mp = 213-
215 °C (EtOH). IR (cm-1) 2225 (CN), 1649 (CO), 1609 (CO). 1H NMR (CDCl3) δ 2.29 (s, 3H, 6-CH3), 
3.96 (s, 2H, CHCCH2), 6.79 (s, 1H, Ar), 7.41 (d, 2H, Ar, J = 7.0 Hz), 7.65 (d, 2H, Ar, J = 6.9 Hz), 10.61 
(exch br s, 1H, NH).  MS (ESI) calcd. For C25H29N3O4, 435,52. Found: m/z 436.23 [M + H]+. 
 
General Procedure for 66a-c. A mixture of compound 63, 64 or 65 (0.79 mmol), K2CO3 (1.58 
mmol) and N-(4-bromophenyl)-2-chloroacetamide 22 (1.19 mmol) in CH3CN (2 mL), was refluxed under 
stirring for 2-3 h. The mixture was then concentrated in vacuo and diluted with cold water. After 1 h 
stirring in ice-bath, the precipitate was filtered off by suction and purified by flash column 
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chromatography using alternatively CH2Cl2/CH3OH 9.5:05 (for 66a), CH2Cl2/CH3OH 9.9:0.1 (for 66b) or 
CH2Cl2/CH3OH/NH4OH 9.5:0.5:0.05 (for 66c) as eluents.  
5.2.223          4-{2-[(4-Bromophenycarbamoyl)methyl]-6-methyl-3-oxo-2,3-dihydropyridazin-
4-ylmethyl}benzamide (66a) 
N N
O
O
NH2
O H
N Br
 
Yield = 59 %; mp = 168-171 °C (EtOH). IR (cm-1) 3200 (NH2), 1654 (CO), 1609 (CO). 1H NMR 
(CDCl3) δ 2.31 (s, 3H, 6-CH3), 3.99 (s, 2H, CHCCH2), 4.93 (s, 2H, NCH2CO), 6.81 (s, 1H, Ar), 7.34-7.41 
(m, 6H, Ar), 7.80 (d, 2H, Ar, J = 8.1 Hz), 8.89 (exch br s, 1H, NH). 
5.2.224 N-(4-Bromophenyl)-2-[5-(4-cyanobenzyl)-3-methyl-6-oxopyridazin-1(6H)-
yl])acetamide (66b) 
N N
O
CN
O H
N Br
 
Yield = 19 %; mp = 210-211 °C (EtOH). IR (cm-1) 2225 (CN), 1650 (CO), 1598 (CO). 1H NMR (CDCl3) 
δ 2.33 (s, 3H, 3-CH3), 3.99 (s, 2H, CHCCH2), 4.93 (s, 2H, NCH2CO), 6.85 (s, 1H, Ar), 7.39 (q, 6H, Ar, J 
= 8.3 Hz), 7.65 (d, 2H, Ar, J = 8.2 Hz), 8.77 (exch br s, 1H, NH).   
5.2.225 N-(4-Bromophenyl)-2-[3-methyl-6-oxo-5-(pyridin-3-ylmethyl)-pyridazin-
1(6H)-yl]acetamide (66c) 
N N
O
N
O H
N Br
 
Yield = 61 %; mp = 216-218 °C (EtOH). 1H NMR (CDCl3) δ 2.30 (s, 3H, 3-CH3), 3.92 (s, 2H, CHCCH2), 
4.93 (s, 2H, NCH2CO), 6.86 (s, 1H, Ar), 7.27-7.33 (m, 5H, Ar), 7.61 (d, 1H, Ar, J = 7.8 Hz), 8.54 (d, 2H, 
Ar, J = 6.2 Hz), 9.29 (exch br s, 1H, NH).   
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5.2.226 Ethyl-2-[5-(4-carbamoylbenzyl)-3-methyl-6-oxopyridazin-1(6H)-yl]acetate (67) 
N N
O
O
NH2
O
O
 
A mixture of compound 64 (1.56 mmol), K2CO3 (3.12 mmol) and ethyl bromoacetate (2.34 mmol) in 
CH3CN (6 mL), was refluxed under stirring for 2 h. The mixture was then concentrated in vacuo and 
diluted with cold water. After 1h stirring in ice-bath, the yellow precipitate was filtered off by suction and 
purified by recrystallization in ethanol. Yield = 78 %; mp = 174-76 °C (EtOH). 1H NMR (CDCl3) δ 1.31 
(t, 3H, CH2CH3), 2.25 (s, 3H, 3-CH3), 3.96 (s, 2H, CHCCH2), 4.26 (q, 2H, CH2CH3, J = 7.2 Hz), 4.86 (s, 
2H, NCH2CO), 6.70 (s, 1H, Ar), 7.34 (d, 2H, Ar, J = 7.7 Hz), 7.80 (d, 2H, Ar, J = 7.7 Hz).   
 
5.2.227      4-{[2-(Carboxymethyl)-6-methyl-3-oxo-2,3-dihydropyridazin-4-yl]methyl} benzoic 
acid (68) 
N N
O
O
OH
O
OH
 
A suspension of the intermediate 67 (1.22 mmol) in 6 N NaOH (5 mL) was stirred at 60 °C for 2 h. The 
mixture was diluted with ice-cold water (3 mL), acidified with 6 N HCl and the final product 68 was then 
filtered off by suction and recrystallized from ethanol. Yield = 76 %; mp = 225-27 °C (EtOH). 1H NMR 
(CDCl3) δ 2.22 (s, 3H, 6-CH3), 3.87 (s, 2H, CHCCH2), 4.69 (s, 2H, NCH2CO), 7.15 (s, 1H, Ar), 7.39 (d, 
2H, Ar, J = 8.0 Hz), 7.88 (d, 2H, Ar, J = 8.0 Hz), 13.01 (exch br s, 1H, OH).   
 
5.2.228 N-(4-Bromophenyl)-4-{2-[(4-bromophenylcarbamoyl)methyl]-6-methyl-3-oxo-
2,3-dihydropyridazin-4-ylmethyl}benzamide (69) 
N N
O
O
H
N
O H
N Br
Br
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To a cooled (-5 °C) and stirred solution of compound 68 (0.93 mmol) in anhydrous tetrahydrofuran (7 
mL), Et3N (3.26 mmol) was added. After 30 min, the mixture was allowed to warm up to 0 °C and ethyl 
chloroformate (1.02 mmol) was added. After 1 h, 4-bromo aniline (1.86 mmol) was added. The reaction 
was carried out at room temperature for 12 h. The mixture was then concentrated in vacuo, diluted with 
cold water (15 mL) and extracted with CH2Cl2 (3 x 15 mL). After removal of the solvent, the residue was 
purified by column chromatography using CH2Cl2/CH3OH/NH4OH 9.5:0.5:0.05 as eluent. The analytical 
sample of compound 69 was obtained from a further purification through a silica gel preparative TLC 
(eluent: CH2Cl2/CH3OH/NH4OH 9.5:0.5:0.05). Yield = 10 %; mp = 226-228 °C (EtOH). 1H NMR 
(CDCl3) δ 2.31 (s, 3H, 6-CH3), 4.00 (s, 2H, CHCCH2), 4.93 (s, 2H, NCH2CO), 6.83 (s, 1H, Ar), 7.40 (t, 
6H, Ar, J = 8.4 Hz), 7.51 (d, 2H, Ar, J = 8.7 Hz), 7.57 (d, 2H, Ar, J = 8.9 Hz), 7.84 (d, 2H, Ar, J = 7.7 
Hz), 8.67 (exch br s, 1H, NH).  MS (ESI) calcd. For C27H22Br2N4O3, 610.30. Found: m/z 609 [M - H]-, 
611.2 [M + H]+. 
 
5.2.229 4-(3-Methoxybenzoyl)-6-methylpyridazin-3(2H)-one (70) 
HN N
O
O
O
 
To a stirred and heated (60 °C) suspension of compound 43 (2.39 mmol) in 15 mL of 50 % (v/v) acetic 
acid, Ce(NH4)2(NO3)6 (7.17 mmol) was slowly added over 0.5 h and the reaction is carried out at 60 °C 
for additional 1 h. The mixture was then diluted with ice-cold water (10 mL) and extracted with CH2Cl2 
(15 mL). After washing with H2O (3 x 10 mL), the organic layer was evaporated under vacuo and the 
residue was purified by CombyFlash® (eluent: cyclohexane/ethyl acetate, gradient 1:1 to 1:3). Yield = 17 
%; oil. 1H NMR (CDCl3) δ 2.25 (s, 3H, 6-CH3), 3.92 (s, 3H, OCH3), 6.74-6.95 (m, 4H, Ar), 7.31 (t, 1H, 
Ar, J = 7.8 Hz), 11.32 (exch br s, 1H, NH).  
 
5.2.230 N-(4-Bromophenyl)-2-[5-(3-methoxybenzoyl)-3-methyl-6-oxopyridazin-1(6H)-
yl]acetamide (71) 
N N
O
O H
N Br
O
O
 
A mixture of intermediate 70 (0.41 mmol), K2CO3 (0.82 mmol) and N-(4-bromophenyl)-2-
chloroacetamide 22 (0.61 mmol) in CH3CN (5 mL), was refluxed under stirring for 6 h. The mixture was 
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then concentrated in vacuo and extracted with CH2Cl2 (3 x 15 mL). After removal of the solvent under 
vacuo the residue was purified by flash column chromatography  using NH4OH/EtOH/CH2Cl2/petroleum 
ether 4:25:150:269 as eluent. Yield = 10 %; mp = 176-177 °C (EtOH). 1H NMR (CDCl3) δ 2.32 (s, 3H, 3-
CH3), 3.82 (s, 3H, OCH3), 4.92 (s, 2H, NCH2CO), 6.62 (s, 1H, Ar), 6.69 (t, 1H, Ar, J = 2.1 Hz), 6.74 (d, 
1H, Ar, J = 7.5 Hz), 6.85 (dd, 1H, Ar, J = 6.3 Hz, J = 2.0 Hz), 7.29 (t, 1H, Ar, J = 8.2 Hz), 7.38-7.46 (m, 
4H, Ar), 9.10 (exch br s, 1H, NH).  MS (ESI) calcd. For C21H18BrN3O4, 456,29. Found: m/z 457.20 [M + 
H]+. 
 
5.2.231 4-(4-Methoxyphenyl)-6-methylpyridazin-3(2H)-one (74) 
HN N
O
O
 
To an ice-cold solution of (E)-methyl 2-(4-methoxyphenyl)-4-oxopent-2-enoate 73 (0.34 mmol) in dry 
toluene (3 mL), hydrazine hydrate (0.68 mmol) was added drop-wise. The solution was stirred at reflux 
temperature for 2 h. The solvent was evaporated and ice-cold water (5 mL) was added to the residue. The 
aqueous layer was extracted with CH2Cl2 (3 x 15 mL) and the combined organic layers were dried over 
Na2SO4 and evaporated in vacuo. The crude product was purified by flash column chromatography 
(eluent: cyclohexane/ethyl acetate 1:3) to yield 74 as an amorphous white solid. Yield = 55 %; mp = 155-
158 °C (EtOH). 1H NMR (CDCl3) δ 2.39 (s, 3H, 6-CH3), 3.88 (s, 3H, OCH3), 6.99 (d, 2H, Ar, J = 8.9 
Hz), 7.24 (s, 1H, Ar), 7.86 (d, 2H, Ar, J = 8.9 Hz), 10.51 (exch br s, 1H, NH).   
 
5.2.233 Ethyl-2-[5-(4-methoxyphenyl)-3-methyl-6-oxopyridazin-1(6H)-yl]acetate (75) 
N N
O
O
O
O
 
A mixture of the intermediate 74 (0.18 mmol), K2CO3 (0.36 mmol) and ethyl bromoacetate (0.28 mmol) 
in CH3CN (2 mL), was refluxed under stirring for 1.5 h. The mixture was then concentrated in vacuo and 
extracted with CH2Cl2 (3 x 10 mL). After removal of the solvent under vacuo the residue was purified by 
flash column chromatography  using cyclohexane/ethyl acetate 1:1 as eluent. Yield ~ 100 %; colorless oil. 
1H NMR (CDCl3) δ 1.30 (t, 3H, CH2CH3, J = 7.0 Hz), 2.37 (s, 3H, 3-CH3), 3.92 (s, 3H, OCH3), 4.23 (q, 
2H, CH2CH3, J = 7.0 Hz), 4.89 (s, 2H, NCH2CO), 6.94 (d, 2H, Ar, J = 8.8 Hz), 7.21 (s, 1H, Ar), 7.81 (d, 
2H, Ar, J = 8.8 Hz). 
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5.2.234 2-[5-(4-Methoxyphenyl)-3-methyl-6-oxopyridazin-1(6H)-yl]acetic acid (76) 
N N
O
O
O
OH
 
A suspension of the intermediate 75 (0.20 mmol) in 6 N NaOH (1.5 mL) was stirred at 60 °C for 0.5 h. 
The mixture was diluted with ice-cold water (1 mL), acidified with 6 N HCl and the final product 68 was 
then filtered off by suction and recrystallized from ethanol. Yield ~ 100 %; mp = 202-203 °C (EtOH). 1H 
NMR (CDCl3) δ 2.41 (s, 3H, 3-CH3), 3.87 (s, 3H, OCH3), 4.99 (s, 2H, NCH2CO), 6.98 (d, 2H, Ar, J = 8.8 
Hz), 7.26 (s, 1H, Ar), 7.82 (d, 2H, Ar, J = 8.8 Hz).   
 
5.2.235 N-(4-Bromophenyl)-2-[5-(4-methoxyphenyl)-3-methyl-6-oxo-pyridazin-1(6H)-
yl]acetamide (77) 
N N
O
O
O H
N Br
 
To a cooled (-5 °C) and stirred solutions of compound 76 (0.20 mmol) in anhydrous tetrahydrofuran (2 
mL), Et3N (0.70 mmol) was added. After 30 min, the mixture was allowed to warm up to 0 °C and ethyl 
chloroformate (0.22 mmol) was added. After 1 h, 4-bromoaniline (0.40 mmol) was added and the reaction 
was carried out at room temperature for 12 h. The mixture was then concentrated in vacuo, diluted with 
cold water (5 mL) and extracted with CH2Cl2 (3 x 10 mL). After removal of the solvent, the residue was 
purified by column chromatography using cyclohexane/ethyl acetate 2:1 as eluent. Yield = 35 %; mp = 
251-253 °C (EtOH). 1H NMR (CDCl3) δ 2.43 (s, 3H, 6-CH3), 3.88 (s, 3H, OCH3), 5.00 (s, 2H, NCH2CO), 
7.00 (d, 2H, Ar, J = 8.7 Hz), 7.27 (s, 1H, Ar), 7.40 (q, 4H, Ar, J = 9.2 Hz), 7.80 (d, 2H, Ar, J = 8.7 Hz), 
9.07 (exch br s, 1H, NH). 
 
5.2.236 Ethyl-2-[4-acetyl-5-amino-3-methyl-6-oxopyridazin-1(6H)-yl]acetate (80) 
N N
O
O
H2N
O
O
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A mixture of the intermediate 79 (0.99 mmol), K2CO3 (1.98 mmol), and ethyl bromoacetate (1.34 mmol) 
in CH3CN (3 mL) was refluxed under stirring for 3 h. The mixture was then concentrated in vacuo, 
diluted with cold water, and extracted with CH2Cl2 (3 x 15 mL). The solvent was evaporated in vacuo, 
and compound 80 was purified by recrystallization from ethanol. Yield = 44 %; mp = 145-46 °C (EtOH). 
1H NMR (CDCl3) δ 1.32 (t, 3H, CH2CH3, J = 7.2 Hz), 2.53 (s, 3H, 3-CH3), 2.60 (s, 3H, COCH3), 4.27 (q, 
2H, OCH2CH3, J = 7.1 Hz), 4.83 (s, 2H, NCH2CO), 7.75 (exch br s, 1H, NH).  
 
5.2.237 Ethyl-2-[4-acetyl-5-(4-methoxyphenylamino)-3-methyl-6-oxopyridazin-1(6H)-
yl]acetate (81) 
N N
O
O
NH
O
O
O
 
To the suspension of 80 (0.91 mmol), copper acetate (1.36 mmol) and 4-methoxyphenylboronic acid 
(1.82 mmol) in CH2Cl2 (4 mL), Et3N (1.82 mmol) was added and the mixture was stirred at room 
temperature for 12 h. The suspension was extracted with 15% aqueous ammonia (3 x 10 mL), then the 
organic layer was washed with water (10 mL) and dried over Na2SO4. After removal of the solvent in 
vacuo, the residue was purified by flash column chromatography using cyclohexane/ethyl acetate 1:3 as 
eluent. Yield = 61 %; mp = 115-17 °C (EtOH). 1H NMR (CDCl3) δ 1.34 (t, 3H, CH2CH3, J = 7.2 Hz), 
1.88 (s, 3H, COCH3), 2.14 (s, 3H, 3-CH3), 3.81 (s, 3H, OCH3), 4.29 (q, 2H, OCH2CH3, J = 7.2 Hz), 4.88 
(s, 2H, COCH2N), 6.85 (d, 2H, Ar, J = 6.7 Hz), 7.04 (d, 2H, Ar, J = 8.9 Hz), 7.62 (exch br s, 1H, NH).  
 
5.2.238 2-[4-Acetyl-5-(4-methoxyphenylamino)-3-methyl-6-oxopyridazin-1(6H)-
yl]acetic acid (82) 
N N
O
O
NH
O
OH
O
 
A suspension of the intermediate 81 (0.39 mmol) in 6 N NaOH (10 mL) was stirred at rt to 80 °C for 1.5 
h. The mixture was diluted with cold water and acidified with 6 N HCl. After 1 h stirring in ice-bath, the 
product 82 was filtered off by suction and recrystallized from ethanol. Yield = 76 %; mp = 104-06 °C 
(EtOH). 1H NMR (CDCl3) δ 1.88 (s, 3H, COCH3), 2.10 (exch br s, 1H, OH), 2.16 (s, 3H, 3-CH3), 3.82 (s, 
3H, OCH3), 4.95 (s, 2H, COCH2N), 6.86 (d, 2H, Ar, J = 8.6 Hz), 7.05 (d, 2H, Ar, J = 8.6 Hz), 7.62 (exch 
br s, 1H, NH).  
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5.2.239 N-(4-Bromophenyl)-2-[4-acetyl-5-(4-methoxyphenylamino)-3-methyl-6-
oxopyridazin-1(6H)-yl]acetamide (83) 
N N
O
O
NH
O H
N
O
Br
 
To a cooled (-5 °C) and stirred solution of 82 (0.30 mmol) in anhydrous tetrahydrofuran (3 mL), Et3N 
(1.06 mmol) was added. After 30 min, the mixture was allowed to warm up to 0 °C and ethyl 
chloroformate (0.33 mmol) was added. After 1 h, 4-bromo aniline (0.60 mmol) was added and the 
reaction was carried out at room temperature for 12 h. The mixture was then concentrated in vacuo, 
diluted with cold water (10 mL), and extracted with CH2Cl2 (3 x 15 mL). The organic layer was dried 
over Na2SO4 and the solvent was evaporated to afford final compound 83, which was purified by flash 
column chromatography using cyclohexane/ethyl acetate 1:1 as eluent. Yield = 62 %; mp = 210-11 °C 
(EtOH). 1H NMR (CDCl3) δ 1.88 (s, 3H, COCH3), 2.19 (s, 3H, 3-CH3), 3.83 (s, 3H, OCH3), 4.97 (s, 2H, 
COCH2N), 6.87 (d, 2H, Ar, J = 8.9 Hz), 7.05 (d, 2H, Ar, J = 8.9 Hz), 7.44 (td, 4H, Ar, J = 2.8 Hz, J = 6.5 
Hz), 7.65 (exch br s, 1H, NH), 8.64 (exch br s, 1H, NH). 
 
5.2.240 Ethyl-2-[5-amino-3-methyl-6-oxopyridazin-1(6H)-yl]acetate (85)  
N N
O
H2N
O
O
 
A mixture of 84 (0.80 mmol), K2CO3 (1.60 mmol) and ethyl bromoacetate (1.20 mmol) in CH3CN (5 mL) 
was refluxed under stirring for 3 h. The solvent was removed under reduced pressure, then the crude 
mixture was diluted with cold water (10 mL) and extracted with CH2Cl2 (3 x 15 mL). The organic layer 
was dried over Na2SO4 and evaporated in vacuo; finally compound 85 was purified by column 
chromatography using CH2Cl2/CH3OH 95:5 as eluent. Yield = 71 %; oil. 1H NMR (CDCl3) δ 1.30 (t, 3H, 
CH2CH3, J = 7.1 Hz), 2.22 (s, 3H, 3-CH3), 4.25 (qd, 2H, OCH2CH3, J = 4.1 Hz, J = 3.0 Hz), 4.84 (s, 2H, 
NCH2CO), 6.17 (s, 1H, Ar).  
 
5.2.241 2-[5-Amino-3-methyl-6-oxopyridazin-1(6H)-yl]acetic acid (86)  
N N
O
H2N
O
OH
 
5. Experimental Chemistry 
 
 164
A suspension of compound 85 (0.28 mmol) in 6 NaOH (2 mL) was stirred at rt to 80 °C for 2 h. The 
mixture was diluted with ice-cold water (1 mL), acidified with 6 N HCl and the aqueous phase was 
evaporated in vacuo. The crude residue was dissolved in ethanol and the precipitate was filered off. 
Finally, evaporation of the solvent afforded compound 86, which was purified by crystallization from 
cyclohexane. Yield ~ 100 %; mp = 234-36 °C (cyclohexane). 1H NMR (CDCl3) δ 2.09 (s, 3H, 3-CH3), 
4.62 (s, 2H, NCH2CO), 6.13 (s, 1H, Ar), 6.37 (exch br s, 2H, NH2), 6.55 (exch br s, 1H, OH).  
 
5.2.242       N-(4-Bromophenyl)-2-[5-amino-3-methyl-6-oxopyridazin-1(6H)-yl]acetamide (87)  
N N
O
H2N
O H
N Br
 
To a cooled (-5 °C) and stirred solution of compound 86 (0.33 mmol), in anhydrous tetrahydrofuran (3 
mL), Et3N (1.15 mmol) was added. After 30 min, the mixture was allowed to warm up to 0 °C and ethyl 
chloroformate (0.36 mmol) was added. After 1 h 4-bromo aniline (0.66 mmol) was added and the reaction 
was carried out at room temperature for 12 h. The mixture was then concentrated in vacuo, diluted with 
ice-cold water (10 mL) and extracted with CH2Cl2 (3 x 15 mL). The solvent was evaporated to afford 
final compound 87, which was purified by flash column chromatography using cyclohexane/ethyl acetate 
1:1 as eluent. Yield = 50 %; mp = 244-45 °C (EtOH). 1H NMR (CDCl3) δ 2.27 (s, 3H, 3-CH3), 4.93 (s, 
2H, COCH2N), 6.24 (s, 1H, Ar), 7.42 (s, 4H, Ar), 8.83 (exch br s, 1H, NH), 8.64 (exch br s, 1H, NH). 
 
5.2.243 N-(4-Bromophenyl)-2-[5-(4-methoxyphenylamino)-3-methyl-6-oxopyridazin-
1(6H)-yl]acetamide (88)  
N N
O
HN
O H
N
O
Br
 
To a suspension of 87 (0.36 mmol), copper acetate (0.53 mmol) and 4-methoxyphenylboronic acid (0.36 
mmol) in CH2Cl2 (3 mL), Et3N (0.72 mmol) was added and the mixture was stirred at room temperature 
for 12 h. The suspension was extracted with 15% aqueous ammonia (3 x 10 mL), and the organic layer 
was washed with 10 mL of water and dried over Na2SO4. After removal of the solvent under reduced 
pressure, the residue was purified by flash column chromatography using CH2Cl2/CH3OH 9.5:0.5 as 
eluent. The analytical sample of compound 88 was obtained from a further purification through a silica 
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gel preparative TLC (eluent: CH2Cl2/CH3OH 9.5:0.5). Yield = 10 %; mp = 249-51 °C (EtOH). 1H NMR 
(CDCl3) δ 2.26 (s, 3H, 3-CH3), 3.86 (s, 3H, OCH3), 4.97 (s, 2H, COCH2N), 6.38 (s, 1H, Ar), 6.97 (d, 2H, 
Ar, J = 8.9 Hz), 7.18 (d, 2H, Ar, J = 8.9 Hz), 7.35 (exch br s, 1H, NH), 7.44 (dd, 4H, Ar, J = 5.5 Hz, J = 
9.1 Hz), 8.77 (exch br s, 1H, NH). 
 
General Procedure for 89a,b. A solution of compound 87 (0.21 mmol), Et3N (5 drops) and the 
appropriate substituted benzoyl chloride (0.25 mmol), in dry CH2Cl2 (5 mL), was stirred at 0 °C for 1 h. 
Extra benzoyl chloride (0.25 mmol) was added. The reaction was carried out always at 0 °C for additional 
3 h and then, 12 h at room temperature. The mixture was extracted with 6 N NaOH (3 x 10 mL), then the 
organic layer was washed with water (10 mL) and dried over Na2SO4. After removal of the solvent in 
vacuo, compound 89a was purified by two consecutive silica gel preparative TLC using in both cases 
cyclohexane/ethyl acetate 1:2 as eluent. Differently, in the case of compound 89b the residue was purified 
by flash column chromatography using cyclohexane/ethyl acetate 1:3 as eluent. 
5.2.244 4-Bromo-N-{2-[2-(4-bromophenylcarbamoyl)methyl]-6-methyl-3-oxo-2,3-
dihydropyridazin-4-yl}benzamide (89a)  
N N
O
HN
O H
N
O
Br
Br
 
Yield = 10 %; colorless oil. 1H NMR (CDCl3) δ 2.43 (s, 3H, 6-CH3), 4.98 (s, 2H, COCH2N), 7.44 (s, 4H, 
Ar), 7.69 (d, 2H, Ar, J = 8.6 Hz), 7.82 (d, 2H, Ar, J = 8.6 Hz), 8.24 (s, 1H, Ar). 
5.2.245 3-Metoxy-N-{2-[(4-bromophenylcarbamoyl)methyl]-6-methyl-3-oxo-2,3-
dihydropyridazin-4-yl}benzamide (89b)  
N N
O
HN
O H
N
O
Br
O
 
Yield = 13 %; mp = 226-28 °C (EtOH). 1H NMR (CDCl3) δ 2.27 (s, 3H, 6-CH3), 3.89 (s, 3H, OCH3), 
4.93 (s, 2H, COCH2N), 4.98 (exch br s, 1H, NH), 6.24 (s, 1H, Ar), 7.16-7.19 (m, 1H, Ar), 7.39-7.45 (m, 
5H, Ar), 7.63 (t, 1H, Ar, J = 2.5 Hz), 7.73 (dd, 1H, Ar, J = 5.3 Hz, J = 1.0 Hz), 8.83 (exch br s, 1H, Ar). 
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5.2.246 Ethyl-2-{5-[bis(4-methoxyphenyl)amino]-3-methyl-6-oxopyridazin-1(6H)-
yl}acetate (90)  
N N
O
N
O
O
O
O
 
To a suspension of compound 85 (0.57 mmol), copper acetate (0.85 mmol) and 4-methoxyphenylboronic 
acid (1.14 mmol) in CH2Cl2 (3 mL), Et3N (0.64 mmol) was added and the mixture was stirred at room 
temperature for 14 h. The mixture was extracted with 15% aqueous ammonia (3 x 10 mL) and the organic 
layer was washed with 10 mL of water and dried over Na2SO4. After removal of the solvent in vacuo, the 
residue was purified by flash column chromatography using cyclohexane/ethyl acetate 1:3 as eluent. 
Yield = 21 %; colorless oil. 1H NMR (CDCl3) δ 1.28 (t, 3H, CH2CH3, J = 7.2 Hz), 2.18 (s, 3H, 3-CH3), 
3.81 (s, 6H, 2 x OCH3), 4.21 (q, 2H, CH2CH3, J = 7.2 Hz), 4.83 (s, 2H, NCH2CO), 6.32 (s, 1H, Ar), 6.86 
(dd, 4H, Ar, J = 3.4 Hz, J = 2.3 Hz), 6.99 (dd, 4H, Ar, J = 4.5 Hz, J = 2.3 Hz). 
 
5.2.247 2-{5-[Bis-(4-methoxyphenyl)amino]-3-methyl-6-oxopyridazin-1(6H)-yl}acetic 
acid (91)  
N N
O
N
O
OH
O
O
 
A suspension of the intermediate 90 (0.12 mmol), 6 NaOH (10 mL) and EtOH (3 mL) was stirred at rt 12 
h. After removal of the solvent under vacuo, the mixture was diluted with ice-cold water and acidified 
with 6 N HCl. After 1 h stirring in ice-bath, the product 91 was filtered off by suction and recrystallized 
from ethanol. Yield = 84 %; mp = 192-93 °C (EtOH). 1H NMR (CDCl3) δ 2.20 (s, 3H, 3-CH3), 3.82 (s, 
6H, 2 x OCH3), 4.88 (s, 2H, NCH2CO), 6.34 (s, 1H, Ar), 6.86 (d, 4H, Ar, J = 8.8 Hz), 6.99 (d, 4H, Ar, J = 
8.8 Hz). 
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5.2.248  N-(4-Bromophenyl)-2-{5-[bis(4-methoxyphenyl)amino]-3-methyl-6-oxopyridazin-
1(6H)-yl}acetamide (92) 
N N
O
N
O H
N
O
O
Br
 
To a cooled (-5 °C) and stirred solution of compound 91 (0.10 mmol) in anhydrous tetrahydrofuran (4 
mL), Et3N (0.35 mmol) was added. After 30 min, the mixture was allowed to warm up to 0 °C and ethyl 
chloroformate (0.11 mmol) was added. After 1 h 4-bromo aniline (0.20 mmol) was added and the reaction 
was carried out at room temperature for 12 h. The mixture was then concentrated in vacuo, diluted with 
cold water (10 mL) and extracted with CH2Cl2 (3 x 15 mL). The solvent was evaporated to afford final 
compound 92, which was purified by flash column chromatography using cyclohexane/ethyl acetate 1:1 
as eluent. Yield = 55 %; mp = 244-245 °C (EtOH). 1H NMR (CDCl3) δ 2.23 (s, 3H, 3-CH3), 3.79 (s, 6H, 
2 x OCH3), 4.81 (s, 2H, NCH2CO), 6.39 (s, 1H, Ar), 6.84 (dd, 4H, Ar, J = 4.6 Hz, J = 2.2 Hz), 6.99 (dd, 
4H, Ar, J = 2.2 Hz, J = 3.4 Hz), 7.25-7.38 (m, 4H, Ar), 9.00 (exch br s, 1H, NH). 
 
General Procedure for 93a,b. A mixture of 43 (1.13 mmol), K2CO3 (2.26 mmol), and the 
appropriate alkyl halide (1.70 mmol) in CH3CN (3 mL) was refluxed under stirring for 6 h. The mixture 
was then concentrated in vacuo, diluted with cold water and extracted with CH2Cl2 (3 x 15 mL). The 
solvent was evaporated in vacuo and compounds 93a,b were purified by column chromatography using 
cyclohexane/ethyl acetate 1:1 as eluent.  
5.2.249 Ethyl-3-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-1(6H)-yl]propanoate 
(93a)  
N N
O
O
O
O
 
Yield = 86 %; oil. 1H NMR (CDCl3) δ 1.26 (t, 3H, OCH2CH3, J = 7.1 Hz), 2.22 (s, 3H, 3-CH3), 2.84 (t, 
2H, NCH2CH2CO, J = 7.2 Hz), 3.83 (s, 3H, OCH3), 3.87 (s, 2H, CH2-Ar), 4.17 (q, 2H, OCH2CH3, J = 7.1 
Hz), 4.45 (t, 2H, NCH2CH2COO, J = 7.3 Hz), 6.64 (s, 1H, Ar), 6.80 (s, 1H, Ar), 6.83 (d, 2H, Ar, J = 7.9 
Hz), 7.26-7.30 (m, 1H, Ar). 
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5.2.250     Ethyl-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-1(6H)-yl]propanoate (93b) 
N N
O
O
O
O
 
Yield = 85 %; oil. 1H NMR (CDCl3) δ 1.22 (t, 3H, OCH2CH3, J = 7.1 Hz), 1.65 (d, 3H,CH3CHN, J = 7.2 
Hz), 2.21 (s, 3H, 3-CH3), 3.78 (s, 3H, OCH3), 3.84 (s, 2H, CH2-Ar), 4.19 (q, 2H, OCH2CH3, J = 6.7 Hz), 
5.51 (q, 1H, CH3CHN, J = 7.2 Hz), 6.64 (s, 1H, Ar), 6.77-6.81 (m, 3H, Ar), 7.22-7.26 (m, 1H, Ar). 
 
General Procedure for 94a,b. A suspension of the appropriate intermediate type 93 (93a,b) (0.5 
mmol), and 6 N NaOH (6 mL) in ethanol (2 mL) was stirred at rt to 80 °C for 1 h. The mixture was then 
concentrated in vacuo, diluted with cold water and acidified with 6 N HCl.  Compound 94a was filtered 
off by suction and recrystallized from ethanol. For compound 94b differently, after acidification with 6 N 
HCl, the mixture was extracted with CH2Cl2 (3 x 15 mL) and the solvent was evaporated in vacuo to give 
the pure compound as an oil. 
5.2.251          3-[5-(3-Methoxybenzyl)-3-methyl-6-oxopyridazin-1(6H)-yl]propanoic acid (94a) 
N N
O
O
O
OH
 
Yield = 96 %; mp = 86-88 °C (EtOH). 1H NMR (CDCl3) δ 2.22 (s, 3H, 3-CH3), 2.89 (t, 2H, 
NCH2CH2CO, J = 7.2 Hz), 3.81 (s, 3H, OCH3), 3.87 (s, 2H, CH2-Ar), 4.46 (t, 2H, NCH2CH2CO, J = 7.2 
Hz), 6.66 (s, 1H, Ar), 6.78 (s, 1H, Ar), 6.81-6.85 (m, 2H, Ar), 7.25-7.29 (m, 1H, Ar), 9.99 (exch br s, 1H, 
OH). 
5.2.252          2-[5-(3-Methoxybenzyl)-3-methyl-6-oxopyridazin-1(6H)-yl]propanoic acid (94b) 
N N
O
O
O
OH
 
Yield = 85 %; oil. 1H NMR (CDCl3) δ 1.71 (d, 3H, CH3CHN, J = 7.2 Hz), 2.25 (s, 3H, 3-CH3), 3.81 (s, 
3H, OCH3), 3.88 (s, 2H, CH2-Ar), 5.54 (q, 1H, CH3CHN, J = 7.2 Hz), 6.67 (s, 1H, Ar), 6.79-6.85 (m, 3H, 
Ar), 7.26-7.29 (m, 1H, Ar). 
  
5. Experimental Chemistry 
 169 
General Procedure for 95a,b. To a cooled (-5 °C) and stirred solution of compound 94a or 94b 
(0.35 mmol), in anhydrous tetrahydrofuran (3-5 mL), Et3N (1.22 mmol) was added. After 30 min, the 
mixture was allowed to warm up to 0 °C and ethyl chloroformate (0.38 mmol) was added. After 1 h, 4-
bromoaniline (0.7 mmol) was added and the reaction was carried out at room temperature for 12 h. The 
mixture was then concentrated in vacuo, diluted with cold water (20-30 mL) and extracted with CH2Cl2 (3 
x 15 mL). The solvent was evaporated to afford the final compounds 95a,b, which were purified by 
column chromatography using cyclohexane/ethyl acetate 1:2 as eluent for compound 95a, 
cyclohexane/ethyl acetate 2:1 for compound 95b. 
5.2.253 N-(4-Bromophenyl)-3-[5-(3-methoxybenzyl)-3-methyl-6-oxo-pyridazin-1(6H)-
yl]propanamide (95a) 
N N
O
O
O
HN Br
 
Yield = 82 %; mp = 123-125 °C (EtOH). IR (cm-1) 3297 (NH), 1710 (CO), 1644 (CO). 1H NMR (CDCl3) 
δ 2.27 (s, 3H, 3-CH3), 3.00 (t, 2H, NCH2CH2CO, J = 6.3 Hz), 3.80 (s, 3H, OCH3), 3.88 (s, 2H, CH2-Ar), 
4.54 (t, 2H, NCH2CH2COO, J = 6.3 Hz), 6.76-6.84 (m, 4H, Ar), 7.25 (t, 1H, Ar, J = 7.9 Hz), 7.40 (d, 2H, 
Ar, J = 8.8 Hz), 7.50 (d, 2H, Ar, J = 8.8 Hz), 9.29 (exch br s, 1H, NH). MS (ESI) calcd. For 
C22H22BrN3O3, 456.33. Found: m/z 456.09 [M]+. 
5.2.254 (±)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-pyridazin-
1(6H)-yl]propanamide (95b) 
N N
O
O
O H
N Br
 
Yield = 53 %; oil; IR (cm-1) 3300 (NH), 1709 (CO), 1643 (CO). 1H NMR (CDCl3) δ 1.71 (d, 3H, 
CH3CHN, J = 7.1 Hz), 2.31 (s, 3H, 3-CH3), 3.80 (s, 3H, OCH3), 3.90 (s, 2H, CH2-Ar), 5.71 (q, 1H, 
CH3CHN, J = 7.0 Hz), 6.79-6.85 (m, 4H, Ar), 7.25-7.29 (m, 1H, Ar), 7.35-7.36 (m, 4H, Ar), 9.18 (exch 
br s, 1H, NH). MS (ESI) calcd. For C22H22BrN3O3, 456.33. Found: m/z 456.09 [M]+. 
 
General Procedure for 96a,b. A mixture of 43 (1.13 mmol), K2CO3 (2.26 mmol), and 
appropriate alkyl halide (1.70 mmol) in CH3CN (3 mL) was refluxed under stirring for 6 h. The mixture 
was then concentrated in vacuo, diluted with cold water and extracted with CH2Cl2 (3 x 15 mL). The 
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solvent was evaporated in vacuo and compounds 96a,b were purified by column chromatography using 
cyclohexane/ethyl acetate 2:1 for 96a and cyclohexane/ethyl acetate 1:1 for 96b as eluents.  
5.2.255 2-(4-Bromobenzyl)-4-(3-methoxybenzyl)-6-methyl-pyridazin-3(2H)-one (96a) 
N N
O
O
Br
 
Yield = 68 %; mp = 112-114 °C (EtOH). IR (cm-1) 1638 (CO). 1H NMR (CDCl3) δ 2.23 (s, 3H, 6-CH3), 
3.81 (s, 3H, OCH3), 3.86 (s, 2H, CH2-Ar), 5.25 (s, 2H, NCH2Ar), 6.64 (s, 1H, Ar), 6.78-6.85 (m, 3H, Ar), 
7.26-7.30 (m, 1H, Ar), 7.35 (d, 2H, Ar, J = 8.4 Hz), 7.45-7.47 (m, 2H, Ar). MS (ESI) calcd. For 
C20H19BrN2O2, 399.28. Found: m/z 399.07 [M]+. 
5.2.256  2-[2-(4-Bromophenyl)-2-oxo-ethyl]-4-(3-methoxybenzyl)-6-methyl-pyridazin-
3(2H)-one (96b) 
N N
O
O
O
Br
 
 Yield = 95 %; oil. IR (cm-1) 1715 (CO), 1644 (CO). 1H NMR (CDCl3) δ 2.25 (s, 3H, 6-CH3), 3.83 (s, 3H, 
OCH3), 3.89 (s, 2H, CH2-Ar), 5.52 (s, 2H, NCH2CO), 6.72 (s, 1H, Ar), 6.80 (s, 1H, Ar), 6.84 (d, 2H, Ar, J 
= 7.9 Hz), 7.27-7.31 (m, 1H, Ar), 7.66 (d, 2H, Ar, J = 8.6 Hz), 7.88 (d, 2H, Ar, J = 8.5 Hz). MS (ESI) 
calcd. For C21H19BrN2O3, 427.29. Found: m/z 427.07 [M]+. 
 
General Procedure for 97a,b. A mixture of 43a (0.32 mmol), 40% formaldehyde (3 mL) and 
33% NH3 (1.5 mL) in dioxane (1.5-2 mL) was heated at 50 °C for 1 h. The solvent was then evaporated in 
vacuo, and the residue was extracted with CH2Cl2 (3 x 15 mL). The organic layer was dried with Na2SO4 
and evaporated to afford an oil. For compound 97a, the residual oil was dissolved in 2 mL of anhydrous 
CH2Cl2 and 4-bromophenyl isocyanate (0.35 mmol) was added. The mixture was stirred at room 
temperature for 12 h, then the solid residue was filtered off and the solution was evaporated in vacuo to 
afford compound 97a, which was purified by flash chromatography using cyclohexane/ethyl acetate 3:1 
as eluent. For compound 97b, the residual oil was dissolved in 3 mL of anhydrous CH2Cl2 and, after 
cooling (0 °C), 4-bromobenzoyl chloride (0.44 mmol) was added and the mixture was stirred at 0 °C for 6 
h. Finally, the residue was washed with cold 0.5 N NaOH (3 x 10 mL) and with cold water (2 x 10 mL). 
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Evaporation of the organic layer afforded compound 97b, which was purified by flash chromatography 
using cyclohexane/ethyl acetate 3:1 as eluent.  
5.2.257 1-(4-Bromophenyl)-3-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-
ylmethyl]-urea (97a) 
N N
O
HN
O
O
HN Br
 
Yield = 27 %; mp = 112- 114 °C (EtOH). IR (cm-1) 3270 (NH), 3265 (NH), 1708 (CO), 1630 (CO). 1H 
NMR (CDCl3) δ 2.25 (s, 3H, 3-CH3), 3.82 (s, 3H, OCH3), 3.88 (s, 2H, CH2-Ar), 6.13 (s, 2H,NCH2N), 
6.68 (s, 1H, Ar), 6.78-6.81 (m, 1H, Ar), 6.83-6.86 (m, 2H, Ar), 6.99 (exch br s, 1H, NH), 7.27-7.31 (m, 
3H, Ar), 7.41 (m, 2H, Ar, J = 8.8 Hz). MS (ESI) calcd. For C21H21BrN4O3, 457.32. Found: m/z 458.07 [M 
+ H]+. 
5.2.258 4-Bromo-N-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-ylmethyl]-
benzamide (97b) 
N N
O
HN
O
O
Br
 
Yield = 30 %; oil. IR (cm-1) 3290 (NH), 1708 (CO), 1640 (CO). 1H NMR (CDCl3) δ 2.26 (s, 3H, 3-CH3), 
3.83 (s, 3H, OCH3), 3.90 (s, 2H, CH2-Ar), 6.29 (s, 2H, NCH2N), 6.69 (s, 1H, Ar), 6.81-6.87 (m, 3H, Ar), 
7.28-7.32 (m, 1H, Ar), 7.58 (d, 2H, Ar, J = 8.6 Hz), 7.94 (d, 2H, Ar, J = 8.6 Hz). MS (ESI) calcd. For 
C21H20BrN3O3, 442.31. Found: m/z 443.06 [M + H]+. 
 
5.2.259 2-(2-Hydroxyethyl)-4-(3-methoxybenzyl)-6-methyl-pyridazin-3(2H)-one (98) 
N N
O
O
OH
 
To a refluxed mixture of compound 44 (0.47 mmol) and NaBH4 (2.64 mmol) in anhydrous THF (6 mL), 
CH3OH (1.45 mL) was slowly added. After stirring for 1 h at 60 °C, the mixture was concentrated in 
vacuo, diluted with cold water (10-15 mL), and extracted with CH2Cl2 (3 x 15 mL). Evaporation of the 
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solvent afforded compound 98. Yield = 95 %; oil. 1H NMR (CDCl3) δ 2.23 (s, 3H, 6-CH3), 3.80 (s, 
3H,OCH3), 3.86 (s, 2H, CH2-Ar), 4.00 (t, 2H, NCH2CH2OH, J = 5.1 Hz), 4.35 (t, 2H, NCH2CH2OH, J = 
5.0 Hz), 4.66 (exch br s, 1H, OH), 6.68 (s, 1H, Ar), 6.78-6.84 (m, 3H, Ar), 7.25-7.29 (m, 1H, Ar). 
 
5.2.260 Methanesulfonic acid 2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-
yl]ethyl ester (99) 
N N
O
O
O S
O
O
 
To a cooled (0 °C) and stirred solution of 98 (0.47 mmol) and pyridine (0.5 mmol) in anhydrous CH2Cl2 
(2 mL), methanesulfonyl chloride (0.61 mmol) was added dropwise, and the mixture was stirred at room 
temperature for 4 h. Then ice cold water was added and the mixture was extracted with CH2Cl2 (3 x 15 
mL): evaporation of the solvent afforded the desired compound. Yield = 85 %; oil. 1H NMR (CDCl3) δ 
2.22 (s, 3H, 3-CH3), 2.98 (s, 3H, CH3SO3), 3.80 (s, 3H, OCH3), 3.86 (s, 2H, CH2-Ar), 3.87-3.90 (m, 2H, 
NCH2CH2O), 4.45 (t, 2H, NCH2CH2O, J = 6.6 Hz), 6.66 (s, 1H, Ar), 6.78 (s, 1H, Ar), 6.82 (d, 2H, Ar, J = 
8.1 Hz), 7.24-7.28 (m, 1H, Ar). 
 
5.2.261 2-[2-(4-Bromophenylamino)-ethyl]-4-(3-methoxybenzyl)-6-methyl-pyridazin-
3(2H)-one (100) 
N N
O
O
H
N Br
 
A solution of 99 (0.4 mmol) and 4-bromoaniline (0.8 mmol) in 2-propanol (2 mL) was heated under 
stirring for 6 h at 60 °C. Then, the mixture was concentrated in vacuo, cold water (30 mL) was added and 
the suspension was extracted with CH2Cl2 (3 x 15 mL). Evaporation of the solvent afforded the final 
compound 100, which was purified by column chromatography using toluene/ethyl acetate 8:2 as eluent. 
Yield = 58 %; mp = 86-88 °C (EtOH). IR (cm-1) 3350 (NH), 1643 (CO). 1H NMR (CDCl3) δ 2.24 (s, 3H, 
6-CH3), 3.58 (t, 2H, NCH2CH2NHAr, J = 5.7 Hz), 3.82 (s, 3H, OCH3), 3.86 (s, 2H, CH2-Ar), 4.46 (t, 2H, 
NCH2CH2NHAr, J = 5.8 Hz), 6.65-6.68 (m, 3H, Ar), 6.79-6.86 (m, 3H, Ar), 7.27-7.31 (m, 3H, Ar). MS 
(ESI) calcd. For C21H22BrN3O2, 428.32. Found: m/z 428.10 [M]+. 
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5.2.262 2-[2-(4-Bromophenoxy)-ethyl]-4-(3-methoxybenzyl)-6-methyl-pyridazin-3(2H)-
one (101) 
N N
O
O
O Br
 
To a suspension of 98 (0.55 mmol), copper acetate (0.82 mmol) and 4-bromophenylboronic acid (1.08 
mmol) in CH2Cl2 (2 mL), Et3N (1.08 mmol) was added and the mixture was stirred at room temperature 
for 12 h. The suspension was extracted with 15% aqueous ammonia (10 mL), then the organic layer was 
washed with water (10 mL) and dried over Na2SO4. After removal of the solvent, the residue was purified 
by flash column chromatography using toluene/ethyl acetate 8:2 as eluent. Yield = 26 %; mp = 82-83 °C 
(EtOH). IR (cm-1) 1643 (CO). 1H NMR (CDCl3) δ 2.24 (s, 3H, 6-CH3), 3.82 (s, 3H, OCH3), 3.87 (s, 2H, 
CH2-Ar), 4.36 (t, 2H, NCH2CH2O, J = 5.9 Hz), 4.54 (t, 2H, NCH2CH2O, J = 5.8 Hz), 6.66 (s, 1H, Ar), 
6.79-6.86 (m, 5H, Ar), 7.27-7.35 (m, 1H, Ar), 7.35-7.37 (m, 2H, Ar). MS (ESI) calcd. For C21H21BrN2O3, 
429.31. Found: m/z 430.08 [M + H]+. 
 
5.2.263 2-(2-Aminoethyl)-4-(3-methoxybenzyl)-6-methyl-pyridazin-3(2H)-one (102) 
N N
O
O
NH2
 
A mixture of 99 (0.43 mmol) and 33% NH3 (3 mL) in isopropanol (2 mL) was stirred at 60 °C for 3 h. 
After concentration of the solvent and dilution with cold water (20 mL), the mixture was extracted with 
CH2Cl2 (3 x 15 mL). Evaporation of the solvent afforded desired compound 102. Yield = 68 %; oil. 1H 
NMR (CDCl3) δ 2.25 (s, 3H, 6-CH3), 3.82 (s, 3H, OCH3), 3.88 (s, 2H, CH2-Ar), 4.02-4.04 (m, 2H, 
NCH2CH2NH2), 4.37 (t, 2H, NCH2CH2NH2, J = 4.9 Hz), 5.38 (exch br s, 2H, NH2), 6.69 (s, 1H, Ar), 
6.79-6.85 (m, 3H, Ar), 7.26-7.30 (m, 1H, Ar). 
 
General Procedure for 103a,b. Compounds 103a,b were obtained starting from the intermediate 
102. For compound 103a, to a cooled (0 °C) and stirred solution of compound 102 (0.35 mmol) in 
anhydrous CH2Cl2 (2 mL), 4-bromophenyl isocyanate (0.40 mmol) was added. The mixture was stirred at 
0 °C to rt 6 h. Removal of the solvent gave a residue that was purified by column chromatography using 
cyclohexane/ethyl acetate 1:1 as eluent. For compound 103b, Et3N (1.8 mmol) and 4-bromobenzoyl 
chloride (1.43 mmol) were added to a cooled (0 °C) and stirred solution of 102 (0.73 mmol) in anhydrous 
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CH2Cl2 (2 mL) and the mixture was stirred at 0 °C for 6 h. The solid residue was filtered off and, in turn, 
the organic layer was washed with 6 N NaOH (3 x 10 mL) and with cold water (2 x 10 mL). The organic 
layer was dried with Na2SO4 and evaporated in vacuo to afford compound 103b, which was purified by 
flash chromatography using CH2Cl2/CH3OH 99:1 as eluent. 
5.2.264 1-(4-Bromophenyl)-3-{2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-
yl]-ethyl}-urea (103a) 
N N
O
O
H
N
HN
O
Br
 
Yield = 15 %; mp = 114-115 °C (EtOH). IR (cm-1) 3270 (NH), 3265 (NH), 1705 (CO), 1630 (CO). 1H 
NMR (CDCl3) δ 2.23 (s, 3H, 3-CH3), 3.81 (s, 3H, OCH3), 3.87 (s, 2H, CH2-Ar), 4.47 (t, 2H, 
NCH2CH2NH, J = 5.2 Hz), 4.57 (t, 2H, NCH2CH2NH, J = 5.1 Hz), 6.69 (s, 1H, Ar), 6.78-6.84 (m, 3H, 
Ar), 7.04 (exch br s, 1H, NH), 7.25-7.28 (m, 3H, Ar), 7.41 (d, 2H, Ar, J = 8.8 Hz). MS (ESI) calcd. For 
C22H23BrN4O3, 471.35. Found: m/z 472.08 [M + H]+. 
5.2.265 4-Bromo-N-{2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-yl]-
ethyl}-benzamide (103b) 
N N
O
O
H
N
O
Br
 
Yield = 13 %; oil. IR (cm-1) 3300 (NH), 1707 (CO), 1643 (CO). 1H NMR (CDCl3) δ 2.18 (s, 3H, 3-CH3), 
3.82 (s, 3H, OCH3), 3.87 (s, 2H, CH2-Ar), 4.55 (t, 2H, NCH2CH2NH, J = 5.4 Hz), 4.70 (t, 2H, 
NCH2CH2NH, J = 5.4 Hz), 6.67 (s, 1H, Ar), 6.68-6.85 (m, 3H, Ar), 7.26 (d, 1H, Ar, J = 7.8 Hz), 7.56 (d, 
2H, Ar, J = 8.5 Hz), 7.86 (d, 2H, Ar, J = 8.5 Hz). MS (ESI) calcd. For C22H22BrN3O3, 456.33. Found: m/z 
457.08 [M + H]+. 
 
General Procedure for 104a-c. To a cooled (-5 °C) and stirred solution of compound 45 (0.35 
mmol) in anhydrous tetrahydrofuran (3-5 mL), Et3N (1.22 mmol) was added. After 30 min, the mixture 
was allowed to warm up to 0 °C, and ethyl chloroformate (0.38 mmol) was added. After 1 h, the 4-
Bromobenzylamine, 4-Bromophenol or 4-Bromo-N-methylaniline (0.7 mmol) were respectively added. 
The reaction was carried out at room temperature for 12 h. The mixture was then concentrated in vacuo, 
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diluted with cold water (20-30 mL) and extracted with CH2Cl2 (3 x 15 mL). The solvent was evaporated 
to afford final compounds 104a-c, which were purified by column chromatography using 
cyclohexane/ethyl acetate 1:2 for compounds 104a and cyclohexane/ethyl acetate 2:1 for 104b,c as 
eluents. 
5.2.266 N-(4-Bromobenzyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-
yl]acetamide (104a) 
N N
O
O
O H
N
Br
 
Yield = 97 %; mp = 184-185 °C (EtOH). IR (cm-1) 3300 (NH), 1708 (CO), 1644 (CO). 1H NMR (DMSO-
d6) δ 2.21 (s, 3H, 3-CH3), 3.73 (s, 3H,OCH3), 3.76 (s, 2H, CH2NHCO), 4.27 (d, 2H, OCH3-C6H4-CH2), 
4.68 (s, 2H, NCH2CO), 6.80-6.86 (m, 3H, Ar), 7.05 (s, 1H, Ar), 7.23-7.26 (m, 3H, Ar), 7.51 (d, 2H, Ar, J 
= 8.3 Hz), 8.63 (exch br t, 1H, NH, J = 5.8 Hz). MS (ESI) calcd. For C22H22BrN3O3, 456.33. Found: m/z 
456.09 [M]+. 
5.2.267 [5-(3-Methoxybenzyl)-3-methyl-6-oxo-6H-pyridazin-1-yl]acetic acid-(4-bromo-
phenyl)ester (104b) 
N N
O
O
O
O Br
 
Yield = 97 %; mp = 111-112 °C (EtOH). IR (cm-1) 3300 (NH), 1745 (CO), 1644 (CO). 1H NMR (CDCl3) 
δ 2.27 (s, 3H, 3-CH3), 3.81 (s, 3H, OCH3), 3.90 (s, 2H, CH2-Ar), 5.10 (s, 2H, NCH2COO), 6.73 (s, 1H, 
Ar), 6.80 (s, 1H, Ar), 6.83-6.86 (m, 2H, Ar), 7.05 (d, 2H, Ar, J = 8.7 Hz), 7.26-7.30 (m, 1H, Ar), 7.50 (d, 
2H, Ar, J = 8.7 Hz). MS (ESI) calcd. For C21H19BrN2O4, 443.29. Found: m/z 443.06 [M]+. 
5.2.268 N-(4-Methoxyphenyl)-N-methyl-2-[5-(3-Methoxybenzyl)-3-methyl-6-oxo-6H-
pyridazin-1-yl]acetamide (104c) 
N N
O
O
O
N Br
 
5. Experimental Chemistry 
 
 176
Yield = 45 %; mp = 125-127 °C (EtOH). IR (cm-1) 1709 (CO), 1644 (CO). 1H NMR (CDCl3) δ 2.21 (s, 
3H, 3-CH3), 3.32 (s, 3H, CH3N), 3.82 (s, 3H, OCH3), 3.86 (s, 2H, CH2-Ar), 4.64 (s, 2H, NCH2CO), 6.62 
(s, 1H, Ar), 6.77 (s, 1H, Ar), 6.80-6.85 (m, 2H, Ar), 7.26-7.30 (m, 3H, Ar), 7.60 (d, 2H, Ar, J = 8.4 Hz). 
MS (ESI) calcd. For C22H22BrN3O3, 456.33. Found: m/z 456.09 [M]+. 
 
5.2.269 N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo-pyridazin-1(6H)-
yl]ethanethioamide (105) 
N N
O
S H
N Br
O
 
Lawesson’s reagent (0.28 mmol) was slowly added to a stirred solution of compound 46a (0.14 mmol) in 
toluene (3 mL) and the reaction was carried out at reflux for 3 h. The solvent was removed in vacuo and 
the mixture was diluted with ice-cold water and extracted with CH2Cl2 (3 x 10 mL). The crude product 
was finally purified by flash column chromatography using cyclohexane/ethyl acetate 1:1 as eluent, to 
yield 105 as an amorphous solid. Yield = 30 %; mp = 68-70 °C (EtOH). 1H NMR (CDCl3) δ 2.32 (s, 3H, 
3-CH3), 3.81 (s, 3H, OCH3), 3.92 (s, 2H, CH2-Ar), 5.37 (s, 2H, NCH2CS), 6.81 (s, 1H, Ar), 6.83-6.87 (m, 
3H, Ar), 7.28 (t, 1H, Ar, J = 5.0 Hz), 7.48 (d, 2H, Ar, J = 8.8 Hz), 7.74 (d, 2H, Ar, J = 8.8 Hz), 11.46 
(exch br s, 1H, NH). MS (ESI) calcd. For C22H22BrN3O3, 458.37. Found: m/z 458.17 [M + H]+, 482.36 
[M + Na]+, 378.45 [M - Br]+, 231.17 [M - C8H7BrNS]+. 
 
5.2.270 2-(3-Methoxybenzyl)-6-methylpyridazin-3(2H)-one (106) 
N N
O
O
 
A mixture of 54b (1.13 mmol), K2CO3 (2.26 mmol) and 3-methoxybenzyl chloride (1.70 mmol) in 
CH3CN (3 mL) was refluxed under stirring for 6 h. The mixture was then concentrated in vacuo, diluted 
with cold water and extracted with CH2Cl2 (3 x 15 mL). The solvent was evaporated in vacuo and 
compound 106 was purified by flash chromatography using CH2Cl2/CH3OH 9.9:0.1 as eluent. Yield = 86 
%; mp = 53-55 °C (cyclohexane). 1H NMR (CDCl3) δ 2.32 (s, 3H, 6-CH3), 3.80 (s, 3H, OCH3), 5.26 (s, 
2H, NCH2), 6.81-6.84 (m, 1H, Ar), 6.87 (d, 1H, Ar, J = 9.4 Hz), 6.97-7.05 (m, 2H, Ar), 7.07 (d, 1H, Ar, J 
= 9.4 Hz), 7.22-7.26 (m, 1H, Ar). 
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5.2.271 4-Amino-2-(3-methoxybenzyl)-6-methylpyridazin-3(2H)-one (107) 
N N
O
O
H2N
 
A suspension of 106 (0.78 mmol) and hydrazine hydrate (3.12 mmol) was stirred in a sealed tube at 180 
°C for 12 h. After cooling, ice-cold water was added. The suspension was kept at 0 °C in ice-bath for 2 h 
and the precipitate was then filtered off to give a first batch of 107. The solution was saturated with 
NH4Cl and extracted with CH2Cl2 (3 x 25 mL). Removal of the solvent afforded a second batch of 
product. Yield = 89 %; mp = 96-98 °C (EtOH). 1H NMR (CDCl3) δ 2.23 (s, 3H,CH3), 3.81 (s, 3H,OCH3), 
4.85 (exch br s, 2H, NH2), 5.27 (s, 2H,CH2), 6.16 (s, 1H, Ar), 6.81-6.85 (m, 1H, Ar), 6.97-7.02 (m, 2H, 
Ar), 7.23-7.28 (m, 1H, Ar). 
 
5.2.272 4-Bromo-N-[2-(3-methoxybenzyl)-6-methyl-3-oxo-2,3-dihydro-pyridazin-4-
yl]benzamide (108) 
N N
O
O
HN
O
Br
 
Et3N (1.8 mmol) and 4-bromobenzoyl chloride (1.43 mmol) were added to a cooled (0 °C) and stirred 
solution of 107 (0.73 mmol) in anhydrous CH2Cl2 (2 mL), and the mixture was monitored under stirring 
at 0 °C for 10 h. The solid residue was removed by filtration. The organic layer was washed with 6 N 
NaOH (3 x 10 mL) and with cold water (2 x 10 mL). Drying with Na2SO4 and evaporation of the solvent 
in vacuo afforded compound 108, which was purified by flash chromatography using cyclohexane/ethyl 
acetate 3:1 as eluent. Yield = 28 %; mp = 162-164 °C (EtOH). IR (cm-1) 3300 (NH), 1709 (CO), 1644 
(CO). 1H NMR (CDCl3) δ 2.40 (s, 3H, CH3), 3.82 (s, 3H, OCH3), 5.32 (s, 2H,CH2), 6.84-6.87 (m, 1H, 
Ar), 6.98-7.02 (m, 2H, Ar), 7.26-7.30 (m, 1H, Ar), 7.66 (d, 1H, Ar, J = 8.7 Hz), 7.80 (d, 2H, Ar, J = 8.6 
Hz), 8.14 (s, 1H, Ar), 9.37 (exch br s, 1H, NH). MS (ESI) calcd. For C20H18BrN3O3, 428.28. Found: m/z 
428.06 [M]+. 
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5.2.273 1-(4-Bromophenyl)-3-[2-(3-methoxybenzyl)-6-methyl-3-oxo-2,3-dihydro 
pyridazin-4-yl]urea (109) 
N N
O
O
HN
O
H
N Br
 
To a stirred solution of compound 107 (0.35 mmol) in anhydrous toluene (2 mL), 4-bromophenyl 
isocyanate (0.40 mmol) was added. The mixture was refluxed for 7 h and after cooling, the solvent was 
removed under reduced pressure. The mixture was diluted with ice-cold water and extracted with CH2Cl2 
(3 x 15 mL). Evaporation of the solvent gave a crude product that was purified by column 
chromatography using firstly CH2Cl2, to remove the 4-bromophenyl urea, and then cyclohexane/ethyl 
acetate 2:1 as eluent. Yield = 56 %; mp = 207-209 °C (EtOH). IR (cm-1) 3270 (NH), 3265 (NH), 1705 
(CO), 1630 (CO). 1H NMR (CDCl3) δ 2.12 (s, 3H,CH3), 3.57 (s, 3H, OCH3), 5.08 (s, 2H, CH2), 6.51-6.58 
(m, 3H, Ar), 6.97- 7.04 (m, 3H, Ar), 7.23 (d, 2H, Ar, J = 8.7 Hz), 7.86 (s, 1H, Ar), 8.70 (exch br s, 1H, 
NH), 8,94 (exch br s, 1H, NH). MS (ESI) calcd. For C20H19BrN4O3, 443.29. Found: m/z 443.07 [M]+. 
 
5.2.274 4-(4-methoxybenzyl)-6-methylpyridazine-3(2H)-thione (110) 
HN N
O
S
 
Lawesson’s reagent (0.87 mmol) was slowly added to a stirred solution of compound 58e (0.87 mmol) in 
toluene (3 mL) and the reaction was carried out at reflux for 2 h. The mixture was cooled and after 1 h 
stirring in ice-bath the precipitate was filtered off and purified by recrystallization from ethanol. Yield = 
47 %; mp = 191-93 °C (EtOH). 1H NMR (CDCl3) δ 2.30 (s, 3H, 3-CH3), 3.85 (s, 3H, OCH3), 4.11 (s, 2H, 
CH2-Ar), 6.57 (s, 1H, Ar), 6.93 (d, 2H, Ar, J = 8.5 Hz), 7.17 (d, 2H, Ar, J = 8.5 Hz), 12.12 (exch br s, 1H, 
SH).  
5.2.275 N-(4-Bromophenyl)-2-[4-(4-methoxybenzyl)-6-methylpyridazin-3-ylthio] 
acetamide (111) 
N N
O
S
O
NH
Br
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A mixture of 110 (0.41 mmol), K2CO3 (0.82 mmol), and N-(4-bromophenyl)-2-chloro acetamide 22 (0.61 
mmol) in CH3CN (4 mL) was refluxed under stirring for 1.5 h. After cooling, the solvent was evaporated  
and the mixture was diluted with cold water. The precipitate was filtered off and purified by flash 
chromatography using cyclohexane/ethyl acetate 1:2 as eluent. Yield = 96 %; mp = 116-118 °C (EtOH). 
1H NMR (CDCl3) δ 2.62 (s, 3H, 6-CH3), 3.84 (s, 3H, OCH3), 3.87 (s, 2H, CH2-Ar), 4.08 (s, 2H, 
SCH2CO), 6.84 (s, 1H, Ar), 6.92 (d, 2H, Ar, J = 8.5 Hz), 7.11 (d, 2H, Ar, J = 8.5 Hz), 7.38 (d, 2H, Ar, J = 
8.8 Hz), 7.48 (d, 2H, Ar, J = 8.8 Hz), 10.26 (exch br s, 1H, NH). 
 
General Procedure for R-(+)-112 and S-(-)-112. To a stirred solution of the suitable 
bromopropionic acid [R-(+)- or S-(-)-] (1.31 mmol), in anhydrous CH2Cl2 (5 mL), SOCl2 (7.86 mmol) 
was added dropwise and the reaction was carried out at 40 °C for 4 h. The mixture was allowed to cool 
down and then the solvent and the excess of SOCl2 were removed in vacuo. The residue was dissolved in 
anhydrous THF (5 mL) and 4-bromoaniline (2.62 mmol) was added. The reaction was stirred for 
additional 4 h at room temperature. After removal of the solvent under reduced pressure, the mixture was 
dissolved in CH2Cl2 and washed, in turn, with 2 N HCl (3 x 15 mL), 2 N NaOH (3 x 15 mL) and with 
H2O (15 mL). The organic layer was dried over Na2SO4 and evaporated under vacuo to give the crude 
products which were purified by flash column chromatography using toluene/ethyl acetate 6:1 as eluents.  
5.2.276 R-(+)-2-Bromo-N-(4-bromophenyl)propanamide [R-(+)-112] 
Br
HN
O
Br
 
Yield = 12 %; mp = 150-51 °C (EtOH). [α]20D = + 25° (c = 1, CHCl3). e.e. > 99.9 % (determined by 
analytical chiral HPLC). 1H NMR (CDCl3) δ 1.98 (d, 3H, CHCH3, J = 7.0 Hz), 4.56 (q, 1H, CHCH3, J = 
7.0 Hz), 7.45-7.50 (dd, 4H, Ar, J = 6.3 Hz, J = 2.9 Hz), 8.09 (exch br s, 1H, NH). 
5.2.277 S-(-)-2-Bromo-N-(4-bromophenyl)propanamide [S-(-)-112] 
Br
HN
O
Br
 
Yield = 15 %; mp = 150-51 °C (EtOH). [α]20D = - 25° (c = 1, CHCl3). e.e. > 99.9 % (determined by 
analytical chiral HPLC). 1H NMR (CDCl3) δ 1.99 (d, 3H, CHCH3, J = 7.0 Hz), 4.56 (q, 1H, CHCH3, J = 
7.0 Hz), 7.46-7.50 (dd, 4H, Ar, J = 3.7 Hz, J = 2.6 Hz), 8.07 (exch br s, 1H, NH). 
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General procedure for (+)-113 [rac 70:30, from S-(-)-112] and (-)-113 [rac 60:40, from R-(+)-
112]. A mixture of intermediate 43 (0.17 mmol), K2CO3 (0.34 mmol) and R-(+)-112 or S-(-)-112 (0.19 
mmol) respectively, in CH3CN (3 mL) were refluxed under stirring for 2 h. After cooling, the solvent was 
evaporated and the mixture was diluted with ice-cold water and extracted using CH2Cl2 (3 x 10 mL). The 
organic layer was collected, dried over Na2SO4 and evaporated in vacuo. The crude residues were purified 
by flash column chromatography using cyclohexane/ethyl acetate 2:1 as eluent.  
5.2.278 (+)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]propanamide [(+)-113, rac 70:30] 
N N
O
∗
O H
N Br
O
 
Yield = 90 %; mp = 63-64 °C (n-hexane). [α]20D = + 35° (c = 1, CHCl3). e.e. = 70 % (of the (+)-
enantiomer, determined by analytical chiral HPLC). 1H NMR (CDCl3) δ 1.71 (d, 3H, CHCH3, J = 7.1 
Hz), 2.30 (s, 3H, 3-CH3), 3.81 (s, 3H, OCH3), 3.91 (s, 2H, CH2-Ar), 5.71 (q, 1H, CHCH3, J = 7.1 Hz), 
6.79 (d, 2H, Ar, J = 7.6 Hz), 6.84 (d, 2H, Ar, J = 8.3 Hz), 7.28 (t, 1H, Ar, J = 9.1 Hz), 7.38 (d, 4H, Ar, J = 
6.0 Hz), 9.09 (exch br s, 1H, NH). 
5.2.279 (-)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]propanamide [(-)-113, rac 60:40] 
N N
O
∗
O H
N Br
O
 
Yield = 93 %; mp = 63-64 °C (n-hexane). [α]20D = - 30° (c = 1, CHCl3). e.e. = 60 % (of the n (-)-
enantiomer, determined by analytical chiral HPLC). 1H NMR (CDCl3) δ 1.71 (d, 3H, CHCH3, J = 7.1 
Hz), 2.31 (s, 3H, 3-CH3), 3.80 (s, 3H, OCH3), 3.90 (s, 2H, CH2-Ar), 5.71 (q, 1H, CHCH3, J = 7.1 Hz), 
6.79 (q, 2H, Ar, J = 1.0 Hz), 6.84 (dd, 2H, Ar, J = 6.0 Hz, J = 1.0 Hz), 7.27 (t, 1H, Ar, J = 8.2 Hz), 7.36 
(d, 4H, Ar, J = 6.0 Hz), 9.16 (exch br s, 1H, NH). 
 
General Procedure for racemates (±)-115a-f and 116. Compounds (±)-115a-f and 116 were 
synthesized using the suitable carboxylic acid and following the same procedure exploited for R-(+)- and 
S-(-)-112.  
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5.2.280 (±)-2-Bromo-N-(4-bromophenyl)pentanamide [(±)-115b] 
Br
HN
O
∗
Br
 
Yield = 10 %; mp = 94-96 °C (EtOH). 1H NMR (CDCl3) δ 1.00 (t, 3H, CH2CH3, J = 7.4 Hz), 1.50-1.65 
(m, 2H, CH2CH2CH2CH3), 2.05-2.16 (m, 1H, COCHCH-HCH2), 2.20-2.25 (m, 1H, COCHCH-HCH2), 
4.47 (dd, 1H, COCHCH2, J = 3.1 Hz, J = 5.2 Hz), 7.43-7.50 (m, 4H, Ar), 8.10 (exch br s, 1H, NH). 
5.2.281 (±)-2-Bromo-N-(4-bromophenyl)hexanamide [(±)-115d] 
Br
HN
O
∗
Br
 
Yield = 10 %; mp = 114-15 °C (EtOH). 1H NMR (CDCl3) δ 0.95 (t, 3H, CH2CH3, J = 7.2 Hz), 1.37-1.44 
(m, 2H, CH2CH2CH2CH3), 1.48-1.57 (m, 2H, CH2CH2CH2CH3), 2.06-2.14 (m, 1H, COCHCH-HCH2), 
2.20-2.29 (m, 1H, COCHCH-HCH2), 4.45 (dd, 1H, COCHCH2, J = 7.9 Hz, J = 5.2 Hz), 7.44-7.50 (m, 
4H, Ar), 8.07 (exch br s, 1H, NH). 
 
General Procedure for racemates (±)-117a-f and 118. A mixture of compound 43 (0.13 mmol), 
K2CO3 (0.26 mmol) and the suitable intermediate type 115 [(±)-115a-f] or 116 (0.14 mmol), in CH3CN (3 
mL) was refluxed under stirring for 4-5 h. After cooling, the solvent was evaporated and ice-cold water 
was added to the mixture. For racemate (±)-117a, after 1 h stirring in ice-bath the precipitate was filtered 
off and purified by crystallization in cyclohexane. For racemates (±)-117b-f and compound 118, 
differently, the mixture was extracted using CH2Cl2 (3 x 10 mL). The organic layer was collected, dried 
over Na2SO4 and evaporated in vacuo. The crude residue was purified by flash column chromatography 
using as eluent cyclohexane/ethyl acetate 2:1 for racemates (±)-117b-d, cyclohexane/ ethyl acetate 1:3 for 
racemate (±)-117e and cyclohexane/ethyl acetate 1:1 for compounds (±)-117f and 118.  
5.2.282 (±)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]butanamide [(±)-117a] 
N N
O
∗
O H
N Br
O
 
Yield = 98 %; mp = 79-81 °C (cyclohexane). 1H NMR (CDCl3) δ 0.95 (t, 3H, CHCH3, J = 7.4 Hz), 2.19-
2.38 (m, 5H, 3-CH3 + CH2CH3), 3.81 (s, 3H, OCH3), 3.91 (s, 2H, CH2-Ar), 5.46 (dd, 1H, NCHCH2, J = 
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1.4 Hz, J = 6.9 Hz), 6.77-6.85 (m, 4H, Ar), 7.27 (t, 1H, Ar, J = 7.9 Hz), 7.30-7.44 (m, 4H, Ar), 9.13 (exch 
br s, 1H, NH). 
5.2.283 (±)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]pentanamide [(±)-117b] 
N N
O
∗
O H
N Br
O
 
Yield = 94 %; colorless oil. 1H NMR (CDCl3) δ 0.98 (t, 3H, CHCH3, J = 7.6 Hz), 1.26-1.40 (m, 2H, 
CH2CH2CH3), 2.17-2.28 (m, 2H, CHCH2CH2), 2.30 (s, 3H, 3-CH3), 3.81 (s, 3H, OCH3), 3.90 (s, 2H, 
CH2-Ar), 5.56 (t, 1H, NCHCH2, J = 8.2 Hz), 6.75 (s, 1H, Ar), 6.79 (s, 1H, Ar), 6.82-6.86 (m, 2H, Ar), 
7.27 (t, 1H, Ar, J = 7.8 Hz), 7.38 (s, 4H, Ar), 9.03 (exch br s, 1H, NH). 
5.2.284 (±)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]-3-methylbutanamide [(±)-117c] 
N N
O
∗
O H
N Br
O
 
Yield = 80 %; mp = 161-62 °C (n-hexane). 1H NMR (CDCl3) δ 0.83 (d, 3H, CHCH3, J = 6.6 Hz), 1.16 (d, 
3H, CHCH3, J = 6.6 Hz), 2.30 (s, 3H, 3-CH3), 2.85-2.98 (m, 1H, CHCH3), 3.81 (s, 3H, OCH3), 3.90 (s, 
2H, CH2-Ar), 5.14 (d, 1H, NCHCHCH, J = 11.0 Hz), 6.72 (s, 1H, Ar), 6.78-6.85 (m, 3H, Ar), 7.28 (t, 1H, 
Ar, J = 7.8 Hz), 7.39-7.44 (m, 4H, Ar), 9.06 (exch br s, 1H, NH). 
5.2.285 (±)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]hexanamide [(±)-117d] 
N N
O
∗
O H
N Br
O
 
Yield = 93 %; colorless oil. 1H NMR (CDCl3) δ 0.92 (t, 3H, CHCH3, J = 7.3 Hz), 1.24-1.43 (m, 4H, 
CH2CH2CH2CH3), 2.22-2.30 (m, 5H, 3-CH3 + CHCH2CH2CH2CH3), 3.81 (s, 3H, OCH3), 3.91 (s, 2H, 
CH2-Ar), 5.53 (dd, 1H, NCHCH2, J = 1.3 Hz, J = 6.9 Hz), 6.74 (s, 1H, Ar), 6.80-6.86 (m, 3H, Ar), 7.28 (t, 
1H, Ar, J = 8.5 Hz), 7.35-7.45 (m, 4H, Ar), 8.98 (exch br s, 1H, NH). 
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5.2.286 (±)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]-2-phenylacetamide [(±)-117e] 
N N
O
∗
O H
N Br
O
 
Yield = 42 %; mp = 117-19 °C (EtOH). 1H NMR (CDCl3) δ 2.26 (s, 3H, 3-CH3), 3.81 (s, 3H, OCH3), 
3.89 (s, 2H, CH2-Ar), 6.67 (s, 1H, Ar), 6.87-6.87 (m, 4H, NCHCO + 3 x Ar), 7.28 (t, 1H, Ar, J = 7.6 Hz), 
7.36-7.45 (m, 7H, Ar), 7.56-7.59 (m, 2H, Ar), 8.33 (exch br s, 1H, NH). 
5.2.287 (±)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]-2-methylbutanamide [(±)-117f] 
N N
O
∗
O H
N Br
O
 
Yield = 60 %; mp = 141-42 °C (n-hexane). 1H NMR (CDCl3) δ 0.90 (t, 3H, CH2CH3, J = 7.3 Hz), 1.83 (s, 
3H, COCCH3), 2.25 (sext, 1H, NCCH-HCH3, J = 6.9 Hz), 2.38 (sext, 1H, NCCH-HCH3, J = 7.4 Hz), 
2.59 (s, 3H, 3-CH3), 3.78 (s, 3H, OCH3), 3.97 (qd, 2H, CH2-Ar, J = 3.3 Hz, J = 16.2 Hz), 6.73 (s, 1H, Ar), 
6.77 (d, 1H, Ar, J = 7.6 Hz), 6.85 (dd, 1H, Ar, J = 6.0 Hz, J = 1.9 Hz), 7.09 (s, 1H, Ar), 7.23 (d, 2H, Ar, J 
= 8.9 Hz), 7.29 (t, 1H, Ar, J = 8.0 Hz), 7.37 (d, 2H, Ar, J = 8.8 Hz),  8.15 (exch br s, 1H, NH). 
5.2.288 N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-1(6H)-
yl]-2-methylpropanamide [(±)-118] 
N N
O
O H
N Br
O
 
Yield = 65 %; mp = 58-60 °C (n-hexane). 1H NMR (CDCl3) δ 1.83 (s, 6H, 2 x NCCH3), 2.61 (s, 3H, 3-
CH3), 3.80 (s, 3H, OCH3), 3.97 (s, 2H, CH2-Ar, J = 3.3 Hz), 6.76-6.88 (m, 3H, Ar), 7.11 (s, 1H, Ar), 
7.27-7.32 (m, 3H, Ar), 7.37 (dd, 2H, Ar, J = 4.7 Hz, J = 2.0 Hz), 8.26 (exch br s, 1H, NH). 
 
HPLC resolution of (±)-95b and (±)-117a by Chiral Phase HPLC. Both racemates were 
separated by chiral-phase HPLC with a Chiralcel OD® (250mm x 4.6mm I.D., 10 µm particle size) 
column. The eluent mixture n-hexane/IPA 95:5 was used in isocratic mode with the flow 1.2 mL/min at 
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25 °C and the UV signal was followed at λ = 250 nm. Racemates were dissolved in ethanol (1 mg/mL 
solution) and 50 µL were injected each time. In order to separate about 20 mg of racemic mixtures 600 
injections were needed and it took about 200 h to obtain the resolved enantiomeric pairs S-(+)95b/R-(-)-
95b (tR = 19.2, tR = 23.2) and S-(+)-117a/R-(-)-117a (tR = 15.9, tR = 17.9) (see section 3.3.6.4 for the 
assignment of the absolute configuration).  
5.2.289 S-(+)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]propanamide [S-(+)-95b] 
N N
O
O H
N Br
O
 
Light-yellow oil. [α]20D = + 80° (c = 1, CHCl3). e.e. > 99.9 % (determined by analytical chiral HPLC). 1H 
NMR (CDCl3) δ 1.71 (d, 3H, CHCH3, J = 7.0 Hz), 2.29 (s, 3H, 3-CH3), 3.82 (s, 3H, OCH3), 3.91 (s, 2H, 
CH2-Ar), 5.71 (q, 1H, CHCH3, J = 7.0 Hz), 6.78 (s, 1H, Ar), 6.81(s, 1H, Ar), 6.84 (d, 2H, Ar, J = 7.4 Hz), 
7.28 (t, 1H, Ar, J = 9.0 Hz), 7.40 (d, 4H, Ar, J = 4.9 Hz), 8.99 (exch br s, 1H, NH). 
5.2.290 R-(-)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]propanamide [R-(-)-95b] 
N N
O
O H
N Br
O
 
Light-yellow oil. [α]20D = - 78° (c = 1, CHCl3). e.e. = 97.4 % (determined by analytical chiral HPLC). 1H 
NMR (CDCl3) δ 1.71 (d, 3H, CHCH3, J = 7.0 Hz), 2.30 (s, 3H, 3-CH3), 3.81 (s, 3H, OCH3), 3.91 (s, 2H, 
CH2-Ar), 5.71 (q, 1H, CHCH3, J = 7.0 Hz), 6.78 (s, 1H, Ar), 6.81(s, 1H, Ar), 6.84 (d, 2H, Ar, J = 8.3 Hz), 
7.28 (t, 1H, Ar, J = 8.8 Hz), 7.40 (d, 4H, Ar, J = 3.0 Hz), 9.01 (exch br s, 1H, NH). 
5.2.291 S-(+)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]butanamide [S-(+)-117a]  
N N
O
O H
N Br
O
 
Light-yellow oil. [α]20D + 129° (c = 1, CHCl3). e.e. > 99.9 % (determined by analytical  chiral HPLC). 1H 
NMR (CDCl3) δ 0.96 (t, 3H, CHCH3, J = 7.4 Hz), 2.18-2.39 (m, 5H, 3-CH3 + CH2CH3), 3.81 (s, 3H, 
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OCH3), 3.90 (s, 2H, CH2-Ar), 5.47 (dd, 1H, NCHCH2, J = 1.5 Hz, J = 6.9 Hz), 6.75 (s, 1H, Ar), 6.79 (d, 
1H, Ar, J = 1.9 Hz), 6.82-6.86 (m, 2H, Ar), 7.28 (t, 1H, Ar, J = 7.9 Hz), 7.35-7.41 (m, 4H, Ar), 9.08 (exch 
br s, 1H, NH). 
5.2.292 R-(-)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]butanamide [R-(-)-117a] 
N N
O
O H
N Br
O
 
Light-yellow oil. [α]20D - 129° (c = 1, CHCl3). e.e. = 98.0 % (determined by analytical chiral HPLC). 1H 
NMR (CDCl3) δ 0.96 (t, 3H, CHCH3, J = 7.4 Hz), 2.18-2.39 (m, 5H, 3-CH3 + CH2CH3), 3.81 (s, 3H, 
OCH3), 3.91 (s, 2H, CH2-Ar), 5.47 (dd, 1H, NCHCH2, J = 1.2 Hz, J = 7.0 Hz), 6.75 (s, 1H, Ar), 6.79 (s, 
1H, Ar), 6.82-6.86 (m, 2H, Ar), 7.28 (t, 1H, Ar, J = 8.1 Hz), 7.36-7.41 (m, 4H, Ar), 9.08 (exch br s, 1H, 
NH). 
 
HPLC resolution of (±)-117b-f by Chiral Phase HPLC. Racemates were separated by chiral-
phase HPLC with a Lux Amylose-2® (250 mm x 4.6 mm I.D., 5 µm particle size) column. The eluent 
mixture n-hexane/IPA 60:40 was used in isocratic mode with the flow 1.5 mL/min at  40 °C and the UV 
signal was followed at λ = 250 nm. Racemates were dissolved in ethanol (2 mg/mL solution), then 100 
µL of (±)-117b-e and 80 µL of (±)-117f were injected each time. In order to separate about 20 mg of 
racemic mixtures 50 injections were needed and it took about 10 h to obtain the resolved enantiomeric 
pairs S-(+)117b/R-(-)-117b (tR = 5.1, tR = 9.4), S-(+)-117c/R-(-)-117c (tR = 3.9, tR = 10.1), S-(+)-117d/R-
(-)-117d (tR = 5.4, tR = 9.7), R-(-)-117e/S-(+)-117e (tR = 7.6, tR = 12.3) and R-(-)-117f/S-(+)-117f (tR = 
6.7, tR = 8.6) (see section 3.3.6.4 for the assignment of the absolute configuration).  
5.2.293 S-(+)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]pentanamide [S-(+)-117b]  
N N
O
O H
N Br
O
 
Light-yellow oil. [α]20D + 139° (c = 1, CHCl3). e.e. > 99.9 % (determined by analytical  chiral HPLC). 1H 
NMR (CDCl3) δ 0.98 (t, 3H, CHCH3, J = 7.3 Hz), 1.27-1.42 (m, 2H, CH2CH2CH3), 2.15-2.28 (m, 2H, 
CHCH2CH2), 2.30 (s, 3H, 3-CH3), 3.81 (s, 3H, OCH3), 3.90 (s, 2H, CH2-Ar), 5.56 (t, 1H, NCHCH2, J = 
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8.2 Hz), 6.75 (s, 1H, Ar), 6.79 (d, 1H, Ar, J = 1.9 Hz), 6.82-6.86 (m, 2H, Ar), 7.28 (t, 1H, Ar, J = 9.0 Hz), 
7.39 (s, 4H, Ar), 9.02 (exch br s, 1H, NH). 
5.2.294 R-(-)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]pentanamide [R-(-)-117b]  
N N
O
O H
N Br
O
 
Light-yellow oil. [α]20D - 137° (c = 1, CHCl3). e.e. = 99.9 % (determined by analytical chiral HPLC). 1H 
NMR (CDCl3) δ 0.98 (t, 3H, CHCH3, J = 7.4 Hz), 1.28-1.40 (m, 2H, CH2CH2CH3), 2.17-2.28 (m, 2H, 
CHCH2CH2), 2.30 (s, 3H, 6-CH3), 3.81 (s, 3H, OCH3), 3.90 (s, 2H, CH2-Ar), 5.56 (t, 1H, NCHCH2, J = 
7.2 Hz), 6.75 (s, 1H, Ar), 6.79 (d, 1H, Ar, J = 1.5  Hz), 6.82-6.86 (m, 2H, Ar), 7.28 (t, 1H, Ar, J = 9.0 
Hz), 7.39 (s, 4H, Ar), 9.14 (exch br s, 1H, NH). 
5.2.295 S-(+)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]-3-methylbutanamide [S-(+)-117c]  
N N
O
O H
N Br
O
 
mp 63-65 °C. [α]20D + 99° (c = 1, CHCl3). e.e. > 99.9 % (determined by analytical  chiral HPLC). 1H 
NMR (CDCl3) δ 0.83 (d, 3H, CHCH3, J = 6.6 Hz), 1.16 (d, 3H, CHCH3, J = 6.6 Hz), 2.31 (s, 3H, 3-CH3), 
2.86-2.96 (m, 1H, CHCH3), 3.81 (s, 3H, OCH3), 3.90 (s, 2H, CH2-Ar), 5.14 (d, 1H, NCHCHCH, J = 11.0 
Hz), 6.71 (s, 1H, Ar), 6.78 (s, 1H, Ar), 6.81-6.86 (m, 2H, Ar), 7.28 (t, 1H, Ar, J = 7.5 Hz), 7.38-7.44 (m, 
4H, Ar), 9.06 (exch br s, 1H, NH). 
5.2.296 R-(-)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]-3-methylbutanamide [R-(-)-117c] 
N N
O
O H
N Br
O
 
mp 63-65 °C. [α]20D - 97° (c = 1, CHCl3). e.e. = 99.9 % (determined by analytical chiral HPLC). 1H NMR 
(CDCl3) δ 0.83 (d, 3H, CHCH3, J = 6.6 Hz), 1.16 (d, 3H, CHCH3, J = 6.6 Hz), 2.30 (s, 3H, 3-CH3), 2.86-
2.96 (m, 1H, CHCH3), 3.81 (s, 3H, OCH3), 3.90 (s, 2H, CH2-Ar), 5.14 (d, 1H, NCHCHCH, J = 11.0 Hz), 
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6.71 (s, 1H, Ar), 6.78 (s, 1H, Ar), 6.81-6.86 (m, 3H, Ar), 7.28 (t, 1H, Ar, J = 7.8 Hz), 7.38-7.44 (m, 4H, 
Ar), 9.06 (exch br s, 1H, NH). 
5.2.297 S-(+)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]hexanamide [S-(+)-117d]  
N N
O
O H
N Br
O
 
Light-yellow oil. [α]20D + 111° (c = 1, CHCl3). e.e. > 99.9 % (determined by analytical chiral HPLC). 1H 
NMR (CDCl3) δ 0.92 (t, 3H, CHCH3, J = 7.3 Hz), 1.17-1.46 (m, 4H, CH2CH2CH2CH3), 2.14-2.34 (m, 
5H, 6-CH3 + CHCH2CH2CH2CH3), 3.81 (s, 3H, OCH3), 3.91 (s, 2H, CH2-Ar), 5.54 (dd, 1H, NCHCH2, J 
= 1.3 Hz, J = 6.9 Hz), 6.75 (d, 1H, Ar, J = 1.1 Hz), 6.79 (t, 1H, Ar, J = 1.7 Hz), 6.82-6.86 (m, 2H, Ar), 
7.28 (t, 1H, Ar, J = 9.4 Hz), 7.38 (s, 4H, Ar), 9.04 (exch br s, 1H, NH). 
5.2.298 R-(-)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxopyridazin-
1(6H)-yl]hexanamide [R-(-)-117d]  
N N
O
O H
N Br
O
 
Light-yellow oil. [α]20D - 110° (c = 1, CHCl3). e.e. = 99.9 % (determined by analytical chiral HPLC). 1H 
NMR (CDCl3) δ 0.92 (t, 3H, CHCH3, J = 7.3 Hz), 1.17-1.46 (m, 4H, CH2CH2CH2CH3), 2.16-2.34 (m, 
5H, 6-CH3 + CHCH2CH2CH2CH3), 3.81 (s, 3H, OCH3), 3.90 (s, 2H, CH2-Ar), 5.54 (dd, 1H, NCHCH2, J 
= 1.2 Hz, J = 6.9 Hz), 6.75 (s, 1H, Ar), 6.79 (d, 1H, Ar, J = 2.0 Hz), 6.82-6.86 (m, 2H, Ar), 7.28 (t, 1H, 
Ar, J = 9.3 Hz), 7.36-7.41 (s, 4H, Ar), 9.04 (exch br s, 1H, NH). 
5.2.299 R-(-)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo 
pyridazin-1(6H)-yl]-2-phenylacetamide [R-(-)-117e]  
N N
O
O H
N Br
O
 
Light-yellow oil. [α]20D - 17° (c = 1, CHCl3). e.e. = 99.9 % (determined by analytical chiral HPLC). 1H 
NMR (CDCl3) δ 2.26 (s, 3H, 3-CH3), 3.81 (s, 3H, OCH3), 3.89 (s, 2H, CH2-Ar), 6.68 (s, 1H, Ar), 6.77 (s, 
1H, Ar), 6.80-6.85 (m, 2H, Ar), 6.88 (s, 1H, NCHCO), 7.28 (t, 1H, Ar, J = 7.6 Hz), 7.36-7.45 (m, 7H, 
5. Experimental Chemistry 
 
 188
Ar), 7.56-7.59 (m, 2H, Ar), 8.33 (exch br s, 1H, NH). MS (ESI) calcd. For C27H24BrN3O3, 518.40. Found: 
m/z 519.10 [M + H]+, 541.30 [M + Na]+. 
5.2.300 S-(-)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo 
pyridazin-1(6H)-yl]-2-phenylacetamide [S-(+)-117e]  
N N
O
O H
N Br
O
 
Light-yellow oil. [α]20D + 16° (c = 1, CHCl3). e.e. > 99.9 % (determined by analytical  chiral HPLC). 1H 
NMR (CDCl3) δ 2.26 (s, 3H, 3-CH3), 3.80 (s, 3H, OCH3), 3.89 (s, 2H, CH2-Ar), 6.68 (s, 1H, Ar), 6.77 (s, 
1H, Ar), 6.80-6.85 (m, 2H, Ar), 6.88 (s, 1H, NCHCO), 7.28 (t, 1H, Ar, J = 7.6 Hz), 7.36-7.45 (m, 7H, 
Ar), 7.56-7.59 (m, 2H, Ar), 8.33 (exch br s, 1H, NH). MS (ESI) calcd. For C27H24BrN3O3, 518.40. Found: 
m/z 519.10 [M + H]+, 541.30 [M + Na]+. 
5.2.301 R-(-)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo 
pyridazin-1(6H)-yl]-2-methylbutanamide [R-(-)-117f]  
N N
O
O H
N Br
O
 
mp 108-09 °C. [α]20D - 18° (c = 1, CHCl3). e.e. > 99.9 % (determined by analytical chiral HPLC). 1H 
NMR (CDCl3) δ 0.90 (t, 3H, CH2CH3, J = 7.4 Hz), 1.83 (s, 3H, NCCH3), 2.26 (sext, 1H, NCCH-HCH3, J 
= 7.4 Hz), 2.39 (sext, 1H, NCCH-HCH3, J = 7.4 Hz), 2.60 (s, 3H, 6-CH3), 3.79 (s, 3H, OCH3), 3.97 (d, 
2H, CH2-Ar, J = 3.0 Hz, J = 16.2 Hz), 6.73 (s, 1H, Ar), 6.77 (d, 1H, Ar, J = 7.6 Hz), 6.85 (d, 1H, Ar, J = 
8.1 Hz), 7.10 (s, 1H, Ar), 7.23 (d, 2H, Ar, J = 8.8 Hz), 7.30 (t, 1H, Ar, J = 8.1 Hz), 7.38 (d, 2H, Ar, J = 
8.7 Hz),  8.13 (exch br s, 1H, NH). 
5.2.302 S-(+)-N-(4-Bromophenyl)-2-[5-(3-methoxybenzyl)-3-methyl-6-oxo 
pyridazin-1(6H)-yl]-2-methylbutanamide [S-(+)-117f]  
N N
O
O H
N Br
O
 
mp 108-09 °C. [α]20D + 17 (c = 1, CHCl3). e.e. = 99.3 % (determined by analytical  chiral HPLC). 1H 
NMR (CDCl3) δ 0.90 (t, 3H, CH2CH3, J = 7.4 Hz), 1.83 (s, 3H, NCCH3), 2.26 (sext, 1H, NCCH-HCH3, J 
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= 7.4 Hz), 2.39 (sext, 1H, NCCH-HCH3, J = 7.1 Hz), 2.60 (s, 3H, 6-CH3), 3.79 (s, 3H, OCH3), 3.97 (qd, 
2H, CH2-Ar, J = 3.0 Hz, J = 16.2 Hz), 6.73 (s, 1H, Ar), 6.77 (d, 1H, Ar, J = 7.5 Hz), 6.85 (dd, 1H, Ar, J = 
6.3 Hz, J = 1.9 Hz), 7.10 (s, 1H, Ar), 7.23 (d, 2H, Ar, J = 8.7 Hz), 7.29 (t, 1H, Ar, J = 7.9 Hz), 7.38 (d, 
2H, Ar, J = 8.7 Hz),  8.13 (exch br s, 1H, NH). 
 
General Procedure for reference compounds R-(-)-119 and S-(-)-120. To an aqueous (75 mL) 
solution of R-(-)-2-phenylglycine or S-(-)-α-Methylvaline (99.33 mmol) respectively, acetic anhydride 
(0.75 mol) was added. The mixture was stirred for 0.5 h at 70 °C until all the amino acid was dissolved. 
When the reaction mixture was cooled to 5 °C, the crystallized amide was separated by filtration and the 
final products were purified by recrystallization from ethanol. 
5.2.303 S-(-)-2-Acetamido-2,3-dimethylbutanoic acid [S-(-)-120]  
OH
O
NH
O
 
Yield = 36 %; mp = 213-14 °C (EtOH). [α]20D = - 1.4° (c = 1, EtOH). e.e. > 99.9 % (determined by 
analytical chiral HPLC). 1H NMR (DMSO-d6) δ 0.84 (d, 3H, CHCH3, J = 6.8 Hz), 0.91 (d, 3H, CHCH3, J 
= 6.8 Hz), 1.25 (s, 3H, CHCCH3), 1.81 (s, 3H, COCH3), 1.91-1.99 (m, 1H, CCH(CH3)2), 7.07 (exch br s, 
1H, NH), 12.08 (exch br s, 1H, OH).    
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6.1 Cell Culture   
Human promyelocytic leukemia HL-60 cells stably transfected with FPR1 (HL-60-FPR1), FPR2 (HL-60-
FPR2), or FPR3 (HL-60-FPR3) were cultured in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal calf serum, 10 mM HEPES, 100 µg/ml streptomycin, 100 U/ml penicillin, and G418 (1 
mg/mL), as previously described.315 Wild-type HL-60 cells were cultured under the same conditions, but 
without G418.  
 
6.2 Isolation of Human Neutrophils 
Blood was collected from healthy donors in accordance with a protocol approved by the Institutional 
Review Board at Montana State University. Neutrophils were purified from the blood using dextran 
sedimentation, followed by Histopaque 1077 gradient separation and hypotonic lysis of red blood cells, as 
previously described.204 Isolated neutrophils were washed twice and resuspended in HBSS without Ca2+ 
and Mg2+ (HBSS-). Neutrophil preparations were routinely > 95 % pure, as determined by light 
microscopy, and > 98 % viable, as determined by trypan blue exclusion.  
 
6.3 Ca2+ Mobilization Assay 
Changes in intracellular Ca2+ were measured with a FlexStation II scanning fluorometer using a FLIPR 3 
calcium assay kit (Molecular Devices, Sunnyvale, CA) for human neutrophils and HL-60 cells. All active 
compounds were evaluated in parent (wild-type) HL-60 cells for supporting that the agonists are inactive 
in non-transfected cells. Human neutrophils or HL-60 cells, suspended in HBSS- containing 10 mM 
HEPES, were loaded with Fluo-4 AM dye (Invitrogen) (1.25 µg/mL final concentration) and incubated 
for 30 min in the dark at 37 °C. After dye loading, the cells were washed with HBSS- containing 10 mM 
HEPES, resuspended in HBSS containing 10 mM HEPES and Ca2+ and Mg2+ (HBSS+), and aliquotted 
into the wells of a flat-bottomed, half-area-well black microtiter plates (2 x 105 cells/well). The compound 
source plate contained dilutions of test compounds in HBSS+. Changes in fluorescence were monitored 
(λex = 485 nm, λem = 538 nm) every 5 s for 240 s at room temperature after automated addition of 
compounds. Maximum change in fluorescence, expressed in arbitrary units over baseline, was used to 
determine agonist response. Responses were normalized to the response induced by 5 nM fMLF (Sigma 
Chemical Co., St. Louis, MO) for HL-60-FPR1 and neutrophils, or 5 nM WKYMVm (Calbiochem, San 
Diego, CA) for HL-60-FPR2 and HL-60-FPR3 cells, which were assigned a value of 100%. Curve fitting 
(5-6 points) and calculation of median effective concentration values (EC50) were performed by nonlinear 
regression analysis of the dose-response curves generated using Prism 5 (GraphPad Software, Inc., San 
Diego, CA).  
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6.4 Chemotaxis Assay 
Neutrophils were suspended in HBSS+ containing 2% (v/v) fetal bovine serum (FBS) (2 x 106 cells/mL), 
and chemotaxis was analyzed in 96-well ChemoTx chemotaxis chambers (Neuroprobe, Gaithersburg, 
MD), as previously described.204 In brief, lower wells were loaded with 30 µL of HBSS+ containing 2% 
(v/v) FBS and the indicated concentrations of test compound, DMSO (negative control), and 1 nM fMLF 
as a positive control. The number of migrated cells was determined by measuring ATP in lysates of 
transmigrated cells using a luminescence-based assay (CellTiter-Glo; Promega, Madison, WI), and 
luminescence measurements were converted to absolute cell numbers by comparison of the values with 
standard curves obtained with known numbers of neutrophils. The results are expressed as percentage of 
negative control and were calculated as follows: (number of cells migrating in response to test 
compounds/spontaneous cell migration in response to control medium) x 100. EC50 values were 
determined by nonlinear regression analysis of the dose-response curves generated using Prism 5 
software.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
7. BIBLIOGRAPHIC REFERENCES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Bibliographic References 
 197 
(1) Nauseef, W. M.; Clark, R. A. In Basic Principles in the Diagnosis and Management of Infectious 
Diseases. Mandel, G. L., Bennett, J. E., Dolin, R., Eds; Churchill Livingstone: New York, 2000; 
vol. 1, pp. 89-112.  
(2) Bruno, O.; Brullo, C.; Bondavalli, F.; Schenone, S.; Ranise, A.; Arduino, N.; Bertolotto, M. B.; 
Montecucco, F.; Ottonello, L.; Dallegri, F.; Tognolini, M.; Ballabeni, V.; Bertoni, S.; Barocelli E. 
Synthesis and Biological Evaluation of N-Pyrazolyl-N’-alkyl/benzyl/phenylureas: a New Class of 
Potent Inhibitors of Interleukin 8-Induced Neutrophil Chemotaxis. J. Med. Chem. 2007, 50, 3618-
3626. 
(3)  Lee, H. Y.; Bae, Y. S. The Anti-infective Peptide, Innate Defense-Regulator Peptide, Stimulates 
Neutrophil Chemotaxis Via a Formyl Peptide Receptor. Biochem. Biophys. Res. Commun. 2008, 
369, 573-578. 
(4) Gouin, J. P.; Hantsoo, L.; Kiekolt-Glaser, J. K. Immune Disregulation and Chronic Stress Among 
Older Adults: A Review. Neuroimmunomod. 2008, 15, 251-259. 
(5) Jones, R. N. Resistance Patterns Among Nosocomial Phatogens: Trends Over the Past Few 
Years. Chest 2001, 119, 397S-404S. 
(6) Gilroy, D. W.; Lawrence, T.; Perretti, P.; Rossi, A. G. Inflammatory Resolution: new 
opportunities for drug discovery. Nat. Rev. Drug Discov. 2004, 3, 401-416. 
(7) Zhang, L.; Falla, T. J. Host Defense Peptides for Use as Potential Therapeutics. Curr. Opin. 
Invest. Drugs 2009, 10, 164-171. 
(8) LaFleur-Brooks, M. In Exploring Medical Language, 7th ed.: A Student-Directed Approach. 
Mosby Elsevier: St. Louis, Missouri, 2008; pp. 398. 
(9) Blumenreich, M. S. In Clinical Methods, 3rd ed.: The History, Physical, and Laboratory 
Examinations. Chapter 153: The White Blood Cell and Differential Count. Walker H. K., Hall W. 
D., Hurst J. W., Eds; Boston: Butterworths, 1990; pp. 724-727. 
(10) Gartner, L. P.; Hiatt, J. L. In Color Textbook of Histology, 3rd ed. Saunders Elsevier: 
Philadelphia, 2007; pp. 225. 
(11) Nathan, C. Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 2006, 6, 
173-182. 
(12) Klebanoff, S. J.; Clark, R. A. The Neutrophil: Function and Clinical Disorders. Elsevier/North-
Holland: Amsterdam, 1978. 
(13) Waugh, D. J.; Wilson C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 2008,  14, 6735-
6741. 
(14)  De Larco, J. E.; Wuertz, B. R. K.; Furcht, L. T. The Potential Role of Neutrophils in Promoting 
the Metastatic Phenotype of Tumors Releasing Interleukin-8. Clin. Cancer Res. 2004, 10, 4895-
4900. 
(15) Cohen, S. S.; Burns, R. C.; Eds. In Pathways of the pulp, 8th ed. Mosby Elsevier: St. Louis, 
Missouri, 2002; pp. 465. 
(16) Witko-Sarsat, V.; Rieu, P.; Descamps-Latscha, B.; Lesavre, P.; Halbwachs-Mecarelli L. 
Neutrophils: molecules, functions and pathophysiological aspects. Lab. Invest. 2000, 80, 617-653. 
(17) Hickey, M. J.; Kubes, P. Intravascular immunity: the host-pathogen encounter in blood vessels. 
Nat. Rev. Immunol. 2009, 9, 364-375. 
(18) Ear, T.; McDonald, P. P. Cytokine generation, promoter activation, and oxidant-independent NF-
κB activation in a transfectable human neutrophilic cellular model. BMC Immunol. 2008, 9, 14.  
(19) Voehringer, D. The role of basophils in helminth infection. Trends in Parasitol. 2009, 25, 551-
556. 
(20) Janeway, C. A., Jr.; Travers, P.; Walport, M.; Shlomchik, M. J.; et al. Immunobiology, 5th ed. 
(electronic full text via NCBI Bookshelf). Garland Publishing: New York and London, 2001. 
(21) Schroeder, J. T. Basophils beyond effector cells of allergic inflammation. Adv. Immunol. 2009, 
101, 123-161. 
7. Bibliographic References 
 
 198
(22) Young, B.; Lowe, J. S.; Stevens, A.; Heath, J. W.; et al. Wheater's Functional Histology, 5th ed.: a 
Text and Colour Atlas. Elsevier Limited: Philadelphia, 2006. 
(23) Rothenberg, M. E.; Hogan, S. P. The eosinophil. Annu. Rev. Immunol. 2006, 24, 147-174. 
(24) Yamaguchi, Y.; Suda, T.; Suda, J.; Eguchi, M.; Miura, Y.; Harad, N.; Tominaga, A.; Takatsu, K. 
Purified interleukin-5 supports the terminal differentiation and proliferation of murine eosinophilic 
precursors. J. Exp. Med. 1988, 167, 43-56. 
(25) Trulson, A.; Byström, J.; Engström, A.; Larsson, R.; Venge, P. The functional heterogeneity of 
eosinophil cationic protein is determined by a gene polymorphism and post-translational 
modifications. Clin. Exp. Allergy 2007, 37, 208-218. 
(26) Gleich, G.; Adolphson, C. The eosinophilic leukocyte: structure and function. Adv. Immunol. 
1986, 39, 177-253. 
(27) Bandeira-Melo, C.; Bozza, P. T.; Weller P. F. The cellular biology of eosinophil eicosanoid 
formation and function. J. Allergy Clin. Immunol. 2002, 109, 393-400. 
(28) Kato, Y.; Fujisawa, T.; Nishimori, H.; Katsumata, H.; Atsuta, J.; Iguchi, K.; Kamiya, H. 
Leukotriene D4 induces production of transforming growth factor-beta1 by eosinophils. Int. Arch. 
Allergy Immunol. 2005, 137 (Suppl 1), 17-20.  
(29) Horiuchi, T.; Weller, P. F. Expression of vascular endothelial growth factor by human eosinophils: 
upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am. J. 
Respir. Cell Mol. Biol. 1997, 17, 70-77. 
(30) Abbas A. K.; Lichtman A. H. Cellular and Molecular Immunology, 5th ed. Saunders Elsevier: 
Philadelphia, 2003. 
(31) Kumar, V.; Abbas, A. K.; Fausto, N. Rpbbons & Cotran Pathologic Basis of Disease, 7th ed. 
Saunders Elsevier: Philadelphia, 2005. 
(32) Pantaleo, G.; Demarest, J. F.; Soudeyns, H.; Graziosi, C.; Denis, F.; Adelsberger, J. W.; Borrow, 
P.; Saag, M. S.; Shaw, G. M.; Sekaly, R. P.; Fauci A. S. Major expansion of CD8+ T cells with a 
predominant V beta usage during the primary immune response to HIV. Nature 1994, 370, 463-
467. 
(33) Swirski, F. K.; Nahrendorf, M.; Etzrodt, M.; Wildgruber, M.; Cortez-Retamozo, V.; Panizzi, P.; 
Figueiredo, J.-L.; Kohler, R. H.; Chudnovskiy, A.; Waterman, P.; Aikawa, E.; Mempel, T. R.; 
Libby, P.; Weissleder R.; Pittet, M. J. Identification of Splenic Reservoir Monocytes and Their 
Deployment to Inflammatory Sites. Science 2009, 325, 612-616. 
(34) Ziegler-Heitbrock, H. W. L. The CD14+ CD16+ blood monocytes: their role in infection and 
inflammation. J. Leukoc. Biol. 2007, 81, 584-592. 
(35) Fingerle, G.;  Pforte, A.; Passlick, B.; Blumenstein, M.; Strobel, M.; Ziegler- Heitbrock, H. W. L. 
The Novel Subset of CD14+/CD16+ Blood Monocytes Is Expanded in Sepsis Patients. Blood 
1993, 82, 3170-3176. 
(36) McKenna, K.; Beignon, A.; Bhardwaj, N.  Plasmacytoid dendritic cells: linking innate and 
adaptive immunity. J. Virol. 2005, 79, 17-27. 
(37) Steinman, R. M.; Cohn, Z. A. Identification of a novel cell type in peripheral lymphoid organs of 
mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 1973, 137, 1142-1162. 
(38) Sallusto F, Lanzavecchia A. The instructive role of dendritic cells on T-cell responses. Arthritis 
Res. 2002, 4 (Suppl 3), S127-132. 
(39) Beutler, B. Innate immunity: An overview. Mol. Immunol. 2004, 40, 845-859. 
(40) Le, Y.; Murphy P. M.; Wang J. M. Formyl-peptide receptors revisited. Trends Immunol 2002, 23, 
541-548. 
(41) Le, Y.; Ye, R. D.; Gong, W.; Li, J.; Iribarren, P.; Wang J. M. Identification of functional domains 
in the formyl peptide receptor-like 1 for agonist-induced cell chemotaxis. FEBS Journal 2005, 
272, 769–778. 
(42) Snyderman, R.; Uhing R. J. In Inflammation: Basic Principles and Clinical , 2nd ed. Gallin, J. I., 
Goldstein, I. M. and Snyderman, R., Eds.; Raven Press: New York, 1992, pp. 421-439. 
7. Bibliographic References 
 199 
(43) Beutler, B.; Hoebe, K.; Du, X.; Ulevitch, R. J. How we detect microbes and respond to them: the 
Toll-like receptors and their transducers. J. Leukoc. Biol. 2003, 74, 479-485. 
(44) Guo, R. F.; Ward, P. A. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 2005, 23, 
821-852. 
(45) Sun, R.; Iribarren, P.; Zhang, N.; Zhou, Y.; Gong, W.; Cho, E. H.; Lockett, S.; Chertov, O.; 
Bednar, F.; Rogers, T. J.; Oppenheim, J. J.; Wang J. M. Identification of Neutrophil Granule 
Protein Cathepsin G as a Novel Chemotactic Agonist for the G Protein-coupled Formyl Peptide 
Receptor. J. Immunol. 2004, 173, 428-436. 
(46) Kobayashi, S. D.; Voyich, J. M.; De Leo, F. R. Regulation of the neutrophil-mediated 
inflammatory response to infection. Microbes Infect. 2003, 5, 1337-1344. 
(47) Delves, P. J.; Roitt, I. M. The immune system. Second of two parts. N. Engl. J. Med. 2000, 343, 
108-117. 
(48) Migeotte, I.; Communi, D.; Parmentier, M.; Formyl peptide receptors: a promiscuous subfamily of 
G protein-coupled receptors controlling immune responses. Cytok. Growth Factor Rev. 2006, 17, 
501-519. 
(49) Ye, R. D.; Boulay, F.; Wang, J. M.; Dahlgren, C.; Gerard, C.; Parmentier, M.; Serhan, C. N.; 
Murphy, P. M. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature 
for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 2009, 61,119-161. 
(50) Bokoch, G. M.; Gilman, A. G. Inhibition of Receptor-Mediated Release of Arachidonic Acid by 
Pertussis Toxin. Cell 1984, 39, 301-308. 
(51) Simon, M. I.; Strathmann, M. P.; Gautam, N. Diversity of G proteins in signal transduction. 
Science 1991, 252, 802-808. 
(52) Bokoch, G. M.; Katada, T.; Northup, J. K.; Ui, M.; Gilman, A. G. Purification and properties of 
the inhibitory guanine nucleotide-binding regulatory component of adenylate cyclase. J. Biol. 
Chem. 1984, 259, 3560-3567. 
(53) Gierschik, P.; Sidiropoulos, D.; Jakobs, K. H. Two distinct Gi-proteins mediate formyl peptide 
receptor signal transduction in human leukemia (HL-60) cells. J. Biol. Chem. 1989, 264, 21470-
21473. 
(54) Schiffmann, E.; Showell, H. V.; Corcoran, B. A.; Ward, P. A.; Smith, E.; Becker, E. L. The 
isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J. 
Immunol. 1975, 114, 1831-1837. 
(55) Schiffmann, E.; Corcoran, B. A.; Wahl, S. M. N-formylmethionyl peptides as chemoattractants for 
leucocytes. Proc. Natl. Acad. Sci. USA 1975, 72, 1059-1062. 
(56) Freer, R. J.; Day, A. R.; Radding, J. A.; Schiffmann, E.; Aswanikumar, S.; Showell H. J.; Becker, 
E. L. Further studies on the structural requirements for synthetic peptide chemoattractants. 
Biochemistry 1980, 19, 2404-10.  
(57) Showell, H. J.; Freer, R. J.; Zigmond, S. H.; Schiffmann, E.; Aswanikumar, S.; Corcoran, B.; 
Becker, E. L. The structure-activity relations of synthetic peptides as chemotactic factors and 
inducers of lysosomal secretion for neutrophils. J. Exp. Med. 1976, 143, 1154–1169. 
(58) Prossnitz ER and Ye RD (1997) Pharmacol Ther 74:73–102;  
(59) Mills, J. S.; Miettinen, H. M.; Jesaitis A.J. In Molecular Biology of Inflammation: The N-formyl 
peptide receptor: Structure, signaling and disease. Serhan, C. N. and Ward, P. A., Eds); Humana 
Press: Totowa, NJ, 1999; pp.215-245. 
(60) Gao, J. L.; Lee, E. J.; Murphy, P. M. Impaired antibacterial host defense in mice lacking the N-
formylpeptide receptor. J. Exp. Med. 1999, 189, 657-662. 
(61) Nanamori, M.; Cheng, X.; Mei, J.; Sang, H.; Xuan, Y.; Zhou, C.; Wang, M. W.; Ye, R. D. A 
Novel Nonpeptide Ligand for Formyl Peptide Receptor-Like 1. Mol. Pharmacol. 2004, 66, 1213-
1222. 
7. Bibliographic References 
 
 200
(62) Yang, D.; Chen, Q.; Gertz, B.; He, R.; Phulsuksombati, M.; Ye, R. D.; Oppenheim, J. J. Human 
dendritic cells express functional formyl peptide receptor-like-2 (FPRL2) throughout maturation. 
J. Leukoc. Biol. 2002, 72, 598-607. 
(63)  Yang, D.; Chen, Q.; Le, Y.; Wang, J. M.; Oppenheim, J. J. Differential regulation of formyl 
peptide receptor-like 1 expression during the differentiation of monocytes to dendritic cells and 
macrophages. J. Immunol. 2001, 166, 4092-4098. 
(64) Allen, R. A.; Jesaitis, A. J.; Cochrane, C. G. In Cellular and Molecular Mechanisms of 
Inflammation. Academic Press, San Diego, CA, 1990; Vol. 1, pp. 83-112 
(65) Boulay, F.; Tardif, M.; Brouchon, L.; Vignais, P. Synthesis and use of a novel N-formyl peptide 
derivative to isolate a human N-formyl peptide receptor cDNA. Biochem. Biophys. Res. Commun. 
1990, 168, 1103-1109. 
(66) Boulay, F.; Tardif, M.; Brouchon, L.; Vignais, P. The human N-formylpeptide receptor. 
Characterization of two cDNA isolates and evidence for a new subfamily of G-protein-coupled 
receptors. Biochemistry 1990, 29, 11123-11133. 
(67) Quehenberger, O.; Prossnitz, E. R.; Cavanagh, S. L.; Cochrane, C. G.; Ye, R. D. Multiple domains 
of the N-formyl peptide receptor are required for high-affinity ligand binding. Construction and 
analysis of chimeric N-formyl peptide receptors. J. Biol. Chem. 1993, 268, 18167-18175. 
(68) Ye, R. D.; Quehenberger, O.; Thomas, K. M.; Navarro, J.; Cavanagh, S. L.; Prossnitz, E. R.; 
Cochrane, C. G. The rabbit neutrophil N-formyl peptide receptor. cDNA cloning, expression, and 
structure/function implications. J. Immunol. 1993, 150, 1383-1394. 
(69) Kirpotina, L. N.; Khlebnikov, A. I.; Schepetkin, I. A.; Ye, R. D.; Rabiet, M. J.; Jutila, M. A.; 
Quinn, M. T. Identification of novel small-molecule agonists for human formyl peptide receptors 
and pharmacophore models of their recognition. Mol. Pharmacol. 2010, 77, 159-170. 
(70) Becker, E. L.; Forouhar, F. A.; Grunnet, M. L.; Boulay, F.; Tardif, M.; Bormann, B. J.; Sodja, D.; 
Ye, R. D.; Woska, J. R. Jr, Murphy, P. M. Broad immunocytochemical localization of the 
formylpeptide receptor in human organs, tissues, and cells. Cell Tissue Res. 1998, 292, 129-35. 
(71) Murphy, P. M.; Ozçelik, T.; Kenney, R. T.; Tiffany, H. L.; McDermott, D.; Franche, U. A 
structural homologue of the N-formyl peptide receptor. Characterization and chromosome 
mapping of a peptide chemoattractant receptor family. J. Biol. Chem. 1992, 267, 7637-7643. 
(72) Perez, H. D.; Holmes, R.; Kelly, E.; McClary, J.; Andrews, W. H. Cloning of a cDNA encoding a 
receptor related to the formyl peptide receptor of human neutrophils. Gene 1992, 118, 303-304. 
(73) Ye, R. D.; Cavanagh, S. L.; Quehenberger, O.; Prossnitz, E. R.; Cochrane, C. G. Isolation of a 
cDNA that encodes a novel granulocyte N-formyl peptide receptor. Biochem. Biophys. Res. 
Commun. 1992, 184, 582-589. 
(74) Bao, L.; Gerard, N. P.; Eddy, R. L. Jr; Shows, T. B.; Gerard, C. Mapping of genes for the human 
C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homologue orphan 
receptors (FPRH1, FPRH2) to chromosome 19. Genomics 1992, 13,437-440. 
(75) Nomura, H.; Nielsen, B. W.; Matsushima, K. Molecular cloning of cDNAs encoding a LD78 
receptor and putative leukocyte chemotactic peptide receptors. Int. Immunol. 1993, 5, 1239-1249. 
(76) Perretti, M.; Chiang, N.; La, M.; Fierro, I. M.; Marullo, S.; Gettino, S. J.; Solito, E.; Serhan, C. N. 
Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid 
and aspirin treatment activate the lipoxin A4 receptor. Nat. Med. 2002, 8, 1296-1302. 
(77) Resnati, M.; Pallavicini, I.; Wang, J. M.; Oppenheim, J.; Serhan, C. N.; Romano, M.; Blasi, F. The 
fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor 
FPRL1/LXA4R. Proc. Natl. Acad. Sci. USA 2002, 99, 1359-1364. 
(78) Fiore, S.; Maddox, J. F.; Perez, H. D.; Serhan, C. N. Identification of a human cDNA encoding a 
functional high affinity lipoxin A4 receptor. J. Exp. Med. 1994, 180, 253-260. 
(79) Chiang, N.; Serhan, C. N.; Dahlén, S. E.; Drazen, J. M.; Hay, D. W.; Rovati, G. E.; Shimizu, T.; 
Yokomizo, T.; Brink, C. The lipoxin receptor ALX: potent ligand-specific and stereoselective 
actions in vivo. Pharmacol. Rev. 2006, 58, 463-487. 
7. Bibliographic References 
 201 
(80) Le, Y.; Oppenheim, J. J.; Wang, J. M. Pleiotropic roles of formyl peptide receptors. Cytok. Growth 
Factor Rev. 2001, 12, 91-105. 
(81) Brink, C.; Dahlén, S. E.; Drazen, J.; Evans, J. F.; Hay, D. W.; Nicosia, S.; Serhan, C. N.; Shimizu, 
T.; Yokomizo, T. International Union of Pharmacology XXXVII. Nomenclature for leukotriene 
and lipoxin receptors. Pharmacol. Rev. 2003, 55, 195-227. 
(82) Rabiet, M. J.; Huet, E.; Boulay, F. Human mitochondria-derived N-formylated peptides are novel 
agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides 
preferentially activate FPR. Eur. J. Immunol. 2005, 35, 2486-2495. 
(83) Durstin, M.; Gao, J. L.; Tiffany, H. L.; McDermott, D.; Murphy, P. M. Differential expression of 
members of the N-formylpeptide receptor gene cluster in human phagocytes. Biochem. Biophys. 
Res. Commun. 1994, 201, 174-179.  
(84) Christophe, T.; Karlsson, A.; Dugave, C.; Rabiet, M. J.; Boulay, F.; Dahlgren, C. The synthetic 
peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin 
A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor 
FPRL2. J. Biol. Chem. 2001, 276, 21585–21593. 
(85) Betten, A.; Bylund, J.; Christophe, T.; Cristophe, T.; Boulay, F.; Romero, A.; Hellstrand, K.; 
Dahlgren, C. A proinflammatory peptide from Helicobacter pylori activates monocytes to induce 
lymphocyte dysfunction and apoptosis. J. Clin. Invest. 2001, 108,1221–1228. 
(86) Migeotte, I.; Riboldi, E.; Franssen, J. D.; Grégoire, F.; Loison, C.; Wittamer, V.; Detheux, M.; 
Robberecht, P.; Costagliola, S.; Vassart, G.; Sozzani, S.; Parmentier, M.; Communi, D. 
Identification and characterization of an endogenous chemotactic ligand specific for FPRL2. J. 
Exp. Med. 2005, 201, 83-93.  
(87) Dufton, N.; Perretti, M. Therapeutic anti-inflammatory potential of formyl-peptide receptor 
agonists. Pharmacol. Ther. 2010, 127, 175-188. 
(88) Rabiet, M. J., Huet, E.; Boulay, F. The N-formyl peptide receptors and the anaphylatoxin C5a 
receptors: an overview. Biochimie 2007, 89, 1089–1106. 
(89) Partida-Sánchez, S.; Iribarren, P.; Moreno-García, M. E.; Gao, J. L.; Murphy, P. M.; 
Oppenheimer, N.; Wang, J. M.; Lund, F. E. Chemotaxis and calcium responses of phagocytes to 
formyl peptide receptor ligands is differentially regulated by cyclic ADP ribose. J. Immunol. 2004, 
172, 1896-1906. 
(90) Katanaev, V. L. Signal transduction in neutrophil chemotaxis. Biochemistry 2001, 66, 351-368. 
(91) Hanahan, D. J. Platelet activating factor: A biologically activephosphoglyceride. Annu. Rev. 
Biochem. 1986, 55, 483-509. 
(92) Crooks, S. W.; Stockley, R. A. Leukotriene B4. Int. J. Biochem. Cell Biol. 1998, 30, 173-178. 
(93) Gerard, C.; Gerard, N. P. C5a anaphylatoxin and its seven transmembrane-segment receptor. 
Annu. Rev. Immunol. 1994, 12, 775-808. 
(94) Baggiolini, M. Chemokines and leukocyte traffic. Nature 1998, 392, 565-568. 
(95) Ali, H.; Richardson, R. M.; Haribabu, B.; Snyderman, R. Chemoattractant receptor cross-
desensitization. J. Biol. Chem. 1999, 274, 6027–6030. 
(96) Panaro, M. A.; Mitolo, V. Cellular responses to FMLP challenging:A mini-review. 
Immunopharmacol. Immunotoxicol. 1999, 21, 397-419. 
(97) Selvatici, R.; Falzarano, S.; Mollica, A.; Spisani, S. Signal transduction pathways triggered by 
selective formylpeptide analogues in human neutrophils. Eur. J. Pharmacol. 2006, 534, 1-11. 
(98) Campbell, J. J.; Foxman, E. F.; Butcher, E. C. Chemoattractant receptor cross talk as a regulatory 
mechanism in leukocyte adhesion and migration. Eur. J. Immunol. 1997, 27, 2571-2578.  
(99) Foxman, E. F.; Campbell, J. J.; Butcher, E. C. Multistep navigation and the combinatorial control 
of leukocyte chemotaxis. J. Cell Biol. 1997, 139, 1349-1360. 
(100) Foxman, E. F.; Kunkel, E. J.; Butcher, E. C. Integrating conflicting chemotactic signals. The role 
of memory in leukocyte navigation. J. Cell Biol. 1999, 147, 577-588. 
7. Bibliographic References 
 
 202
(101) Heit, B.; Robbins, S. M.; Downey, C. M.; Guan, Z.; Colarusso, P.; Miller, B. J.; Jirik, F. R.; 
Kubes, P. PTEN functions to ‘prioritize’ chemotactic cues and prevent ‘distraction’ in migrating 
neutrophils. Nat. Immunol. 2008, 9,743-752. 
(102) Heit, B.; Tavener, S.; Raharjo, E.; Kubes, P. An intracellular signalling ierarchy determines 
direction of migration in opposing chemotactic gradients. J. Cell Biol. 2002, 159, 91-102. 
(103) Boxer,  L. A.; Yoder, M.; Bonsib, S.; Schmidt, M.; Ho, P.; Jersild, R.; Baehner, R. L. Effects of a 
chemotactic factor, N-formylmethionyl peptide, on adherence, superoxide anion generation, 
phagocytosis, and microtubule assembly of human polymorphonuclear leukocytes. J. Lab. Clin. 
Med. 1979, 93, 506-514.  
(104) Lehmeyer, J. E.; Snyderman, R.; Johnston, R. B. Jr. Stimulation of neutrophil oxidative 
metabolism by chemotactic peptides: influence of calcium ion concentration and cytochalasin B 
and comparison with stimulation by phorbol myristate acetate. Blood 1979, 54, 35-45. 
(105) Babior, B. M.; Lambeth, J. D.; Nauseef, W. The neutrophil NADPH oxidase. Arch. Biochem. 
Biophys. 2002, 397, 342-344. 
(106) Karnad, A. B.; Hartshorn, K. L.; Wright, J.; Myers, J. B.; Schwartz, J. H.; Tauber, A. I. Priming of 
human neutrophils with N-formyl-methionyl-leucyl-phenylalanine by a calcium-independent, 
pertussis toxin-insensitive pathway. Blood 1989, 74, 2519-2526. 
(107) Bentwood, B. J.; Henson, P. M. The sequential release of granule constitutents from human 
neutrophils. J. Immunol. 1980, 124, 855-862. 
(108) Nauseef, W. M. How human neutrophils kill and degrade microbes: an integrated view. Immunol. 
Rev. 2007, 219, 88-102. 
(109) Sengeløv, H.; Boulay, F.; Kjeldsen, L.; Borregaard, N. Subcellular localization and translocation 
of the receptor for N-formylmethionyl-leucyl-phenylalanine in human neutrophils. Biochem. J. 
1994,  299, 473-479. 
(110) Bylund, J.; Karlsson, A.; Boulay, F.; Dahlgren, C. Lipopolysaccharide-induced granule 
mobilization and priming of the neutrophil response to Helicobacter pylori peptide Hp(2–20), 
which activates formyl peptide receptor-like 1. Infect. Immun. 2002, 70, 2908-2914. 
(111) Smith, R. J.; Sam, L. M.; Justen, J. M. Diacylglycerols modulate human polymorphonuclear 
neutrophil responsiveness: effects on intracellular calcium mobilization, granule exocytosis, and 
superoxide anion production. J. Leukoc. Biol. 1998, 43, 411-419. 
(112) Sengeløv, H.; Kjeldsen, L.; Borregaard, N. Control of exocytosis in early neutrophil activation. J. 
Immunol. 1993, 150, 1535-1543. 
(113) Lloyd, A. R.; Oppenheim, J. J. Poly’s lament: the neglected role of the polymorphonuclear 
neutrophil in the afferent limb of the immune response. Immunol. Today 1992, 13, 169-172. 
(114) Cassatela, M. A.; Bazzoni, F.; Ceska, M.; Ferro, I.; Baggiolini, M.; Berton, G. IL-8 production by 
human polymorphonuclear leukocytes. The chemoattractant formylmethionyl- leucyl-
phenylalanine induces the gene expression and release of IL-8 through a pertussis toxin-sensitive 
pathway. J. Immunol. 1992, 148, 3216-3220. 
(115) McDonald, P. P.; Bald, A.; Cassatella, M. A. Activation of the NF-kappaB pathway by 
inflammatory stimuli in human neutrophils. Blood 1997, 89, 3421-3433. 
(116) He, R.; Sang, H.; Ye, R. D. Serum amyloid A induces IL-8 secretion through a G protein-coupled 
receptor, FPRL1/LXA4R. Blood 2003, 101, 1572-1581. 
(117) Ye, R. D. Regulation of nuclear factor kappaB activation by G-protein-coupled receptors. J. 
Leukoc. Biol. 2001, 70, 839-848. 
(118) Perretti, M. The annexin 1 receptor(s): is the plot unravelling? Trends Pharmacol. Sci. 2003, 24, 
574-579. 
(119) József, L.; Zouki, C.; Petasis, N. A.; Serhan, C. N.; Filep, J. G. Lipoxin A4 and aspirin-triggered 
15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene 
expression in human leukocytes. Proc. Natl. Acad. Sci. USA 2002, 99, 13266-13271. 
7. Bibliographic References 
 203 
(120) Damian, M.; Mary, S.; Martin, A.; Pin, J. P.; Banères, J. L. G protein activation by the leukotriene 
B4 receptor dimer. Evidence for an absence of trans-activation. J. Biol. Chem. 2008, 283, 21084-
21092. 
(121) Su, S. B.; Gong, W.; Gao, J. L.; Shen, W.; Murphy, P. M.; Oppenheim, J. J.; Wang, J. M. A 
seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of 
serum amyloid A for human phagocytic cells. J. Exp. Med. 1999, 189, 395-402.  
(122) Bae, Y. S.; Park, J. C.; He, R.; Ye, R. D.; Kwak, J. Y.; Suh, P. G.; Ho Ryu S. Differential 
signaling of formyl peptide receptor-like 1 by Trp-Lys-Tyr-Met-Val-Met-CONH2 or lipoxin A4 in 
human neutrophils. Mol. Pharmacol. 2003, 64, 721-730.  
(123) Prat, C.; Bestebroer, J.; de Haas, C. J.; van Strijp, J. A.; van Kessel, K. P. A new staphylococcal 
anti-inflammatory protein that antagonizes the formyl peptide receptor-like 1. J. Immunol. 2006, 
177, 8017-8026.  
(124) Maddox, J. F.; Hachicha, M.; Takano, T.; Petasis, N. A.; Fokin, V. V.; Serhan, C. N. Lipoxin A4 
stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-
protein-linked lipoxin A4 receptor. J. Biol. Chem. 1997, 272, 6972-6978. 
(125) Savill, J. Apoptosis in resolution of inflammation. J. Leukoc. Biol. 1997, 61, 375-380. 
(126) Colotta, F.; Re, F.; Polentarutti, N.; Sozzani, S.; Mantovani, A. Modulation of granulocyte 
survival and programmed cell death by cytokines and bacterial products. Blood 1992, 80, 2012-
2020. 
(127) Kettritz, R.; Falk, R. J.; Jennette, J. C.; Gaido, M. L. Neutrophil superoxide release is required for 
spontaneous and FMLP-mediated but not for TNF alphamediated apoptosis. J. Am. Soc. Nephrol. 
1997, 8, 1091-1100. 
(128) Cui, Y.; Le, Y.; Yazawa, H.; Gong, W.; Wang, J. M. Potential role of the formyl peptide receptor-
like 1 (FPRL1) in inflammatory aspects of Alzheimer's disease. J. Leukoc. Biol. 2002, 72, 628-
635. 
(129) Arterburn, J. B.; Oprea, T. I.; Prossnitz, E. R.; Edwards, B. S.; Sklar, L. A. Discovery of selective 
probes and antagonists for G-protein-coupled receptors FPR/FPRL1 and GPR30. Curr. Top. Med. 
Chem. 2009, 9, 1227-1236. 
(130) Tsuruky, T.; Takahata, K.; Yoshikawa, M. Mechanism of protective effect of intraperitoneally 
administered agonists for Formyl Peptide Receptors against Chemotherapy induced alopecia, 
Biosci. Biothecol. Bochem. 2007, 71, 1198-1202. 
(131) Zhou, H.; Zhou, X.; Kouadir, M.; Zhang, Z.; Yin, X.; Yang, L.; Zhao, D. Induction of macrophage 
migration by neurotoxic prion protein fragment. J. Neurosci. Methods 2009, 181, 1-5.  
(132) Wild, C.; Dubay, J. W.; Greenwell, T.; Baird, T. Jr; Oas, T. G.; McDanal, C.; Hunter, E.; 
Matthews, T. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 
1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the 
glycoprotein complex. Proc. Natl. Acad. Sci. USA 1994, 91, 12676-12680. 
(133) Kilby, J. M.; Hopkins, S.; Venetta, T. M.; Di Massimo, B.; Cloud, G. A.; Lee, J. Y.; Alldredge, L.; 
Hunter, E.; Lambertm D.; Bolognesi, D.; Matthews, T.; Johnson, M. R.; Nowak, M. A.; Shaw, G. 
M.; Saag, M. S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of 
gp41-mediated virus entry. Nat. Med. 1998, 4, 1302-1307. 
(134) Walther, A.; Riehemann, K.; Gerke, V. A novel ligand of the formyl peptide receptor: annexin I 
regulates neutrophil extravasation by interacting with the FPR. Mol Cell. 2000, 5, 831-840. 
(135) de Paulis, A.; Florio, G.; Prevete, N.; Triggiani, M.; Fiorentino, I.; Genovese, A.; Marone, G. 
HIV-1 Envelope gp41 Peptides Promote Migration of Human FcєRI+ Cells and Inhibit IL-13 
Synthesis Through Interaction with Formyl Peptide Receptors. J. Immunol. 2002, 169, 4559-4567. 
(136) de Paulis, A.; Montuori, N.; Prevete, N.; Fiorentino, I.; Rossi, F. W.; Visconte, V.; Rossi, G.; 
Marone, G.; Ragno, P. Urokinase induces basophil chemotaxis through a urokinase receptor 
epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2. J. Immunol. 
2004, 173,  5739-5748. 
7. Bibliographic References 
 
 204
(137) de Paulis, A.; Prevete, N.; Fiorentino, I.; Walls, A. F.; Curto, M.; Petraroli, A.; Castaldo, V.; 
Ceppa, P.; Fiocca, R.; Marone, G. Basophils infiltrate human gastric mucosa at sites of 
Helicobacter pylori infection, and exhibit chemotaxis in response to H. pylori-derived peptide 
Hp(2–20). J. Immunol. 2004, 172, 7734-7743. 
(138) Pieretti, S.; Di Giannuario, A.; De Felice, M.; Perretti, M.; Cirino, G. Stimulus-dependent 
specificity for annexin 1 inhibition of the inflammatory nociceptive response: the involvement of 
the receptor for formylated peptides. Pain 2004, 109, 52-63. 
(139) Edwards, B. S.; Bologa, C.; Young, S. M.; Balakin, K. V.; Prossnitz, E. R.; Savchuck, N. P.; 
Sklar, L. A.; Oprea, T. I. Integration of virtual screening with high-throughput flow cytometry to 
identify novel small molecule formylpeptide receptor antagonists. Mol. Pharmacol. 2005, 68, 
1301-1310.  
(140) Medzhitov, R.; Janeway, C. Jr. Innate immune recognition: mechanisms and pathways. Immunol. 
Rev. 2000, 173, 89-97. 
 (141) Gulden, P. H.; Fischer, P. 3rd; Sherman, N. E.; Wang, W.; Engelhard, V. H.; Shabanowitz, J.; 
Hunt, D. F.; Pamer, E. G. A Listeria monocytogenes pentapeptide is presented to cytolytic T 
lymphocytes by the H2–M3 MHC class Ib molecule. Immunity 1996, 5, 73-79. 
(142) Chen, J.; Bernstein, H. S.; Chen, M.; Wang, L.; Ishii, M.; Turck, C. W.; Coughlin, S. R. Tethered 
ligand library for discovery of peptide agonists. J. Biol. Chem. 1995,  270, 23398-23401. 
(143) Hashimoto, Y.; Niikura, T.; Ito, Y.; Sudo, H.; Hata, M.; Arakawa, E.; Abe, Y.; Kita, Y.; 
Nishimoto, I. Detailed characterization of neuroprotection by a rescue factor humanin against 
various Alzheimer’s disease-relevant insults. J. Neurosci. 2001, 21,  9235-9245. 
(144) Ying, G.; Iribarren, P.; Zhou, Y.; Gong, W.; Zhang, N.; Yu, Z. X.; Le, Y.; Cui, Y.; Wang, J. M. 
Humanin, a newly identified neuroprotective factor, uses the G proteincoupled formylpeptide 
receptor-like-1 as a functional receptor. J. Immunol. 2004, 172, 7078-7085. 
(145) Harada, M.; Habata, Y.; Hosoya, M.; Nishi, K.; Fujii, R.; Kobayashi, M.; Hinuma, S. N-
Formylated humanin activates both formyl peptide receptor-like 1 and 2. Biochem. Biophys. Res. 
Commun. 2004, 324, 255-261. 
(146) Mills, J. S.; Miettinen, H. M.; Barnidge, D.; Vlases, M. J.; Wimer-Mackin, S.; Dratz, E. A.; 
Sunner, J.; Jesaitis, A. J. Identification of a ligand binding site in the human neutrophil formyl 
peptide receptor using a site-specific fluorescent photoaffinity label and mass spectrometry. J. 
Biol. Chem. 1998, 273, 10428-10435. 
(147) Su, S. B.; Gao, J.; Gong, W.; Dunlop, N. M.; Murphy, P. M.; Oppenheim, J. J.; Wang, J. M. 
T21/DP107, A synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and 
activates human phagocytes by using G-protein-coupled Formyl peptide receptors. J. Immunol. 
1999, 162, 5924-5930.  
(148) Su, S. B.; Gong, W. H.; Gao, J. L.; Shen, W. P.; Grimm, M. C.; Deng, X.; Murphy, P. M.; 
Oppenheim, J. J.; Wang, J. M. T20/DP178, an ectodomain peptide of human immunodeficiency 
virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor. Blood 1999, 93, 
3885-3892.  
(149) Le, Y.; Jiang, S.; Hu, J.; Gong, W.; Su, S.; Dunlop, N. M.; Shen, W.; Li, B.; Wang J.  M. N36, a 
synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of 
human phagocytes. Clin. Immunol. 2000, 96, 236-242.  
(150) Hartt, J. K.; Liang, T.; Sahagun-Ruiz, A.; Wang, J. M.; Gao, J. L.; Murphy, P. M. The HIV-1 cell 
entry inhibitor T-20 potently chemoattracts neutrophils by specifically activating the N-
formylpeptide receptor. Biochem. Biophys. Res. Commun. 2000,  272, 699-704. 
(151) Shen, W.; Proost, P.; Li, B.; Gong, W.; Le, Y.; Sargeant, R.; Murphy, P. M.; Van Damme, J.; 
Wang, J. M. Activation of the chemotactic peptide receptor FPRL1 in monocytes phosphorylates 
the chemokine receptor CCR5 and attenuates cell responses to selected chemokines. Biochem. 
Biophys. Res. Commun. 2000, 272, 276-283. 
7. Bibliographic References 
 205 
(152) Bellner, L.; Thorén, F.; Nygren, E.; Liljeqvist, J. A.; Karlsson, A.; Eriksson, K. A 
proinflammatory peptide from herpes simplex virus type 2 glycoprotein G affects neutrophil, 
monocyte, and NK cell functions. J. Immunol. 2005, 174, 2235-2241.  
(153) Mills, J. S. Peptides derived from HIV-1, HIV-2, Ebola virus, SARS coronavirus and coronavirus 
229E exhibit high affinity binding to the formyl peptide receptor. Biochim. Biophys. Acta 2006, 
1762, 693-703. 
(154) Kushner, I.; Rzewnicki, D. Acute phase response, In Inflammation: Basic Principles and Clinical 
Correlates. Gallin, J. I. and Snyderman, R. Eds. Lippincott Willams & Wilkins: Philadelphia, 
1999; pp. 317-329. 
(155) Lee, H. Y.; Kim, M. K.; Park, K. S.; Shin, E. H.; Jo, S. H.; Kim, S. D.; Jo, E. J.; Lee, Y. N.; Lee, 
C.; Baek, S. H.; Bae, Y. S. Serum amyloid A induces contrary immune responses via formyl 
peptide receptor-like 1 in human monocytes. Mol. Pharmacol. 2006, 70, 241-248. 
(156) O’Hara, R.; Murphy, E. P.; Whitehead, A. S.; FitzGerald, O.; Bresnihan, B. Local expression of 
the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with 
matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum. 
2004,  50, 1788-1799. 
(157) Sodin-Semrl, S.; Spagnolo, A.; Mikus, R.; Barbaro, B.; Varga, J.; Fiore, S. Opposing regulation of 
interleukin-8 and NF-kappaB responses by lipoxin A4 and serum amyloid A via the common 
lipoxin A receptor. Int. J. Immunopathol. Pharmacol. 2004, 17, 145-156. 
(158) Lee, M. S.; Yoo, S. A.; Cho, C. S.; Suh, P. G.; Kim, W. U.; Ryu, S. H. Serum amyloid A binding 
to formyl peptide receptor-like 1 induces synovial hyperplasia and angiogenesis. J. Immunol. 
2006,  177, 5585-5594. 
(159) Björkman, L.; Karlsson, J.; Karlsson, A.; Rabiet, M. J.; Boulay, F.; Fu, H.; Bylund, J.; Dahlgren, 
C. Serum amyloid A mediates human neutrophil production of reactive oxygen species through a 
receptor independent of formyl peptide receptor like-1. J. Leukoc. Biol. 2008,  83, 245-253. 
(160) Le, Y.; Gong, W.; Tiffany, H. L.; Tumanov, A.; Nedospasov, S.; Shen, W.; Dunlop, N. M.; Gao, J. 
L.; Murphy, P. M.; Oppenheim, J. J.; Wang, J. M. Amyloid (beta)42 activates a G-protein-coupled 
chemoattractant receptor, FPR-like-1. J. Neurosci. 2001, 21, RC123. 
(161) Tiffany, H. L.; Lavigne, M. C.; Cui, Y. H.; Wang, J. M.; Leto, T. L.; Gao, J. L.; Murphy, P. M. 
Amyloid-beta induces chemotaxis and oxidant stress by acting at formyl peptide receptor 2, a G 
protein-coupled receptor expressed in phagocytes and brain. J. Biol. Chem. 2001, 276, 23645-
23652. 
(162) Le, Y.; Yazawa, H.; Gong, W.; Yu, Z.; Ferrans, V. J.; Murphy, P. M.; Wang, J. M. The neurotoxic 
prion peptide fragment PrP(106–126) is a chemotactic agonist for the G protein-coupled receptor 
formyl peptide receptor-like 1. J. Immunol. 2001, 166, 1448-1451. 
(163) Chen, K.; Iribarren, P.; Hu, J.; Chen, J.; Gong, W.; Cho, E. H.; Lockett, S.; Dunlop, N M.; Wang, 
J. M. Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-
associated amyloid beta peptide. J. Biol. Chem. 2006, 281, 3651-3659. 
(164) Yazawa, H.; Yu, Z. X.; Takeda, L. Y.; Gong, W.; Ferrans, V. J.; Oppenheim, J. J.; Li, C. C.; 
Wang, J. M. Beta amyloid peptide (Abeta42) is internalized via the G-protein coupled receptor 
FPRL1 and forms fibrillar aggregates in macrophages. Faseb J. 2001, 15, 2454-2462. 
(165) Hashimoto, Y.; Niikura, T.; Ito, Y.; Sudo, H.; Hata, M.; Arakawa, E.; Abe, Y.; Kita, Y.; 
Nishimoto, I. Detailed characterization of neuroprotection by a rescue factor humanin against 
various Alzheimer’s disease-relevant insults. J. Neurosci. 2001, 21, 9235-9245. 
(166) Harada, M.; Habata, Y.; Hosoya, M.; Nishi, K.; Fujii, R.; Kobayashi, M.; Hinuma, S. N-
Formylated humanin activates both formyl peptide receptor-like 1 and 2. Biochem Biophys. Res. 
Commun. 2004, 324, 255-261.  
(167) Ying, G.; Iribarren, P.; Zhou, Y.; Gong, W.; Zhang, N.; Yu, Z. X.; Le, Y.; Cui, Y.; Wang, J. M. 
Humanin, a newly identified neuroprotective factor, uses the G proteincoupled formylpeptide 
receptor-like-1 as a functional receptor. J. Immunol. 2004, 172, 7078-7085. 
7. Bibliographic References 
 
 206
(168) Gargiulo, L.; Longanesi-Cattani, I.; Bifulco, K.; Franco, P.; Raiola, R.; Campiglia, P.; Grieco, P.; 
Peluso, G.; Stoppelli, M. P.; Carriero M. V. Cross-talk between fMLP and vitronectin receptors 
triggered by urokinase receptor-derived SRSRY peptide. J. Biol. Chem. 2005, 280, 25225-25232. 
(169) Furlan, F.; Orlando, S.; Laudanna, C.; Resnati, M.; Basso, V.; Blasi, F.; Mondino, A. The soluble 
D2D3(88–274) fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-
dependent cell adhesion. J. Cell. Sci. 2004, 117, 2909-2916. 
(170) Yang, D.; Chen, Q.; Schmidt, A. P.; Anderson, G. M.; Wang, J. M.; Wooters, J.; Oppenheiml, J. 
J.; Chertov, O. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes 
formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood 
neutrophils, monocytes, and T cells. J. Exp. Med. 2000, 192, 1069-1074. 
(171) Koczulla, R.; von Degenfeld, G.; Kupatt, C.; Krötz, F.; Zahler, S.; Gloe, T.; Issbrücker, K.; 
Unterberger, P.; Zaiou, M.; Lebherz, C.; Karl, A.; Raake, P.; Pfosser, A.; Boekstegers, P.; Welsch, 
U.; Hiemstra, P. S.; Vogelmeier, C.; Gallo, R. L.; Clauss, M.; Bals, R. An angiogenic role for the 
human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. 2003, 111, 1665-1672.  
(172) Sun, R.; Iribarren, P.; Zhang, N.; Zhou, Y.; Gong, W.; Cho, E. H.; Lockett, S.; Chertov, O.; 
Bednar, F.; Rogers, T. J.; Oppenheim, J. J.; Wang, J. M. Identification of neutrophil granule 
protein cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide 
receptor. J. Immunol. 2004, 173, 428-436. 
(173) Ernst, S.; Lange, C.; Wilbers, A.; Goebeler, V.; Gerke, V.; Rescher, U. An annexin 1 N-terminal 
peptide activates leukocytes by triggering different members of the formyl peptide receptor 
family. J. Immunol. 2004, 172, 7669-7676.  
(174) Karlsson, J.; Fu, H.; Boulay, F.; Dahlgren, C.; Hellstrand, K.; Movitz, C. Neutrophil NADPH-
oxidase activation by an annexin AI peptide is transduced by the formyl peptide receptor (FPR), 
whereas an inhibitory signal is generated independently of the FPR family receptors. J. Leukoc. 
Biol. 2005, 78, 762-771. 
(175) Serhan, C. N.; Maddox, J. F.; Petasis, N. A.; Akritopoulou-Zanze, I.; Papayianni, A.; Brady, H. R.; 
Colgan, S. P.; Madara, J. L. Design of lipoxin A4 stable analogs that block transmigration and 
adhesion of human neutrophils. Biochemistry 1995, 34, 14609-14615. 
(176) Serhan, C. N. Resolution phase of inflammation: novel endogenous anti-inflammatory and 
proresolving lipid mediators and pathways. Annu. Rev. Immunol. 2007, 25, 101-137. 
(177) Fiore, S.; Ryeom, S. W.; Weller, P. F.; Serhan, C. N. Lipoxin recognition sites. Specific binding of 
labeled lipoxin A4 with human neutrophils. J. Biol. Chem. 1992,  267, 16168-16176. 
(178) Nigam, S.; Fiore, S.; Luscinskas, F. W.; Serhan, C. N. Lipoxin A4 and lipoxin B4 stimulate the 
release but not the oxygenation of arachidonic acid in human neutrophils: dissociation between 
lipid remodeling and adhesion. J. Cell. Physiol. 1990, 143, 512-523. 
(179) Fiore, S.; Romano, M.; Reardon, E. M.; Serhan, C. N. Induction of functional lipoxin A4 receptors 
in HL-60 cells. Blood 1993, 81, 3395-3403. 
(180) Serhan, C. N. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of 
endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent. Fatty Acids 2005, 
73, 141-162. 
(181) O’Meara, S. J.; Rodgers, K.; Godson, C. Lipoxins: update and impact of endogenous pro-
resolution lipid mediators. Rev. Physiol. Biochem. Pharmacol. 2008, 160, 47-70.  
(182) Takano, T.; Clish, C. B.; Gronert, K.; Petasis, N.; Serhan, C. N. Neutrophilmediated changes in 
vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 
and novel lipoxin B4 stable analogues. J. Clin. Invest. 1998, 101, 819-826.  
(183) Takano, T.; Fiore, S.; Maddox, J. F.; Brady, H. R.; Petasis, N. A.; Serhan, C. N. Aspirin-triggered 
15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute 
inflammation: evidence for anti-inflammatory receptors. J. Exp. Med. 1997, 185, 1693-1704. 
7. Bibliographic References 
 207 
(184) Hachicha, M.; Pouliot, M.; Petasis, N. A.; Serhan, C. N. Lipoxin (LX)A4 and aspirin-triggered 15-
epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: 
regulators of a cytokine-chemokine axis. J. Exp. Med. 1999, 189, 1923-1930. 
(185) Colgan, S. P.; Serhan, C. N.; Parkos, C. A.; Delp-Archer, C.; Madara, J. L. Lipoxin A4 modulates 
transmigration of human neutrophils across intestinal epithelial monolayers. J. Clin. Invest. 1993, 
92, 75-82.  
(186) Kucharzik, T.; Gewirtz, A. T.; Merlin, D.; Madara, J. L.; Williams, I. R. Lateral membrane LXA4 
receptors mediate LXA4’s anti-inflammatory actions on intestinal epithelium. Am. J. Physiol. Cell 
Physiol. 2003, 284, C888-896. 
(187) Paul-Clark, M. J.; Van Cao, T.; Moradi-Bidhendi, N.; Cooper, D.; Gilroy, D. W. 15-epi-lipoxin 
A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J. Exp. 
Med. 2004, 200, 69-78. 
(188) Wu, S. H.; Lu, C.; Dong, L.; Zhou, G. P.; He, Z. G.; Chen, Z. Q. Lipoxin A4 inhibits TNF-alpha-
induced production of interleukins and proliferation of rat mesangial cells. Kidney Int. 2005, 68, 
35-46. 
(189) Bonnans, C.; Gras, D.; Chavis, C.; Mainprice, B.; Vachier, I.; Godard, P.; Chanez, P. Synthesis 
and anti-inflammatory effect of lipoxins in human airway epithelial cells. Biomed. Pharmacother. 
2007, 61, 261-267. 
(190) Wu, S. H.; Liao, P. Y.; Dong, L.; Chen, Z. Q. Signal pathway involved in inhibition by lipoxin 
A(4) of production of interleukins induced in endothelial cells by lipopolysaccharide. Inflamm. 
Res. 2008, 57, 430-437. 
(191) Aliberti, J.; Hieny, S.; Reis, C.; Sousa, C.; Serhan, C. N.; Sher, A. Lipoxinmediated inhibition of 
IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat. Immunol. 
2002, 3, 76-82.  
(192) Aliberti, J.; Serhan, C.; Sher, A. Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 
production and immunopathology in Toxoplasma gondii infection. J Exp. Med. 2002, 196, 1253-
1262. 
(193) Svensson, C. I.; Zattoni, M.; Serhan, C. N. Lipoxins and aspirin-triggered lipoxin inhibit 
inflammatory pain processing. J. Exp. Med. 2007, 204, 245-252. 
(194) Godson, C.; Mitchell, S.; Harvey, K.; Petasis, N. A.; Hogg, N.; Brady, H. R. Cutting edge: 
lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-
derived macrophages. J. Immunol. 2002, 164, 1663-1667. 
(195) Baek, S. H.; Seo, J. K.; Chae, C. B.; Suh, P. G.; Ryu, S. H. Identification of the peptides that 
stimulate the phosphoinositide hydrolysis in lymphocyte cell lines from peptide libraries. J. Biol. 
Chem. 1996, 271, 8170-8175. 
(196) Le, Y.; Gong, W.; Li, B.; Dunlop, N. M.; Shen, W.; Su, S. B.; Ye, R. D.; Wang, J. M. Utilization 
of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and 
formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. 
J. Immunol. 1999, 163, 6777-6784. 
(197) Kang, H. K.; Lee, H. Y.; Kim, M. K.; Park, K. S.; Park, Y. M.; Kwak, J. Y.; Bae, Y. S. The 
synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met inhibits human monocyte-derived dendritic cell 
maturation via formyl peptide receptor and formyl peptide receptorlike 2. J. Immunol. 2005, 175, 
685-692. 
(198) Karlsson, J.; Fu, H.; Boulay, F.; Bylund, J.; Dahlgren, C. The peptide Trp-Lys-Tyr-Met-Val-D-
Met activates neutrophils through the formyl peptide receptor only when signaling through the 
formylpeptide receptor like 1 is blocked. A receptor switch with implications for signal 
transduction studies with inhibitors and receptor antagonists. Biochem. Pharmacol. 2006, 71, 
1488-1496. 
7. Bibliographic References 
 
 208
(199) Klein, C.; Paul, J. I.; Sauvé, K.; Schmidt, M. M.; Arcangeli, L.; Ransom, J.; Trueheart, J.; 
Manfredi, J. P.; Broach, J. R.; Murphy, A. J. Identification of surrogate agonists for the human 
FPRL-1 receptor by autocrine selection in yeast. Nat. Biotechnol. 1998, 16, 1334-1337. 
(200) Hu, J. Y.; Le, Y.; Gong, W.; Dunlop, N. M.; Gao, J.L.; Murphy, P. M.; Wang, J. M. Synthetic 
peptide MMK-1 is a highly specific chemotactic agonist for leukocyte FPRL1. J. Leukoc. Biol. 
2001, 70, 155-161. 
(201) Chen, J.; Bernstein, H. S.; Chen, M.; Wang, L.; Ishii, M.; Turck, C. W.; Coughlin, S. R. Tethered 
ligand library for discovery of peptide agonists. J. Biol. Chem. 1995, 270, 23398-23401. 
(202) Bürli, R. W.; Xu, H.; Zou, X.; Muller, K.; Golden, J.; Frohn, M.; Adlam, M.; Plant, M. H.; Wong, 
M.; McElvain, M.; Regal, K.; Viswanadhan, V. N.; Tagari, P.; Hungate, R. Potent hFPRL1 
(ALXR) agonists as potential anti-inflammatory agents. Bioorg. Med. Chem. Lett. 2006, 16, 3713-
3718. 
(203) Frohn, M.; Xu, H.; Zou, X.; Chang, C.; McElvain, M.; Plant, M. H.; Wong, M.; Tagari, P.; 
Hungate, R.; Bürli R. W. New 'chemical probes' to examine the role of the hFPRL1 (or ALXR) 
receptor in inflammation. Bioorg. Med. Chem. Lett. 2007, 17, 6633-6637. 
(204) Schepetkin, I. A.; Kirpotina, L. N.; Khlebnikov, A. I.; Quinn, M. T. Highthroughput screening for 
small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor 
agonists. Mol. Pharmacol. 2007, 71, 1061-1074. 
(205) Schepetkin I. A.; Kirpotina, L. N.; Tian, J.; Khlebnikov, A. I.; Ye, R. D.; Quinn, M. T. 
Identification of novel formyl peptide receptor-like 1 agonists that induce macrophage tumor 
necrosis factor alpha production. Mol. Pharmacol. 2008, 74, 392-402.  
(206) Kirpotina, L. N.; Khlebnikov, A. I.; Schepetkin, I. A.; Ye, R. D.; Rabiet, M. J.; Jutila, M. A.; 
Quinn, M. T. Identification of Novel Small-Molecule Agonists for Human Formyl Peptide 
Receptors and Pharmacophore Models of Their Recognition. Mol. Pharmacol. 2010, 77, 159-170. 
(207) Khlebnikov, A. I.; Schepetkin, I. A.; Quinn, M. T. Computational structure-activity relationship 
analysis of small-molecule agonists for human Formyl peptide receptors. Europ. J. Med. Chem. 
2010, 45, 5406-5419. 
(208) Gavins, F. N.; Yona, S.; Kamal, A. M.; Flower, R. J.; Perretti, M. Leukocyte antiadhesive actions 
of annexin 1: ALXR- and FPR-related anti-inflammatory mechanisms. Blood 2003, 101, 4140-
4147. 
(209) Machado, F. S.; Johndrow, J. E.; Esper, L.; Dias, A.; Bafica, A.; Serhan, C. N.; Aliberti, J. Anti-
inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat. 
Med. 2006, 12, 330-334. 
(210) Stenfeldt, A. L.; Karlsson, J.; Wennerås, C.; Bylund, J.; Fu, H.; Dahlgren, C. Cyclosporin H, Boc-
MLF and Boc-FLFLF are antagonists that preferentially inhibit activity triggered through the 
formyl peptide receptor. Inflammation 2007, 30, 224-229. 
(211) Wenzel-Seifert, K.; Grünbaum, L.; Seifert, R. Differential inhibition of human neutrophil 
activation by cyclosporins A, D, and H. Cyclosporin H is a potent and effective inhibitor of formyl 
peptide-induced superoxide formation. J. Immunol. 1991, 147, 1940-1946. 
(212) Wenzel-Seifert, K.; Seifert, R. Cyclosporin H is a potent and selective Formyl peptide receptor 
antagonist. Comparison with N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-
leucyl-L-phenylalanine and cyclosporins A, B, C, D, and E. J. Immunol. 1993, 150, 4591-4599. 
(213) Wenzel-Seifert, K.; Hurt, C. M.; Seifert, R. High constitutive activity of the human formyl peptide 
receptor. J. Biol. Chem. 1998, 273, 24181-24189. 
(214) Yamamoto, Y.; Kanazawa, T.; Shimamura, M.; Ueki, M.; Hazato, T. Inhibitory effects of 
spinorphin, a novel endogenous regulator, on chemotaxis, O2- generation, and exocytosis by N-
formylmethionyl-leucyl-phenylalanine (FMLP)-stimulated neutrophils. Biochem. Pharmacol. 
1997, 54, 695-701. 
7. Bibliographic References 
 209 
(215) Liang, T. S.; Gao, J. L.; Fatemi, O.; Lavigne, M.; Leto, T. L.; Murphy, P. M. The endogenous 
opioid spinorphin blocks fMet-Leu-Phe-induced neutrophil chemotaxis by acting as a specific 
antagonist at the N-formylpeptide receptor subtype FPR. J. Immunol. 2001, 167, 6609-6614. 
(216) Chen, X.; Mellon, R. D.; Yang, L.; Dong, H.; Oppenheim, J. J.; Howard, O. M. Regulatory effects 
of deoxycholic acid, a component of the anti-inflammatory traditional Chinese medicine 
Niuhuang, on human leukocyte response to chemoattractants. Biochem. Pharmacol. 2002, 63, 
533-541.  
(217) Chen, X.; Yang, D.; Shen, W.; Dong, H. F.; Wang, J. M.; Oppenheim, J. J.; Howard, M. Z. 
Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl 
peptide receptors. Inflamm. Res. 2000, 49, 744-755. 
(218) Haas, P. J.; de Haas, C. J.; Kleibeuker, W.; Poppelier, M. J.; van Kessel, K. P.; Kruijtzer, J. A.; 
Liskamp, R. M.; van Strijp, J. A. N-terminal residues of the chemotaxis inhibitory protein of 
Staphylococcus aureus are essential for blocking formylated peptide receptor but not C5a receptor. 
J. Immunol. 2004, 173, 5704-5711. 
(219) Zhou, C.; Zhang, S.; Nanamori, M.; Zhang, Y.; Liu, Q.; Li, N.; Sun, M.; Tian, J.; Ye, P. P.; 
Cheng, N.; Ye, R. D.; Wang, M. W. Pharmacological characterization of a novel nonpeptide 
antagonist for formyl peptide receptor-like 1. Mol. Pharmacol. 2007, 72, 976-983. 
(220) Dal Piaz, V.; Giovannoni, M. P.; Castellana, C.; Palacios, J. M.; Beleta, J.; Doménech, T.: 
Segarra, V. Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV 
inhibitors. J. Med. Chem. 1997, 40, 1417-1421. 
(221) Azzolina, O.; Dal Piaz, V.; Collina, S.; Giovannoni, M. P.; Tadini, C. Chiral resolution and 
absolute configuration of the enantiomers of 5-acetyl-2-methyl-4-methylsulfinyl-6-phenyl-3(2H)-
pyridazinone and evaluation of their platelet aggregation inhibitory activity. Chirality 1997, 9, 
681-685. 
(222) Barlocco, D.; Cignarella, G.; Vinello, P.; Dal Piaz, V.; Giovannoni, M. P.; Malandrino, S.; 
Barocelli, E.; Chiavarini, M.; Impicciatore, M. Indenopyridazinone derivatives as potential 
antisecretory and antiulcer agents. Drug Des. Discov. 1997, 15, 95-103. 
(223) Costantino, L.; Rastelli, G.; Gamberoni, M. C.; Giovannoni, M. P.; Dal Piaz, V.; Vinello, P.; 
Barlocco, D. Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose 
reductase inhibitors. J. Med. Chem. 1999, 42, 1894-900. 
(224) Dal Piaz, V.; Giovannoni, M. P. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, 
as promising agents for the treatment of asthma and other pathologies. Eur J. Med. Chem. 2000, 
35, 463-480.  
(225) Dal Piaz, V.; Castellana, M. C.; Vergelli, C.; Giovannoni, M. P.; Gavaldà, A.; Segarra, V.; Belata, 
J.; Ryder, H.; Palacios, J. M. Synthesis and evaluation of some pyrazolo[3,4-d]pyridazinones and 
analogues as PDE 5 inhibitors potentially useful as peripheral vasodilator agents. J. Enz. Inhib. 
Med. Chem. 2002, 17, 227-233. 
(226) Dal Piaz, V.; Rascón, A.; Dubra, M. E.; Giovannoni, M. P.; Vergelli, C.; Castellana, M. C. 
Isoxazolo[3,4-d]pyridazinones and analogues as Leishmania mexicana PDE inhibitors. Farmaco 
2002, 57, 89-96. 
(227) Feixas, J.; Giovannoni, M. P.; Vergelli, C.; Gavaldà, A.; Cesari, N.; Graziano, A.; Dal Piaz, V. 
New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 
inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 2381-2384. 
(228) Giovannoni, M. P.; Vergelli, C.; Biancalani, C.; Cesari, N.; Graziano, A.; Biagini, P.; Gracia, J.; 
Gavaldà, A.; Dal Piaz, V. Novel pyrazolopyrimidopyridazinones with potent and selective 
phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile 
dysfunction. J. Med. Chem. 2006, 49, 5363-5371. 
(229) Vergelli, C.; Giovannoni, M. P.; Pieretti, S.; Di Giannuario, A.; Dal Piaz, V.; Biagini, P.; 
Biancalani, C.; Graziano, A.; Cesari, N. 4-Amino-5-vinyl-3(2H)-pyridazinones and analogues as 
7. Bibliographic References 
 
 210
potent antinociceptive agents: Synthesis, SARs, and preliminary studies on the mechanism of 
action. Bioorg. Med. Chem. 2007, 15, 5563-5575. 
(230) Giovannoni, M. P.; Cesari, N.; Vergelli, C.; Graziano, A.; Biancalani, C.; Biagini, P.; Ghelardini, 
C.; Vivoli, E.; Dal Piaz, V. 4-amino-5-substituted-3(2H)-pyridazinones as orally active 
antinociceptive agents: synthesis and studies on the mechanism of action. J. Med. Chem. 2007, 50, 
3945-3953. 
(231) Biancalani, C.; Giovannoni, M. P.; Pieretti, S.; Cesari, N.; Graziano, A.; Vergelli, C.; Cilibrizzi, 
A.; Di Gianuario, A.; Colucci, M.; Mangano, G.; Garrone, B.; Polenzani, L.; Dal Piaz, V. Further 
studies on arylpiperazinyl alkyl pyridazinones: discovery of an exceptionally potent, orally active, 
antinociceptive agent in thermally induced pain. J. Med. Chem. 2009, 52, 7397-7409. 
(232) Giovannoni, M. P.; Vergelli, C.; Cilibrizzi, A.; Crocetti, L.; Biancalani, C.; Graziano, A.; Dal 
Piaz, V.; Loza, M. I.; Cadavid, M. I.; Díaz, J. L.; Gavaldà, A. Pyrazolo- [1',5':1,6]pyrimido[4,5-
d]pyridazin-4(3H)-ones as selective human A1 adenosine receptor ligands. Bioorg. Med. Chem. 
2010, 18, 7890-7899. 
(233) Cilibrizzi, A.; Quinn, M. T.; Kirpotina, L. N.; Schepetkin, I. A.; Holderness, J.; Ye, R. D.; Rabiet, 
M. J.; Biancalani, C.; Cesari, N.; Graziano, A.; Vergelli, C.; Pieretti, S.; Dal Piaz, V.; Giovannoni, 
M. P. 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones: a novel class of small-molecule agonists 
for formyl peptide receptors. J. Med. Chem. 2009, 52, 5044-5057. 
(234) El-Gendy, A. A.; Osman, A. N.; Khalifa, M. Synthesis of 3-Indoleacetyl Derivatives of Certain 
Amino and Phenolic Compounds Likely to Possess Antiinflammatory Activity. Pharmazie 1982, 
37, 481-482. 
(235) Hermecz, I.; Mészáros, Z.; Vasvári-Debreczy, L.; Horváth, A.; Horváth, G.; Pongor-Csákvári M. 
Nitrogen bridgehead compounds. Part 4. 1 → 3 N→C-acyl migration. Part 2. J. Chem. Soc., 
Perkin Trans. 1 1977, 789-795. 
(236) Adams, R.; Pachter, I. J. Ultraviolet Spectra and Structures of the Pyrido [1,2-a]pyrimidones. J. 
Amer. Chem. Soc. 1952, 74, 5491-5497. 
(237) Kato, T.; Katagiri, N.; Wagai, A. Synthesis of methylpyridine derivatives-XXXIII Chem. Pharm. 
Bull. 25, 203 (1977): Phosphonylation and chlorination of methylpyridine and 3-nitro-
methylpyridine derivatives. Tetrahedron 1978, 34, 3445-3449. 
(238) Takahashi, K.; Mitsuhashi, K. Conversion of the carboxyl group to the corresponding 
trichloromethyl group in the quinoline series. J. Heterocycl. Chem. 1977, 14, 881-884. 
(239) Conrad, M.; Limpach, L. Beiträge zur Kenntniss des γ-Oxychinaldins. Berichte 1888, 21, 1965-
1984.  
(240) Kato, T.; Katagiri, N.; Wagai, A. Trichloromethylquinolines: Synthesis and Reaction with 
Trimethyl Phosphite. Chem. Pharm. Bull. 1981, 29, 1069-1075. 
(241) Baraldi, P. G.; Preti, D.; Tabrizi, M. A.; Fruttarolo, F.; Saponaro, G.; Baraldi, S.; Romagnoli, R.; 
Moorman, A. R.; Gessi, S.; Varani, K.; Borea, P. A. N6-[(Hetero)aryl/(cyclo)alkyl-carbamoyl-
methoxy-phenyl]-(2-chloro)-5′-N-Ethylcarbox-amido-adenosines: The first example of adenosine-
related structures with potent agonist activity at the human A2B adenosine receptor. Bioorg. Med. 
Chem. 2007, 15, 2514-2527. 
(242) Galin, F. Z.; Sakhautdinov, I. M.; Tukhvatullin, O.R. Synthesis of pyrrolo[2,1-a]phthalazine-2,6-
dione derivative from dioxophthalazine-containing sulfur ylide. Russ. Chem. Bull. 2007, 56, 2305-
2307. 
(243) Choi, W. Y.; Cho, S. D. ; Kim, S. K.; Yoon, Y. J. Synthesis and reactions of 1-(2-
oxopropyl)pyridazin-6-ones. J. Heterocycl. Chem. 1997, 34, 1307-1313. 
(244) Lee, S. G.; Kweon, D. H.; Yoon, Y. J. Synthesis of Novel Pyridazine Nucleosides. J. Hetrocycl. 
Chem. 2001, 38, 1179-1183. 
(245) Gong, Y.; He, W. A Direct Approach to the Synthesis of 5-Aryl-4-chloropyridazinone: From 
Microwave Assisted Catalyst Screen to Room Temperature Regio- and Chemoselective Suzuki 
Arylation. Heterocycles 2004, 62,851-856. 
7. Bibliographic References 
 211 
(246) Sotelo, E. Pyridazines. Part 37: Facile solution phase combinatorial synthesis of highly substituted 
pyridazin-3-ones. Mol. Divers. 2004, 8,159-163. 
(247) Mátyus, P.; Maes, B. U. W.; Riedl, Z.; Hajós, G.; Lemière,G. L. F.; Tapolcsányi, P.; Monsieurs, 
K.; Éliás, O.; Dommisse, R. A.; Krajsovszky, G. New Pathways Towards Pyridazino-Fused Ring 
Systems. Synlett. 2004, 7, 1123-1139. 
(248) Renzi, G.; Dal Piaz, V. Investigation on some 4,5-disubstituted-3-ethoxycarbonyl isoxaloles. 
Gazz. Chim. Ital. 1965, 95, 1478-1491. 
(249) Renzi, G.; Pinzauti, S. New derivatives of the isoxazolo-(3,4-d)-pyridazin-7-one system. Gazz. 
Chim. Ital. 1968, 98, 656-668.  
(250) Renzi, G.; Pinzauti, S. New derivatives of the isoxazolo-(3,4-d)-pyridazin-7-one system. Farmaco 
Sci. 1969, 24, 885-892.  
(251) Overend, W. G.; Wiggins, L. F. The conversion of sucrose into pyridazine derivatives. Part II. 4-
Amino-2-phenyl-6-methyl-3-pyridazinone, 4-Amino-2-(p-nitrophenyl)-6-methyl-3-pyridazone, 
and their sulfalinamido-derivatives. J. Chem. Soc. 1947, 549-554. 
(252) Reddy, R. S.; Saravanan, K.; Kumar, P. An efficient approach to γ-alkylidene γ-butyrolactones: 
Application to the syntheses of pyridazinones and diazocinones. Tetrahedron 1998, 54, 6553-
6564.  
(253) Meng, Q.; Hesse, M. N-N Bond Cleavage: A Route to Macrocyclic Dilactams. Synlett 1990, 3, 
148-150. 
(254) Druey, J. Pyridazine in der Arzneimittelsynthese. Angew. Chem. 1958, 70, 5-13.  
(255) Barberis, M.; Pérez-Prieto, J. Enantioselective synthesis of sabina ketone. Tetrahedron lett. 2003, 
44, 6683-6685. 
(256) Shinkai, H.; Ozeki, H.; Motomura, T.; Ohta, T.; Furukawa, N.; Uchida, I. 4-(trans-4-
Methylcyclohexyl)-4-Oxobutyric Acid (JTT-608). A New Class of Antidiabetic Agent. J. Med. 
Chem., 1998, 41, 5420–5428. 
(257) Singh, S.; Verma, M.; Singh, K. N. Superoxide ion induced oxidation of γ-lactones to γ-
ketocarboxylic acids in aprotic medium. Synthetic Commun. 2004, 34, 4471-4475.   
(258) Grundmann, C. Über Sulfanilamido-pyridazine (Heterocyclische Sulfonamide, I. Mitteil). Chem. 
Ber. 1948, 81, 1-11.  
(259) Gouault, N.; Cupif, J. F.; Picard, S.; Lecat, A.; David, M. Synthesis of diverse 4,5-dihydro-3(2H)-
pyridazinones on Wang resin. J. Pharm. Pharmacol. 2001, 53, 981-985.  
(260) Banerjee, P. S.; Sharma, P. K.; Nema, R. K. Synthesis and Anticonvulsant Activity of 
Pyridazinone Derivatives. Int. J. ChemTech Res. 2009, 1, 522-525. 
(261) Steiner, G.; Gries, J.; Lenke, D. Synthesis and antihypertensive activity of new 6-heteroaryl-3-
hydrazinopyridazine derivatives. J. Med. Chem.1981, 24, 59-63. 
(262) Kaupp, G.; Schmeyers, J. Solid-state reactivity of the hydrazine–hydroquinone complex. J. Phys. 
Org. Chem. 2000, 13, 388-394. 
(263) Hu, W.; Ralay Ranaivo, H.; Roy, S. M.; Behanna, H. A.; Wing, L. K.; Munoz, L.; Guo, L.; Van 
Eldik, L. J.; Watterson, D. M. Development of a novel therapeutic suppressor of brain 
proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral 
deficits. Bioorg. Med. Chem. Lett. 2007, 17, 414-418. 
(264) Steck, E. A.; Brundage, R. P.; Fletcher, L. T. Pyridazine Derivatives. I. Some Amebacidal 3-
Pyridazones. J. Am. Chem. Soc. 1953, 75, 1117-1119. 
(265) Castleman, E. R.; Wiselogle, F. Y. Studies in the Pyridazine Series. The Absorption Spectrum of 
Pyridazine. J. Am. Chem. Soc. 1945, 67, 60-62. 
(266) Kaddah, A. M.; Khalil, A. M. Reactions of 3-pyridazinones with aldehydes and Grignard reagents. 
Indian J. Chem. 1977, 15B, 1025-1028. 
(267) Overend, W. G.; Wiggins, L. F. The conversion of sucrose into pyridazine derivatives. Part I. 3-
Sulfanilamido-6-methylpyridazine. J. Chem. Soc. 1947, 239-244. 
7. Bibliographic References 
 
 212
(268) Sotelo, E.; Fraiz, N.; Yáñez, M.; Terrades, V.; Laguna, R.; Cano, E.; Raviña, E. Pyridazines. Part 
XXIX: synthesis and platelet aggregation inhibition activity of 5-substituted-6-phenyl-3(2H)-
pyridazinones. Novel aspects of their biological actions. Bioorg. Med. Chem. 2002, 10, 2873-
1882. 
(269) Wermuth, C. G.; Leclerc, G. Pyridazine derivatives of therapeutic interest.  VI. Synthesis of 2-
morpholinoethyl-4-methyl-6-phenyl-3-pyridazone (Ag 246) analogs modified in the aminoalkyl 
side chain. Chim. Ther. 1970, 5, 243-246. 
(270) Ismail, M. F.; El Khamry, A. A.; Shams, N. A.; El Sawy, O. M. Base-catalyzed condensation of 
aromatic aldehydes with 4,5-dihydro-6-methylpyridazin-3(2H)-one. Indian J. Chem. 1980, 
19B, 203-205.  
(271) Ismail, M. F.; Shams, N. A.; El Sawy, O. M. Synthesis of some 3-mercaptopyridazine derivatives. 
Synthesis 1980, 5, 410-412.  
(272) Kandile, N. G.; Ahmed, E. A. Synthesis of some new pyridazinones. Acta Chim. Hung. 
1990, 127, 829-835.  
(273) Powell, P.; Sosabowski, M. H. Preparation and reactions of some 2-thienyl- and 3-
thienylpyridazinones and -pyridazines. J. Chem. Res. (S) 1995, 8, 306-307. 
(274) Ismail, M. F.; Shams, N. A.; El Sawy, O. M. Some reactions with 4-(arylmethyl)-6-
methylpyridazin-3(2H)-ones. Egypt. J. Chem. 1982, 24, 223-226.  
(275) Nakanishi, M.; Bolm, C. Iron-catalyzed benzylic oxidation with aqueous tert-butyl hydroperoxide. 
Adv. Synth. Cat. 2007, 349, 861-864.  
(276) Ma, M.; Li, C.; Peng, L.; Xie, F.; Zhang, X.; Wang, J. An efficient synthesis of aryl α-keto 
esters. Tetrahedron Lett. 2005, 46 , 3927-3929. 
(277) Romo, D.; Romine, J. L.; Midura, W.; Meyers, A. I. Diastereoselective cyclopropanations of 
chiral bicyclic lactams leading to enantiomerically pure cyclopropanes. Application to the total 
synthesis of CIS-(1S, 3R)-deltamethrinic acid and R-(-)- dictyopterene C.  Tetrahedron 1990, 46, 
4951-4994. 
(278) Collomb, D.; Chantegrel, B.; Deshayes C. D.  Chemoselectivity in the rhodium(II) acetate 
catalysed decomposition of α-diazo-β-keto-γ,δ-alkenyl-δ-aryl compounds: Aromatic C-H insertion 
reaction or wolff rearrangement-electrocyclization. Tetrahedron 1996, 52,10455-10472. 
(279) Lerche, H.; Koenig, D.; Severin, T. Reactions with nitroenamines.  XII.  Reaction of esters and 
lactones with nitroenamines. Chem. Ber. 1974, 107, 1509-1517.  
(280) Giovannoni, M. P.; Vergelli, C.; Ghelardini, C.; Galeotti, N.; Bartolini, A.; Dal Piaz, V. [(3-
Chlorophenyl)piperazinylpropyl]pyridazinones and Analogues as Potent Antinociceptive Agents. 
J. Med. Chem. 2003, 46, 1055-1059.  
(281) Coates, W. J.; McKillop, A. Preparation of 4-amino-3(2H)-pyridazinones by direct amination of 
3(2H)-pyridazinones with hydrazine. Heterocycles 1989, 29, 1077-1090. 
(282) Youssef, A. S. A.; Marzouk, M. I.; Madkour, H. M. F.; El-Soll, A. M. A.; El-Hashash, M. A. 
Synthesis of some heterocyclic systems of anticipated biological activities via 6-aryl-4-pyrazol-1-
ylpyridazin-3-one. Can. J. Chem. 2005, 83, 251-259.  
(283) Guandalini, L.; Martini, E.; Dei, S.; Manetti, D.; Scapecchi, S.; Teodori, E.; Romanelli, M. N.; 
Varani, K.; Greco, G.; Spadola, L.; Novellino, E. Design of novel nicotinic ligands through 3D 
database searching. Bioorg. Med. Chem. 2005, 13, 799-807.  
(284) Jesberger, M.; Davis, T. P.; Barner, L. Applications of Lawesson's reagent in organic and 
organometallic syntheses. Synthesis 2003, 13, 1929-1958.  
(285) Ammazzalorso, A.; Amoroso, R.; Bettoni, G.; De Filippis, B. Synthesis of diastereomerically 
enriched 2-bromoesters and their reaction with nucleophiles. Chirality 2001, 13, 102-108.  
(286) Tanasova, M.; Yang, Q.; Olmsted, C. C.; Vasileiou, C.; Li, X.; Anyika, M.; Borhan, B. An 
Unusual Conformation of α-Haloamides Due to Cooperative Binding with Zincated Porphyrins. 
Eur. J. Org. Chem. 2009, 25, 4242-4253.  
7. Bibliographic References 
 213 
(287) Bergman, J.; Brynolf, A. Synthesis of chrysogine, a metabolite of Penicillium chrysogenum and 
some related 2-substituted 4-(3H)-quinazolinones. Tetrahedron 1990, 46, 1295-1310. 
(288) Maes, B.; Lemière, G. Pyridazines and their benzo derivatives. In: Six-membered rings with two 
heteroatoms, and their fused carbocyclic derivatives. Aitken, R. A., Eds.; Elsevier: Amsterdam, 
2008, pp. 1-116. 
(289) Wermuth, C. G.; Leclerc, G.; Schreiber, J. Pyridazine derivatives of therapeutic interest.  VII. 
Synthesis of 2-morpholinoethyl-4-methyl-6-phenyl-3-pyridazone (Ag 246) analogs modified on 
carbon atoms 4 and 5. Chim. Ther. 1971, 6, 109-115.  
(290) Laborit, H.; Wermuth, C. G.; Weber, B. P.; Delbarre, B.; Chekler, Cl.; Baron, C.; Rosengarten, H. 
A psychotropic compound with central and periphereal effect showing anesthetic, anticonvulsant, 
antiinflammatory, and antiparkinsonian activity and no ventilatory depressive effects. 2-
Morpholinoethyl-4-methyl-6-phenyl-3-pyridazone hydrochloride. Agressologie 1965, 6, 415-460. 
(291) Eloy, F.; Deryckere, A. Thienopyridines. Bull. SOC. Chim. Belg. 1970, 79, 301-311. 
(292) Robba, M.; Lecomte, J. M.; Cugnon de Sevricourt, M. Thienopyrimidines.  V. Thieno[2,3-
d]pyrimidones. Bull. SOC. Chim. Fr. 1975, 3/4, 587-591.  
(293) Tornoe, C. W.; Davis, P.; Porreca, F.; Meldal, M. α-Azido acids for direct use in solid-phase 
peptide synthesis. J. Peptide Sci. 2000, 6, 594-602.  
(294) Freund, H. E.; Arndt, F.; Rusch, R. Selective herbicides. EP, DE 1189312 19650318, 1965. 
(295) Kozlov, N. S.; Pak, V. D.; Mashevskii, V. V. 1,3-Diaryl-2,2-dihaloethylenimines. Tr. Perm. 
Sel'skokhoz. Inst. 1971, 79, 35-40.  
(296) Mashevskii, V. V.; Pak, V. D.; Zalesov, V. S.; Karavaeva, E. G. Products of 1,2-diaryl-3,3-
dihaloethylenimine hydrolysis and the study of their physiological action. Tr. Perm. Sel’skokhoz. 
Inst. 1975, 112, 51-54. 
(297) Maran, F.; Vianello, E. Electrogenerated carbanions and self-protonation. Bull. Electrochem. 
1990, 6, 276-277.  
(298) Maran, F.; Roffia, S.; Severin, Maria, G.; Vianello, E. Study on a proton transfer reaction between 
electrogenerated carbon bases and parent nitrogen acids. Electrochim. Acta 1990, 35, 81-88. 
(299) Okamoto, M. Reversal of elution order during the chiral separation in high performance liquid 
chromatography. J. Pharm. Biom. Anal. 2002, 27, 401-407. 
(300) Roussel, C.; Vanthuyne, N.; Serradeil-Albalat, M.; Vallejos, J. C. True or apparent reversal of 
elution order during chiral high-performance liquid chromatography monitored by a polarimetric 
detector under different mobile phase conditions. J. Chromatogr. A 2003, 995, 79-85.  
(301) Collina, S.; Loddo, G.; Urbano, M.; Rossi, D.; Mamolo, M. G.; Zampieri, D.; Alcaro, S.; Gallelli, 
A.; Azzolina, O. Enantioselective chromatography and absolute configuration of N,N-dimethyl-3-
(naphthalen-2-yl)-butan-1-amines: potential sigma1 ligands. Chirality 2006, 18, 245-253. 
(302) Comini, M.; Pozzoli, C.; Incerti, M.; Rossi, D.; Collina, S.; Azzolina, O.; Di Vittorio, E.; Morini, 
G.; Poli, E. Stereospecific effects of benzo[d]isothiazolyloxy-propanolamine derivatives at beta-
adrenoceptors: synthesis, chiral resolution, and biological activity in vitro. 
Chirality 2009, 21, 284-291.  
(303) Azzolina, O.; Collina, S.; Brusotti, G.; Rossi, D.; Callegari, A.; Linati, L.; Barbieri, A.; Ghislandi, 
V. Chemical and biological profile of racemic and optically active dialkyl-aminoalkylnaphthalenes 
with analgesic activity. Tetrahedron: Asym. 2002, 13, 1073-1081.  
(304) Azzolina, O.; Collina, S.; Urbano, M.; Fata, E.; Loddo, G.; Linati, L.; Lanza, E.; Barbieri, A. 
Highly diastereoselective synthesis of enantiopure naphthyl amino alcohols with analgesic 
properties. Chirality 2006, 18, 841-848.  
(305) Cirilli, R.; Ferretti, R.; Gallinella, B.; Turchetto, L.; Bolasco, A.; Secci, D.; Chimenti, P.; Pierini, 
M.; Fares, V.; Befani, O.; La Torre, F. Enantiomers of C5-chiral 1-acetyl-3,5-diphenyl-4,5-
dihydro-(1H)-pyrazole derivatives: Analytical and semipreparative HPLC separation, chiroptical 
properties, absolute configuration, and inhibitory activity against monoamine oxidase. 
Chirality 2004, 16, 625-636.  
7. Bibliographic References 
 
 214
(306) Scapecchi, S.; Nesi, M.; Matucci, R.; Bellucci, C.; Buccioni, M.; Dei, S.; Guandalini, L.; Manetti, 
D.; Martelli, C.; Martini, E.; Marucci, G.; Orlandi, F.; Romanelli, M. N.; Teodori, E.; Cirilli, R. 
Synthesis, Affinity Profile and Functional Activity of Potent Chiral Muscarinic Antagonists with a 
Pyrrolidinylfuran Structure. J. Med. Chem. 2010, 53, 201-207. 
(307) Qiu, Y. L.; Hempel, A.; Camerman, N.; Camerman, A.; Geiser, F.; Ptak, R. G.; Breitenbach, J. M.; 
Kira, T.; Li, L.; Gullen, E.; Cheng, Y. C.; Drach, J. C.; Zemlicka, J. (R)-(-)- and (S)-(+)-
Synadenol: Synthesis, Absolute Configuration, and Enantioselectivity of Antiviral Effect. J. Med. 
Chem. 1998, 41, 5257-5264.  
(308) Ahmadian, H.; Nielsen, B.; Braeuner-Osborne, H.; Johansen, T. N.; Stensbol, T. B.; Slok, F. A.; 
Sekiyama, N.; Nakanishi, S.; Krogsgaard-Larsen, P.; Madsen, U. (S)-Homo-AMPA, a Specific 
Agonist at the mGlu6 Subtype of Metabotropic Glutamic Acid Receptors. J. Med. 
Chem. 1997, 40, 3700-3705.  
(309) Salas-Coronado, R.; Vasquez-Badillo, A.; Medina-Garcia, M.; Garcia-Colon, J. G.; Noth, H.; 
Contreras, R.; Flores-Parra, A. Hydrogen bonds and preferred conformation of optically active 
amides. J. Mol. Struc. THEOCHEM 2001, 543, 259-275. 
(310) Fadnavis, N. W.; Reddy, N. P.; Bhalerao, U. T. Reverse micelles, an alternative to aqueous 
medium for microbial reactions:  yeast mediated resolution of α-amino acids in reverse micelles. J. 
Org. Chem. 1989, 54, 3218-3221.  
(311) Beller, M.; Moradi, W. A.; Eckert, M.; Neumann, H. A new improved palladium-catalyzed 
amidocarbonylation. Tetrahedron Lett. 1999, 40, 4523-4526. 
(312) Adam, W.; Roschmann, K. J.; Saha-Moller, C. R. Catalytic asymmetric aziridination of enol 
derivatives in the presence of chiral copper complexes to give optically active α-amino ketones. 
Eur. J. Org. Chem. 2000, 3, 557-561. 
(313) Didsbury, J. R.; Uhing, R. J.; Tomhave, E.; Gerard, C.; Gerard, N.; Snyderman, R. Functional high 
efficiency expression of cloned leukocyte chemoattractant receptor cDNAs. FEBS Lett 1992, 297, 
275-279. 
(314) Prossnitz, E. R.; Quehenberger, O.; Cochrane, C. G.; Ye, R. D. Transmembrane signalling by the 
N-formyl peptide receptor in stably transfected fibroblasts. Biochem. Biophys. Res. Commun. 
1991, 179, 471-476. 
(315) Christophe, T.; Karlsson, A.; Rabiet, M. J.; Boulay, F.; Dahlgren, C. Phagocyte Activation by Trp-
Lys-Tyr-Met-Val-Met, Acting Through FPRL1/LXA4R, Is Not Affected by Lipoxin A4. Scand. J. 
Immunol. 2002, 56, 470-476. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
8. SUPPLEMENT :  
 
Solid-Phase Synthesis of Transition State Mimetics in 
the Quorum Sensing System of Staphylococcus 
Aureus to Develop Catalytic Antibodies 
 
 
7-months training period at Chemistry Department of the  
University of Cambridge 
 
 
 
 
 
Supervisor: Dr. David R. Spring 
Tutor: Dr. Albert Isidro-Llobet 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. Supplement 
 217 
8.1 INTRODUCTION 
8.1.1 Antibiotics today: an overview 
The development of antibacterial agents is arguably one of the greatest successes of the 20th century 
medicine.1 Antibiotic drugs have played an essential role in the global increase in life expectancy and 
quality that has occurred over the last century.2 However, since the “glory days” of antibiotic discovery in 
the 1960s and 1970s, there has been a sharp decline in investment for new antibacterial interventions by 
the large pharmaceutical companies. Concomitantly, the incidence of resistance among clinical isolates 
against conventional antibiotics is on the increase.3 Indeed, bacteria have quickly become resistant to the 
most commonly prescribed antibiotics.4 As a result, we are left with a legacy of relatively few efficacious 
drugs and,1 unfortunately, pathogens continue to adapt faster than new antimicrobial agents can be 
developed to control them.5 Thus, bacterial infection, particularly from multi-drug resistant strains, 
remains a serious threat to human lives.1,4 Indeed, the scarcity of new antibiotic products has prompted 
some commentators to refer to an impending “pharmageddon” and to an impending return to the “pre-
antibiotic” era, at least for the treatment of some bacterial organisms. Consequently, the development of 
novel therapies for the treatment of human bacterial infections is of paramount importance.6  
Existing antibiotics generally inhibit bacterial cellular processes that are essential for microbial 
survival.7,8 An inherent problem with this approach is that it creates a selection pressure for drug-resistant 
mutations.9,10 Antivirulence therapies seek to address this issue.7,8 These methods aim to target bacterial 
systems associated with virulence rather than essential cellular process and the hope is that such strategies 
will reduce selective survival pressures and slow the development of resistance.11  
Over the last decade, the work of many groups has shown that systems associated with virulence in 
bacteria are valid targets for the development of new antibacterial agents. Although virulence is a multi-
factorial phenotype, in many clinically-relevant bacteria the trait is controlled by a relatively small 
number of signalling pathways.12,13 Crucially for the current proposal, small molecules are often found at 
the apex of these signalling pathways, so that theoretically by eliminating these compounds from the 
growth medium, the virulence of the organism in question should be reduced. Indeed, disruption of these 
signalling pathways, either through mutation or through chemical intervention, is a proven way of 
diminishing the pathogenicity of a number of organisms and facilitating their immune clearance from the 
infected host. In addition, to reduce the selection pressure for drug-resistant mutations, non-lethal 
alternatives to antibiotic interventions are an attractive therapeutic strategy as well because, by 
specifically targeting virulence, it is possible to decrease the potential negative impact of treatment on the 
patient.12 Recent years have witnessed a growing realisation that antivirulence therapies represent a 
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potentially valuable alternative to traditional antibiotic methods for the treatment of bacterial infections.  
In this context, bacterial quorum sensing (QS) systems offer an attractive target.14,15 
 
8.1.2 Quorum sensing (QS) 
QS is a method of intercellular communication employed by many species of bacteria. This signalling 
process is used by bacterial colonies to coordinate gene expression in a cell density-dependent manner.16-
18
 Several clinically relevant pathogens use quorum-sensing systems to regulate processes associated with 
virulence.19 However, quorum sensing is not directly involved in biological processes that are essential 
for bacterial survival.20,21 Thus, selective disruption of QS (so-called “quorum quenching”) using non-
native small molecule entities represents a strategy to attenuate bacterial pathogenicity without imposing 
an intense selective pressure for the development of resistant mutants,22,23 compared to existing antibiotic 
treatments.24 
Quorum sensing is mediated by small diffusible molecules termed autoinducers.  These small molecule 
entities are synthesized intracellularly (throughout the growth of the bacteria) and released into the 
surrounding growth medium. The extracellular concentration of the small molecules led to an increase of 
the cell density. In fact, when this concentration exceeds a certain value, the accumulated signal 
molecules are sensed by specific receptors on the bacterial.25 The binding of the autoinducers to the 
receptors occurs and starting from this, a signal transduction cascade leads to a change in gene 
expression.15,26,27 In this way, the bacterial population reaches a critical “threshold” cell density which is 
of primary importance for its virulence.  
In the case of pathogens, QS-controlled genes often encode virulence factors.28 Indeed, virulence factor 
production in several clinically relevant pathogenic bacteria including Staphylococcus aureus, 
Clostridium difficile and Pseudomonas aeruginosa is known to be regulated by QS systems. In this 
scenario, at low cell densities, the cells do not produce virulence factors and therefore appear “innocent” 
to the host. However, once the population becomes quorate, the QS system simultaneously stimulates 
virulence factor production, ensuring that the population as a whole produces a welter of tissue-damaging 
proteins in a highly coordinated and cooperative manner.29-32 Nature is known to have evolved quorum-
quenching enzyme that are capable of hydrolyzing quorum sensing QS molecules and,23,33-35  recently, the 
concept of quorum quenching using the catalytic antibody technology directed towards the development 
of functionally equivalent “unnatural” enzymes, has been introduced.36-38 This approach uses small 
molecules as haptens to elicit antibodies capable of catalyzing QS molecules hydrolysis and thus inhibit 
quorum sensing. The hypothesis underpinning this aim is that by selectively depleting these small 
molecules from the site of bacterial infection, the invading organism will be made less aggressive 
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allowing the host immune system a better chance of clearing the infection before the bacteria cause too 
much tissue damage. 
 
8.1.3 Catalytic antibodies through Transition State (TS) mimetics 
Catalytic antibodies or “abzymes” are essentially tailor-made biological catalysts capable of accelerating 
the rate of a specific chemical reaction by preferentially stabilizing the transition state of the intended 
“natural” substrate to product conversion,37 following the same way of enzymes. Although several 
abzymes, that catalyze a variety of chemical transformations, have been generated, the most active 
antibodies have usually been found to provide rate enhancements for reactions with intrinsically low 
activation energy barriers.36 That is, abzymes generally catalyze reactions that happen at a slow, but 
measurable rate under ambient conditions. The procurement of catalytic antibodies for a specific reaction 
typically requires the use of a molecule which has been designed to be a stable mimic of the transition 
state structure associated with the reaction.39 The aim is to obtain antibodies that bind to this transition 
state analogue with high affinity; such antibodies should therefore be able to bind tightly to, and 
preferentially stabilise, the transition state of the reaction of interest thus decreasing the activation energy 
barrier to the process (figure 8.1).40-43 Since abzymes are far more structurally-constrained than their 
enzyme counterparts, their catalytic activity is often relatively poor in comparison with the latter. 
However, they still provide rate enhancements of 104 or more over the uncatalyzed reaction and they have 
proven therapeutic potential in the treatment of drug addiction.44   
 
 
Figure 8.1. Energy diagram for an antibody-catalyzed and uncatalyzed transformation of a substrate S to a 
product P proceeding via a transition state (TS*) or an antibody-bound transition state (Ab.TS*). The catalytic 
effect of the antibody is given by ∆∆G*, which corresponds to the transition state dissociation constant KTS. 
Adapted from Reymond (2002). 44 
 
The improved pharmacological potential of many abzymes (compared to non host-derived enzymes) 
comes from the fact that, as in much of the proposed work, they can be based around a human antibody 
framework and are therefore not targets for immune clearance. A more recent work has shown that the 
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kinetic parameters of abzymes can be improved through targeted design strategies, and it is now clear that 
in some cases, residues in the substrate-binding site can also make additional catalytic contributions 
through, for example, acid-base catalysis.45 
 
8.1.4 Transition state mimetics and quorum quenching 
In principle, if stable small molecules that mimic the transition states associated with possible 
decomposition pathways of autoinducers can be synthesized, it should be possible to use these molecules 
to generate catalytic antibodies capable of degrading said autoinducers (“quorum quenching”), thereby 
interfering with the quorum sensing process. Since different species of bacteria generally use different 
autoinducer molecules, the nature of the transition state mimics required to elicit catalytic antibodies is 
species-dependent. In this work we focused upon quorum sensing in the Gram positive bacterium 
Staphylococcus aureus where stable structural moieties that mimic the transition states associated with the 
degradation reaction of the autoinducers need to be identified.5   
 
8.1.5 Quorum sensing in Staphylococcus aureus 
Staphylococcus aureus is a prevalent and highly adaptable Gram-positive bacterium responsible for 
numerous clinical infections.46 It is one of the most dreaded pathogens in hospitals and causes more 
nosocomial infections than any other Gram-positive bacterium. Methicillin-resistant strains of S. aureus 
(MRSA) represent an important problem, since infections can advance so rapidly that they become life-
threatening before clinical intervention can be realised. The treatment issue is compounded by the fact 
that MRSA strains are resistant to most clinically-used β-lactam antibiotics, so vancomycin, “the 
antibiotic of last resort”, is often the necessary choice of treatment. Worryingly, vancomycin-resistant S. 
aureus strains are now also appearing in hospitals, reinforcing the need for new anti-staphylococcal 
interventions. The emergence of antibiotic resistance in this and other species has become a serious 
concern in the medical community.6 
Various aspects of virulence in S. aureus are known to be regulated by a quorum sensing system which 
employs small autoinducing (oligo)peptides (AIPs), comprised of 7-10 amino acid residues, as the 
signalling molecules. AIPs function as extracellular signalling molecules that allow individual cells to 
sense the surrounding population density. Once a “quorum” of cells has been achieved, the bacteria 
modulate their gene expression to facilitate cooperative behaviours that confer survivability to the 
developing colony.47 The discovery of this global regulatory system for virulence in S. aureus has 
provided an avenue for interrupting these defenses.48,49 AIP mimics that perturb this system would be 
useful chemical probes and could potentially be developed for therapeutic applications.5 
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8.1.6 Autoinducing (oligo)peptides (AIPs) 
The quorum sensing circuit outlined in figure 8.2 represent the basic paradigm for AIP-mediated 
signalling in S. aureus. QS in S. aureus is encoded by the accessory gene regulator (agr) locus.50 Each 
bacterium secretes AIPs that accumulate in the extracellular environment. Once these ligands reach a 
threshold concentration, they will bind productively to a cognate receptor protein located on the cell 
exterior named AgrC. AIP binding activates a two-component intracellular signalling system that up-
regulates the production of virulence determinant-encoding genes (including genes that encode toxins, 
host cell-adhesion factors and extracellular hemolytic/proteolytic enzymes) and also up-regulates 
production of the four agr proteins (AgrA-D). 
 
Figure 8.2. Proposed mechanism of the two-component agr autoinduction system in S. aureus. AgrB processes 
the propeptide AgrD to generate an AIP and secretes it into the extracellular environment. The AIPs bind to the 
AgrC receptor, a histidine-kinase that phosphorylates the intracellular response regulator AgrA. This second 
signalling component then promotes gene transcription that induces virulence and produces the agr proteins, 
completing the autoinduction circuit. Adapted from Gorske and Blackwell (2006).5 
 
The agr-mediated QS systems in S. aureus have evolutionarily diverged into four different sub-groups 
(AIP-I/IV) (figure 8.3). 
 
Figure 8.3. Chemical structure of AIP-I and peptide sequences of AIPs I through IV. The cysteine residue that 
forms the thiolactone is highlighted in blue. Adapted from Gorske and Blackwell (2006).5 
 
Each sub-group is associated with a distinct AIP. However, in all cases, the AIPs have a similar core 
structure; they all comprise a macrocylic thiolactone and a conjoined linear tail moiety. The macrocyle 
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appears to be the main determinant required for molecular recognition by the membrane receptor AgrC, 
while the exocyclic peptide moiety is required for receptor activation. The conserved thiolactone is labile 
and it is known that cleavage of this ring abolishes agonistic activity in the AIPs. Thus the thiolactone 
ring moiety is an excellent target for the development of catalytic antibodies. If stable small molecules 
that mimic possible transition states associated with the rate determining steps of thiolactone ring 
hydrolysis can be identified, in theory, these could be used to elicit antibodies that are capable of 
catalysing this hydrolysis step, thereby inhibiting QS in S. aureus and thus attenuating its virulence.5,51 
 
8.2 BACKGROUND AND AIMS OF THE PROJECT 
The main goal of the proposed study is the synthesis of transition state (TS) mimetics of the degradation 
reaction of the AIPs, that could potentially be used to elicit catalytic antibodies capable to attenuate the 
expression of virulence determinants in the Gram positive bacterium S. aureus. To achieve this aim, our 
primary experimental objective was the synthesis of macrocyclic phosphopeptides as new structural 
peptidomimetic analogues that mimic the transition state associated with the degradation of AIPs 
involved in the population cell density-control of S. aureus. This approach will hopefully reduce or 
abolish the expression of virulence determinants associated with the AIPs and allow the establishment of 
structure-activity relationships (SARs) in these systems, to better understand quorum sensing signalling 
pathway and be able to develop new peptidomimetic inhibitors. 
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Figure 8.4. Structure of the natural autoinducing (oligo)peptide AIP-III. The cysteine residue that forms the 
thiolactone is highlighted in blue. 
 
AIP-III (figure 8.4)  was chosen as the reference peptide, because it is the substrate of EMRSA-16, an 
important Methicillin-resistant S. aureus strain available at the Biochemistry Department of the 
University of Cambridge and because all the AIP peptides have a similar core structure being the 
macrocycle the main determinant required for the activity. Therefore, one of the aims of the project was 
the total synthesis of the natural substrate (AIP-III),52 to use it as reference in the biological tests, 
following a Fmoc/t-Bu solid-phase synthesis.51 The thioester group (figure 8.4), as previously 
mentioned, is an excellent target to develop catalytic antibodies since cleavage of the thiolactone ring 
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abolishes agonistic activity of the AIPs. As phosphate derivatives are structurally similar to thioester 
bonds, the most important aim of this project is the synthesis, using a Fmoc/t-Bu solid-phase strategy, of 
two phosphorus AIP-III analogues as potential TS mimetics (figure 8.5).53   
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Figure 8.5. Structures of the “serine building blocks” and the two AIP-III analogues designed (A and B). The 
phosphodipeptide inserted in the macrocycle is highlighted in red. The structure A is reported as 23 in the 
section 8.3.2.2 (scheme S.5). 
 
 
In these new molecules the thioester group is replaced by a phosphate group, previously built in a “serine 
building block” (figure 8.5). It should be noted that the two new macrocycles, compared to the natural 
peptide, have two members more, one O and one CH2 but the size of the cycle does not seem to be crucial 
for the activity.52  
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Figure 8.6. The biotinylated variants of the AIP-III analogue designed. 
 
The transition state mimetics will be tested to evaluate their activity as quorum quenching agents and later 
on will be attached to a biotin-tag (figure 8.6) for phage library screening.23  
 
8.3 CHEMISTRY 
The chemistry of this project is divided in 3 parts: synthesis of the “serine building blocks” (section 
8.3.1), synthesis of the phosphorus cyclic peptides (section 8.3.2), synthesis of the natural substrate (AIP-
III) (section 8.3.3). 
 
8.3.1 Synthesis of the “serine building blocks” 
The two “serine building blocks” (figure 8.5) which will be incorporated in the phosphorus cyclic 
peptides were prepared following the synthetic pathways depicted in schemes S.1-S.3. 
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8.3.1.1    Protection of the starting amino acids and amino alcohols 
N-α-Fmoc-serine-t-butyl ester 1 (scheme S.1) was readily obtained in quantitative yield following the 
literature.54 
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Scheme S.1. Reagents and conditions: a) t-Butyl-trichloroacetimidate (4 equiv), CHX/EtOAc, rt, o/n. 
 
On the other hand, reaction of the amino alcohols, ethanolamine and L-leucinol (obtained in quantitative 
yield by reduction of L-leucine,55 scheme S.2), with allyl chloroformate yielded the corresponding Alloc 
protected ethanolamine (2) and L-leucinol (3)  with 97% and 86% yield respectively after purification by 
flash chromatography (scheme S.2).56 The Alloc group was chosen because its Pd catalyzed removal is 
compatible with Fmoc/t-Bu solid-phase strategy that will be used in the phosphopeptides synthesis.57  
 
H2N OH
O
b H2N OH
H2N OH
R
a HN OH
R
Al locO Cl
O
+
R = H (ethanolamine) ,
isobutyl (L-leucinol)
H2N OH
O
c
O Cl
O
+
H
N OH
O
Alloc
O
OAlloc =
2 (R = H),
3 (R = isobutyl)
L-Leu 4, L- leucinol
L-Leu 5
allylchloroformate
(1.1 equiv.)
allylchloroformate
(1 equiv.)
 
Scheme S.2. Reagents and conditions: a) NaHCO3 (1.1 equiv), dioxane/water (1:1), 0 °C → rt, 3 h, b) LiBH4 
(2 equiv), trimethylsilyl chloride (4 equiv), THF anhydrous, 0 °C → rt , 16 h, c) NaN3 (1.5 equiv), 
dioxane/water, Na2CO3 1% in water, rt, 1 d (10% Na2CO3 in water is added to keep the pH between 8-10). 
 
Another necessary building block for the phosphopeptide synthesis was Alloc-L-Leu-OH, which was 
obtained in 77% yield by reaction of in situ generated allyl carbonazidate with L-leucine (scheme S.2).58 
 
8.3.1.2    Phosphorus couplings 
The desired “serine building blocks” were obtained in 4 synthetic steps (scheme S.3) using the 
commercially available 2-cyanoethyl-N,N-diisopropyl-chlorophosphoramidite as the phosphorus 
source.59-61 The first reaction is a coupling of the Alloc-ethanolamine (2) or Alloc-L-leucinol (3) on the 2-
cyanoethyl-N,N-diisopropyl-chlorophosphoramidite (scheme S.3).62,63 The purified products must be 
stored under N2 at -20 ºC, since they decompose to complex mixtures after few days at room temperature. 
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The following reaction of of N-α-Fmoc-serine-t-butyl ester 1 with compounds 6 and 7 (scheme S.3) was 
performed in the presence of tetrazole.64,65 
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O P O
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H
N
O O
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a
R
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d
O
OAlloc =
O
O
Fmoc =
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Scheme S.3. Reagents and conditions: a) Alloc-ethanolamine (2) or Alloc-L-leucinol (3) (0.7 equiv), DIPEA 
(4.7 equiv), CH2Cl2 anhydrous, N2, rt, 2-3 h; b) Fmoc-L-Ser-t-Bu ester (1) (1 equiv), tetrazole (1.2 equiv), THF 
anhydrous, N2, rt, o/n; c) t-BuOOH, THF anhydrous, N2, rt, 3-4 h; d) TFA (20 equiv), CH2Cl2, rt, 2-3h. 
  
When explosive tetrazole was replaced by 4,5-dicyanoimidazole, the crude product obtained was much 
less pure both by 1H NMR and TLC.66 The obtained phosphite intermediates 8 and 9 are unstable trivalent 
phosphorus species which could be isolated by flash chromatography on silica gel, but it is more 
convenient to oxidyze them straight away to afford the more stable pentavalent species 10 and 11 
(scheme S.3).61,67 m-CPBA was initially used as an oxidizing agent but the yields were very low. In 
contrast, when tert-butyl hydroperoxide was used, fully protected phospho-amino acids 10 (R = H) and 
11 (R = Isobutyl) were obtained in 57 and 20% yield respectively over two steps (scheme S.3). 
Subsequent treatment of 10 and 11 with 50% trifluoroacetic acid afforded  the free acids 12 (R = H) and 
13 (R = Isobutyl). It is important to note that compounds 10, 11 and the corresponding free carboxylic 
acids (12 and 13) were obtained as diastereomeric mixtures because the chiral centre on the phosphorus 
was present in its 2 configurations. These diastereomeric mixtures were inseparable by flash 
chromatography or HPLC and made the 1H NMR analysis more complex. However, once the cyanoethyl 
group was removed during the treatment with piperidine to remove the Fmoc group, performed in the 
phosphopeptide synthesis (scheme S.4), the phosphorus center is no longer chiral, leading to only one 
stereoisomer of the desired phosphopeptide. 
 
8.3.2 Synthesis of the phosphorus cyclic peptides 
Linear and branched solid-phase syntheses of AIPs analogues using different orthogonal protecting 
schemes have been described in literature.51,68 In most of them the cyclization and final deprotection are 
performed in solution.5,51,52 We decided to adapt these strategies to the synthesis of phosphorus analogues 
of AIP-III. Our strategy is divided in two main parts: 1) Fmoc/t-Bu solid-phase synthesis of branched 
peptides (scheme S.4); 2) Cyclization and final deprotection in solution (scheme S.5). In the latter case, 
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the final cyclization is carried out through the formation of an amide bond between L-leucine and L-
phenylalanine and there is no risk of a five-member ring formation.  
 
8.3.2.1    Fmoc/t-Bu solid-phase synthesis of the branched peptides 
Solid-phase synthesis of protected peptides requires a resin that facilitates the cleavage of the peptide 
without removing the side-chain protecting groups.69,70 The resin of choice was the commercially 
available super-acid-labile chlorotrityl chloride polystyrene (CTC) resin (scheme S.4) which allows the 
release of peptides with 1-2 % of TFA in CH2Cl2 or even with trifluoroethanol solutions.71,72 An 
additional advantage of the CTC resin is that its hindered structure minimizes the formation of 
diketopiperazines (DKP) during removal of the temporary protecting group of the second amino acid.73,74 
The Fmoc/t-Bu solid-phase strategy involves the use of the base labile Fmoc group for α-amino 
protection and t-Bu-based protecting groups for side chain protection. t-Bu-based protecting groups are 
highly convenient because they are removed with high concentrations of trifluoroacetic acid (TFA) in the 
presence of scavengers, being stable to piperidine, used to remove the Fmoc group, and to low 
concentrations of TFA, used to cleave the peptide from the CTC resin. In addition, they are also stable to 
the Pd(0) treatment required to remove the Alloc group. The branched approach depicted in scheme S.4 
was chosen in order to avoid the risk of cyclization on the free phosphate group which would lead to a 
stable five-member ring. 
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Scheme S.4. Reagents and conditions: a) Fmoc-L-Phe-OH (0.7 equiv), DIPEA (2.1 + 4.2 equiv), CH2Cl2, rt, 
45 min; b) Fmoc-removal: piperidine-DMF (2:8, v/v) (1 x 2 min, 2 x 10 min); c) Fmoc-L-Asp-(O-t-Bu) (4 
equiv), ethylcyanoglyoxylate-2-oxime (4 equiv), DIC (4 equiv), DMF, rt, 1.5 h; d) Fmoc-removal; e) 12 (3 
equiv), PyAOP (3 equiv), DIPEA (3 + 6 equiv), DMF, rt, 2 h; f) Fmoc-removal; g) Fmoc-L-Asn-OH (4 equiv), 
ethylcyano-glyoxylate-2-oxime (4 equiv), DIC (4 equiv), DMF, rt, 1.5 h; h) Fmoc-removal; i) Boc-L-Ile-OH (4 
equiv), ethylcyanoglyoxylate-2-oxime (4 equiv), DIC (4 equiv), DMF, rt, 1.5 h; j) Alloc-removal: Pd(PPh3)4 
(0.1 equiv), PhSiH3 (10 equiv), CH2Cl2 (3 x 15 min); k) Alloc-L-Leu-OH (5) (4 equiv), ethylcyanoglyoxylate-2-
oxime (4 equiv), DIC (4 equiv), DMF, rt, 1.5 h; l) Alloc-removal; m) TFA:Et3SiH:CH2Cl2 (1:1:98), rt, 1h.  
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The  first coupling of Fmoc-L-Phe-OH on the resin was carried out using DIPEA as a base. The following 
amino acid-couplings were performed using diisopropylcarbodiimide (DIC), to activate the carboxylic 
group, and ethylcyanoglyoxylate-2-oxime, to minimize the epimerization. This new “anti-epimerization 
agent” has recently been reported to be a more efficient non-explosive alternative to the commonly used 
HOBt or HOAt.75  
The couplings of the phosphorus building blocks 12 and 13 (scheme S.3) were performed using PyAOP 
and DIPEA (scheme S.4). Phosphonium derivatives such as PyAOP are more convenient for slow 
couplings compared with aminium/uronium reagents such as HATU, since this latter can terminate the 
peptide chain through a guanidination reaction.76 Furthermore, PyAOP contains HOAt, which is the most 
reactive benzotriazole.77 Unfortunately, the coupling reaction worked fine only for building block 12 but 
not for the more hindered 13.  
The Chloranil test for detection of primary and secondary amines was performed after each coupling to 
confirm the coupling completion.78-80 When the test was negative (absence of free amines) the Fmoc 
group was removed with piperidine-DMF (2:8, v/v). Otherwise the corresponding Fmoc-amino acid was 
re-coupled in the same conditions. It should be noted that the phosphate only loses the β-cyanoethyl 
protecting group (scheme S.3 and S.4) after the piperidine-induced Fmoc removal.66,81 This α-elimination 
removal of the cyanoethyl group allowed the solid phase synthesis of the remaining phosphoserine 
peptide using Fmoc-based chemistry.82-84 Washings between deprotection, coupling and again 
deprotection steps were performed with DMF and CH2Cl2. The Alloc group was removed by Pd(0), using 
a catalytic amount of Tetrakis(triphenylphosphine)-palladium(0), in rather neutral conditions and in the 
presence of phenylsilane as a scavenger of the allyl carbocations (scheme S.4).85,86 Washings after 
deprotection steps were performed using CH2Cl2, DMF and a solution 0.02 M of sodium 
diethyldithiocarbamate in DMF. Peptide synthesis transformations and washings were always done at 25 
°C. Synthesis carried out on solid-phase were controlled by HPLC of the intermediates obtained after 
cleaving an aliquot (approximately 2 mg) of the peptidyl-resin with TFA/Et3SiH/CH2Cl2 (1:1:98) for 1 
hour (scheme S.4). The required polymer-bound branched protected peptide 22 obtained via standard 
Fmoc/t-Bu solid-phase peptide assembly was subsequently treated with TFA/Et3SiH/CH2Cl2 (1:1:98 v/v) 
for 1 hour. This step resulted in the chemoselective acidolysis of the 2-chlorotrityl ester resin linkage and 
afforded the partially protected heptapeptide 21 in typically quantitative yields. Partial purification of 21 
was accomplished by filtration of the acidolytic resin suspension into pyridine-methanol (1.5:75 v/v) and 
evaporation of the filtrate to dryness in vacuo. A small fraction of the dried partially protected peptide 21 
was exposed to TFA/H2O/Et3SiH (90:5:5) for 1 h to remove the protecting groups, followed by HPLC-
UV analysis, which revealed a peptide purity >80%.  
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8.3.2.2      Macrocyclization 
The cyclization of the branched peptide 21 was the limiting step of this synthetic strategy. As shown in 
table 8.1, several macrocyclization conditions were screened. Even when the desired cyclic product was 
detected, it was part of very complex mixtures.  
 
 Coupling reagents solvent time work up HPLC-UV-MS results 
 
 
1 
N-polystyrene methyl-N’-
cyclohexylcarbo-diimide (e 
equiv), DMAP (0.1 equiv), 
HOAt (5 equiv) 
 
 
CHCl3 
 
 
2 d 
 
 
filtration and evaporation 
 
CM*. No branched (SM§) 
and no cyclic peptide (22) 
 
 
2 
N-polystyrene methyl-N’-
cyclohexylcarbo-diimide (5 
equiv), DMAP (0.1 equiv), 
Ethylcyanoglyoxylate-2-
oxime (5 equiv) 
 
 
CHCl3 
 
 
2 d 
 
 
filtration and evaporation 
 
CM. No branched peptide 
(SM). The peak of 22 is 
too weak. 
 
 
3 
N-polystyrene methyl-N’-
cyclohexylcarbo-diimide (5 
equiv), DMAP (0.1 equiv) 
 
CHCl3 
 
3d 
 
filtration and evaporation 
CM. No branched peptide 
(SM). The peak (+ Na) of 
22 is big enough to be 
detected.  
 
 
4 
N-polystyrene methyl-N’-
cyclohexylcarbo-diimide (5 
equiv), DMAP (0.1 equiv), 
HOAt(5 equiv) 
 
 
CH2Cl2 
 
 
1 d 
 
 
filtration and evaporation 
 
CM. No cyclic peptide 
(22). The SM is still in a 
high amount. 
 
5 
N-polystyrene methyl-N’-
cyclohexylcarbo-diimide (5 
equiv), DMAP (0.1 equiv) 
 
CH2Cl2 
 
1 d 
 
filtration and evaporation 
CM. No branched (SM) 
and no cyclic peptide (22) 
 
6 
N-polystyrene methyl-N’-
cyclohexylcarbo-diimide (5 
equiv), HOAt (5 equiv) 
 
CH2Cl2 
 
1 d 
 
filtration and evaporation 
CM. No branched (SM) 
and no cyclic peptide (22) 
 
7 EDC (5 equiv), DMAP (0.1 
equiv), HOAt (5 equiv)  
 
CH2Cl2 
 
1 d Extraction with citric acid 
and H2O, evaporation  
CM. The SM is still in a 
high amount. 
 
8 EDC (5 equiv), DMAP (0.1 
equiv) 
 
CH2Cl2 
 
1 d Extraction with citric acid 
and H2O, evaporation 
CM. No branched (SM) 
and no cyclic peptide (22) 
 
9 EDC (5 equiv), DMAP (0.1 
equiv) 
 
CHCl3 
 
2 d Extraction with citric acid 
and H2O, evaporation 
CM. No branched (SM) 
and no cyclic peptide (22) 
 
10 PyAOP (1 + 1 equiv), DIEA (2 equiv)  
 
CH2Cl2 
 
1 d Extraction with H2O, 
evaporation 
CM. No branched (SM) 
and no cyclic peptide (22) 
 
11 DIC (5 equiv), HOAt (5 
equiv) 
 
CH2Cl2 
 
1 d 
 
evaporation CM. The peak of 22 is big 
enough to be detected. 
Table 8.1. Macrocyclization conditions screened for the synthesis of  transition state mimetic  23 [* CM = 
complex mixture; § SM = starting material (21)]. 
 
On the basis of the screening, we concluded that the methods based on N-polystyrene methyl-N’-
cyclohexylcarbodiimide/DMAP (entry 3, table 8.1) or DIC/HOAt (entry 11, table 8.1) as coupling 
reagents gave better results because, although we had always a very complex crude mixture to purify, it 
was possible to detect the peak of the right cyclic peptide, after hydrolysis of the protecting groups (Boc 
and t-Bu), by UV and mass spectrometry HPLC analysis. Therefore, for the purpose of the this 
dissertation, only these cyclization conditions will be described in detail. In the first case, 
macrocyclization was achieved by exposing a dilute solution of 21 in CHCl3 (2 mM) to N-polystyrene 
methyl-N’-cyclohexylcarbodiimide, a commercially available polymer-supported carbodiimide analogue 
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of N-polystyrene methyl-N’-isopropylcarbodiimide,87,88 in the presence of 4-dimethylaminopyridine 
(DMAP) for 3 days at room temperature (scheme S.5). In the second case macrocyclization was carried 
out always by exposing a dilute solution of 21 in CH2Cl2 to DIC in the presence of 7-aza-1-
hydroxybenzotriazole (HOAt) (scheme S.5).89 
 
Boc-Ile-Asn-Ser-Asp(OtBu)-Phe-OH
P OHO
O
N
H
Leu-H
Boc-Ile-Asn-Ser-Asp(OtBu)
P OHO
O
N
H
H-Ile-Asn-Ser-Asp
P OHO
O
N
H
Leu
a b
21 22 23
Phe
Leu
Phe
 
Scheme S.5. Reagents and conditions: a) see table 8.1; b) TFA:Et3SiH:H2O (90:5:5), rt, 1-1.5 h. 
 
In both cyclization rections, after a standard workup, 90% TFA-mediated acidolytic treatment of the 
crude protected macrocyclic peptide 22 afforded a complex mixture containing the desired phophorus-
peptide analogue 23. Significantly, HPLC analysis showed virtually absence of the starting branched 
peptide. Unfortunately, after purification by semi-preparative HPLC the cyclic heptapeptide 23 was not 
obtained as a pure compound. 
 
8.3.3 Total synthesis of the AIP-III 
The natural substrate AIP-III, involved in the quorum sensing system of S. aureus, had been already 
obtained through different synthetic strategies based on either Fmoc/t-Bu or Boc/Bn chemistry.5,52,68 We 
used a synthetic pathway described in literature for a similar peptide,51 based on the Fmoc/t-Bu solid-
phase synthesis of a linear peptide followed by macrocyclization in solution.90-93 For this linear approach 
the macrocyclization was carried out through the formation of a thioester bond between the L-Cys 
sulfhydryl and the C-terminus carboxyl group of the L-Leu (scheme S.6).94-96 
H-Leu O Boc-Ile-Asn-Cys(Mmt)-Asp(OtBu)-Phe-Leu-Leu O
Boc-Ile -Asn-Cys-Asp(OtBu)-Phe-Leu-Leu OH
Boc-Ile-Asn-Cys-Asp(OtBu)-Phe-Leu-Leu
S
Cl
Cl
a, b
CTC
c, d
e f g
24 25
26 27 28 (AIP-III)
H-Ile-Asn-Cys-Asp-Phe-Leu-Leu
S
 
Scheme S.6. Reagents and conditions: a) Fmoc-L-Leu-OH (0.7 equiv), DIPEA (2.1 + 4.2 equiv), CH2Cl2, rt, 
45 min; b) Fmoc-removal: piperidine-DMF (2:8, v/v) (1 x 2 min, 2 x 10 min); c) Fmoc-L-aa-OH or Boc-L-Ile-
OH (4 equiv), ethylcyano glyoxylate-2-oxime (4 equiv), DIC (4 equiv), DMF, rt, 1.5-2 h; d) Fmoc-removal (for 
deprotection of all the aa used with the exception of Boc-L-Ile-OH); e)TFA:Et3SiH:CH2Cl2 (1:1:98), rt, 1h; f) 
see table 8.2; g) TFA:Et3SiH:H2O (90:5:5), rt, 1.5 h. 
 
Solid-phase synthesis was undertaken using a tetra-orthogonal protecting scheme similar to that 
previously used to obtain the phosphorus cyclic peptide 23 (scheme S.4 and S.5) and it was performed in 
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polypropylene syringes (12 mL) fitted with a polyethylene porous disc. Solvents and soluble reagents 
were removed by suction. CTC, protected Fmoc amino acids and all the coupling reagents used during the 
synthesis are commercially available. After the first coupling of Fmoc-L-leucine on the CTC, carried out 
using DIEA as a base, all the following amino acid couplings were performed using 
diisopropylcarbodiimide, to activate the carboxylic group, and ethylcyanoglyoxylate-2-oxime to prevent 
or minimize epimerization. After each coupling the reaction was checked always by the previous 
mentioned Chloranil test,78-80 and the Fmoc group was removed using a piperidine/DMF solution (2:8 
v/v). The following treatment of the resin-bonded peptide 25 with TFA/Et3SiH/CH2Cl2 (1:1:98, v/v), raise 
concomitantly chemoselective unmasking of the Cys sulfhydryl group and release from the solid support. 
Partial purification of 26 was accomplished by filtration of the acidolytic resin suspension into pyridine-
methanol (1.5:75 v/v) and evaporation of the filtrate to dryness in vacuo. After trituration of the residue 
with ice-water and filtration, the dried partially protected peptide 26 was macrocyclized using a 
commercially available dialkylcarbodiimide reagent, followed by TFA-mediated global deprotection to 
afford the desired thiolactone peptide 28 (AIP-III). As shown in table 8.2, we tried the cyclization of the 
partially protected peptide screening several coupling methods. A range of results were obtained 
depending on the carbodiimide involved in the reaction. 
 
 Coupling reagents solvent time work up HPLC-UV-MS results 
 
 
1 
N-polystyrene methyl-N’-
cyclohexylcarbo-diimide (5 
equiv), DMAP (0.1 equiv), 
HOAt (5 equiv) 
 
 
CHCl3 
 
 
3 d 
 
 
filtration and evaporation 
 
CM. No linear peptide 
(SM). The peak of 27 is too 
weak. 
 
 
2 
N-polystyrene methyl-N’-
cyclohexylcarbo-diimide (5 
equiv), DMAP (0.1 equiv), 
ethylcyano-glyoxylate-2-
oxime (5 equiv) 
 
 
 
CHCl3 
 
 
 
3 d 
 
 
 
filtration and evaporation 
 
 
CM. No linear peptide 
(SM). The peak of 27 is too 
weak. 
 
3 
N-polystyrene methyl-N’-
cyclohexylcarbo-diimide (5 
equiv), DMAP (0.1 equiv) 
 
CHCl3 
 
4 d 
 
filtration and evaporation 
CM. The SM is still in a 
high amount. It is possible 
to detect the peak of 27 
 
 
4 
EDC (5 equiv), DMAP (0.1 
equiv), ethylcyano- 
glyoxylate-2-oxime (5 
equiv) 
 
 
CHCl3 
 
 
1 d 
 
extraction with citric acid 
and H2O, evaporation 
 
CM. No linear (SM) and no 
cyclic peptide (27) 
 
 
5 
 
EDC (5 equiv), DMAP (0.1 
equiv) 
 
 
CHCl3 
 
 
4 d 
 
extraction with citric acid 
and H2O, evaporation 
CM. No linear peptide 
(SM). The peak of 27 is 
detected in a relatively high 
amount. 
 
6 
 
 
DCC (5 equiv), DMAP (0.1 
equiv) 
 
CHCl3 
 
4 d 
 
filtration and evaporation 
CM. The SM is still in a 
high amount. It is possible 
to detect the peak of 27 
Table 8.2. Coupling methods screened to carry out the cyclization for the synthesis of the AIP-III (28). 
 
On the basis of this screening, considering the conversion of the linear peptide 26 in the cyclic one 27, we 
concluded that the method based on EDC and DMAP gave the best results (entry 5, table 8.2) in terms of 
8. Supplement 
 231 
yields and purity, estimated from the absence of side-products in the HPLC chromatograms. Therefore, a 
new macrocyclization was carried out following the entry 5 in table 8.2 conditions: a dilute solution of 
26 in chloroform (2 mM solution) was treated with EDC, in the presence of DMAP for 3 days at room 
temperature. The crude mixture was washed with a 5 % citric acid solution and water, to remove the 
excess of carbodiimide and of urea formed during the reaction. The crude protected macrocyclic peptide 
27 was treated with TFA/H2O/Et3SiH (90:5:5) to afford the desired natural cyclic peptide 28 (AIP-III) in 
a complex mixture (scheme S.6). Significantly, HPLC analysis showed virtually absence of the starting 
linear peptide. After purification by semi-preparative HPLC, the thiolacton heptapeptide 28 was obtained 
with 10-15% yield, as stated in literature.50,58,62 
 
8.4 RESULTS AND CONCLUSIONS 
The initial aim of this project was the synthesis of two transition state mimetics of the natural 
oligopeptide AIP-III involved in quorum sensing-system of S. aureus. The synthetic strategy involved 
the use of a Fmoc/t-Bu solid-phase methodology and serine phosphodiesters 12 and 13 as the key 
building-blocks. This required the development of an efficient synthetic route for 12 and 13 (scheme S.3), 
which was achieved after preliminary protection of the starting amino acids and aminoalcohols (schemes 
S.1 and S.2). The synthetic route outlined in section 8.3.1 is relatively simple and high-yielding and has 
been proven to be suitable for scaling-up. The availability of these building blocks is of vital importance 
to allow us the synthesis of a peptide sequence using standard Fmoc-based chemistry. Unexpectedly, 
during the solid phase synthesis of the branched peptide (scheme S.4) it was possible to introduce in the 
peptide sequence just the “serine building block” 12. In contrast, the coupling reaction of phosphodiester 
13 in the peptide chain didn’t work, probably because 13 is more sterically hindered than 12. However, 
our data show that the Fmoc/t-Bu solid-phase strategy is an efficient way to obtain the branched phospho-
peptide 21 (scheme S.4) in good yield. The cyclization process was much more difficult to understand. 
Several coupling methods were screened and different coupling reagents were used (table 8.1) to obtain 
the phosphorus cyclic peptide. Even if the cyclization reaction involved simply the formation of an amide 
bond (scheme S.5), some coupling reagents resulted quite inefficient and when the cyclic product was 
present, it was part of a complex mixture. On the basis of the screening, N-polystyrene methyl-N’-
cyclohexylcarbodiimide or DIC gave better results as coupling reagent. Although  very complex mixtures 
were always obtained, it was possible to detect the peak of the right cyclic peptide by UV and mass 
spectrometry. In addition, HPLC analysis showed virtually absence of the starting branched peptide 21. 
The main problems for the cyclization were obviously the side reactions and the instability of the 
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phosphate group. One of the most frequent fragment and two possible side products that could occur 
during the cyclization, confirmed by mass spectrometry analysis, are shown in the figure 8.7.  
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Figure 8.7. A frequent fragment detected by mass spectrometry due to the instability of the phosphate group 
and two possible side products that could occur during the cyclization. 
 
It is not completely sure that the two presumed side products (figure 8.7) could be formed during the 
reaction. Considering a difficult event the formation of an eight-member ring, perhaps the aspartimide or 
aminosuccinimide (3-amino-pyrrolidine-2,5-dione, Asu) formation is a more realistic hypothesis.97 In fact 
it is the first step of the well-known degradation, at alkaline, neutral and acidic pH, of peptides and 
proteins containing aspartic acids/ asparagines.98-100 The reaction results in a variety of rearranged and 
racemized products and it is especially problematic in Fmoc/t-Bu SPPS because strong base, such as 
piperidine, promotes Asu formation.101 Semi-preparative HPLC did not afford the cyclic heptapeptide 23 
(scheme S.4) as a pure compound due to the high complexity of the crude mixture. Work is underway to 
better understand the reasons of this evident degradation and formation of side products. The imminent 
future work will involve a previous purification of the branched peptide 21 by semipreparative HPLC, in 
order to obtain a crude mixture less complex and easier to purify after cyclization. Moreover, alternative 
coupling reagents and conditions will be screened in order to improve the yield of the final cyclization for 
the achievement of 23. 
The total synthesis of the AIP-III was the ultimate goal of this project. On the basis of the literature 
results, the Fmoc/t-Bu solid-phase strategy was always the selected methodology for the synthesis of the 
linear peptide. After cyclization carried out in solution, the AIP-III (28) has been obtained and it will be 
useful as reference compound in the biological tests. 
 
In conclusion, this work presents a facile and efficient synthesis of caged phospho-amino acids suitable 
for Fmoc-based SPPS. Moreover, the total synthesis of the natural substrate AIP-III had been 
successfully carried out and the transition state mimetic analogue 23 had been obtained, but its yield and 
purity must be improved in order to start the biological assays. 
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8.5 EXPERIMENTAL CHEMISTRY 
8.5.1 Materials and Methods 
Reactions were performed using oven-dried glassware apparatus (130 °C) under an atmosphere of 
nitrogen with anhydrous, freshly distilled solvents unless otherwise stated. Anhydrous reactions were 
carried out under nitrogen atmosphere. Solvents were distilled prior to use. Reagents/solvents for 
anhydrous reactions were dried as follows: THF was dried over wire Na and distilled from a mixture of 
CaH2
 
and LiAlH4
 
with triphenylmethane as indicator; diethyl ether was distilled over a mixture of CaH2
 
and LiAlH4; petroleum ether was distilled before use and refers to the fraction between 30-40 °C; 
dichloromethane, methanol, n-hexane, acetonitrile and toluene were distilled from CaH2.
 
All other 
reagents were purified in accordance with the instructions in “Purification of Laboratory Chemicals”,102
 
or 
obtained from commercial sources.  
Room temperature (rt) refers to ambient temperature.  Temperatures of 0 °C were maintained using an 
ice-water bath. 
Yields refer to chromatographically and spectroscopically pure compounds. All reactions were monitored 
by thin layer chromatography (TLC) using glass plates precoated with Merck silica gel 60 F254 or 
aluminum oxide 60 F254. Visualization was performed by the quenching of UV fluorescence (λmax
 
= 254 
nm) or by staining with ceric ammonium molybdate or potassium permanganate or Dragendorff’s reagent 
(0.08% w/v bismuth subnitrate and 2% w/v KI in 3M aq. AcOH). Flash column chromatography was 
performed using slurry-packed Merck 9325 Kieselgel 60 silica gel (230-400 mesh) unless otherwise 
stated, eluting with distilled solvents as described. 
Melting points were obtained using a Reichert hot plate microscope with a digital thermometer 
attachment and are uncorrected. 
Proton magnetic resonance (1H NMR) spectra were recorded using an internal deuterium lock at ambient 
probe temperatures (unless otherwise stated) on the following instruments: Bruker DPX-400 (400 MHz), 
Bruker Avance 400 QNP (400 MHz), Bruker Avance 500 BB ATM (500 MHz) and Bruker Avance 500 
Cryo Ultrashield (500 MHz), Bruker Avance 700 MHz Fourier transform spectrometers in 
deuterochloroform or deuterodimethyl sulfoxide operating at 400, 500 and 700 MHz respectively and 
using an internal deuterium lock at ambient probe temperatures (unless otherwise stated). Chemical shifts 
(δ) are quoted in ppm, to the nearest 0.01 ppm and are referred to the residual non-deuterated solvent 
peak. Coupling constants (J values) are given in Hz and were calculated using ‘Mestre-C 2.3a’ software 
rounded to the nearest 0.5 Hz.103
 
Data are reported as follows: chemical shift, multiplicity [exch, 
exchange; br, broad; s, singlet; d, doublet; t, triplet; q, quartet; quin, quintet; sept, septet; m, multiplet; or 
as a combination of these (e.g. dd, dt etc.)], integration, assignment and coupling constant(s). The 
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numbering/lettering on selected structures does not follow the IUPAC naming system and is used for the 
assignment of the 1H NMR. Proton assignments were determined either on the basis of unambiguous 
chemical shift or coupling pattern, by analogy to fully interpreted spectra for related compounds.  
Diastereotopic protons are assigned as H and H.  
Analytical LC-MS spectra were recorded on an HP/Agilent MSD LC-MS APCI 120-1000 full gradient 
ACq T = 1 min 1µL. High resolution mass measurements were made using a Micromass Quadrapole-
Time of Flight (Q-ToF) spectrometer and reported mass values are within the error limits of ±5 ppm mass 
units. The ionisation technique used is indicated by the following abbreviations: CI = chemical ionisation; 
EI = electron ionisation; ESI = electrospray ionisation; FAB (LSIMIS) =  fast atom bombardment (liquid 
secondary ion mass spectrometry); MALDI =  matrix-assisted laser desorption /ionisation.  
Semi-preparative HPLC putifications were performed on an Agilent HP 1100 series chromatograph 
(Supelco ABZ+PLUS, 10cm x 2.1mm, 5µm) attached to a HP MSD mass spectrometer with a multimode 
ESI/APCI ionisation source in ESI/APCI mode. Elution was carried out at a flow rate of 1.0 mL/min 
using a reverse phase gradient of acetonitrile and water containing 0.1 % formic acid and detection was 
with diode array detection (λ = 195, 210, 215, 220 and 254 nm). Retention times (in min) are reported 
below as tR. MALDI-TOF and MS (ESI) analysis of peptide samples were performed in a PerSeptive 
Biosystems Voyager DE RP, using ACH matrix, and in a Waters Micromass ZQ spectrometer and in an 
Agilent Ion Trap 1100 Series LC/MSDTrap.  
The “&” symbol is used in the nomenclature for cyclic peptides and precursors.104 The appearance of “&” 
in a given position of the one-line formula indicates the location of one end of a chemical bond and the 
second “&” the point to which this bond is attached. Thus, “&” represents the start or the end of a 
chemical bond, which is ‘cut’ with the aim to facilitate the view of a complex formula. In this way, two 
“&” symbols indicate one chemical bond. 
 
8.5.2 Protection of amino acids and amino alcohols 
8.5.2.1       tert-Butyl-2-{[(9H-fluoren-9-yl)methoxy]carbonylamino}-3-hydroxy propanoate, 
“Fmoc-Ser-O-t-Bu” (1) 
N
H
HO
O
O O
O
 
To a solution of Fmoc-Ser-OH (1.0 g, 3.10 mmol, 1 equiv) in EtOAc (30 ml), a solution of t-
Butyltrichloro-acetimidate (2.6 g, 12.20 mmol, 4 equiv) in CHX (10 ml) was added at rt. The mixture was 
stirred at rt until TLC analysis (Hex/EtOAc 2:1) showed absence of Fmoc-L-Ser-OH (12 h). The solvents 
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were removed under reduced pressure and the crude residue was purified by flash column 
chromatography (Hex/EtOAc 2:1) to afford the desired compound as a white solid (1.1 g, 2.88 mmol, 94 
% yield). mp = 102-04 °C. 1H NMR (CDCl3) δ 7.78 (d, 2H, Ar, J = 7.5 Hz), 7.62 (d, 2H, Ar, J = 7.5 Hz), 
7.42 (t, 2H, Ar, J = 7.5 Hz), 7.33 (t, 2H, Ar, J = 7.5 Hz), 6.37-6.68 (exch br s, 1H, OH) 5.79 (exch br d, 
2H, NH, J = 6.5 Hz), 4.43 (d, 2H, CH2OCO, J = 7.0 Hz), 4.32-4.38 (m, 1H, CHCH2OCO), 4.24 (t, 1H, 
CHCH2OH, J = 7.0 Hz), 3.92-3.98 (m, 2H, CH2OH), 1.51 (s, 9H, 3 CH3 t-Bu). 
8.5.2.2  Allyl 2-hydroxyethylcarbamate, “Alloc-ethanolamine” (2) 
H
N OHO
O
 
A solution of ethanolamine (1.0 ml, 16.40 mmol, 1 equiv) in dioxane/H2O (1:1, 25.0 ml) was cooled to 0 
°C. NaHCO3 (1.5 g, 18.00 mmol, 1.1 equiv) and allylchloroformate (1.9 ml, 18.00 mmol, 1.1 equiv) were 
added. The mixture was allowed to warm to rt and stirred until TLC analysis (Hex/EtOAc, 1:2) showed 
absence of ethanolamine (3 h). The organic solvent was removed under reduced pressure and the aqueous 
phase was extracted with EtOAc (3 times). The organic layers were then collected, dried (MgSO4) and 
concentrated under reduced pressure.  The resulting oil was purified by flash column chromatography 
(Hex/EtOAc , 1:2) to yield 2 as a colourless oil (2.3 g, 15.70 mmol, 96 % yield). 1H NMR (CDCl3) δ 
5.80-5.90 (m, 1H, CHCH2O), 5.23 (dq, 1H, CH-HCHCH2 allyl, J = 12.5 Hz, J = 1.5 Hz), 5.14 (dt, 1H, 
CH-HCHCH2 allyl, J = 1.5 Hz, J = 1.0 Hz), 4.51 (d, 2H, CH2OCO, J =  5.5 Hz), 3.65 (t, 2H, CH2OH, J = 
6.0 Hz), 3.28 (t, 2H, CH2NH, J = 6.0 Hz).  
8.5.2.3  Allyl 1-hydroxy-4-methylpentan-2-ylcarbamate, “Alloc-L-leucinol” (3) 
H
N OHO
O
 
A solution of L-leucinol (4) (0.9 mg, 7.60 mmol, 1 equiv) in dioxane/H2O (1:1, 25.0 ml) was cooled to 0 
°C. NaHCO3 (0.7 mg, 8.40 mmol, 1.1 equiv) and allylchloroformate (0.9 ml, 8.40 mmol, 1.1 equiv) were 
added. The mixture was allowed to warm to rt and stirred until TLC analysis (Hex/EtOAc, 1:2) showed 
absence of L-leucinol (3 h). The organic solvent was removed under reduced pressure and the aqueous 
phase was extracted with EtOAc (3 times). The organic layers were then collected, dried (MgSO4) and 
concentrated under reduced pressure.  The resulting colourless oil was purified by flash column 
chromatography (Hex/EtOAc 1:2) to yield 3 as a colourless oil (1.3 g, 6.56 mmol, 86 % yield). 1H NMR 
(CDCl3) δ 5.80-5.90 (m, 1H, CHCH2O), 5.24 (dt, 1H, CH-HCHCH2 allyl, J = 12.5 Hz, J = 1.5 Hz), 5.14 
(dd, 1H, CH-HCHCH2 allyl, J = 9.0 Hz, J = 1.5 Hz), 4.80 (exch br d, 1H, NH, J = 8.0 Hz), 4.49 (d, 2H, 
CH2OCO, J = 5.0 Hz), 3.66-3.75 (m, 1H, CHNH), 3.59-3.63 (m, 1H, CH-HOH), 3.44-3.48 (m, 1H, CH-
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HOH), 2.41 (exch br s, 1H, OH), 1.57-1.64 (m, 1H, CH(CH3)2), 1.17-1.34 (m, 2H, CH2CH(CH3)2), 0.87 
(dd, 6H, 2 CH3, J = 5.0 Hz, J = 1.5 Hz).  
8.5.2.4  2-Amino-4-methylpentan-1-ol, “L-leucinol” (4) 
H2N OH
 
Trimethylsylilchloride (3.9 ml, 30.50 mmol, 4 equiv) was added to a cold (0 °C) solution of lithium 
borohydride (0.3 mg, 15.30 mmol, 2 equiv) in 3 ml of anhydrous THF under N2. The cooling ice/water 
bath was removed and the mixture was stirred at rt for 15 min. The mixture was cooled to 0 °C and a 
solution of L-Leu (1.0 g, 7.62 mmol, 1 equiv) in 3 ml of anhydrous THF was added. The cooling bath 
was removed and the reaction mixture was stirred at rt for 16 h.  The mixture was cooled again to 0 °C 
and methanol (7.5 ml) was added dropwise followed by NaOH (4.1 ml, 2.5 N aqueous solution). The 
organic solvents were removed under reduced pressure and the resulting residue was extracted with 
chloroform (3 times). The combined organic extracts were dried (MgSO4) and concentrated under 
reduced pressure to furnish 4 as a colourless oil (0.9 g, 7.59 mmol, quantitative yield).  The product was 
analytically pure and was used in subsequent reactions without further purification. 1H NMR (CDCl3) δ 
3.88 (dd, 1H, CH-HOH, J = 8.0 Hz, J = 3.0 Hz), 3.41-3.47 (m, 1H, CH-HOH), 3.30 (exch br s, 1H, OH), 
3.11-3.16 (m, 1H, CHNH2), 2.47 (exch br s, 2H, NH2), 1.43-1.60 (m, 1H, CH(CH3)2), 1.05-1.15 (m, 2H, 
CH2CH(CH3)2), 0.75-0.81 (m, 6H, 2 CH3).  
8.5.2.5  2-(Allyloxycarbonylamino)-4-methylpentanoic acid, “Alloc-L-Leu-OH” (5) 
H
N OH
O
O
O
 
Allyl-chloroformate (0.7 ml, 6.35 mmol, 1 equiv) was dissolved in dioxane (4.0 ml) and a solution of 
NaN3 (0.6 g, 9.52 mmol, 1.5 equiv) in H2O (3.0 ml) was added at rt. The reaction mixture was stirred at rt 
for 1 h whereupon a solution of L-Leu (1.0 g, 7.62 mmol, 1.2 equiv) in 1% aqueous Na2CO3/dioxane 1:1 
(20.0 ml) was added. The pH of the reaction was monitored periodically and 10% aqueous Na2CO3  was 
added when necessary to keep the pH between 8-10. The reaction was stirred at rt until TLC analysis 
(Hex/EtOAc, 1:4) showed absence of the allyl-chloroformate (24 h). Then the mixture was poured into 
water (100.0 mL), 10% aqueous Na2CO3  was added to keep the pH between 9 and 10 and the aqueous 
phase was extracted several times with tert-butyl methyl ether to remove the by-products (e.g. 
azidoformate, protected dipeptides). The aqueous solution was acidified to pH 2.0 with 2 N aqueous HCl 
and extracted with EtOAc (3 times). The organic phase was dried (MgSO4) and concentrated under 
reduced pressure to yield a colourless oil (1.1 g, 4.8 mmol, 77% yield). The purity of the colorless oil was 
measured by NMR and it was > 95 %. The product was used for the synthesis of 20 without further 
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purification. 1H NMR (CDCl3) δ 10.34 (exch br s, 1H, OH), 5.88-6.02 (m, 1H, CHCH2O), 5.32 (dd, 1H, 
CH-HCHCH2 allyl, J = 17.0 Hz, J = 1.0 Hz), 5.23 (dd, 1H, CH-HCHCH2 allyl, J = 9.0 Hz, J = 1.29 Hz), 
5.19 (exch br s, 1H, NH), 4.60 (d, 2H, CH2OCO, J = 5.5 Hz), 4.37-4.44 (m, 1H, CHNH), 1.68-1.81 (m, 
2H, CH2CH(CH3)2), 1.53-1.62 (m, 1H, CH(CH3)2), 0.98 (d, 6H, 2 CH3, J = 6.5 Hz). 
 
8.5.3 Phosphorus couplings 
8.5.3.1  Allyl-2-(2-cyanoethoxydiisopropylaminophosphinooxy)ethyl carbamate (6) 
N
P O
O CN
H
N O
O
 
To a solution of 2 (0.3 g, 1.80 mmol, 1 equiv) in anhydrous CH2Cl2 (8.0 ml) under N2, DIPEA (2.1 ml, 
12.60 mmol, 7 equiv) and 2-cyanoethyl-N,N-diisopropyl-chloro-phosphoramidite (0.6 ml, 2.70 mmol, 1.5 
equiv) were added at rt. The reaction mixture was stirred at rt until TLC analysis (Hex/EtOAc 1:1) 
showed absence of 2 (1.5 h). The solvent was removed under reduced pressure. The residue was then 
dissolved in EtOAc and washed with brine (3 times). The organic phase was dried (MgSO4) and 
concentrated under reduce pressure. The resulting colourless oil was purified by flash column 
chromatography (Hex/EtOAc 1:1) to furnish  6 as a colourless oil (0.5 g, 1.49 mmol, 83 %). 1H NMR 
(CDCl3) δ 5.81-5.90 (m, 1H, CHCH2O), 5.23 (dd, 1H, CH-HCHCH2 allyl, J = 5.5 Hz, J = 1.5 Hz), 5.14 
(dd, 1H, CH-HCHCH2 allyl, J = 10.45 Hz, J = 1.5 Hz), 5.09 (exch br s, 1H, NH), 4.50 (d, 2H, CH2OCO, 
J = 5.0 Hz), 3.49-3.83 (m, 6H, CH2CH2CN + CH2CH2NH), 3.33 (q, 2H, 2 CH(CH3)2, J = 10.5 Hz), 2.58 
(t, 2H, CH2CN, J = 6.5 Hz), 1.12 (dd, 6H, 2 CH3, J = 6.5 Hz, J = 5.5 Hz). 
8.5.3.2   Allyl-1-(2-cyanoethoxydiisopropylaminophosphinooxy)-4-methyl pentan-2-yl-
carbamate (7) 
N
P O
O CN
H
N O
O
 
To a solution of 3 (0.6 g, 2.82 mmol, 1 equiv) in anhydrous CH2Cl2 (10.0 ml) under N2, DIPEA (3.3 ml, 
19.76 mmol, 7 equiv) and 2-cyanoethyl-N,N-diisopropyl-chlorophosphoramidite (0.9 ml, 4.23 mmol, 1.5 
equiv) were added at rt. The reaction mixture was stirred at rt until TLC analysis (Hex/EtOAc 1:1) 
showed absence of 3 (1.5 h). The solvent was removed under reduced pressure. The residue was then 
dissolved in EtOAc and washed with brine (3 times). The organic phase was dried (MgSO4) and 
concentrated under reduce pressure.  The resulting colourless oil was purified by flash column 
chromatography (Hex/EtOAc 1:1) to furnish 7 as a colourless oil (1.0 g, 2.55 mmol, 90 % yield). 1H 
NMR (CDCl3) δ 9.19 (exch br s, 1H, NH), 5.80-5.96 (m, 1H, CHCH2O), 5.23 (dq, 1H, CH-HCHCH2 
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allyl, J = 12.5 Hz, J = 1.5 Hz), 5.17-5.12 (m, 1H, CH-HCHCH2 allyl), 4.47-4.53 (m, 2H, CH2OCO), 4.21-
4.27 (m, 1H, CHNH), 3.96-4.12 (m, 2H, CH2CH2CN), 3.71-3.89 (m, 2H, CH2CHNH), 3.50-3.57 (m, 2H, 
2 CH(CH3)2), 2.63-2.72 (m, 1H, CH-H-CN), 2.53-2.60 (m, 1H, CH-H-CN), 1.54-1.66 (m, 1H, 
CH2CH(CH3)2), 1.17-1.19 (m, 2H, CHCH2CH), 1.11 (dd, 12H, 2 x (CH3)2CHN, J = 4.0 Hz, J = 3.0 Hz), 
0.86 (dt, 6H, 2 x CH3CHCH2, J = 3.5 Hz, J = 3.0 Hz). 
8.5.3.3      tert-Butyl-8-(2-cyanoethoxy)-1-(9H-fluoren-9-yl)-3,13-dioxo-2,7,9,14-tetraoxa-4,12-
diaza-8-phosphoryloxyheptadec-16-ene-5-carboxylate (10) 
O P O
O CNH
N
H
N
O O
O
O
O
O O
 
To a solution of 6 (500.0 mg, 1.50 mmol, 1 equiv) in anhydrous THF (6.0 ml) under N2,  a solution of 
tetrazole (130.0 mg, 1.80 mmol, 1.2 equiv) in anhydrous THF (6.0 ml) was added at rt. The solution was 
stirred at rt for 15 min and then added dropwise to a previously prepared solution of 1 (580.0 g, 1.50 
mmol, 1 equiv) in anhydrous THF (8.0 ml) under N2 at rt. The mixture was stirred at rt until TLC analysis 
(Hex/EtOAc 1:3) showed absence of 6 (15 h). The solvent was then removed under reduced pressure and 
the resulting residue was dissolved in EtOAc and washed with 10 % aqueous NaHCO3 (2 times) and 
brine. The organic layer was dried (MgSO4) and concentrated under reduced pressure to yield the 
corresponding unstable phosphite 8 (940.0 mg, 1.50 mmol, quantitative yield).  
To a solution of 8 (940.0 g, 1.50 mmol, 1 equiv) in anhydrous THF (15.0 ml) under N2, t-
butylhydroperoxide (0.3 ml, 3.00 mmol, 2 equiv) was added at rt. The reaction was stirred at rt until TLC 
analysis (Hex/EtOAc 1:3) showed absence of the phosphite (2 h). The solvent was then removed under 
reduced pressure. The residue was dissolved in EtOAc and washed with 10% aqueous NaHCO3 (2 times) 
and brine. The organic layer was dried (MgSO4) and concentrated under reduced pressure. The resulting 
colourless oil was then purified by flash column chromatography (Hex/EtOAc gradient 1:1 to 1:3) to 
afford 10 as a clear oil (540 mg, 0.84 mmol,  57 % yield over 2 steps from 6). 1H NMR (CDCl3) δ 7.69 (d, 
2H, Ar, J = 7.5 Hz), 7.55 (t, 2H, Ar, J = 6.0 Hz), 7.33 (t, 2H, Ar, J = 7.5 Hz), 7.24 (t, 2H, Ar, J = 11.0 
Hz), 5.77-5.89 (m, 1H, CHCH2O allyl), 5.32 (exch br s, 1H, NH), 5.20 (d, 1H, CH-HCHCH2 allyl, J = 
17.0 Hz), 5.11 (d, 1H, CH-HCHCH2 allyl, J = 10.5 Hz), 4.48 (d, 2H, CH2OCO allyl, J = 4.5 Hz), 4.30-
4.42 (m, 4H, CHCH2OCO + CH2CHCOO), 4.10-4.18 (m, 4H, CH2CH2CN + CH2CH2NH), 4.02-4.08 (m, 
3H, CH2CH2NH + CHCH2OCO), 3.38 (d, 1H, CH2CHCOO, J = 5.0 Hz), 2.63 (t, 2H, CH2CH2CN, J = 6.0 
Hz), 1.42 (s, 9H, 3 CH3-CO). MS (ESI) calcd. For C31H38N3O10P, 643.621. Found: m/z 644.13 [M + H]+, 
588.50 [M + H - t-Bu]+. 
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8.5.3.4        tert-Butyl-8-(2-cyanoethoxy)-1-(9H-fluoren-9-yl)-11-isobutyl-3,13-dioxo-2,7,9,14-
tetraoxa-4,12-diaza-8-phosphoryloxyheptadec-16-ene-5-carboxylate (11) 
O P O
O CNH
N
H
N
O O
O
O
O
O O
 
To a solution of 7 (1.0 g, 2.54 mmol, 1 equiv) in anhydrous THF (8.0 ml) under N2, a solution of tetrazole 
(0.2 g, 3.05 mmol, 1.2 equiv) in anhydrous THF (8.0 ml) was added at rt. The solution was stirred at rt for 
15 min and then added dropwise to a previously prepared solution of 1 (1.0 g, 2.54 mmol, 1 equiv) in 
anhydrous THF (9.0 ml) under N2 at rt. The mixture was stirred at rt until TLC analysis (Hex/EtOAc 1:3) 
showed absence of 7 (15 h). The solvent was then removed under reduced pressure and the resultant 
residue was dissolved in EtOAc and washed with 10 % aqueous NaHCO3 (2 times) and brine. The 
organic layer was dried (MgSO4) and concentrated under reduced pressure. The crude mixture of the 
phosphite 9 was directly used without purification for the following oxidation reaction to get the 
compound 11, as already seen for the analogue unstable compound 8 (1.7 g, 2.54 mmol, quantitative 
yield). 
To a solution of 9 (1.7 g, 2.54 mmol, 1 equiv) in anhydrous THF (15.0 ml) under N2, t-
butylhydroperoxide (0.5 ml, 5.08 mmol, 2 equiv) was added at rt. The reaction was stirred at rt until TLC 
analysis (Hex/EtOAc 1:2) showed absence of the phosphite (2.5 h). The solvent was then removed under 
reduced pressure. The residue was dissolved in EtOAc and washed with 10% aqueous NaHCO3 (2 times) 
and brine. The organic layer was dried (MgSO4) and concentrated under reduced pressure. The resulting 
colourless oil was then purified by flash column chromatography (Hex/EtOAc gradient 1:1 to 1:2) to 
afford 11 as a clear oil (350.0 mg, 0.50 mmol,  20 % yield over 2 steps from 7). 1H NMR (CDCl3) δ 8.62 
(exch br s, 1H, NH), 7.78 (d, 2H, Ar, J = 7.5 Hz), 7.64 (d, 2H, Ar, J = 7.0 Hz), 7.42 (t, 2H, Ar, J = 7.5 
Hz), 7.33 (t, 2H, Ar, J = 7.5 Hz), 5.88-5.99 (m, 1H, CHCH2O allyl), 5.30 (dq, 1H, CH-HCHCH2 allyl, J = 
5.5 Hz, J = 1.5 Hz), 5.18-5.24 (m, 1H, CH-HCHCH2 allyl), 4.56 (d, 2H, CH2OCO allyl, J = 5.0 Hz), 4.37-
4.45 (m, 2H, CH2CHCOO), 4.15-4.29 (m, 2H, CHCH2CO), 4.10-4.16 (m, 2H, CH2CH2CN), 3.96 (d, 2H, 
CH2CHNH, J = 5.5 Hz), 3.88-3.97 (m, 1H, CHCH2OCO), 3.74-3.77 (m, 1H, CH2CHCOO), 3.39-3.51 (m, 
1H, CH2CHNH), 2.61 (t, 2H, CH2CH2CN, J = 6.0 Hz), 1.65-1.72 (m, 1H, CHCH3), 1.52 (s, 9H, 3 CH3-
CO), 1.33-1.44 (m, 2H, CHCH2CH), 0.95 (d, 6H, 2 CH3CH, J = 6.5 Hz). MS (ESI) calcd. For 
C35H46N3O10P, 699.73. Found: m/z 700.17 [M + H]+, 644.50 [M + H - t-Bu]+, 616.16 [M + H - Alloc]+. 
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8.5.3.5       8-(2-Cyanoethoxy)-1-(9H-fluoren-9-yl)-3,13-dioxo-2,7,9,14-tetraoxa-4,12-diaza-8-
phosphoryloxyheptadec-16-ene-5-carboxylic acid (12) 
O P O
O CN
H
N
H
N
HO O
O
O
O
O O
 
TFA (1.3 ml, 16.93 mmol, 20 equiv) was added to a solution of 10 (540 mg, 0.85 mmol, 1 equiv) in 
CH2Cl2 (1.3 ml) at rt. The reaction was stirred at rt until TLC analysis (Hex/EtOAc 1:3) showed absence 
of 10 (2.5 h). The excess TFA was removed by co-evaporation with CH2Cl2 under reduced pressure (5 
times). The residue was dried in a vacuum desiccator o/n to yield 12 as a colourless oil (480.0 mg, 0.82 
mmol, 97 %). The compound was used in subsequent SPPS without further purification. 1H NMR 
(CDCl3) δ 8.20 (exch br s, 1H, NH), 7.69 (d, 2H, Ar, J = 7.5 Hz), 7.52 (d, 2H, Ar, J = 4.5 Hz), 7.33 (t, 
2H, Ar, J = 7.5 Hz), 7.24 (t, 2H, Ar, J = 7.0 Hz), 5.80-5.84 (m, 1H, CHCH2O allyl), 5.23 (d, 1H, CH-
HCHCH2 allyl, J = 5.0 Hz), 5.13 (d, 1H, CH-HCHCH2 allyl, J = 4.0 Hz), 4.50-4.57 (m, 4H, CH2OCO 
allyl, CHCH2OCO), 4.32-4.38 (m, 3H, CH2CH2CN + CHCH2OCO), 4.04-4.16 (m, 6H, + CH2CHCOO + 
CH2CH2NH), 3.28-3.43 (m, 1H, CH2CHCOO), 2.65 (t, 2H, CH2CH2CN, J = 5.5 Hz). MS (ESI) calcd. For 
C27H30N3O10P, 587.51. Found: m/z 588.06 [M + H]+. 
8.5.3.6  8-(2-Cyanoethoxy)-1-(9H-fluoren-9-yl)-11-isobutyl-3,13-dioxo-2,7,9,14-
tetraoxa-4,12-diaza-8-phosphoryloxyheptadec-16-ene-5-carboxylic acid (13) 
O P O
O CNH
N
H
N
HO O
O
O
O
O O
 
TFA (0.7 ml, 9.66 mmol, 20 equiv) was added to a solution of 11 (0.3 g, 0.48 mmol, 1 equiv) in CH2Cl2 
(0.7 ml) at rt. The reaction was stirred at rt until TLC analysis (Hex/EtOAc 1:3) showed absence of 11 
(2.5 h). The excess TFA was removed by co-evaporation with CH2Cl2 under reduced pressure (5 times). 
The residue was dried in a vacuum desiccator o/n to yield 13 as a colourless oil (0.3 g, 0.47 mmol, 97 %). 
The compound was used in subsequent SPPS without further purification. 1H NMR (CDCl3) δ 7.99 (exch 
br s, 1H, NH), 7.69 (d, 2H, Ar, J = 7.5 Hz), 7.56 (t, 2H, Ar, J = 6.0 Hz), 7.33 (t, 2H, Ar, J = 7.5 Hz), 7.24 
(t, 2H, Ar, J = 14.0 Hz) 5.79-5.88 (m, 1H, CHCH2O allyl), 5.23 (d, 1H, CH-HCHCH2 allyl, J = 17.0 Hz), 
5.13 (d, 1H, CH-HCHCH2 allyl, J = 10.0 Hz), 4.47-4.58 (m, 3H, CH2OCO allyl + CHCH2OCO), 4.26-
4.35 (m, 2H, CH2CHCOO), 4.10-4.19 (m, 2H, CHCH2CO), 4.00-4.08 (m, 1H, CH2CHCOO), 3.77-3.96 
(m, 4H, CH2CHNH + CH2CH2CN), 3.34-3.43 (m, 1H, CH2CHNH), 2.63-2.70 (m, 2H, CH2CH2CN), 
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1.58-1.64 (m, 1H, CHCH3), 1.28 (t, 2H, CHCH2CH, J = 2.0 Hz), 0.87 (d, 6H, 2 CH3CH, J = 6.5 Hz). MS 
(ESI) calcd. For C31H38N3O10P, 643.62. Found: m/z 644.14 [M + H]+. 
 
8.5.4 Total synthesis of the TS mimetic 
8.5.4.1      H-Phe-O-CTC
 
(14)  
Cl-TrtCl-resin (0.2 g, 1.01 mmol/g) was placed in a 20 ml polypropylene syringe fitted with a 
polyethylene filter disk. The resin was then washed with CH2Cl2 (5 x 0.5 min) and a solution of Fmoc-L-
Phe-OH (54.2 mg, 0.14 mmol, 0.7 equiv) and DIPEA (70.0 µL, 0.42 mmol, 2.1 equiv) in CH2Cl2 (2.5 ml) 
was added. The mixture was then stirred for 15 min. Extra DIPEA (140.0 µL, 0.85 mmol, 4.2 equiv) was 
added and the mixture was stirred for an additional 45 min. The reaction was stopped by adding MeOH 
(320.0 µl) and stirred for 10 min. The aim of this procedure was to obtain a resin loading of 0.7 mmol/g. 
The Fmoc-L-Phe-O-TrtCl-resin was subjected to the following washings/treatments with CH2Cl2 (3 x 0.5 
min), DMF (3 x 0.5 min) and piperidine-DMF solution to remove the Fmoc as indicated in the following 
General Procedure for Fmoc-removal (section 8.5.4.2).  
8.5.4.2    General Procedure for Fmoc-removal: the Fmoc group was removed by treatment 
with piperidine/DMF (2:8, v/v) (1 x 2 min, 2 x 10 min). Washings between deprotection, coupling, and 
again deprotection steps were performed with DMF (5 x 0.5 min) and CH2Cl2 (5 x 0.5 min) using 10.0 ml 
solvent/g resin each time. 
8.5.4.3      H-Asp(O-t-Bu)-Phe-O-CTC (15) 
Fmoc-L-Asp(O-t-Bu)-OH (230.4 mg, 0.56 mmol, 4 equiv), DIC (86.8 µL, 0.56 mmol, 4 equiv) and 
Ethylcyanoglyoxylate-2-oxime (79.6 mg, 0.56 mmol, 4 equiv) in DMF (2.5 ml) were added to the above 
obtained H-Phe-O-CTC (14). After 90 min of coupling, the chloranil test was negative. Removal of Fmoc 
group and washings were performed as described in General Procedures for Fmoc-removal (section 
8.5.4.2).  
8.5.4.4      H-Ser[P(OC2H4-NH-Alloc)O2H]-Asp(O-t-Bu)-Phe-O-CTC (16) 
Fmoc-Ser[P(OC2H4CN)(OC2H4-NH-Alloc)O2H] (12) (246.8 mg, 0.42 mmol, 3 equiv), PyAOP (218.9 
mg, 2.5 mmol, 3 equiv) and DIPEA (308.2 µL, 1.86 mmol, 9 equiv) were added to the above obtained H-
Asp(O-t-Bu)-Phe-O-CTC (15). After 2 h, the peptidyl-resin was subjected to the following 
washings/treatments with CH2Cl2 (3 x 0.5 min), DMF (3 x 0.5 min). Before the piperidine treatment for 
Fmoc-removal, an aliquot of the peptidyl-resin was treated with TFA/Et3SiH/CH2Cl2 (1:1:98) and 
TFA/Et3SiH/H2O (90:5:5). The HPLC analysis (tR = 4.34 min) of the crude obtained after evaporation 
showed a purity of > 95%. MS (ESI) calcd. For C44H51N4O15P, 906.87. Found: m/z 850.11 [M - t-Bu]+. 
Removal of Fmoc group and washings were performed as described in General Procedures for Fmoc-
removal (section 8.5.4.2). 
8. Supplement 
 
 242
8.5.4.5      H-Asn-Ser[P(OC2H4-NH-Alloc)O2H]-Asp(O-t-Bu)-Phe-O-CTC (17) 
Fmoc-L-Asn-OH (198.4 mg, 0.56 mmol, 4 equiv) was added to the above obtained H-Ser[P(OC2H4-NH-
Alloc)O2H]-Asp(O-t-Bu)-Phe-O-CTC (16) using DIC (86.8 µL, 0.56 mmol, 4 equiv) and 
Ethylcyanoglyoxylate-2-oxime (79.6 mg, 0.56 mmol, 4 equiv) in DMF (2.5 ml). After 90 min of 
coupling, the chloranil test was negative. Removal of Fmoc group and washings were performed as 
described in General Procedures for Fmoc-removal (section 8.5.4.2).  
8.5.4.6    Boc-Ile-Asn-Ser[P(OC2H4-NH-Alloc)O2H]-Asp(O-t-Bu)-Phe-O-CTC (18) 
Boc-L-Ile-OH (129.4 mg, 0.56 mmol, 4 equiv) was added to the above obtained H-Asn-Ser[P(OC2H4-
NH-Alloc)O2H]-Asp(O-t-Bu)-Phe-O-CTC (17) using DIC (86.8 µL, 0.56 mmol, 4 equiv) and 
ethylcyanoglyoxylate-2-oxime (79.6 mg, 0.56 mmol, 4 equiv) in DMF (2.5 ml). After 90 min of coupling, 
the chloranil test was positive and the coupling was repeated again in the same conditions. An aliquot of 
the peptidyl-resin was treated with TFA/Et3SiH/CH2Cl2 (1:1:98) and TFA/Et3SiH/H2O (90:5:5). The 
HPLC analysis (tR = 3.27 min) of the crude obtained after evaporation showed a purity of > 90 %. MS 
(ESI) calcd. For C40H59N6O18P, 942,90. Found: m/z 801.11 [M - H - Boc and t-Bu]-. 
8.5.4.6      General procedure for Alloc-removal: Boc-Ile-Asn-Ser[P(OC2H4-NH2)O2H]-
Asp(O-t-Bu)-Phe-O-CTC (19). The Alloc group of the peptide resin (18) was removed with Pd(PPh3)4 
(16.2 mg, 0.04 mmol, 0.1 equiv) in the presence of PhSiH3 (520. µL, 4.21 mmol, 10 equiv) and the resin 
was washed with CH2Cl2 (3 x 0.5 min), DMF (3 x 0.5 min), 0.02 M sodium diethyldithiocarbamate in 
DMF (3 x 15 min) and DMF (3 X 0.5 min). 
8.5.4.7      Boc-Ile-Asn-Ser[P(OC2H4-NH-Leu)O2H]-Asp(O-t-Bu)-Phe-O-CTC (20) 
Alloc-L-Leu-OH (120.5 mg, 0.56 mmol, 4 equiv) was coupled to the above obtained Boc-Ile-Asn-
Ser[P(OC2H4-NH2)O2H]-Asp(O-t-Bu)-Phe-O-CTC (19) using DIC (86.8 µL, 0.56 mmol, 4 equiv) and 
ethylcyanoglyoxylate-2-oxime (79.6 mg, 0.56 mmol, 4 equiv) in DMF (2.5 ml). After 90 min of coupling, 
the chloranil test was negative. The peptidyl-resin was subjected to the following washings/treatments 
with CH2Cl2 (3 x 0.5 min) and DMF (3 x 0.5 min). Removal of Alloc group and washings were 
performed as already described in General Procedures for Alloc-removal (section 8.5.4.6).  
8.5.4.8    Boc-Ile-Asn-Ser[P(OC2H4-NH-Leu-NH2)O2H]-Asp(O-t-Bu)-Phe-OH (21) 
The protected and branched polymer-bound peptide (20) was cleaved from the resin by treatment with 
TFA/Et3SiH/CH2Cl2 (1:1:98, 2.0 ml) for 1 h. Partial purification of 21 was accomplished by filtration of 
the acidic resin suspension in 4.5 ml of pyridine-methanol (1.5:75 v/v) solution and evaporation of the 
filtrate to dryness in vacuo. A small title of the dried partially protected peptide 21 was exposed to 
TFA/H2O/Et3SiH (90:5:5) for 1 h to remove the protecting groups and the HPLC (tR = 11.35 min) of the 
crude obtained after evaporation showed a purity of > 80%. MS (ESI) calcd. For C42H67N8O16P, 971,00. 
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Found: m/z 830.18 [M - Boc and t-Bu]+. MS (MALDI) calcd. for C42H67N8O16P, 971,00. Found: m/z 
831.30 [M + 1 - Boc and t-Bu]+. The product was used without further purification. 
8.5.4.9      Boc-Ile-Asn-Ser{P[OC2H4-NH-Leu(&)]O2H}-Asp(O-t-Bu)-Phe(&) (22) 
Procedure A (entry 3 in table 8.1, section 8.3.2.2): The protected peptide (21) (90.0 mg, 0.09 mmol, 1 
equiv) was dissolved in CHCl3 (45.6 ml, 2 mM solution) and N-polystyrene methyl-N’-
cyclohexylcarbodiimide (197.8 mg, 2.3 mmol/g, 5 equiv) and DMAP (1.10 mg, 0.01 mmol, 0.1 equiv) 
were added. The mixture was stirred for 3 d and the course of the cyclization was checked by HPLC (tR = 
9.34 min). The solid supported corbodiimide was then filtered and the solvent was removed by 
evaporation in vacuo.  
Procedure B (entry 11 in table 8.1, section 8.3.2.2): The protected peptide (21) (25.0 mg, 0.02 mmol, 1 
equiv) was dissolved in CH2Cl2 (9.0 mL, 2 mM solution) and DIC (15.8 µl, 0.10 mmol, 5 equiv) and 
HOAt (17.0 mg, 0.12 mmol, 0.1 equiv) were added. The mixture was stirred for 1 d. The course of the 
cyclization was checked by HPLC (tR = 9.34 min) and the solvent was removed by evaporation under 
reduced pressure.  
8.5.4.10      H-Ile-Asn-Ser{P[OC2H4-NH-Leu(&)]O2H}-Asp-Phe(&) (23) 
In both cyclization reactions the protected cyclic peptide (22) (87.0 mg, 0.09 mmol, 1 equiv) was exposed 
to TFA-mediated acidolytic treatment for 1.5 h with TFA/H2O/Et3SiH (90:5:5, 4 ml). The HPLC (tR = 
13.75 min) of the crude obtained after evaporation showed a purity of < 5 %. MS (ESI) calcd. For 
C34H53N8O13P, 812,80. Found: m/z 813.28 [M + 1]+, 825.50 [M + Na]+. MS (MALDI) calcd. for 
C34H53N8O13P, 812,80. Found: m/z 813.29 [M + 1]+. After semipreparative HPLC (tR = 11.04 min) the 
product 23 was not pure enough for the biological tests. 
 
8.5.5 Total synthesis of the AIP-III 
8.5.5.1      H-Leu-O-CTC
 
(24)
  
Cl-TrtCl-resin (0.2 g, 1.01 mmol/g) was placed in a 20.0 ml polypropylene syringe fitted with a 
polyethylene filter disk. The resin was then washed with CH2Cl2 (5 x 0.5 min), and a solution of Fmoc-L-
Leu-OH (49.4 mg, 0.14 mmol, 0.7 equiv) and DIPEA (70.0 µl, 0.42 mmol, 2.1 equiv) in CH2Cl2 (2.5 ml) 
was added. The mixture was then stirred for 15 min. Extra DIPEA (140.0 µL, 0.85 mmol, 4.2 equiv) was 
added and the mixture was stirred for an additional 45 min. The reaction was stopped by adding MeOH 
(320.0 µl) and stirred for 10 min. The aim of this procedure was obtaining a resin loading of 0.7 mmol/g. 
The Fmoc-L-Leu-O-TrtCl-resin was subjected to the following washings/treatments with CH2Cl2 (3 x 0.5 
min), DMF (3 x 0.5 min), piperidine-DMF solution to remove the Fmoc as indicated in the General 
Procedure for Fmoc-removal (section 8.5.4.2).  
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8.5.5.2       Boc-Ile-Asn-Cys(Mmt)-Asp(O-t-Bu)-Phe-Leu-Leu-O-CTC (25)
 
Fmoc-L-Leu-OH (198.00 mg, 0.56 mmol, 4 equiv), Fmoc-L-Phe-OH (217.00 mg, 0.56 mmol, 4 equiv), 
Fmoc-L-Asp(O-t-Bu)-OH (230.40  mg, 0.56 mmol, 4 equiv), Fmoc-L-Cys(Mmt)-OH (344.80 mg, 0.56 
mmol, 4 equiv), Fmoc-L-Asn-OH (198.40 mg, 0.56 mmol, 4 equiv) and Boc-L-Ile-OH (129.40 mg, 0.56 
mmol, 4 equiv) were added sequentially to the above obtained H-Leu-O-TrtCl-resin (24) using DIC 
(86.80 µL, 0.56 mmol, 4 equiv) and ethylcyanoglyoxylate-2-oxime (79.60 mg, 0.56 mmol, 4 equiv) in 
DMF (2.5 mL). After 90 min shaking, with the exception for Fmoc-L-Cys(Mmt)-OH (2 h), the chloranil 
test was negative for all the amino acids coupled. After each coupling removal of Fmoc group and 
washings were performed as described in General Procedures for Fmoc-removal (section 8.5.4.2), with 
the exception of Boc-L-Ile-OH coupling.  
8.5.5.3      Boc-Ile-Asn-Cys-Asp(O-t-Bu)-Phe-Leu-Leu-OH (26) 
The protected linear polymer-bound peptide (25) was cleaved from the resin by treatment with 
TFA/Et3SiH/CH2Cl2 (1:1:98, 3 ml) for 40 min. Partial purification of 26 was accomplished by filtration of 
the acidolytic resin suspension in 4.5 ml of pyridine-methanol (1.5:75 v/v). After evaporation of the 
solvents, the residue was triturated with ice-water, filtrated and dried under reduced pressure. A small title 
of the dried partially protected peptide 26 was exposed to TFA/H2O/Et3SiH (90:5:5) for 1 h to remove the 
protecting groups and HPLC analysis (tR = 3.69 min) of the crude obtained after evaporation showed a 
purity of > 90%. MS (ESI) calcd. For C47H76N8O13S, 993,22. Found: m/z 837.27 [M - Boc and t-Bu]+. 
The product was used without further purification. 
8.5.5.4      Boc-Ile-Asn-Cys(&)-Asp(O-t-Bu)-Phe-Leu-Leu(&) (27)
 
The protected peptide (26) (80.00 mg, 0.08 mmol, 1 equiv) was dissolved in CHCl3 (40.28 mL, 2 mM 
solution) and EDC (76.70 mg, 0.40 mmol, 5 equiv) and DMAP (1.00 mg, 0.008 mmol, 0.1 equiv) were 
added. The mixture was stirred for 3 d. The course of the cyclization was checked by HPLC (tR = 3.88 
min). The residue was then extracted twice with 5% citric acid solution to remove the excess of 
carbodiimide and washed with water. The organic phase was concentrated by evaporation under reduced 
pressure.  
8.5.5.5      H-Ile-Asn-Cys(&)-Asp-Phe-Leu-Leu(&) (28) (AIP-III)
 
The protected cyclic peptide (27) (78.00 mg, 0.08 mmol, 1 equiv) was exposed to TFA-mediated 
acidolytic treatment for 1.5 h with TFA:H2O:Et3SiH (90:5:5, 4 ml). The crude obtained was dissolved in 
5 ml of water and washed with CHCl3. After evaporation under reduced pressure of the aqueous phase, 
the crude residue was purified by semi-preparative HPLC (tR = 3.97 min) and obtained with 10-15% 
yield. Following HPLC analysis showed a purity between 80 and 90 %. MS (ESI) calcd. For 
C38H58N8O10S, 818,98. Found: m/z 819.30 [M + 1]+. 
 
8. Supplement 
 245 
8.6 BIBLIOGRAPHIC REFERENCES 
(1) Hancock, R. E. The End of an Era. Nat. Rev. Drug Discov. 2007, 6, 28. 
(2) Walsh, C.; Wright, G. Introduction: antibiotic resistance. Chem. Rev. 2005, 105, 391-394. 
(3) Palumbi, S. R. Humans as the world's greatest evolutionary force. Science 2001, 293, 1786-1790. 
(4) Brown,E. D.; Wright,G. D. New targets and screening approaches in antimicrobial drug discovery. 
Chem. Rev. 2005, 105, 759-774. 
(5) Gorske, B. C.; Blackwell, H. E. Interception of quorum sensing in Staphylococcus aureus: a new 
niche for peptidomimetics. Org. Biomol. Chem. 2006, 4, 1441-1445. 
(6) Andersson, D. I. Persistence of antibiotic resistant bacteria. Curr. Opin. Microbiol. 2003, 6, 452-
456. 
(7) Marra, A. Can virulence factors be viable antibacterial targets? Expert Rev. Anti Infect. Ther. 
2004, 2, 61-72. 
(8) Cegelski, L.; Marshall, G. R.; Eldridge, G. R; Hultgren, S. J. The biology and future prospects of 
antivirulence therapies. Nat. Rev. Microbiol. 2008, 6, 17-27. 
(9) Von Nussbaum, F.; Brands, M.; Hinzen, B. Antibacterial natural products in medicinal chemistry 
– exodus or revival? Angew. Chem. Int. Ed. 2006, 45, 5072-5129. 
(10) Everts, S. Bacterial conversations. Chem. Eng. News 2006, 84, 17–26. 
(11) Hentzer, M.; Givskov, M. Pharmacological inhibition of quorum sensing for the treatment of 
chronic bacterial infections. J. Clin. Invest. 2003, 112, 1300-1307.  
(12) Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs: confronting the 
challenges of antibacterial discovery. Nat. Rev. Drug Discov. 2007, 6, 29-40. 
(13) Clatworthy, A. E.; Pierson, E.; Hung, D. T. Targeting virulence: a new paradigm for antimicrobial 
therapy. Nat. Chem. Biol. 2007, 3, 541-548. 
(14) Amer, F. A.; El-Behedy, E. M.; Mohtady, H. A. New targets for antibacterial agents. Biotechnol. 
Mol. Biol. Rev. 2008, 3, 46-57.  
(15) Hentzer, M.; Wu, H.; Andersen, J. B.; Riedel, K.; Rasmussen, T. B.; Bagge, N.; Kumar, N.; 
Schembri, M. A.; Song, Z.; Kristoffersen, P.; Manefield, M.; Costerton, J. W.; Molin, S.; Eberl, 
L.; Steinberg, P.; Kjelleberg, S.; Høiby, N.; Givskov, M. Attenuation of Pseudomonas aeruginosa 
virulence by quorum sensing inhibitors. EMBO J. 2003, 22, 3803-3815. 
(16) Fuqua, W. C.; Winans, S. C.; Greenberg, E. P. Quorum sensing in bacteria: the LuxR-LuxI family 
of cell density-responsive transcriptional regulators. J. Bacteriol. 1994, 176, 269-275.  
(17) Bassler, B. L.; Losick, R. Bacterially speaking. Cell 2006, 125, 237-46. 
(18) Fuqua, C.; Parsek, M. R.; Greenberg E. P. Regulation of gene expression by cell-to-cell 
communication. Annu. Rev. Genet. 2001, 35, 439-468.  
(19) Smith, D.; Wang, J. H.; Swatton, J. E.; Davenport, P.; Price, B.; Mikkelsen, H.; Stickland, H.; 
Nishikawa, K.; Gardiol, N.; Spring, D. R.; Welch. M. Variations on a theme: diverse N-acyl 
homoserine lactone-mediated quorum sensing mechanisms in gram-negative bacteria. Sci. Prog. 
2006, 89, 167-211.   
(20) Rasmussen, T. B.; Givskov, M. Quorum sensing inhibitors: a bargain of effects. Microbiology 
2006, 152, 895-904.  
(21) Galloway, W. R. J. D.; Hodgkinson, J. T.; Welch, M.; Spring, D. R. Mastering the chemical 
language of bacteria. Chem. Biol. 2009, 16, 913-914. 
(22) Amer, F. A. A.; El-Behedy, E. M.; Mohtady, H. A. New Targets for Antibacterial Agents. 
Biotechnol. Mol. Biol. Rev. 2008, 3, 46-57. 
(23) Kapadnis,P. B.; Hall, E; Ramstedt, M.; Galloway, W. R. J. D; Welch, M.; Spring, D. R. Towards 
quorum-quenching catalytic antibodies. Chem. Commun. 2009, 5, 538-540. 
(24) Suga, H.; Smith, K. M. Molecular mechanisms of bacterial quorum sensing as a new drug target. 
Curr. Opin. Chem. Biol. 2003, 7, 586-591. 
8. Supplement 
 
 246
(25) Schuster, M.; Lostroh, C. P.; Ogi, T.; Greenberg, E. P. Identification, timing, and signal specificity 
of Pseudomonas aeruginosa quorum-controlled genes: a transcriptome analysis. J. Bacteriol. 2003, 
185, 2066-2079.  
(26) Welch, M.; Todd, D. E.; Whitehead, N. A.; McGowan, S. J.; Bycroft, B. W.; Salmond, G. P. C. N-
acyl homoserine lactone binding to the CarR receptor determines quorum-sensing specificity in 
Erwinia. EMBO J. 2000, 19, 631-641. 
(27) Wagner, V. E.; Bushnell, D.; Passador, L; Brooks, A. I.; Iglewski, B. H. Microarray analysis of 
Pseudomonas aeruginosa quorum-sensing regulons: effects of growth phase and environment. J. 
Bacteriol. 2003, 185, 2080-2095.  
(28) Wagner, V. E.; Gillis, R. J.; Iglewski, B. H. Transcriptome analysis of quorum-sensing regulation 
and virulence factor expression in Pseudomonas aeruginosa. Vaccine 2004, 22, S 15-20. 
(29) Williams, P.; Camara, M.; Hardman, A.; Swift, S.; Milton, D.; Hope, V. J.; Winzer, K.; 
Middleton, B.; Pritchard, D. I.; Bycroft, B. W. Philos. Trans. R. Soc. London B 2000, 355, 667-
680. 
(30) Miller, M. B.; Bassler, B. L. Quorum sensing in bacteria. Annu. Rev. Microbiol. 2001, 55, 165-
199. 
(31) Winzer, K.; Hardie, K. R.; Williams, P. Bacterial cell-to-cell communication: sorry, can't talk now 
– gone to lunch! Curr. Opin. Microbiol. 2002, 5, 216-222.  
(32) Lyon, G. J.; Muir, T. W. Chemical Signaling among Bacteria and Its Inhibition. Chem. Biol. 2003, 
10, 1007-1010. 
(33) Lin, Y. H.; Xu, J. L.; Hu, J.; Wang, L. H.; Ong, S. L.; Leadbetter, J. R.; Zhang. L. H. Acyl-
homoserine lactone acylase from RalstoniaRalstonia str. XJ12B represents a novel and potent 
class of quorum quenching enzymes. Mol. Microbiol. 2003, 47, 849-860. 
(34) Dong, Y. H.; Xu, J. L.; Li, X. Z.; Zhang, L. H. AiiA, an enzyme that inactivates the 
acylhomoserine lactone quorum-sensing signal and attenuates the virulence of Erwinia carotovora. 
Proc. Natl. Acad. Sci. USA 2000, 97, 3526-3531. 
(35) Teiber J. F.; Horke, S.; Haines, D. C.; Chowdhary, P. K.; Xiao, J.; Kramer, G. L.; Haley, R. W.; 
Draganov, D. I. Dominant Role of Paraoxonases in Inactivation of the Pseudomonas aeruginosa 
Quorum-Sensing Signal N-(3-Oxododecanoyl)-L-Homoserine Lactone  Infect. Immun. 2008, 76, 
2512-2519. 
(36) Schultz, P. G. Catalytic Antibodies. Angew. Chem. Int. Ed. Engl. 1989, 28, 1283-1295. 
(37) Janda, K. D. Catalytic antibodies and enzyme inhibitors. Pure Appl. Chem. 1994, 66, 703-708. 
(38) Marin, S. D.; Xu, Y.; Meijler, M. M.; Janda K. D. Antibody catalyzed hydrolysis of a quorum 
sensing signal found in Gram-negative bacteria. Bioorg. Med. Chem. Lett. 2007, 17, 1549-1552. 
(39) Wentworth, P. Active immunization with a glycolipid transition state analogue protects against 
endotoxic shock. Science 2002, 296, 2247-2249. 
(40) Gao, C.; Lavey, B. J.; Lo, C. H. L.; Datta, A.; Wentworth, P. Jr.; Janda, K. D. Direct Selection for 
Catalysis from Combinatorial Antibody Libraries Using a Boronic Acid Probe: Primary Amide 
Bond Hydrolysis. J. Am. Chem. Soc. 1998, 120, 2211-2217. 
(41) Nevinsky, G. A.; Buneva, V. N. Catalytic antibodies in healthy humans and patients with 
autoimmune and viral diseases. J. Cell. Mol. Med. 2003, 7, 265-276. 
(42) Shokat, K. M.; Ko, M. K.; Scanlan, T. S.; Kochersperger, L.; Yonkovich, S.; Thaisrivongs, S.; 
Schultz, P. G. Catalytic Antibodies: A New Class of Transition-State Analogues Used to Elicit 
Hydrolytic Antibodies. Angew. Chem. Int. Ed. Engl. 1990, 29, 1296-1303. 
(43) Stewart, J. D.; Benkovich, S. J. Transition-state stabilization as a measure of the efficiency of 
antibody catalysis. Nature 1995, 375, 388-391. 
(44) Reymond, J. L. Detection strategies for catalytic antibodies. J. Immunol. Methods 2002, 269, 125-
131. 
(45) Xu, Y.; Yamamoto, N.; Janda, K. D. Catalytic antibodies: hapten design strategies and screening 
methods. Bioorg. Med. Chem. 2004, 12, 5247-5268. 
8. Supplement 
 247 
(46) Fluit, A. C.; Wielders, C. L. C.; Verhoef, J.; Schmitz. F. J. Epidemiology and susceptibility of 
3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European 
SENTRY study. J. Clin. Microbiol. 2001, 39, 3727-3732. 
(47) Recsei, P.; Kreiswirth, B.; O’Reilly, M.; Schlievert, P.; Gruss, A.; Novick, R. P. Regulation of 
exoprotein gene expression in Staphylococcus aureus by agr. Mol. Gen. Genet. 1986, 202, 58-61.  
(48) Ji, G.; Beavis, R. C.; Novick, R. P. Cell density control of staphylococcal virulence mediated by 
an octapeptide pheromone. Proc. Natl. Acad. Sci. USA 1995, 92, 12055-12059. 
(49) Balaban, N.; Goldkorn, T.; Nhan, R. T.; Dang, L. B.; Scott, S.; Ridgley, R. M.; Rasooly, A.; 
Wright, S. C.; Larrick, J. W.; Rasooly, R.; Carlson, J. R. Autoinducer of virulence as a target for 
vaccine and therapy against Staphylococcus aureus. Science 1998, 280, 438-440. 
(50) Lyon, G. J.; Wright, J. S.; Muir, T. W.; Novick, R. P. Key Determinants of Receptor Activation in 
the agr Autoinducing Peptides of Staphylococcus aureus. Biochemistry 2002, 41, 10095-10104. 
(51) Scott, R. J.; Lian, L. Y.; Muharram, S. H.; Cockayne, A.; Wood, S. J.; Bycroft, B. W.; Williams, 
P.; Chan, W. C. Side-chain-to-tail thiolactone peptide inhibitors of the staphylococcal quorum-
sensing system. Bioorg. Med. Chem. Lett. 2003, 13, 2449-2453. 
(52) McDowell, P.; Affas, Z.; Reynolds, C.; Golden, M. T. G.; Wood, S. J.; Saint, S.; Cockayne, A.; 
Hill, P. J.; Dodd, C. E. R.; Bycroft, B. W.; Chan, W. C.; Williams, P. Structure, activity and 
evolution of the group I thiolactone peptide quorum-sensing system of Staphylococcus aureus. 
Mol. Microbiol. 2001, 41, 503-512.  
(53) Schowen, R. L. The elicitation of carboxylesterase activity in antibodies by reactive immunization 
with labile organophosphorus antigens: a role for flexibility. J. Immunol. Meth. 2002, 269, 59-65. 
(54) Le Corre, L. ; Gravier-Pelletier, C.; Le Merrer, Y. Towards New MraY Inhibitors: A Serine 
Template for Uracil and 5-Amino-5-deoxyribosyl Scaffolding. Eur. J. Org. Chem. 2007, 32, 5386-
5394. 
(55) Isidro-Llobet A.; Álvarez, M.; Albericio F. Amino acid-protecting groups. Chem. Rev. 2009, 109, 
2455-2504. 
(56) Townsend, C. A.; Basak, A. Experiments and speculations on the role of oxidative cyclization 
chemistry in natural product biosynthesis. Tetrahedron 1991, 47, 2591-2602. 
(57) Organ, M. G.; Bilokin, Y. V.; Bratovanov, S. Approach toward the Total Synthesis of 
Orevactaene. 2. Convergent and Stereoselective Synthesis of the C18−C31 Domain of 
Orevactaene. Evidence for the Relative Configuration of the Side Chain. J. Org. Chem. 2002, 67, 
5176-5183. 
(58) Cruz, L. J.; Beteta, N. G.; Ewenson, A.; Albericio, F. “One-Pot” Preparation of N-Carbamate 
Protected Amino Acids via the Azide. Org. Process Res. Dev. 2004, 8, 920-924. 
(59) McMurray, J. S.; Coleman, D. R.; Wang, W.; Campbell, M. L. The Synthesis of Phosphopeptides. 
Biopolymers 2001, 60, 3-31.  
(60) Sinha, N. D.; Biernat, J.; Köster, H. β-Cyanoethyl N,N-dialkylamino/N-morpholino-monochloro 
phosphoamidites, new phosphitylating agents facilitating ease of deprotection and work-up of 
synthesized oligonucleotides. Tetrahedron Lett. 1983, 24, 5843-5846. 
(61) Kupihár, Z.; Váradi, G.; Monostori, E.; Tóth, G. K. Preparation of an asymmetrically protected 
phosphoramidite and its application in solid-phase synthesis of phosphopeptides. Tetrahedron 
Lett. 2000, 41, 4457-4461. 
(62) Morales, J. C.; Reina, J. J.; Díaz, I.; Aviñó, A.; Nieto, P. M.; Eritja, R. Experimental measurement 
of carbohydrate aromatic stacking in water using a dangling-ended DNA model system. Chem. 
Eur. J. 2008, 14, 7828-7835.  
(63) Rothman, D. M.; Vazquez, M. E.; Vogel, E. M.; Imperiali, B. General method for the synthesis of 
caged phosphopeptides: Tools for the exploration of signal transduction pathways. Org. Lett. 
2002, 4, 2865-2868. 
(64) Tetzlaff, C. N.; Richert, C. Synthesis and hydrolytic stability of 5′-aminoacylated oligouridylic 
acids, Tetrahedron Lett. 2001, 42, 5681-5684. 
8. Supplement 
 
 248
(65) Nicolaou, K. C.; Flörke, H.; Egan, M. G.; Barth, T.; Estevez, V. A. Carbonucleotoids and 
carbopeptoids: New carbohydrate oligomers. Tetrahedron Lett. 1995,  36, 1775-1778. 
(66) Rothman, D. M.; Vazquez, M. E.; Vogel, E. M.; Imperiali, B. Caged phospho-amino acid building 
blocks for solid-phase peptide synthesis. J. Org. Chem. 2003, 68, 6795-6798. 
(67) Bhandari, R.; Saiardi, A.; Ahmadibeni, Y.; Snowman, A. M.; Resnick, A. C.; Kristiansen, T. Z.; 
Molina, H.; Pandey, A.; Werner, J. K. Jr; Juluri, K. R.; Xu, Y.; Prestwich, G. D.; Parang, K.; 
Snyder, S. H.  Protein pyrophosphorylation by inositol pyrophosphates is a posttranslational event.  
Proc. Natl. Acad. Sci. USA 2007, 104, 15305-15310. 
(68) Chan, W. C.; Coyle, B.; Williams, P. Virulence regulation and quorum sensing in staphylococcal 
infections: competitive AgrC antagonists as quorum sensing inhibitors. J. Med. Chem. 2004, 47, 
4633-4641. 
(69) Lloyd-Williams, P.; Albericio, F.;  Giralt E. Convergent solid-phase peptide synthesis. 
Tetrahedron 1993, 49, 11065-11133. 
(70) Benz, H. The role of solid-phase fragment condensation (SPFC) in peptide synthesis. Synthesis 
1994, 4, 337-358. 
(71) Barlos, K.; Gatos, D.; Schäfer, W. Synthesis of Prothymosin α(ProTα)-a Protein Consisting of 109 
Amino Acid Residues. Angew. Chem. Int. Ed. Engl. 1991, 30, 590-593. 
(72) Barlos, K.; Chatzi, O.; Gatos, D.; Stavropoulos, G. 2-Chlorotrityl chloride resin: studies on 
anchoring of Fmoc-amino acids and peptide cleavage. Int. J. Pept. Protein Res. 1991, 37, 513-520. 
(73) Rovero, P.; Viganò, S.; Pegoraro, S.; Quartana, L. Synthesis of the bradykinin B1 antagonist 
[desArg10]HOE 140 on 2-chlorotrityl resin. Lett. Pept. Sci. 1996, 2, 319-323. 
(74) Chiva, C.; Vilaseca, M.; Giralt, E.; Albericio, F. An HPLC-ESMS study on the solid-phase 
assembly of C-terminal proline peptides. J. Pept. Sci. 1999, 5, 131-140.  
(75) Subirós-Funosas, R.; Prohens, R.; Barbas, R.; El-Faham, A.; Albericio, F. Oxyma: an efficient 
additive for peptide synthesis to replace the benzotriazole-based HOBt and HOAt with a lower 
risk of explosion. Chem. Eur. J. 2009, 15, 9394-9403. 
(76) Albericio, F.; Bofill, J. M.; El-Faham, A.; Kates, S. A. Use of Onium Salt-Based Coupling 
Reagents in Peptide Synthesis. J. Org. Chem. 1998, 63, 9678-9683. 
(77) Carpino, L. A.; El-Faham, A.; Minor, C. A.; Albericio, F. Advantageous applications of 
azabenzotriazole (triazolopyridine)-based coupling reagents to solid-phase peptide synthesis. 
Chem. Commun. 1994, 201-203. 
(78) Christensen, T. Qualitative test for monitoring coupling completeness in solid phase peptide 
synthesis using chloranil. Acta Chem. Scand. Ser. B 1979, 33, 763-766.  
(79) Vojkovsky, T. Detection of secondary amine on solid phase. Peptide Res. 1995, 8, 236-237. 
(80) Vázquez, J.; Qushair, G.; Albericio, F. Qualitative Colorimetric Tests for Solid Phase Synthesis. 
Meth. Enzymol., 2003, 369, 21-35. 
(81) Gegnas, L. D.; Waddell, S. T.; Chabin, R. M.; Reddy, S.; Wong, K. K. Inhibitors of the bacterial 
cell wall biosynthesis enzyme MurD. Bioorg. Med. Chem. 1998, 8, 1643-1648.  
(82) Wakamiya, T.; Saruta, K.; Yasuoka, J.; Kusumoto, S. An efficient procedure for solid-phase 
synthesis of phosphopeptides by the Fmoc strategy. Chem. Lett. 1994, 23, 1099-1102. 
(83) Wang, Q.; Dechert, U.; Jirik, F.; Withers, S. G. Suicide inactivation of human prostatic acid 
phosphatase and a phosphotyrosine phosphatase. Biochem. Biophys. Res. Commun. 1994, 200, 
577-583. 
(84) Letsinger, R. I.; Finnan, J. L.; Heavner, G. A.; Lunsford, W. B. Nucleotide chemistry. XX. 
Phosphite coupling procedure for generating internucleotide links. J. Am. Chem. Soc. 1975, 97, 
3278-3279. 
(85) Allylic protecting groups and their use in a complex environment part I: Allylic protection of 
alcohols. Tetrahedron 1997, 53, 13509-13556. 
8. Supplement 
 249 
(86) Guibé, F. Allylic protecting groups and their use in a complex environment part II: Allylic 
protecting groups and their removal through catalytic palladium π-allyl methodology. Tetrahedron 
1998, 54, 2967-3042. 
(87) Weinshenker, N. M.; Shen, C. M. Polymeric reagents I. Synthesis of an insoluble polymeric 
carbodiimide. Tetrahedron Lett. 1972, 32, 3281-3284. 
(88) Weinshenker, N. M; Shen, C. M.; Wong, J. Y. Polymeric carbodiimide preparation. Org. Synth. 
1977, 56, 95-98. 
(89) Carpino, L. A. 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive. J. Am. 
Chem. Soc. 1993, 115, 4397-4398. 
(90) White, P. D.; Chan, W. C. In Fmoc solid phase peptide synthesis.  Chan, W. C., White, P. D., Eds; 
Oxford University Press: Oxford, 2000. 
(91) Otto, M.; Süssmuth, R.; Jung, G.; Götz, F. Structure of the pheromone peptide of the 
Staphylococcus epidermidis agr system. FEBS Lett. 1998, 424, 89-94. 
(92) Otto, M.; Süssmuth, R.; Vuong, C.; Jung, G.; Götz, F. Inhibition of virulence factor expression in 
Staphylococcus aureus by the Staphylococcus epidermidis agr pheromone and derivatives. FEBS 
Lett. 1999, 450, 257-262. 
(93) Otto, M.; Echner, H; Voelter, W.; Gotz, F. Pheromone cross-inhibition between Staphylococcus 
aureus and Staphylococcus epidermidis. Infect. Immun. 2001, 69, 1957-1960. 
(94) Alsina, J.; Yokum, T. S.; Albericio, F.; Barany, G. Backbone Amide Linker (BAL) Strategy for 
N(alpha)-9-Fluorenylmethoxycarbonyl (Fmoc) Solid-Phase Synthesis of Unprotected Peptide p-
Nitroanilides and Thioesters. J. Org. Chem. 1999, 64, 8761-8769. 
(95) Sewing, A.; Hilvert, D. Fmoc-Compatible Solid-Phase Peptide Synthesis of Long C-Terminal 
Peptide Thioesters. Angew. Chem. Int. Ed. 2001, 40, 3395-3396.  
(96) Von Eggelkraut-Gottanka, R.; Klose, A.; Beck-Sickinger, A. G.; Beyermann, M. Peptide α-
thioester formation using standard Fmoc-chemistry. Tetrahedron Lett. 2003, 44, 3551-3554. 
(97) Barany, G.; Merrifield, R. B. In The Peptides: Analysis, Synthesis and Biology. Gross, E., 
Meienhofer, J., Eds.; Academic Press: New York, 1980; vol. 2, pp. 190-208. 
(98) Radkiewicz, J. L.; Zipse, H.; Clarke, S.; Houk, K. N. Neighboring Side Chain Effects on 
Asparaginyl and Aspartyl Degradation:  An Ab Initio Study of the Relationship between Peptide 
Conformation and Backbone NH Acidity. J. Am. Chem. Soc. 2001, 123, 3499-3506.  
(99) Clarke, S. Aging as war between chemical and biochemical processes: Protein methylation and the 
recognition of age-damaged proteins for repair. Ageing Res. Rev. 2003, 2, 263-285.  
(100) Robinson, N. E.; Robinson, A. B. In Peptides and Proteins. Althouse Press: Cave Junction, OR, 
2004; pp. 1-443. 
(101) Zahariev, S.; Guarnaccia, C.; Pongor, C. I.; Quaroni, L.; Čemažar, M.; Pongor, S. Synthesis of 
‘difficult’ peptides free of aspartimide and related products, using peptoid methodology. 
Tetrahedron Lett. 2006, 47, 4121-4124. 
(102) Perrin, D. D.; Chai, C.; Armarego, W. L. F.; Perrin, D. R. Purification of Laboratory Chemicals, 
5th edition. Butterworth-Heinemann, 2003. 
(103) Mestre-C 2.3a software. 
(104) Spengler, J.; Jiménez, J. C.; Burger, K.; Giralt, E.; Albericio, F. Abbreviated nomenclature for 
cyclic and branched homo- and hetero-detic peptides. J. Pept. Res. 2005, 65, 550-555. 
 
 
 
 
 
 
 
 
